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Neuroblastoma	   is	   a	   childhood	   cancer	   with	   highly	   variable	   clinical	   behaviour	   and	  
outcomes.	  The	  long-­‐term	  survival	  rate	  for	  high-­‐risk	  neuroblastoma	  remains	  poor	  and	  
new	   therapeutic	   advances	   and	   optimisation	   of	   existing	   therapies	   is	   therefore	  
required.	  
	  
Both	  external	  beam	  radiotherapy	  and	  molecular	  radiotherapy	  have	  a	  significant	  role	  
to	  play	   in	  the	  multi-­‐modality	  treatment	  of	  high-­‐risk	  disease.	  This	  collection	  of	  work	  
examines	  ways	  in	  which	  the	  outcome	  for	  neuroblastoma	  may	  be	  improved	  through	  
the	  introduction	  of	  new	  and	  enhancement	  of	  existing	  radiotherapeutic	  techniques.	  
	  
131I-­‐meta-­‐Iodobenzylguanidine	   molecular	   radiotherapy	   has	   been	   used	   in	   the	  
treatment	  of	  neuroblastoma	  since	  the	  mid	  1980’s.	  Despite	  this,	  its	  role	  and	  efficacy	  
remain	   undefined.	   A	   systematic	   review	   of	   131I-­‐mIBG	   therapy	   in	   neuroblastoma	   is	  
therefore	  presented.	  
	  
Radiolabelled	  somatostatin	  analogues	  target	  a	  distinct	  and	  separate	  molecular	  target	  
on	  neuroblastoma	  cells	  to	  the	  noradrenaline	  transporter	  targeted	  by	  131I-­‐mIBG.	  This	  
study	   reports	   on	   the	   use	   of	   radiolabelled	   somatostatin	   analogues	   for	   the	   imaging	  
and	   therapy	   of	   patients	   with	   high-­‐risk	   neuroblastoma.	   The	   expression	   of	   the	   two	  
different	   molecular	   targets	   by	   immunohistochemistry	   for	   the	   noradrenaline	  
transporter	  molecule	  and	   somatostatin	   receptor	   type-­‐2	   in	  archived	  neuroblastoma	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tumour	   samples	   is	   also	   explored.	   The	   radiation	   doses	   received	   by	   comforters	   and	  
carers	   providing	   necessary	   support	   to	   children	   undergoing	  molecular	   radiotherapy	  
over	  a	  10	  year	  period	  is	  presented.	  
	  
The	   gold	   standard	   imaging	  modality	   for	   response	   assessment	   in	   neuroblastoma	   is	  
123I-­‐mIBG	  scinitgraphy.	  The	  role	  of	  other	  functional	   imaging	  techniques	  such	  as	  18F-­‐
FDG	  PET/CT	  remains	  undefined.	  This	  study	  will	  look	  to	  see	  if	  18F-­‐FDG	  PET/CT	  can	  give	  
additional	  information	  with	  regards	  to	  response	  assessment.	  
	  
External	  beam	  radiotherapy	  is	  standardly	  delivered	  using	  conventional	  anterior	  and	  
posterior	   parallel	   opposed	   beams	   and	   this	   can	   result	   in	   a	   compromise	   on	   target	  
volume	   coverage	   to	   stay	   within	   the	   tolerance	   of	   normal	   tissues.	   The	   use	   of	   an	  




	   	  
 5 
Table	  of	  Contents	  
	  
Abstract	   	   	   	   	   	   	   	   	   	   3
	   	   	   	   	   	   	   	   	  
Table	  of	  Contents	   	   	   	   	   	   	   	   	   5
	   	   	   	   	   	   	   	   	  
List	  of	  Figures	   	   	   	   	   	   	   	   	   9
	   	  
List	  of	  Tables	   	   	   	   	   	   	   	   	   11	  
	  
List	  of	  Abbreviations	   	   	   	   	   	   	   	   13	  
	  
Acknowledgements	   	   	   	   	   	   	   	   16	  
	  
	  
Chapter	  1	   	   Introduction	   	   	   	   	   	  
	   	   	   	   	   	   	  
1.1 History	  	   	   	   	   	   	   	   18	  
1.2 Embryology	   	   	   	   	   	   	   19	  
1.3 Epidemiology	   	   	   	   	   	   	   19	  
1.4	   	   	   Genetics	   	   	   	   	   	   	   21	  
1.4.1	   	   	   Familial	  Neuroblastoma	   	   	   	   	   21	  
1.4.2	   	   	   Sporadic	  Neuroblastoma	   	   	   	   	   22	  
1.5	   	   	   Screening	   	   	   	   	   	   	   23	  
1.6	   	   	   Clinical	  Presentation	   	   	   	   	   	   25	  
1.6.1	   	   	   Primary	  Tumours	   	   	   	   	   	   25	  
1.6.2	   	   	   Metastatic	  Disease	   	   	   	   	   	   26	  
1.6.3	   	   	   Paraneoplastic	  Syndromes	   	   	   	   	   27	  
1.7	  	   	   	   Disease	  Assessment	   	   	   	   	   	   28	  
1.7.1	   	   	   Primary	  Tumour	  Assessment	   	   	   	   	   28	  
1.7.2	   	   	   Metastatic	  Disease	  Assessment	   	   	   	   30	  
1.8	   	   	   Risk	  Stratification	   	   	   	   	   	   33	  
1.8.1	   	   	   Stage	  	   	   	   	   	   	   	   	   34	  
1.8.2	   	   	   Age	   	   	   	   	   	   	   	   38	  
 6 
1.8.3	   	   	   Molecular	  Pathology	   	   	   	   	   	   39	  
1.8.4	   	   	   Histology	   	   	   	   	   	   	   40	  
1.8.5	  	   	   	   International	  Neuroblastoma	  Risk	  Group	  	  
Classification	   	   	   	   	   	   	   42	  
1.9	   	   	   Treatment	   	   	   	   	   	   	   44	  
1.9.1	   	   	   Low	  and	  Intermediate	  Risk	  Disease	   	   	   	   44	  
1.9.2	   	   	   High-­‐Risk	  Disease	   	   	   	   	   	   46	  
1.9.2.1	  	   	   Induction	  chemotherapy	   	   	   	   	   47	  
1.9.2.2	  	   	   Surgery	   	   	   	   	   	   	   49	  
1.9.2.3	  	   	   High-­‐dose	  myeloablative	  therapy	   	   	   	   51	  
1.9.2.4	  	   	   External	  beam	  radiotherapy	   	   	   	   	   53	  
1.9.2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   Minimal	  residual	  disease	  therapy	  and	  	  
immunotherapy	   	   	   	   	   	   57	  
1.10	   	   	   Response	  Assessment	  	   	   	   	   	   60	  
1.10.1	   	   	   International	  Neuroblastoma	  Response	  Criteria	   	   60	  
1.10.2	   	   	   Semi-­‐quantitative	  scoring	  of	  mIBG	  scans	   	   	   62	  
1.10.3	   	   	   The	  prognostic	  significance	  of	  mIBG	  scores	   	   	   64	  
1.10.4	   	   	   Detecting	  Minimal	  Residual	  Disease	   	   	   	   66	  
1.11	   	   	   Relapsed	  and	  Refractory	  Disease	   	   	   	   67	  
1.11.1	  	  	   	   Conventional	  Cytotoxic	  Therapies	   	   	   	   68	  
1.11.2	   	   	   New	  Molecular	  Targeted	  Agents	   	   	   	   69	  
1.11.3	  	  	   	   Molecular	  Radiotherapy	   	   	   	   	   71	  
1.12	   	   	   Special	  Clinical	  Scenarios	   	   	   	   	   74	  
1.12.1	   	   	   Spinal	  Cord	  Compression	   	   	   	   	   74	  
1.12.2	   	   	   Brain	  Metastases	   	   	   	   	   	   75	  
1.12.3	   	   	   Opsoclonus	  Myoclonus	  Syndrome	   	   	   	   77	  
1.12.4	   	   	   Neuroblastoma	  in	  Teenagers	  and	  Young	  Adults	   	   78	  
1.13	  	   	   	   Late	  effects	  of	  treatment	   	   	   	   	   82	  
1.14	   	   	   Radiobiology	  of	  Neuroblastoma	   	   	   	   84	  




Chapter	  2	   Radiolabelled	  Somatostatin	  analogues	  for	  the	  
imaging	  and	  treatment	  of	  neuroblastoma	   	   	  
	  
2.1	   Introduction	   	   	   	   	   	   	   89	  
2.2	  	   A	  comparison	  of	  68Ga-­‐DOTATATE	  and	  123I-­‐mIBG	  for	  	  	  
disease	  assessment	  in	  high-­‐risk	  neuroblastoma	   	   96	  
2.2.1	   	   	   Materials	  and	  Methods	   	   	   	   	   96	  
2.2.2	   	   	   Results	  	   	   	   	   	   	   	   99	  
2.3	   177Lutetium	  DOTATATE	  molecular	  radiotherapy	  	   	   	  
for	  neuroblastoma	   	   	   	   	   	   113	  
2.3.1	   	   	   Materials	  and	  Methods	   	   	   	   	   113	  
2.3.2	   	   	   Results	  	   	   	   	   	   	   	   118	  
2.4	  	   	   	   LuDO	  –	  a	  phase	  IIa	  trial	  of	  177Luetium	  DOTATATE	   	  
in	  relapsed	  and	  refractory	  neuroblastoma	   	   	   123	  
2.5	   	   	   Discussion	   	   	   	   	   	   	   128
	   	   	   	   	   	  
	  
Chapter	  3	   Immunohistochemical	  evaluation	  of	  target	  
expression	  in	  high-­‐risk	  neuroblastoma	  tissue	  	  	  	  	  	  	  	  
	  	  
3.1	  	   	   	   Introduction	   	   	   	   	   	   	   135	  
3.2	   	   	   Materials	  and	  methods	   	   	   	   	   138	  
3.3	   	   	   Results	  	   	   	   	   	   	   	   141	  
3.4	   	   	   Discussion	   	   	   	   	   	   	   158	  
	  
Chapter	  4	  	   A	  Systematic	  Review	  of	  131I-­‐metiodobenzylguanidine	  
(mIBG)	  Therapy	  in	  Neuroblastoma	  
	  
4.1	   Introduction	   	   	   	   	   	   	   165	  
4.2	   Materials	  and	  Methods	   	   	   	   	   167	  
4.3	   Results	  	   	   	   	   	   	   	   170	  




Chapter	  5	   Radiation	  doses	  received	  by	  comforters	  and	  carers	  
during	  paediatric	  molecular	  radiotherapy	  
	  
5.1	   Introduction	   	   	   	   	   	   	   199	  
5.2	  	   	   	   Materials	  and	  Methods	   	   	   	   	   206	  
5.3	  	   	   	   Results	  	   	   	   	   	   	   	   209	  
5.4	  	   	   	   Discussion	   	   	   	   	   	   	   214
	   	   	   	   	   	  
	  
Chapter	  6	   18F-­‐Fluorodeoxyglucose	   positron	   emission	  
tomography	   scans	   performed	   before	   and	   after	   131I-­‐
meta-­‐Iodobenzylguanidine	   therapy	   for	   high	   –risk	  
neuroblastoma	  
	  
6.1	   Introduction	   	   	   	   	   	   	   219	  
6.2	  	   	   	   Materials	  and	  Methods	   	   	   	   	   223	  
6.3	   	   	   Results	  	   	   	   	   	   	   	   228	  




Chapter	  7	   Evaluation	  of	  Intensity	  Modulated	  Arc	  Therapy	  for	  
abdominal	  neuroblastoma	  
	  
7.1	   Introduction	   	   	   	   	   	   	   248	  
7.2	   Patients	  and	  methods	  	   	   	   	   	   254	  
7.3	  	   	   	   Results	  	   	   	   	   	   	   	   263	  
7.5	  	   	   	   Discussion	   	   	   	   	   	   	   285	  
	  
Chapter	  8	   	   Discussion	   	   	   	   	   	   	   292	  
	  
References	   	   	   	   	   	   	   	   	   	   301	  
 9 
List	  of	  Figures	  
	  
1.1	   	   Components	  of	  the	  SIOPEN	  high-­‐risk	  neuroblastoma	  trial	   	   46	  
1.2	   	   Curie	  and	  SIOPEN	  semi-­‐quantitative	  mIBG	   	   	   	   	  
scoring	  methods	   	   	   	   	   	   	   63	  
1.3	   	   Potential	  targets	  for	  molecular	  radiotherapy	  in	  	  
neuroblastoma	   	   	   	   	   	   	   72	  
2.1	  	   	   The	  components	  of	  177Lutetium	  DOTATATE	   	   	   	   90	  
2.2	  	   Correlation	  between	  the	  SIOPEN	  scores	  on	  	  
68Ga-­‐DOTATATE	  PET	  and	  123I-­‐mIBG	   	   	   	   	   101	  
2.3	   	   SIOPEN	  scores	  for	  skeletal	  deposits	   	   	   	   	   102	  
2.4	   	   Soft	  tissue	  scores	   	   	   	   	   	   	   103	  
2.5-­‐2.13	   Different	  uptake	  patterns	  seen	  on	  the	  123I-­‐mIBG	  	  
scan	  and	  68Ga-­‐DOTATATE	  PET	   	  	  	  	  	  	   	   	   	   104	  
2.14	   Imaging	  assessment	  prior	  to	  molecular	  radiotherapy	  	  
decision	   	   	   	   	   	   	   	   114	  
2.15	   	   68Ga-­‐DOTATATE	  PET	  images	  pre-­‐therapy	  and	  	  
following	  administration	  of	  177Lu-­‐DOTATATE	  	   	   	   117	  
2.16	   68Ga-­‐DOTATATE	  PET/CT	  before	  and	  after	  4	  administrations	  	  
of	  177Lu-­‐DOTATATE	   	   	   	   	   	   	   121	  
2.17	   68Ga-­‐DOTATATE	  PET/CT	  before	  and	  after	  3	  administrations	  	  
of	  177Lu-­‐DOTATATE	  	   	   	   	   	   	   	   122	  
2.18	   Dosing	  of	  177Lu-­‐DOTATATE	  within	  the	  LuDO	  trial	   	   	   126	  
3.1	  	   	   Heterogeneity	  of	  uptake	  of	  123I-­‐mIBG	  compared	  to	  	  
68Ga-­‐DOTATATE	  	   	   	   	   	   	   	   137	  
3.2	   	   Histograms	  showing	  range	  expression	  scores	  for	  SSTR2	   	   142	  
3.3	   	   Histograms	  showing	  range	  expression	  scores	  for	  NAT	   	   143	  
3.4A	  –	  E	   Examples	  of	  immunostaining	  patterns	   	   	   	   144	  
3.5	  A-­‐B	  	   Correlation	  of	  NAT	  and	  STTR2	  expression	   	   	   	   150	  
3.6	   	   Kaplan	  Meir	  plot	   	   	   	   	   	   	   153	  
 10 
3.7	   	   Martingale	  results	  SSTR2	   	   	   	   	   	   155	  
3.8	   	   Martingale	  results	  NAT	   	   	   	   	   	   157	  
4.1	   	   PRISMA	  flow	  diagram	  	   	   	   	   	   	   171	  
4.2	   Overall	  objective	  tumour	  response	  for	  relapsed	  	  
and	  refractory,	  consolidation	  and	  induction	  studies	  	   	   187	  
4.3	   	   Proportion	  of	  responders	  and	  mean	  cumulative	  	  
administered	  activity	   	   	   	   	   	   	   188	  
4.4	   	   Response	  rate	  and	  administered	  activity	  per	  Kg	   	   	   189	  
5.1	   Administered	  activity	  and	  age	  for	  MATIN	  and	  single	  	  
administered	  activity	  of	  131I-­‐mIBG	   	   	   	   	   210	  
5.2	   Highest	  individual	  comforter	  and	  carer	  dose	  per	  	  
administration	  	   	   	   	   	   	   	   211	  
5.3	  	   Highest	  individual	  comforter	  and	  carer	  exposure	  and	  the	  	  
administered	  activity	  	  	   	   	   	   	   	   212	  
5.4	   Correlation	  between	  the	  age	  of	  the	  child	  and	  the	  highest	  	  
individual	  comforter	  and	  carer	  exposure	  	   	   	   	   213	  
6.1	   Disease	  extent	  on	  two	  imaging	  modalities	  at	  time	  of	  	  
selection	  for	  131I-­‐mIBG	  therapy	   	   	   	   	   231	  
6.2A-­‐D	  	   Clinical	  examples	   	   	   	   	   	   	   235	  
7.1	   Different	  components	  of	  multi-­‐modality	  therapy	  in	  the	  	  
SIOP	  HR-­‐NBL1	  trial	   	   	   	   	   	   	   248	  
7.2	  	   	   Quality	  assurance	  flow	  chart	   	   	   	   	   	   251	  
7.3	  	   	   Left	  sided	  lateralised	  tumour	  	   	   	   	   	   267	  
7.4	   	   Right	  sided	  lateralised	  tumour	   	   	   	   	   269	  
7.5	  	   	   Mid-­‐line	  tumour	   	   	   	   	   	   	   272	  
7.6	  	   	   Non-­‐PTV	  integral	  dose	   	   	   	   	   	   274	  
7.7	   	   Clinical	  case	  1	   	   	   	   	   	   	   	   275	  
7.8	   	   Clinical	  case	  2	   	   	   	   	   	   	   	   280	  
7.9	  	   	   Clinical	  case	  3	   	   	   	   	   	   	   	   282	  
	  
 11 
List	  of	  Tables	  
	  
1.1 International	  Neuroblastoma	  Staging	  System	   	   35	  
1.2 International	  Neuroblastoma	  Risk	  Group	  Staging	  System	   36	  
1.3 Image-­‐Defined	  Risk	  Factors	  in	  Neuroblastic	  Tumours	   37	  
1.4 International	  Neuroblastoma	  Risk	  Group	  (INRG)	  	  
Consensus,	  Pre-­‐treatment	  Classification	  schema	   	   43	  
1.5 The	  International	  Neuroblastoma	  Response	  Criteria	  	   61	  
2.1	   	   	   The	  physical	  properties	  of	  radionuclides	   	   	   94	  
2.2	   Characteristics	  of	  patients	  with	  paired	  123I-­‐mIBG	  and	  	   	  
68Ga-­‐DOTATATE	  scans	  	   	   	   	   	   99	  
2.3	   The	  SIOPEN	  and	  soft	  tissue	  scores	  for	  123I-­‐mIBG	  and	  	  
68Ga-­‐DOTATATE	  scans	  	   	   	   	   	   100	  
2.4	  	   Patient	  characteristics	  of	  those	  treated	  with	  	  
177Lu-­‐DOTATATE	   	   	   	   	   	   118	  
2.5	  	   Cycles	  administered,	  administered	  activities,	  	  
renal	  and	  haematological	  toxicities	  for	  patients	  	  
treated	  with	  177Lu-­‐DOTATATE	  	   	   	   	   119	  
2.6	  	   Radiological	  and	  clinical	  responses	  for	  patients	  	  
treated	  with	  177Lu-­‐DOTATATE	  	   	   	   	   120	  
3.1	   	   	   Change	  of	  expression	  of	  SSTR2	  and	  NAT	  with	  treatment	   149	  
3.2A-­‐E	   Baseline	  characteristics	   	   	   	   	   151	  
3.3A-­‐C	   SSTR2	  analysis	  	   	   	   	   	   	   154	  
3.4A-­‐C	   NAT	  analysis	   	   	   	   	   	   	   156	  
4.1	   	   	   Induction	  study	  interventions	  	   	   	   	   173	  
4.2	   Consolidation	  study	  interventions	   	   	   	   174	  
4.3	   Relapsed	  and	  refractory	  study	  interventions	  	   	   178	  
4.4	   Study	  quality	  assessment	   	   	   	   	   183	  
4.5	   Tumour	  response	  results	   	   	   	   	   185	  
4.6	   Response	  scales	  used	  	   	   	   	   	   186	  
 12 
4.7	   Planned	  or	  observed	  doses	   	   	   	   	   186	  
6.1	  	   	   	   Semi-­‐Quantitative	  Score	  Sheet	   	   	   	   225	  
6.2	  	   	   	   Semi-­‐quantitative	  response	  criteria	   	   	   	   226	  
6.3	   	   	   PERCIST	  for	  18F-­‐FDG	  PET/CT	  scans	   	   	   	   227	  
6.4	   	   	   Patient	  characteristics	   	   	   	   	   227	  
6.5	  	   Semi-­‐quantitative	  scores	  and	  distribution	  of	  disease	  	  
on	  123I-­‐mIBG	  and	  18F-­‐FDG	  PET/CT	  	   	   	   	   230	  
6.6	  	   Response	  on	  123I-­‐mIBG	  and	  18F-­‐FDG	  PET/CT	  by	  semi-­‐
quantitative	  scoring	   	   	   	   	   	   232	  
6.7	  	   Skeletal	  scores	  only	   	   	   	   	   	   233	  
6.8	  	   	   	   Soft	  tissue	  disease	  only	   	   	   	   	   234	  
7.1	   	   	   Radiotherapy	  doses	  in	  protocol	  non-­‐compliant	  group	   255	  
7.2	  	   Comparison	  of	  PTV	  coverage	   	   	   	   	   264	  
7.3	   Liver	  and	  kidney	  doses	  for	  lateralised	  tumours	   	   266	  
	   	  
 13 
List	  of	  Abbreviations	  
	  
AA	   	   	   	   Administered	  Activities	  
	  
AACIS	  	   	   	   	   Automated	  Childhood	  Cancer	  Information	  System	  	  
	  
ABMT	   	   	   	   Autologous	  Bone	  Marrow	  Transplantation	  
	  
ALARA	  	   	   	   As	  low	  as	  reasonably	  achievable	  
	  
ALK	  	   	   	   	   Anaplastic	  lymphoma	  kinase	  	  
	  
ASR	  	   	   	   	   Age-­‐standardised	  incidence	  rate	  	  
	  
CI	   	   	   	   Confidence	  Interval	  
	  
CI	   	   	   	   Conformity	  Index	  
	  
CNS	   	   	   	   Central	  Nervous	  System	  
	  
COG	   	   	   	   Children’s	  Oncology	  Group	  
	  
CR	   	   	   	   Complete	  Response	  
	  
CSI	   	   	   	   Craniospinal	  radiotherapy	  
	  
CT	   	   	   	   Computed	  Tomography	  	  
	  
CTV	   	   	   	   Clinical	  Target	  Volume	  
	  
EFS	   	   	   	   Event	  Free	  Survival	  
	  
18F-­‐FDG	  PET/CT	   flurodeoxyglucose	  positron	  emission	  tomography/	  
computed	  tomography	  
	  
FFPE	  	   Formalin	  fixed	  paraffin	  embedded	  	  
	  
68Ga-­‐DOTATATE	  PET/CT	   68Gallium	  DOTATATE	  positron	  emission	  tomography/	  
computed	  tomography	  
	  
GPOH	   German	  Paediatric	  Oncology	  Group	  
	  
GTV	   Gross	  Tumour	  Volume	  
	  
HI	   Homogeneity	  Index	  
 14 
	  
IDRF	   Image	  Defined	  Risk	  Factors	  
	  
INRC	   International	  Neuroblastoma	  Response	  Criteria	  
	  
INRG	   International	  Neuroblastoma	  Risk	  Group	  
	  
INRGSS	  	   International	  Neuroblastoma	  Risk	  Group	  Staging	  
System	  	  
	  
INPC	  	   International	  Neuroblastoma	  Pathologic	  Classification	  	  
	  
INSS	   International	  Neuroblastoma	  Staging	  System	  
	  
IMAT	   Intensity	  Modulated	  Arc	  Therapy	  
	  
IMRT	   Intensity	  Modulated	  Radiotherapy	  
	  
LuDO	   Lutetium	  DOTATATE	  
	  
MATIN	   mIBG	  and	  Topotecan	  in	  neuroblastoma	  
	  
mIBG	   	   	   	   meta-­‐iodobenzylguanidine	  
	  
MIP	  	   	   	   	   maximum	  intensity	  projection	  	  
	  
MKI	   	   	   	   Mitosis-­‐karyorrhexis	  index	  
	  
MRD	   	   	   	   Minimal	  Residual	  Disease	  
	  
MRI	   	   	   	   Magnetic	  Resonance	  Imaging	  
	  
NAT	   	   	   	   Noradrenaline	  Transporter	  Molecule	  
	  
NPID	   	   	   	   Non-­‐PTV	  Integral	  Dose	  
	  
OMS	   	   	   	   Opsoclonus	  Myoclonus	  Syndrome	  
	  
OR	   Odds	  Ratio	  
	  
OS	  	   Overall	  Survival	  
	  
PBSCT	   Peripheral	  Blood	  Stem	  Cell	  Tranplant	  
	  
PERCIST	  	   PET	  Response	  Criteria	  in	  Solid	  Tumours	  	  
	  
PD	   Progressive	  Disease	  
 15 
	  
PET	   Positron	  Emission	  Tomography	  
	  
PFS	   Progression	  Free	  Survival	  
	  
PR	   Partial	  Response	  
	  
PRRT	   Peptide	  Receptor	  Radionuclide	  Therapy	  
	  
PTV	   Planning	  Target	  Volume	  
	  
RCT	  	   Randomised	  Control	  Trial	  
	  
SCC	   Spinal	  Cord	  Compression	  
	  
SIOPEN	   International	  Society	  of	  Paediatric	  Oncology	  (Europe)	  
Neuroblastoma	  
	  
SPECT	   Single	  photon	  emission	  tomography	  
	  
SSSTR	   Somatostatin	  receptor	  
	  
TBI	   Total	  Body	  Irradiation	  	  
	  
USS	   Ultrasound	  scan	  
	  
VGPR	   Very	  Good	  Partial	  Response	  
	  






The	  majority	  of	  this	  work	  was	  carried	  out	  at	  University	  College	  London	  Hospitals	  NHS	  
Foundations	   Trust.	   It	   was	  made	   possible	   by	   the	   generous	   support	   of	   Yvonne	   and	  
Richard	  Brown	  (J-­‐A-­‐C-­‐K	  Foundation)	  and	  the	  Neuroblastoma	  Alliance.	  	  
	  
There	  are	  many	  people	  that	  I	  would	  like	  to	  thank:	  
	  
• Dr	  Mark	  Gaze,	  University	  College	  London	  Hospitals	  NHS	  Foundation	  Trust,	  to	  
whom	  I	  am	  greatly	  indebted	  for	  his	  ideas,	  enthusiasm	  and	  encouragement.	  	  
	  
• Professor	   Kathryn	   Pritchard-­‐Jones,	   Institute	   of	   Child	   Health,	   University	  
College	  London,	  for	  her	  support	  and	  supervision.	  
	  
• Dr	   Jamshed	   Bomanji	   and	   team,	   Institute	   of	   Nuclear	   Medicine,	   University	  
College	  London	  Hospitals	  NHS	  Foundation	  Trust.	  	  
	  
• Professor	   Neil	   Sebire	   and	   Alex	   Virasami,	   Department	   of	   Histopathology,	  
Great	  Ormond	  Street	  Hospital.	  The	  immunohistochemical	  analysis	  was	  made	  
possible	  by	  generous	  funding	  from	  the	  Adam	  Hay	  Fund	  of	  the	  CCLG.	  	  
	  
• Jayne	   Wilson,	   Veronica	   Moroz	   and	   Professor	   Keith	   Wheatley	   at	   Cancer	  
Research	  UK	  Clinical	  Trials	  Unit,	  University	  of	  Birmingham.	  
	  
• Caroline	  Walker,	  Matt	  Aldridge	  and	  Chris	  Stacey	  at	  University	  College	  London	  
Hospitals	  NHS	  Foundation	  Trust.	  
	  
• Finally,	  my	  thanks	  to	  my	  wonderful	  family	  -­‐	  Steve,	  Natasha	  and	  Annabelle,	  for	  

















Neuroblastoma	   was	   first	   described	   as	   a	   ‘glioma’	   in	   the	   abdomen	   of	   a	   child,	   by	   a	  
German	  physician,	  Rudolf	  Virchow,	  in	  1864.	  Between	  1901	  and	  1910	  three	  important	  
papers	  were	  published	  and	  these	  played	  an	   important	  role	   in	  defining	  the	  disease,	  
neuroblastoma	  (Rothenberg	  2009).	  	  
	  
Two	   of	   the	   physicians,	   William	   Pepper	   and	   Robert	   Hutchinson,	   both	   published	  
papers	   describing	   the	   pattern	   of	   spread	   of	   neuroblastoma,	   although	   they	   both	  
thought	  they	  were	  describing	  a	  ‘sarcoma’.	  In	  1901,	  Pepper	  described	  the	  distinctive	  
pattern	  in	  infants,	  of	  adrenal	  tumours	  and	  massive	  liver	  involvement,	  which	  we	  now	  
know	   as	   stage	  MS	   disease	   (Pepper	   1901).	   Robert	   Hutchinson,	   in	   1907,	   reported	   a	  
series	  of	  older	  children	  with	  disease	  spread	  to	  the	  orbit	  and	  skull	  as	  the	  first	  sign	  of	  
their	  disease,	  which	  we	  now	  recognise	  as	  stage	  M	  (Hutchinson	  1907).	  	  
	  
James	  Homer	  Wright,	   in	  1910,	  was	  the	  first	  person	  to	  understand	  and	  describe	  the	  
tumour	  arising	  from	  primitive	  neural	  cells	  and	  to	  name	  the	  disease	  “neuroblastoma”.	  
He	   recognised	   that	   adrenal	   tumours	   in	   children,	  with	   neural	   fibrils	   and	  bundles	   of	  
cells	   (rosettes),	   resembled	   the	   morphology	   of	   the	   foetal	   adrenal	   (Wright	   1910).	  




1.2 Embryology	  	  
	  
Neuroblastoma	   is	   an	   embryonal	   tumour	   derived	   from	   the	   sympathetic	   nervous	  
system.	  The	  embryonal	  structure	  that	  gives	  rise	  to	  the	  sympathetic	  nervous	  system	  
is	   the	   neural	   crest,	   located	   on	   both	   sides	   of	   the	   developing	   spinal	   cord.	   In	   the	  
developing	   embryo,	   neuroblasts	   migrate	   along	   the	   neuraxis	   and	   populate	  
sympathetic	  ganglia	   in	   the	  adrenal	  medulla	  and	  other	  sites.	   The	  cell	  of	  origin	   for	  a	  
neuroblastoma	   is	   thought	   to	   be	   a	   developing	   precursor	   cell	   derived	   form	   neural-­‐
crest	   tissues.	   The	   embryological	   development	   explains	   why	   neuroblastomas	   can	  
arise	  at	  primary	  sites	  distributed	  along	  the	  length	  of	  the	  body	  from	  the	  neck	  to	  the	  





Neuroblastoma	   accounts	   for	   about	   7%	   of	   all	   childhood	   cancers	   and	   is	   the	  
commonest	   extra-­‐cranial	   solid	   tumour	   of	   childhood.	   The	   Automated	   Childhood	  
Cancer	  Information	  System	  (AACIS)	  is	  a	  framework	  set	  up	  to	  collect	  and	  present	  data	  
on	   childhood	   cancer	   through	   collaboration	   through	   several	   European	   countries.	   A	  
report	  by	   the	  ACCIS	   in	   the	  European	   Journal	  of	  Cancer	   in	  2006	   reported	   incidence	  
and	   survival	   for	   19	   countries	   from	   59	   cancer	   registries	   in	   Europe.	   The	   age-­‐
standardised	   incidence	   rate	   (ASR)	   of	   neuroblastoma	   in	   Europe	   between	   1988	   and	  
 20 
1997	   was	   10.9	   cases	   per	   million	   children	   and	   was	   highest	   in	   infants	   (52.6).	   The	  
incidence	  of	  neuroblastoma	  was	  highest	  in	  the	  first	  year	  of	  life,	  declined	  afterwards	  
and	  was	  rare	  beyond	  10	  years	  of	  age.	  (Spix	  2006)	  
	  
The	   average	   5	   year	   survival	   from	   neuroblastoma	   from	   1988-­‐1997	   in	   Europe	   as	   a	  
whole	  was	  59%.	  There	  was	  a	  significant	  effect	  of	  age	  on	  survival	  with	  infants	  having	  a	  
5	  year	  survival	  of	  84%,	  those	  aged	  between	  1	  -­‐4	  years	  47%	  and	  the	  10-­‐14	  year	  old	  
age	   group	   having	   a	   5	   year	   survival	   of	   38%.	   It	   is	   noted	   that	   data	   on	   the	   stage	   of	  
disease	  was	  not	  collected	  for	  the	  ACCIS	  report.	  (Spix	  2006)	  
	  
There	   were	   also	   significant	   regional	   differences	   in	   survival	   across	   Europe	   with	   all	  
ages	  combined	  –	  47%	  in	  the	  East,	  49%	  in	  the	  British	  Isles,	  62%	  in	  the	  South,	  67%	  in	  
the	  West	  and	  57%	  in	  the	  North	  (Spix	  2006).	  
	  
There	  was	  evidence	  from	  the	  same	  report	  that	  survival	  for	  neuroblastoma	  has	  been	  
improving	  over	  time.	  A	  significant	  increase	  in	  5-­‐year	  survival	  was	  seen	  from	  the	  late	  
1970’s	  (21%)	  to	  the	  mid	  1990’s	  (45%)	  (p<0.001)	  (Spix	  2006).	  
	  
With	  regards	  to	  the	  UK	  alone,	  there	  were	  only	  on	  average	  92	  patients	  aged	  between	  
0-­‐14	  years	  diagnosed	  annually	  in	  the	  UK	  between	  2001	  and	  2007	  (National	  Registry	  
2010).	   This	  means	   that	   there	   are	   too	   few	   patients	   for	   UK-­‐only	   based	   randomised	  
control	  trials	  and	  international	  collaboration	  is	  essential.	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Although	  neuroblastoma	  accounts	   for	  approximately	  7%	  of	  all	   cases	  of	  malignancy	  
diagnosed	  in	  children	  under	  the	  age	  of	  16	  years,	  it	  causes	  a	  disproportionate	  number	  
of	  deaths	  within	  this	  age	  group	  (approximately	  15%).	  
	  
The	   aetiology	   of	   neuroblastoma	   remains	   poorly	   understood.	   No	   definitive	  
association	  has	  been	  found	  between	  maternal	  or	  paternal	  exposures	  or	  occupations,	  
or	  other	  potential	  factors	  (Heck	  2009).	  Genetic	  factors	  are	  likely	  to	  play	  a	  major	  role	  
as	  discussed	  below.	  
	  
1.4	  Genetics	  
1.4.1	  Familial	  Neuroblastoma	  
	  
A	  family	  history	  of	  neuroblastoma	  is	  found	  in	  approximately	  1-­‐2%	  of	  cases.	  There	  is	  
usually	  an	  autosomal	  dominant	  pattern	  of	  inheritance	  with	  incomplete	  penetrance.	  	  
	  
The	  majority	  of	  hereditary	  neuroblastomas	  can	  be	  accounted	  for	  by	  mutations	  in	  the	  
tyrosine	  kinase	  domain	  of	   the	  anaplastic	   lymphoma	  kinase	   (ALK)	  oncogene	   (Mosse	  
2008).	   	  Germ-­‐line	  mutations	  encode	   for	   single	  base	   substitutions	   in	   key	   regions	  of	  
the	  kinase	  domain	  resulting	   in	  constitutive	  activation	  of	  ALK.	  Somatic	  mutations	  of	  




The	   other	   germ	   line	   mutation	   identified	   in	   familial	   neuroblastoma	   is	   PHOX2B.	  
(Trochet	   2004,	   Mosse	   2004).	   Two	   neural	   crest	   developmental	   disorders	   are	  
associated	   with	   PHOX2B	   mutations	   –	   Hirschsprung’s	   disease	   and	   Ondine’s	   curse.	  
Somatic	  mutations	  in	  PHOX2B	  are	  rare.	  	  
	  
1.4.2	  Sporadic	  Neuroblastoma	  
	  
The	   vast	  majority	   of	   neuroblastomas	   are	   sporadic.	   The	  most	   common	   cytogenetic	  
aberrations	  include	  MYCN	  amplification,	  and	  segmental	  chromosomal	  abnormalities	  
such	   as	   deletions	   of	   chromosome	   1p,	   3p,	   11q	   and	   gain	   of	   1q,	   2p	   and	   17q.	   The	  
prognostic	   significance	  of	   these	   is	   discussed	   in	   the	   risk	   stratification	   section	  below	  
(section	  1.8.3).	  
	  
Neuroblastoma	  patients	  are	  risk	  stratified	  into	  prognostic	  groups	  and	  these	  are	  used	  
to	  guide	  treatment	  choice	  and	  indicate	  prognosis.	  The	  groups	  are	  low,	  intermediate	  
and	   high	   risk	   and	   are	   stratified	   by	   disease	   stage,	   age,	   MYCN	   amplification,	  
histopathology,	   and	   allelic	   loss	   of	   chromosomal	   regions	   at	   1p	   and	   11q	   and	   DNA	  
ploidy.	  Despite	  this,	  there	  are	  still	  some	  low	  and	  intermediate	  risk	  patients	  who	  still	  
die	   from	   their	   disease	   and	   some	   low	   risk	   patients	   who	   would	   potentially	  
spontaneously	  regress	  and	  could	  be	  spared	  treatment.	  There	  is	  increasing	  evidence	  
that	  many	  different	  biological	   subgroups	  of	  neuroblastoma	  exist	  and	  differ	   in	   their	  
gene	   expression	   patterns.	   This	   will	   hopefully,	   in	   the	   future,	   help	   us	   to	   improve	  
classification	  of	  neuroblastoma	  patients	  (Oberthuer	  2010).	  A	  retrospective	  study	  by	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the	  SIOPEN/COG/GPOH	  groups	  used	  a	  59-­‐gene	  expression	  signature	  and	  found	  it	  to	  
be	   an	   accurate	   predictor	   of	   outcome	   in	   patients	   with	   neuroblastoma	   (Vermeulen	  





Neuroblastoma	   was	   considered	   to	   be	   a	   good	   candidate	   disease	   for	   a	   screening	  
programme	  for	  several	  reasons	  (Morris	  2002):	  
1. Children	  diagnosed	  under	  the	  age	  of	  18	  months	  are	  known	  to	  have	  a	  better	  
prognosis	  and	  therefore	  diagnosing	  infants	  early	  with	  screening	  was	  hoped	  to	  
have	  an	  impact	  on	  outcome	  
2. Children	  presenting	  with	  advanced	  disease	  have	  a	  worse	  prognosis	  
3. There	   was	   a	   simple	   screening	   test	   available	   –	   measuring	   catecholamine	  
metabolites	   in	  the	  urine,	  sampled	  by	  blotting	  wet	  nappies	  with	   filter	  paper.	  
This	   screening	   test	   had	   been	   found	   to	   detect	   90%	   of	   neuroblastomas	   in	  
children	  screened	  (Tuchman	  1987).	  
	  
Mass	  screening	  was	  adopted	  in	  Japan	  and	  many	  screening	  studies	  were	  performed	  
in	  the	  early	  1990’s	  mostly	   in	  Canada,	  Germany,	  France,	  Austria,	   Italy,	  United	  States	  
and	  Australia.	  	  The	  two	  studies	  measuring	  mortality	  from	  Canada	  and	  Germany	  were	  
reported	   in	   the	   New	   England	   Journal	   of	  Medicine	   in	   2002	   and	   both	   showed	   that	  
screening	   infants	   for	   neuroblastoma	   did	   not	   reduce	   mortality	   from	   the	   disease	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(Woods	   2002,	   Schilling	   2002).	   The	   studies	   showed	   that	   screening	   led	   to	   ‘over-­‐
diagnosis’	   and	   therefore	   ‘over-­‐treatment’	   by	   identifying	   tumours	   that	   would	   have	  
spontaneously	   regressed.	  There	   is	   therefore,	  no	  national	   screening	  programme	   for	  

















1.6	  Clinical	  Presentation	  
	  
The	  clinical	  manifestations	  of	  neuroblastoma	  are	  variable	  depending	  on	   the	  site	  of	  
the	  primary	  tumour	  and	  whether	  metastatic	  disease	  is	  present	  or	  not.	  Symptoms	  of	  
neuroblastomas	   can	   be	   divided	   into	   those	   caused	   by	   the	   primary	   tumour,	   those	  
cause	   by	   the	   presence	   of	   metastases	   of	   those	   caused	   by	   the	   co-­‐existence	   of	   a	  
paraneoplastic	  syndrome.	  
	  
1.6.1	  Primary	  Tumours	  
	  
Neuroblastoma	   is	   an	   embryonal	   tumour	   derived	   from	   cells	   of	   neural	   crest	   origin,	  
which	  form	  the	  sympathetic	  nervous	  system.	  Neuroblastomas	  most	  frequently	  arise	  
in	   the	   adrenal	  medulla	  but	   can	  be	   found	   in	  other	   sites	   related	   to	   the	   sympathetic	  
chain	   or	   paraganglia.	   Approximately	   70%	   of	   primaries	   are	   found	   in	   the	   abdomen	  
(divided	  in	  to	  supra-­‐renal	  and	  retroperitoneal	  locations),	  25%	  in	  the	  thorax	  and	  5%	  in	  
the	  pelvis.	  
	  
A	  child	  with	  a	  hard,	   fixed,	  abdominal	  mass	  causing	  mild	  abdominal	  discomfort	   is	  a	  
frequent	   presentation	   of	   a	   primary	   tumour.	   If	   the	   tumour	   is	   compressing	   renal	  
vessels,	  hypertension	  may	  be	  present.	  Primaries	  presenting	  in	  the	  cervical	  region	  can	  
be	  mistaken	  for	  cervical	  lymph	  nodes	  and	  primaries	  in	  the	  cervical	  or	  thoracic	  region	  
can	  present	  with	  a	  Horner’s	  syndrome.	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Primaries	   in	   the	   thoracic,	   cervical,	   abdominal	   or	   pelvic	   region	   can	   extend	   into	   the	  
neural	   foramina	  and	  compress	  nerve	  roots	  or	  the	  spinal	  cord	  (dumb-­‐bell	   tumours).	  
Up	   to	   5%	  of	   newly	  diagnosed	  patients	   can	  have	  neurological	   signs	   related	   to	   cord	  
impingement	  or	  compression	  (de	  Bernardi	  2005)	  (see	  section	  1.12.1).	  
	  
1.6.2	  Metastatic	  Disease	  
	  
The	  commonest	  sites	  for	  metastases	  in	  neuroblastoma	  are	  bone,	  bone	  marrow,	  liver	  
and	  lymph	  nodes.	  	  Bone	  metastases	  are	  often	  painful	  resulting	  in	  an	  unwell,	  irritable	  
child	  at	  presentation.	  A	   limp	  may	  be	  present	  due	   to	  bone	  metastases	   in	   the	   lower	  
limbs	  or	   the	  pelvis.	   If	   there	   is	  bone	  marrow	   involvement	  this	  usually	  presents	  with	  
anaemia	   and	   later	   thrombocytopenia.	   Orbital	   metastatic	   masses	   can	   cause	  
proptosis.	  	  
	  
Infants	  with	  stage	  MS	  disease	  can	  present	  with	  hugely	  enlarged	  livers	  and	  can	  cause	  
significant	   respiratory	   distress.	   These	   patients	   can	   also	   have	   non-­‐tender,	   bluish	   in	  








1.6.3	  Paraneoplastic	  Syndromes	  
	  
Hypertension,	  tachycardia	  and	  sweating	  are	  less	  common	  in	  neuroblastomas	  than	  in	  
phaeochromocytomas.	  
	  
Opsoclonus	   myoclonus	   syndrome	   is	   a	   rare	   presentation	   of	   neuroblastoma	   and	  
consists	   of	   myoclonic,	   irregular,	   jerking,	   random	   eye	   movements	   and	   cerebellar	  
ataxia.	  It	  occurs	  in	  a	  reported	  2-­‐4%	  of	  children	  with	  neuroblastoma.	  The	  syndrome	  is	  
usually	   associated	  with	   good-­‐prognosis	   disease	   but	   70-­‐80%	  of	   children	  will	   be	   left	  
with	  long-­‐term	  neurological	  deficits	  (see	  section	  1.12.3).	  
	  
Kerner-­‐Morrison	   syndrome	   is	   a	   syndrome	   caused	   by	   secretion	   of	   vasoactive	  
intestinal	  peptide	  (VIP)	  and	  causes	  intractable,	  watery	  diarrhoea.	  It	  usually	  resolves	  









1.7	  Disease	  Assessment	  
	  
	  
Being	  able	  to	  accurately	  stage	  patients	  with	  neuroblastoma	  is	  essential.	  The	  stage	  of	  
disease	  not	  only	  has	  prognostic	   implications	  but	  also	  guides	  the	  treatment	  strategy	  
for	   individual	  patients.	  Having	  an	  International	  staging	  and	  classification	  system	  (as	  
discussed	   in	   section	   1.8)	   facilitates	   the	   standardisation	   of	   risk-­‐based	   clinical	   trials	  
internationally.	  Guidelines	  by	  the	  International	  Neuroblastoma	  Risk	  Group	  (INRG)	  on	  
the	   imaging	   and	   staging	   of	   neuroblastic	   tumours	   have	   recently	   been	   published	  
(Brisse	  2011).	  
	  
A	  definitive	  diagnosis	  of	  neuroblastoma	  is	  normally	  made	  by	  biopsy	  of	  an	  affected	  
site	  but	  diagnosis	  is	  also	  considerably	  helped	  by	  other	  investigations	  listed	  below	  
and	  these	  are	  also	  required	  for	  the	  full	  staging	  of	  the	  disease.	  	  
	  
1.7.1	  Primary	  Tumour	  Assessment	  
	  
Children	  who	  present	  with	  an	  abdominal	  mass	  are	  usually	  initially	  investigated	  with	  
an	  ultrasound	  scan	  (USS)	  as	  it	  is	  a	  non-­‐invasive	  procedure	  and	  is	  widely	  available.	  It	  is	  
often	  able	  to	  guide	  the	  radiologist	  to	  the	  best	  area	  to	  perform	  a	  biopsy	  or	  to	  image	  
next	  with	  a	  Magnetic	  Resonance	  Imaging	  (MRI)	  or	  computed	  tomography	  (CT)	  scan.	  
USS	   does	   have	   limitations	   and	   the	   INRG	   recommends	   an	   MRI	   or	   CT	   as	   well	   for	  
accurate	  staging	  of	  the	  primary	  tumour	  and	  the	  identification	  of	  Imaged	  Defined	  Risk	  
Factors	  (IDRF’s)	  (Brisse	  2011).	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With	   regards	   to	   CT	   versus	   MRI,	   nowadays	   there	   may	   be	   not	   much	   difference	   in	  
image	  quality	  between	   the	   two	  modalities.	  A	  CT	   scan	  has	   the	  advantage	   that	   it:	   is	  
readily	  available	  in	  most	  centres;	  is	  fast	  to	  acquire	  the	  images;	  is	  easily	  reproducible	  
between	  centres;	  can	  in	  many	  cases	  be	  done	  without	  an	  anaesthetic	  as	  it	  is	  quicker	  
and	  less	  claustrophobic	  than	  an	  MRI;	  can	  be	  good	  for	  surgical	  planning	  and	  assessing	  
vascular	  invasion.	  But,	  CT	  does	  involve	  a	  dose	  of	  radiation	  to	  the	  child,	  and,	  often	  CTs	  
may	  be	  done	  without	  contrast	  or	  performed	  on	  adult	  protocols	   resulting	   in	  poorer	  
image	  quality.	  There	  can	  also	  be	  poor	  soft	  tissue	  definition	  with	  CT	  in	  children.	  CT	  is	  
needed	   for	   full	   evaluation	   of	   lung	   parenchyma	   to	   demonstrate	   pulmonary	  
metastases,	  although	  these	  are	  uncommon.	  
	  
MRI	  scans	  do	  not	  involve	  a	  radiation	  exposure	  for	  the	  child	  but	  there	  is	  often	  a	  lack	  
of	  reproducibility	  of	  scans	  between	  centres	  and	  scans	  take	  a	  lot	  longer	  to	  acquire	  
which	  normally	  involve	  a	  general	  anaesthetic	  in	  babies	  and	  younger	  children.	  MRI	  is	  
particularly	  useful	  for	  assessing	  intra-­‐spinal	  masses,	  lymph	  node	  involvement	  and	  
marrow	  invasion.	  Whole	  body	  MRI	  could	  be	  useful	  for	  assessing	  metastatic	  disease	  








1.7.2	  Metastatic	  Disease	  Assessment	  
	  
Functional	   imaging	   with	   123I-­‐mIBG	   is	   the	   gold	   standard	   imaging	   modality	   for	  
diagnosis,	   staging	   and	   response	   assessment	   of	   metastatic	   neuroblastoma.	   The	  
majority	  of	  children	  with	  neuroblastoma,	  approximately	  90%,	  take	  up	  mIBG.	  mIBG	  is	  
a	  guanethidine	  derivative	  and	  can	  be	  labelled	  with	  123I	  for	  imaging	  or	  131I	  for	  therapy.	  
There	   is	   no	   physiological	   uptake	   of	  mIBG	   in	   bone	   or	   bone	  marrow	   and	   therefore	  
mIBG	  scintigraphy	  is	  an	  accurate	  method	  for	  detecting	  metastases	  in	  cortical	  bone	  or	  
bone	  marrow.	  	  
	  
 123I-­‐mIBG	  is	  preferred	  to	  131I-­‐mIBG	  for	  diagnostic	  imaging	  as	  it	  has	  a	  shorter	  half-­‐life	  
therefore	   reducing	   the	   radiation	   exposure.	   The	   γ	   emissions	   are	   also	   of	   a	   lower	  
energy	  contributing	  to	  a	  lower	  radiation	  exposure	  and	  making	  them	  better	  suited	  to	  
γ	  cameras.	  123I-­‐mIBG	  scintigraphy	  has	  a	  high	  sensitivity	  (90%)	  and	  specificity	  (100%)	  
in	  neuroblastoma	  (Lumbroso	  1988,	  Jacobs	  1990).	  It	   is	  essential	  however,	  that	  mIBG	  
scintigraphy	   is	   performed	   with	   standardised	   procedures	   (Bombardieri	   2010)	   and	  
reported	   in	   a	   standardised	   way	   to	   improve	   consistencies	   in	   reporting	   between	  
different	   institutions.	  The	   INRG	  task	  force	  has	  recently	  published	  guidelines	  on	  this	  	  
(Matthay	  2010).	  	  	  
	  
Although	   123I-­‐mIBG	   scintigraphy	   is	   the	   current	   gold	   standard	   imaging	  modality	   for	  
high-­‐risk	  neuroblastoma	  metastatic	  disease,	  it	  does	  has	  limited	  spatial	  resolution	  and	  
small	  amounts	  of	  bone	  marrow	  disease	  can	  go	  undetected	  by	  this	  method.	  Bilateral	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bone	   marrow	   aspirations	   and	   trephines	   are	   still	   therefore	   essential	   for	   detecting	  
bone	  marrow	  disease.	  	  
	  
The	   use	   of	   mIBG	   SPECT	   (single	   photon	   emission	   tomography)	   can	   improve	   the	  
visualisation	  of	  small	  foci	  of	  neuroblastoma	  that	  can	  be	  difficult	  to	  detect	  on	  planar	  
scintigraphy	  and	  is	  becoming	  more	  widely	  available.	  SPECT	  can	  also	  be	  fused	  with	  CT	  
images	  to	  improve	  the	  anatomical	  localisation.	  (Gelfrand	  1994,	  Rozovsky	  2008).	  	  
	  
Historically,	   for	   patients	   with	  mIBG	   negative	   disease,	   a	   99mTc	  MDP	   bone	   scan	   has	  
been	   recommended.	   These	   scans	   are	   often	   difficult	   to	   interpret	   in	   children	   with	  
growing	   bones	   and	   have	   a	   lower	   specificity	   and	   sensitivity	   compared	   to	   123I-­‐mIBG	  
scintigraphy.	  	  
	  
The	   role	  of	   124I-­‐mIBG	  PET/CT	   is	   currently	   under	   investigation	   and	   could	  potentially	  
improve	  the	  spatial	  resolution	  and	  sensitivity	  of	  imaging	  with	  mIBG.	  It	  combines	  the	  
advantage	   of	   the	   specificity	   and	   sensitivity	   of	   mIBG	   with	   the	   superior	   spatial	   and	  
anatomical	   resolution	  of	  PET/CT.	   124I	   is	   cyclotron	  produced	  with	  a	  4.2	  day	  half-­‐life.	  
The	  disadvantage	  is	  that	  124I	  also	  produces	  significant	  high-­‐energy	  gamma	  emissions,	  
which	  makes	  image	  acquisition	  more	  complicated.	  
	  
Several	  other	  functional	  imaging	  modalities	  have	  emerged	  in	  recent	  years	  including	  
18F-­‐FDG	  PET/CT,	  18F-­‐DOPA	  PET/CT	  and	  68Ga-­‐DOTATATE	  PET/CT	  (Sharp	  2009,	  Piccardo	  
2012,	   Kroiss	   2011).	   It	   is	   still	   unclear	   what	   their	   role	   will	   be	   and	   these	   will	   be	  
discussed	  in	  detail	  in	  Chapter	  5.	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Often	   patients	  with	   aggressive	   high-­‐risk	   neuroblastoma	  will	   have	   dissemination	   of	  
disease	   to	   their	   bone	   marrow.	   Accurate	   detection	   of	   bone	   marrow	   disease	   is	  
therefore	   essential	   for	   accurate	   staging	   and	   treatment	   stratification.	   The	   INRGSS	  
states	  that	  bone	  marrow	  involvement	  should	  be	  assessed	  by	  two	  aspirates	  and	  two	  
biopsies	   from	   bilateral	   sites	   (Monclair	   2008).	   This	   should	   be	   performed	   by	   the	  
cytological	   screening	  of	   bone	  marrow	  aspirates	   and	   the	  histological	   assessment	  of	  
bone	  marrow	   biopsies.	   The	   INRGSS	   defines	   cut	   off	   of	   bone	  marrow	   infiltration	   of	  
>10%	   tumour	   cells	   as	   the	   level	   to	   be	   able	   to	   distinguish	   stage	  M	   from	   stage	  MS	  
disease.	  
	  
The	   INRG	   Task	   Force	   has	   published	   and	   defined	   standardised	   procedures	   for	   the	  
determination	   of	   minimal	   residual	   disease	   (MRD)	   by	   immunocytochemistry	   and	  
quantitative	   reverse	   transcriptase-­‐polymerase	   chain	   reaction.	   The	   INRG	   standard	  
operating	   procedures	   define	   methods	   for	   evaluating	   and	   processing	   peripheral	  
blood,	   bone	   marrow	   and	   peripheral	   blood	   stem	   cell	   harvest.	   These	   should	   allow	  
standardisation	   of	   procedures	   and	   facilitate	   their	   use	   in	   clinical	   trials	   on	   a	   multi-­‐
centre	  and	   international	  basis	   (Beiske	  2009).	  Although	  MRD	  is	  used	  clinically	   in	  the	  
management	   of	   Acute	   Lymphoblastic	   Leukaemia,	   the	   measurement	   of	   MRD	   in	  








1.8	  Risk	  Stratification	  	  
	  
Neuroblastoma	  is	  highly	  heterogeneous	  in	  its	  clinical	  behaviour	  and	  can	  range	  from	  
the	   near	   benign,	  with	   spontaneous	   regression	   in	   some	   cases,	   to	   highly	   aggressive	  
disease	   which	   is	   fatal,	   despite	   the	   use	   of	   intensive	   multi-­‐modality	   therapy.	   It	   is	  
essential	   therefore	   that	   neuroblastoma	   patients	   are	   adequately	   staged	   and	   risk	  
stratified	   depending	   on	   prognostic	   variables.	   Risk	   stratification	   should	   enable	  
targeted	  and	  tailored	  therapy	   for	  patients	  with	   the	  aim	  of	   improving	  outcomes	   for	  
high-­‐risk	  patients	  and	  reducing	  the	  toxicity	  of	  treatment	  for	  those	  who	  require	  less	  
intensive	  therapies.	  
	  
The	  International	  Neuroblastoma	  Risk	  Group	  (INRG)	  was	  formed	  in	  2004	  when	  four	  
cooperative	   groups	   encompassing	   Australia,	   Europe,	   Japan	   and	   North	   America	  
agreed	  to	  pool	   their	   information	   (Cohn	  2009).	  A	  database	  of	   thousands	  of	  children	  
diagnosed	  with	  neuroblastoma	  was	  formed	  and	  the	  resulting	  publications	  have	  had	  
a	  large	  impact	  on	  the	  management	  of	  neuroblastoma	  around	  the	  world.	  
 
The	   INRG	  Task	  Force	   looked	  at	  over	  8000	  patients	  with	  neuroblastoma	  from	  North	  
America,	   Australia,	   Europe	   and	   Japan	   and	   examined	   the	   statistical	   and	   clinical	  
significance	   of	   13	   potential	   prognostic	   factors	   (Cohn	   2009).	   The	   stage	   of	  
neuroblastoma,	   age,	   histologic	   category,	   grade	   of	   tumour	   differentiation,	   MYCN	  
oncogene	  status,	  chromosome	  11q	  status	  and	  DNA	  ploidy	  were	  all	  highly	  statistically	  
significant	  for	  predicting	  outcome.	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These	   prognostic	   variables	   formed	   the	   foundation	   for	   the	   International	  
Neuroblastoma	   Risk	   Group	   (INRG)	   Consensus	   Pre	   treatment	   Classification	   (Cohn	  
2009)	  and	  each	  of	  these	  prognostic	  variables	  is	  discussed	  in	  more	  detail	  below.	  
	  
1.8.1	  Stage	  	  
 
Staging	  systems	  for	  neuroblastoma	  have	  evolved	  over	  time.	  The	  first	  staging	  system	  
used	  for	  neuroblastoma	  was	  the	  Evans	  classification	  proposed	  in	  1971	  (Evans	  1971).	  
Following	  on	   from	  this,	   there	  were	  several	  different	  staging	  systems	   in	  use	  around	  
the	   world,	   which	  made	   it	   very	   difficult	   to	   compare	   clinical	   trials	   and	   results	   from	  
around	  the	  world.	   In	  a	   rare	  disease	   like	  neuroblastoma,	   international	  collaboration	  
and	  comparison	  of	  results	  is	  an	  essential	  step	  in	  improving	  outcomes.	  	  
	  
In	  1986,	  an	   international	  meeting	  was	  held	  to	  establish	  a	  consensus	  on	  the	  criteria	  
for	   diagnosis,	   staging	   and	   response	   assessment	   of	   neuroblastoma.	   The	   staging	  
system	  proposed	  was	   the	   International	  Neuroblastoma	  Staging	  System	   (INSS).	   This	  
was	   originally	   published	   in	   1988	   (Brodeur	   1988)	   and	   subsequently	   revised	   in	   1993	  
(Brodeur	  1993).	  The	  INSS	  was	  based	  on	  the	  post-­‐surgical	  assessment	  of	  disease	  and	  















Stage	   Definition	  
1	   Localised	  tumour	  with	  complete	  gross	  excision,	  with	  or	  without	  microscopic	  residual	  
disease;	  representative	  ipsilateral	  lymph	  nosed	  negative	  for	  tumour	  microscopically	  
(nodes	  attached	  to	  and	  removed	  with	  the	  primary	  tumour	  may	  be	  positive)	  
2A	   Localised	  tumour	  with	  incomplete	  gross	  excision;	  representative	  ipsilateral	  non-­‐adherent	  
lymph	  nodes	  negative	  for	  tumour	  microscopically	  
2B	   Localised	  tumour	  with	  or	  without	  complete	  gross	  excision,	  with	  ipsilateral	  non-­‐adherent	  
lymph	  nodes	  positive	  for	  tumour.	  Enlarged	  contralateral	  lymph	  nodes	  must	  be	  negative	  
microscopically.	  
3	   Unresectable	  unilateral	  tumour	  infiltrating	  across	  the	  midline,	  with	  or	  without	  regional	  
lymph	  node	  involvement;	  or	  localised	  unilateral	  tumour	  with	  contralateral	  regional	  lymph	  
node	  involvement;	  or	  midline	  tumour	  with	  bilateral	  extension	  by	  infiltration	  
(unresectable)	  or	  by	  lymph	  node	  involvement	  
4	   Any	  primary	  tumour	  with	  dissemination	  to	  distant	  lymph	  nodes,	  bone,	  bone	  marrow,	  
liver,	  skin	  and	  /or	  other	  organs	  (except	  as	  defined	  for	  4S)	  
4S	   	  Localized	  primary	  tumour	  (as	  defined	  for	  stage	  1,2A	  or	  2B)	  with	  dissemination	  limited	  to	  




In	   recent	   years,	   a	   new	   staging	   system	  has	   been	  developed	  by	   the	   INRG.	   This	   new	  
staging	   system	  enables	   the	   stratification	  of	   patients	   at	   diagnosis	   rather	   than	  post-­‐
surgery	  and	  therefore	  removes	  the	  variation	  in	  the	  extent	  of	  surgery	  or	  the	  variation	  
in	   definitions	   of	   operability.	   The	   International	   Neuroblastoma	   Risk	   Group	   Staging	  
System	   (INRGSS)	   was	   published	   in	   2009	   and	   classifies	   patients	   at	   diagnosis	   and	  
before	  treatment	  into	  one	  of	  four	  groups	  (see	  Figure	  1.2)	  (Monclair	  2009).	  Allocation	  
to	   a	   particular	   stage	   is	   based	   on	   the	   local	   extent	   of	   the	   primary	   tumour	   and	   the	  
absence	  or	  presence	  of	  metastatic	  disease.	  	  
	  
It	  is	  important	  to	  have	  an	  understanding	  of	  the	  both	  of	  the	  staging	  systems	  as	  much	  










Within	  the	  INRGSS,	  the	  primary	  tumour	  is	  assessed	  using	  USS,	  MRI	  and/or	  CT	  for	  the	  
absence	  or	  presence	  of	  image	  defined	  risk	  factors	  (IDRF’s).	  The	  IDRF’s	  are	  surrogates	  
for	   surgical	   risk.	   They	   have	   been	   shown	   to	   predict	   for	   the	   likelihood	   of	   surgical	  
complications	  and	  are	  able	  to	  predict	  the	  likelihood	  of	  a	  complete	  surgical	  resection	  
of	  the	  primary	  tumour	  (see	  Figure	  1.3)	  (Simon	  2008,	  	  De	  Bernardi	  2008).	  
	  
 
123I-­‐mIBG	   is	   the	   gold-­‐standard	   imaging	   modality	   for	   evaluating	   metastatic	   disease	  
but	   this	   is	   supplemented	   with	   bone	   marrow	   disease	   evaluation	   (bone	   marrow	  
aspirates	  and	  trephines).	  	  
	  
Patients	  with	  distant	  metastases	  are	  defined	  as	  stage	  M	  unless	  they	  meet	  the	  strict	  





Stage	   Description	  
L1	   Localized	  tumour	  not	  involving	  vital	  structures	  as	  defined	  by	  the	  list	  
of	  image-­‐defined	  risk	  factors	  and	  confined	  to	  one	  body	  compartment	  
L2	   Loco	  regional	  tumour	  with	  presence	  of	  one	  or	  more	  image-­‐defined	  
risk	  factors	  
M	   Distant	  metastatic	  disease	  (except	  stage	  MS)	  
MS	   Metastatic	  disease	  in	  children	  younger	  than	  18	  months	  with	  








Ipsilateral	  tumour	  extension	  within	  two	  body	  compartments	  
• Neck-­‐chest,	  chest	  abdomen,	  abdomen-­‐pelvis	  
Neck	  
• Tumour	  encasing	  carotid	  and/or	  vertebral	  artery	  and/or	  internal	  jugular	  vein	  
• Tumour	  extending	  to	  the	  base	  of	  skull	  
• Tumour	  compressing	  the	  trachea	  
Cervico-­‐thoracic	  junction	  
• Tumour	  encasing	  brachial	  plexus	  roots	  
• Tumour	  encasing	  subclavian	  vessels	  and/or	  vertebral	  and/or	  carotid	  artery	  
• Tumour	  encasing	  the	  trachea	  
Thorax	  
• Tumour	  encasing	  the	  aorta	  and/or	  major	  branches	  
• Tumour	  compressing	  the	  trachea	  and/or	  principal	  bronchi	  
• Lower	  mediastinal	  tumour,	  infiltrating	  the	  costo-­‐vertebral	  junction	  between	  T9	  and	  T12	  
Thoraco-­‐abdominal	  
• Tumour	  encasing	  the	  aorta	  and/or	  vena	  cava	  
Abdomen/pelvis	  
• Tumour	  infiltrating	  the	  porta	  heaptis	  and/or	  the	  hepatoduodenal	  ligment	  
• Tumour	  encasing	  branches	  of	  the	  superior	  mesenteric	  artery	  at	  the	  mesenteric	  root	  
• Tumour	  encasing	  the	  origin	  of	  the	  coeliac	  axis,	  and/or	  of	  the	  superior	  mesenteric	  artery	  
• Tumour	  invading	  one	  or	  both	  renal	  pedicles	  
• Tumour	  encasing	  the	  aorta	  and/	  or	  vena	  cava	  
• Tumour	  encasing	  the	  iliac	  vessels	  
• Pelvic	  tumour	  crossing	  the	  sciatic	  notch	  
Intraspinal	  tumour	  whatever	  the	  location	  provided	  that:	  
• More	  than	  one	  third	  of	  the	  spinal	  canal	  in	  the	  axial	  plane	  is	  invaded	  and/or	  
• the	  perimedullary	  leptomeningeal	  spaces	  are	  not	  visible	  and/or	  
• 	  the	  spinal	  signal	  is	  abnormal	  
Infiltration	  of	  adjacent	  organs/	  structures	  
• Pericardium,	  diaphragm,	  kidney,	  liver,	  duodeno-­‐pancreatic	  block,	  and	  mesentery	  
Conditions	  to	  be	  recorded,	  but	  not	  considered	  IDRF’s	  
• Multifocal	  primary	  tumours	  
• Pleural	  effusion,	  with	  or	  without	  malignant	  cells	  









The	  stage	  of	  disease	   is	  highly	  predictive	  of	  outcome	   in	  neuroblastoma.	  Those	  with	  
metastatic	   disease	   (part	   from	   stage	  MS)	   have	   a	   poorer	   outcome.	  Within	   the	   INRG	  
patients	  evaluated	  –	  5	  year	  EFS	  was	  35%	  for	  INSS	  stage	  4	  disease	  compared	  to	  83%	  
for	  stage	  1,2,3	  or	  4S	  disease	  (p<0.0001).	  5	  Year	  OS	  was	  42%	  for	  stage	  4	  compared	  to	  





Age	  is	  a	  powerful	  prognostic	  factor	  and	  traditionally	  an	  age	  of	  1	  year	  was	  used	  as	  the	  
cut	  off	  for	  prognostic	  grouping.	  A	  report	  and	  data	  analysis	  by	  London	  et	  al.	  on	  behalf	  
of	  the	   INRG	  has	  shown	  strong	  evidence	  for	  the	  age	  cut	  off	  to	  be	  460	  days	  (London	  
2005).	  Within	  the	  INRG	  classification	  18	  months	  has	  been	  adopted	  as	  the	  new	  binary	  
cut	   off	   point	   (Cohn	   2009).	   For	   babies	   less	   than	   18	   months	   of	   age	   and	   no	   MYCN	  
amplification	  the	  prognosis	  is	  dramatically	  better	  than	  for	  older	  children.	  
	  
With	   the	   raising	   of	   the	   cut	   off	   point	   to	   18	   months	   of	   age,	   greater	   numbers	   of	  
children	  who	   require	   less	   intensive	   treatment	   and	  have	  a	   good	  outcome	  will	   have	  








1.8.3	  Molecular	  Pathology	  
	  
The	  molecular	  pathology	  of	  neuroblastoma	  is	  complex	  and	  many	  molecular	  markers	  
with	  prognostic	   significance	  have	  been	  discovered.	   The	  most	  widely	  used	   is	  MYCN	  
amplification	   but	   other	   molecular	   tumour	   markers	   are	   important.	   The	   INRG	   task	  
force	  identified	  MYCN	  status,	  11q	  allelic	  status	  and	  tumour-­‐cell	  ploidy	  as	  important	  
in	  predicting	  a	  poorer	  outcome	  (Cohn	  2009).	  	  
	  
Association	   of	   the	   amplification	   of	   the	  MYCN	   oncogene	   and	   a	   poor	   prognosis	  was	  
first	  reported	   in	  1985	  (Seeger	  1985).	  The	  amplification	  of	  MYCN	  has	  significance	  at	  
all	   stages	  of	  disease.	   In	   low	  stage	   tumours	   the	   INRG	   found	   that	  patients	  with	   INSS	  
stage	  1	  and	  2	  disease	  had	  a	  worse	  5	  year	  OS	  in	  those	  with	  MYCN	  amplification	  (72%	  
v	  98%)	  (Bagatell	  2009).	  In	  stage	  4	  disease,	  MYCN	  amplification	  is	  also	  prognostically	  
significant.	  Within	   the	   INRG	  classification,	  patients	  older	   than	  547	  days	  and	  with	  a	  
serum	  ferritin	  of	  <92	  and	  a	  MYCN	  amplified	  tumour	  had	  an	  overall	  survival	  of	  27%	  
versus	  53%	  for	  those	  with	  non	  MYCN	  amplified	  tumours.	  For	  those	  patients	  with	  a	  
ferritin	   level	   ≥92,	   overall	   survival	   was	   22%	   if	   they	   had	  MYCN	   amplified	   tumours	  
versus	  30%	  if	  MYCN	  non-­‐amplified	  (Cohn	  2009).	  
	  
MYCN	   amplification	   is	   uncommon	   in	   infants,	   occurring	   in	   approximately	   10%	   of	  
cases.	   It	   is	   however	   predictive	   of	   poor	   survival	   rates	   despite	   aggressive	   treatment	  
amongst	  this	  age	  group	  (Canete	  2009).	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Attiyeh	  et	  al.	   found	  11q	  aberration	   in	  34%	  of	  tumours	   in	  over	  900	  neuroblastomas	  
screened	   (Attiyeh	   2005).	   11q	   aberration	   correlates	   inversely	   with	   the	   presence	   of	  
MYCN	   amplification,	   and	   is	   therefore	   considered	  a	   further	   significant	  biomarker	   in	  
non-­‐MYCN	   amplified	   disease.	   Deletion	   of	   11q	   was	   associated	   with	   poorer	   patient	  
outcomes	   in	   the	   INRG	   classification	   system	   (Cohn	   2009).	   Within	   INRG	   task	   force	  
analysis,	   allelic	   status	   was	   combined	   with	   tumour	   grade	   differentiation	   for	  
prognostic	   purposes	   and	   risk	   stratification	   for	   patients	   aged	   over	   18	  months	  with	  
MYCN	   non-­‐amplified	   INSS	   stage	  2	  or	   3	   tumours.	  Undifferentiated	  histology	   and/or	  
11q	  aberration	  were	  prognostic	  for	  5	  year	  OS	  of	  73%,	  compared	  with	  a	  5	  year	  OS	  of	  
100%	  in	  patients	  without	  either	  factor	  (Cohn	  2009).	  	  
	  
Within	  the	  INRG	  risk	  classification	  tumour	  DNA	  ploidy	  was	  statistically	  significant	   in	  
patients	   younger	   than	   18	   months	   of	   age	   with	   stage	   4	   disease	   and	   MYCN	   non-­‐
amplified	   tumours	   (Cohn	   2009).	   In	   low-­‐stage,	  MYCN	   amplified	   disease,	   outcomes	  
were	  significantly	  greater	  in	  those	  with	  hyperdiploid	  rather	  than	  diploid	  tumours	  (5	  
year	  OS:	  94%	  vs.	  54%)	  (Bagatell	  2009).	  	  
	  
Multiplex	   Ligation-­‐dependent	   Probe	   Amplification	   (MLPA)	   is	   now	   being	   used	   to	  
rapidly	  select	  patients	  with	  segmental	  chromosomal	  abnormalities	  (Combaret	  2012).	  
The	   MLPA	   is	   now	   available	   for	   routine	   laboratory	   testing	   and	   the	   presence	   or	  
absence	  of	   segmental	   chromosomal	  abnormalities	   (SCA)	   is	  being	   incorporated	   into	  
prospective	   clinical	   studies	   for	   example,	   the	   SIOPEN	   Low-­‐	   and	   Intermediate-­‐risk	  





Within	   the	   International	   Neuroblastoma	   Pathologic	   Classification	   (INPC),	   tumours	  
are	  evaluated	  depending	  on	  the	  degree	  of	  neuroblastoma	  maturation,	   the	  amount	  
of	   stromal	   development	   and	   the	   mitosis-­‐karyorrhexis	   index	   of	   the	   cells	   (Shimada	  
1999).	  	  
	  
Tumours	  are	  classified	  into	  four	  categories	  –	  	  
1	  Neuroblastoma	  (Schwannian	  stroma-­‐poor);	  	  
2	  Ganglioneuroblastoma,	  Intermixed	  (Schwannian	  stroma-­‐rich);	  	  
3	  Ganglioneuroma	  (Schwannian	  stroma-­‐dominant);	  	  
4	   Ganglioneuroblastoma,	   Nodular	   (composite,	   Schwannian	   stroma-­‐rich/stroma	  
dominant	  and	  stroma-­‐poor).	  	  
	  
Tumours	  within	  the	  neuroblastoma	  group	  are	  further	  divided	  depending	  on	  	  
1.	  the	  degree	  of	  neuroblastic	  differentiation	  (undifferentiated,	  poorly	  differentiated,	  
and	  differentiating)	  	  
and	  	  
2.	  by	  their	  mitosis-­‐karyorrhexis	  index	  (low,	  intermediate	  or	  high).	  	  
	  
The	  INPC	  histology	  system	  divides	  patients	  into	  favourable	  and	  unfavourable	  groups	  
depending	   on	   the	   patient’s	   age	   at	   diagnosis	   and	   histological	   features	   described	  
above.	  Tumour	  histology	  is	  another	  well-­‐established	  prognostic	  variable.	  Within	  the	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INRG	  classification	   those	  with	   favourable	  histology	  had	  a	  5	   year	  overall	   survival	   of	  
95%	  compared	  to	  49%	  for	  those	  with	  unfavourable	  histology	  (Cohn	  2009).	  Within	  the	  
INRG	   classification	   histological	   categories	   were	   analysed	   independently.	   A	   low	   or	  
intermediate	  MKI	  was	  associated	  with	  a	  better	  outcome	   (5	  year	  overall	   survival	  of	  
82%)	   compared	   to	  a	  high	  MKI	   (44%)	   (p<.0001).	   Those	  patients	  with	  differentiating	  
tumours	   had	   better	   5	   year	   overall	   survival	   at	   89%	   rather	   than	   72%	   for	  
undifferentiating	  tumours	   (p<.0001).	  Neuroblastoma,	  stroma-­‐poor	  patients	  had	  a	  5	  
year	   overall	   survival	   of	   71%;	   ganglioneuroblastoma,	   intermixed,	   stroma-­‐rich	   96%;	  
ganglioneuroma,	   stroma-­‐dominant	   79%;	   and	   ganglioneuroblastoma,	   nodular	  
(composite)	  68%	  (p<.0001).	  Each	  factor	  had	  independent	  prognostic	  value.	  
	  
1.8.5	  International	  Neuroblastoma	  Risk	  Group	  Classification	  
	  
Combining	   INRGSS	   stage	   with	   age	   at	   diagnosis,	   histological	   category,	   grade	   of	  
tumour	  differentiation,	  MYCN	   status,	  chromosome	  11q	  status	  and	  DNA	  ploidy,	   the	  
INRG	  classification	  algorithmically	  stratifies	  individuals	  to	  four	  pre-­‐treatment	  groups	  
of	  broadly	  homogenous	  risk	  banded	  by	  EFS	  at	  five	  years	  (Cohn	  2009).	  Treatment	  can	  
subsequently	   be	   adjusted	   accordingly,	   with	   intensity	   of	   therapy	   guided	   by	   risk	  
assessment	  of	  the	  projected	  behaviour	  of	  the	  disease.	  	  
	  
Patients	   with	   very	   low	   risk	   disease	   often	   undergo	   spontaneous	   regression	   of	   the	  
tumour	   and	   more	   than	   85%	   are	   event	   free	   at	   five	   years.	   Patients	   with	   low	   risk	  
disease	   can	   require	   little	   or	   no	   cytotoxic	   chemotherapy.	   Those	   patients	   with	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intermediate	   risk	   require	   multimodal	   treatment	   and	   those	   in	   the	   high	   risk	   group	  
receive	   aggressive	  multimodal	   therapy	   to	   improve	   their	   poor	   outcome.	   Prognostic	  
variables	   that	   can	   reliably	   guide	   risk-­‐group	   stratification	   and	   eschew	   the	   potential	  
late	  effects	  following	  aggressive	  treatment	  are	  highly	  desirable.	  
	  
Table	  1.4	  
The	   International	   Neuroblastoma	   Risk	   Group	   (INRG)	   Consensus,	   Pre-­‐treatment	  
Classification	  schema	  (adapted	  from	  Cohn	  2009).	  
	  




Grade	  of	  tumour	  
differentiation	  





L1/L2	   	   GN	  Maturing;	  
GNB	  Intermixed	  
	   	   	   	   Very	  Low	  
L1	   	   Any,	  except	  GN	  
maturing	  or	  
	   NA	  
	  
	   	   Very	  Low	  
	   	   GNB	  intermixed	   	   Amp	   	   	   High	  
L2	   	  
<	  18	  
Any,	  except	  GN	  
maturing	  or	  




	   	  
Low	  
	   	   GNB	  intermixed	   	   	   Yes	   	   Intermediate	  








	   	  
Low	  
	   	   	   	   	   Yes	   	   	  
	   	   	   Poorly	  
differentiated	  or	  
undifferentiated	  
NA	   	   	   Intermediate	  
	   	   	   	   Amp	   	   	   High	  
M	   <18	   	   	   NA	   	   Hyperdiploid	   Low	  
	   <12	   	   	   NA	   	   Diploid	   Intermediate	  
	   12	  to	  <18	   	   	   NA	   	   Diploid	   Intermediate	  
	   <18	   	   	   Amp	   	   	   High	  
	   ≥18	   	   	   	   	   	   High	  
MS	   	   	   	   	   No	   	   Very	  Low	  
	   	   	   	   NA	   Yes	   	   High	  














As	   has	   been	   discussed	   above,	   patients	   with	   neuroblastoma	   are	   risk	   stratified	  
depending	   on	   age,	   stage	   and	   molecular	   pathology.	   I	   will	   briefly	   discuss	   the	  
management	  of	  low	  and	  intermediate	  risk	  neuroblastoma	  but	  will	  focus	  on	  high-­‐risk	  
disease	  as	  this	  is	  the	  main	  area	  where	  radiotherapeutic	  modalities	  are	  used.	  
	  
	  
1.9.1	  Low	  and	  Intermediate	  Risk	  Disease	  
	  
As	  the	  EFS	  and	  OS	  for	  low-­‐	  and	  intermediate-­‐	  risk	  neuroblastoma	  have	  increased,	  the	  
focus	   has	   been	   on	   reducing	   treatment	   intensity	   with	   the	   aim	   of	   minimizing	   the	  
treatment	  burden,	  toxicity	  and	  long-­‐term	  effects.	  
	  
Infants	  with	  neuroblastoma	  without	  MYCN	  gene	  amplification	  generally	  have	  good	  
outcomes.	  Those	  with	  unresectable	  disease	  and	  no	  MYCN	  amplification	  have	  had	  OS	  
rates	   of	   95–100%	   in	   the	   past	   with	   chemotherapy;	   however,	   there	   have	   been	  
concerns	   over	   the	   long-­‐term	   toxicity	   of	   such	   treatment.	   The	   INES	   99.1	   study	  
evaluated	  the	  efficacy	  of	  low-­‐dose	  chemotherapy	  in	  infants	  with	  non-­‐metastatic	  and	  
unresectable	  neuroblastoma	  without	  MYCN	  amplification	  with	   the	  aim	  of	   reducing	  
total	   chemotherapy	  doses	   and	  avoiding	   anthracyclines	  without	   affecting	  outcomes	  
for	   these	   infants.	   Low-­‐dose	   chemotherapy	  without	   anthracyclines	  was	   effective	   in	  
62%	   of	   infants	   with	   unresectable,	   non	   MYCN-­‐amplified	   tumors.	   This	   did	   not	  
 45 
compromise	  on	  OS	  (5-­‐year	  OS:	  99%)	  and	  may	   improve	   late	  toxicities	   for	  this	  group	  
(Rubie	  2010).	  
	  
With	   regards	   to	   infants	   with	   disseminated	   neuroblastoma	   without	   MYCN	  
amplification,	  most	   have	   a	   good	  outcome	   and	  De	  Bernardi	  et	   al.	   reported	   on	   two	  
European	  trials	  focusing	  on	  reducing	  treatment	  intensity	  for	  this	  group.	  In	  trial	  99.2,	  
infants	  with	   either	   stage	   4S	   disease	   or	  with	   stage	   4	   disease	  with	   a	   primary	   tumor	  
crossing	   the	   midline	   or	   positive	   skeletal	   scintigraphy	   and	   no	   symptoms	   were	  
observed.	   In	   trial	   99.3,	   infants	   with	   overt	  metastases	   to	   the	   skeleton	   and/or	   lung	  
and/or	  CNS	  were	  treated	  with	  a	  minimum	  of	  four	  chemotherapy	  courses.	  Both	  trials	  
had	  OS	  rates	  of	  greater	  than	  95%	  (De	  Bernadi	  2009).	  
	  
Within	  the	  European,	  LINES	  2009	  study	  (Low	  and	  Intermediate	  Risk	  Neuroblastoma	  
European	  Study),	  the	  primary	  aim	  for	  the	  low	  risk	  patients	  is	  to	  minimise	  the	  amount	  
of	   treatment	   for	   appropriate	   low–risk	   patients	   whilst	   maintaining	   their	   excellent	  
long-­‐term	  outcome.	  Patients	  requiring	  radiotherapy	  include	  those	  with	  INSS	  Stage	  1	  
neuroblastoma	  with	  MYCN	  amplification	  and	  those	  with	  Stage	  L2,	  age	  >	  18	  months,	  
MYCN	   non-­‐amplified,	   poorly	   differentiated	   and	   undifferentiated	   neuroblastoma	   or	  







1.9.2	  High-­‐risk	  disease	  
	  
As	   discussed	   earlier	   it	   is	   not	   possible	   to	   perform	   clinical	   trials	   of	   high-­‐risk	   disease	  
treatment	   in	   the	   UK	   alone,	   as	   patient	   numbers	   are	   too	   small.	   Therefore,	  
International	   collaboration	   for	   clinical	   trials	   is	   essential.	   International	   high-­‐risk	  
neuroblastoma	   trial	   protocols	   all	   involve	   a	  multimodality	   approach	   to	   treatment.	   I	  
will	  focus	  on	  the	  current	  European	  high-­‐risk	  neuroblastoma	  study	  –	  SIOPEN,	  but	  the	  
on-­‐going	   trials	   in	   the	   US,	   Germany	   and	   Japan	   all	   follow	   a	   similar	   multi-­‐modality	  
structure.	  This	  involves	  an	  induction	  chemotherapy	  regime,	  surgical	  resection	  of	  the	  
primary	  tumour,	  high-­‐dose	  myeloablative	  chemotherapy	  and	  peripheral	  blood	  stem	  
cell	   support,	   external	   beam	   radiotherapy	   to	   the	   primary	   site	   and	  minimal	   residual	  
disease	  therapy	  including	  immunotherapy.	  Each	  of	  these	  elements	  to	  therapy	  along	  
with	  their	  evidence	  base	  will	  be	  discussed	  below.	  
	  
Figure	  1.1	  





1.9.2.1	  Induction	  Chemotherapy	  
	  
Induction	   therapy	   is	   given	   with	   the	   aim	   of	   reducing	   the	   primary	   tumour	   size	   and	  
hopefully	   facilitating	   a	   full	   surgical	   resection	   but	   also	   aims	   to	   increase	   the	  
effectiveness	  of	  myeloablative	  therapy	  by	  reducing	  the	  metastatic	  burden.	  
	  
A	   good	   response	   to	   initial	   induction	   therapy	   has	   been	   shown	   to	   correlate	   with	   a	  
better	  outcome	  in	  high-­‐risk	  neuroblastoma	  (Kushner	  1994).	  Within	  the	  COG	  high-­‐risk	  
study	  patients	  with	  a	  CR	  or	  VGPR	  after	  induction	  had	  a	  significantly	  better	  outcome	  
(Matthay	  2009).	  
	  
Unfortunately,	   approximately	   one	   third	   of	   high-­‐risk	   patients	   do	   not	   respond	   to	  
induction	  therapy	  and	  the	  outcome	  for	  these	  patients	  is	  very	  poor	  (Ladenstein	  2010).	  
Recent	   clinical	   trials	   have	   aimed	   to	   improve	   response	   rates	   by	   either	   using	   rapid	  
induction	  schedules,	  increasing	  the	  dose	  intensity	  or	  the	  addition	  of	  new	  agents.	  
	  
Most	   induction	   regimes	   include	   the	   following	   chemotherapy	   agents	   –	   cisplatin	  
and/or	   carboplatin,	   cyclophosphamide,	   etoposide,	   vincristine	   and	   doxorubicin	   in	  
some.	  The	  current	  SIOPEN	  high-­‐risk	   trial	  uses	   rapid	  COJEC	   -­‐	  a	  dose	   intensive,	   rapid	  
induction	  regime.	  This	  regime	  was	  shown	  to	  improve	  the	  3	  year	  EFS	  when	  compared	  
to	  a	  standard	  regime	  (OPEC)	  within	  the	  ENSG	  5	  trial	  (Pearson	  2008).	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The	  highest	   response	   rates	   to	   induction	   therapy	   (CR	  plus	  VGPR	   in	  85%)	  have	  been	  
reported	  by	  Kushner	  et	  al	  in	  the	  early	  1990’s	  using	  the	  N6	  protocol	  and	  subsequently	  
these	   results	   were	   replicated	  with	   the	   N7	   protocol	   (Kushner	   1994,	   Cheung	   2001).	  
The	  SIOPEN	  high-­‐risk	   trial	  will	  now	  randomise	  between	  a	  modified	  N7	  regime	   (N5)	  
and	  rapid	  COJEC	  (Valteau-­‐Couanet	  2005,	  Kohler	  2007,	  Valteau-­‐Couanet	  2014).	  
	  
An	  alternative	  strategy	  to	  improve	  response	  rates	  to	  induction	  therapy	  is	  to	  use	  new	  
agents	  with	  different	  cytotoxic	  mechanisms.	  Topotecan,	  a	  topoisomerase	  I	  inhibitor	  
has	   been	   shown	   to	   be	   effective	   in	   induction	   regimes	   in	   early	   phase	   clinical	   trials	  
(Park	  2011,	  De	  Ioris	  2011	  )	  and	  is	  now	  being	  incorporated	  into	  the	  COG	  phase	  II	  trial	  
(COG-­‐ANBL0532)	   as	  well	   as	   the	   current	   German	   high-­‐risk	   neuroblastoma	   phase	   III	  
trial.	  	  
	  
Some	  groups	  have	  used	  a	  different	  approach	  and	  given	  molecular	  radiotherapy	  with	  













Surgical	   resection	  of	   the	  primary	   tumour	   is	   attempted	  after	   induction	   therapy	  and	  
prior	   to	   high-­‐dose	  myeloablative	   therapy.	   Pre-­‐operative	   imaging	   is	   used	   to	   define	  
image	   defined	   risk	   factors	   (IDRF’s)	   for	   being	   unable	   to	   fully	   resect	   the	   primary	  
tumour	  (see	  Table	  1.3).	  	  
	  
There	   is	   conflicting	   evidence	   from	   different	   groups	   as	   to	   whether	   the	   extent	   of	  
surgical	   resection	   impacts	   on	   outcome	   (Mc	   Gregor	   2005,	   von	   Schweinitz	   2002,	  	  
Castel	  2002).	  	  
	  
La	  Quaglia	  et	  al	  found	  that	  in	  141	  high-­‐risk	  neuroblastoma	  patients	  evaluated,	  local	  
progression	  was	  50%	  in	  un-­‐resected	  compared	  to	  10%	  in	  patients	  with	  a	  gross	  total	  
resection	   (p<0.01).	   Overall	   survival	   was	   50%	   in	   resected	   compared	   to	   11%	   in	   un-­‐
resected	  patients	  (p<0.01)	  (La	  Quaglia	  2004).	  
	  
Simon	  et	  al	  looked	  at	  the	  German	  prospective	  NB97	  trial	  of	  patients	  greater	  that	  18	  
moths	   of	   age	  with	   stage	   4	   disease	   and	   correlated	   the	   extent	   of	   tumour	   resection	  
with	   local	   control	   rate	   and	   outcome.	   A	   total	   of	   278	   patients	  were	   included	   in	   the	  
analysis.	   Following	   induction	   chemotherapy,	   54.75	   of	   patients	   underwent	   a	  
complete	   surgical	   resection,	   30.6%	  underwent	   an	   incomplete	   resection	   and	   13.3%	  
had	  a	  biopsy	  only	  or	  no	  surgical	  resection	  of	  the	  primary	  tumour.	  The	  extent	  of	  the	  
surgery	  had	  no	  impact	  on	  EFS,	  LPFS	  or	  OS	  (Simon	  2013).	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Recent	   unpublished	   but	   presented	   data	   from	   the	   SIOPEN	   high-­‐risk	   neuroblastoma	  
trial	  suggests	  that	  extent	  of	  surgical	  resection	  did	  have	  an	  impact	  on	  outcome	  in	  this	  
trial	   (Holmes	   2011).	   Overall	   EFS	   was	   53%	   at	   3	   years	   for	   those	   with	   a	   complete	  
surgical	   excision	   versus	   EFS	   of	   41%	   for	   those	   with	   an	   incomplete	   resection.	  With	  
regards	   to	   Stage	   4	   only	   patients,	   the	   3	   year	   EFS	  was	   46%	   for	   completely	   resected	  
patients	  versus	  38%	  for	  those	  without	  (p=0.035).	  	  
	  
Whether	   surgical	   resection	   is	   just	   a	   surrogate	   for	   the	   biological	   behaviour	   of	   the	  
















1.9.2.3	  High-­‐Dose	  Myeloablative	  Therapy	  
	  
There	  were	  several	  reported	  studies	  in	  the	  early	  1990’s	  of	   induction	  chemotherapy	  
followed	  by	  high-­‐dose	  myeloablative	  therapy	  and	  bone	  marrow	  transplantation	  with	  
mixed	  results	   (Pinkerton	  1991,Ohnuma	  1995,	  Garaventa	  1996).	  Subsequently	  three	  
randomised	  control	  trials	  were	  performed	  as	  discussed	  below.	  
	  
There	  has	  been	  a	   recently	  published	  Cochrane	   review	  on	  high-­‐dose	   chemotherapy	  
and	   autologous	   haematopoietic	   stem	   cell	   rescue	   for	   children	   with	   high-­‐risk	  
neuroblastoma	   (Yalcin	   2010).	   Three	   randomised	   controlled	   trials	   comparing	  
myeloablative	   therapy	   to	   conventional	   therapy	   in	   high-­‐risk	   neuroblastoma	   were	  
identified	   (Matthay	   1999,	   Pritchard	   2005,	   Berthold	   2006,	   Matthay	   2009).	   This	  
totalled	  739	  children	  in	  these	  three	  studies.	  The	  meta-­‐analysis	  of	  event	  free-­‐survival	  
performed	   found	   a	   significant	   difference	   in	   favour	   of	   the	  myeloablative	   treatment	  
approach	   (HR	  0.78;	  95%	  CI	  0.67	   to	  0.90).	  The	  meta-­‐analysis	  of	  overall	   survival	  was	  
also	   in	   favour	   of	   the	   myeolablative	   group	   (HR	   0.74;	   95%	   CI	   0.57	   to	   0.98).	   The	  
treatment	  of	  these	  patients	  with	  myeolablative	  therapy	  is	  likely	  to	  be	  more	  toxic.	  	  
	  
It	   is	  not	  known	  what	  the	  best	   treatment	  regime	  for	  myeoablative	  therapy	   is	  and	   it	  
varies	   between	   continents.	   The	   varying	   results	   may	   be	   influenced	   by	   the	   other	  
components	  of	  multi-­‐modality	  therapy	  including	  the	  induction	  regime	  that	  is	  used.	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The	  standard	  regime	  in	  the	  United	  States	  Children	  Oncology	  Group	  studies	  has	  been	  
CEM	  (carboplatin,	  etoposide	  and	  melphalan).	  Unpublished	  but	  presented	  data	  from	  
the	  European	  SIOPEN	  high-­‐risk	  study	  has	  shown	  a	  significant	  difference	  in	  EFS	  (3	  year	  
EFS	   49%	   vs	   35%)	   and	   OS	   (3	   year	   OS	   60%	   v	   48%)	   (p=0.003)	   in	   favour	   of	   BuMel	  
(Busulfan	   and	   melphalan)	   over	   CEM	   in	   the	   high-­‐dose	   myeloablative	   therapy	  
randomisation.	  (Ladenstein	  et	  al.	  ASCO	  2011,	  ANR	  Toronto	  2012).	  The	  severe	  toxicity	  
rate	  was	  higher	  in	  the	  CEM	  arm.	  The	  acute	  toxicity	  profile	  favoured	  BuMel	  although	  
the	   incidence	   of	   VOD	   was	   higher	   for	   BuMel	   than	   CEM.	   The	   publication	   of	   these	  
results	  is	  awaited.	  However,	  there	  have	  been	  concerns	  that	  the	  EFS	  for	  the	  CEM	  arm	  
in	   the	   European	   study	   is	   less	   than	  normally	   seen	   in	   the	  US	   group	   and	   it	   has	   been	  
postulated	  that	  CEM	  may	  be	   less	  effective	   if	  a	  high	   ‘platinum’	  containing	   induction	  











1.9.2.4	  External	  Beam	  Radiotherapy	  
	  
Both	  surgical	  resection	  and	  external	  beam	  radiotherapy	  contribute	  to	  obtaining	  local	  
control	  in	  high-­‐risk	  patients.	  As	  discussed	  above	  there	  is	  some	  evidence	  from	  surgical	  
data	   that	   extent	   of	   surgical	   resection	   and	   local	   control	   can	   have	   an	   impact	   on	  
outcome	  for	  high-­‐risk	  neuroblastoma	  patients.	  
	  
There	  have	  been	  no	  randomised	  control	  trials	  in	  Stage	  M	  neuroblastoma	  comparing	  
patients	  receiving	  radiotherapy	  against	  those	  with	  no	  radiotherapy	  and	  most	  of	  the	  
radiotherapy	  data	  is	  historical	  case	  series.	  The	  reported	  studies	  have	  used	  a	  variety	  
of	  doses	  and	  techniques	  with	  many	  different	  high-­‐risk	  multi-­‐modality	  protocols	  used.	  
	  
Rosen	   et	   al.	   reported	   on	   118	   patients	  with	   neuroblastoma	   treated	   between	   1970	  
and	   1980.	   For	   the	   stage	   IV	   patients,	   doses	   of	   between	   12Gy	   and	   37.5Gy	   were	  
delivered.	  In	  the	  irradiated	  group,	  local	  failure	  was	  reported	  in	  7	  out	  of	  22	  patients	  
compared	   to	   a	   local	   failure	   in	   17	   out	   of	   21	   patients	   in	   the	   non-­‐irradiated	   group	  
(Rosen	  1984).	  
	  
With	   regards	   to	   localised	   disease,	   Castleberry	   et	   al.	   performed	   a	   prospective	  
randomised	   control	   trial	   of	   chemotherapy	   +/	   -­‐	   radiotherapy	   to	   the	   primary	   and	  
regional	   lymph	   nodes	   (24-­‐30Gy	   in	   16-­‐20♯)	   in	   patients	   with	   Paediatric	   Oncology	  
Group	   stage	   C	   disease	   (primary	   tumour	   with	   positive	   intracavity	   lymph	   nodes).	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Statistically	   significant	   EFS	   and	   OS	  were	   seen	   in	   the	   combined	   chemotherapy	   and	  
radiotherapy	  arm	  (Castleberry	  1991).	  
	  
The	  largest	  reported	  study	  of	  the	  effect	  of	  radiotherapy	  on	  local	  control	  in	  high-­‐risk	  
neuroblastoma	  was	  by	   the	  Children’s	  Cancer	  Group	  Study.	  This	  was	  a	  multi-­‐centre	  
study	   of	   539	   patients.	   The	   aim	   of	   the	   study	   was	   to	   examine	   the	   effect	   of	   local	  
radiation	  given	  to	  primary	  disease	  sites	  in	  high-­‐risk	  neuroblastoma	  patients.	  Patients	  
were	  treated	  on	  protocol	  CCG-­‐3891	  which	  consisted	  of	  chemotherapy,	  surgery	  and	  
10Gy	   of	   external	   beam	   radiotherapy	   to	   gross	   residual	   disease	   and	   followed	   by	  
randomisation	   between	   continuation	   chemotherapy	   (CC)	   OR	   autologous	   bone	  
marrow	  transplantation.	  Those	  receiving	  ABMT	  had	  total	  body	  irradiation	  (3.33Gy	  x	  
3#).	   5	   year	   loco-­‐regional	   recurrence	   rates	   were	   51%+/-­‐	   5%	   for	   the	   CC	   arm	   and	  
35%+/-­‐2%	   for	   the	   ABMT	   patients	   (p=0.004).	   For	   the	   patients	   given	   10Gy	   to	   the	  
primary,	  the	  addition	  of	  10Gy	  of	  TBI	  and	  ABMT	  resulted	  in	  reduced	  local	  recurrence	  
(22%+/-­‐12%)	  compared	  to	  the	  CC	  arm	  (52%	  +/-­‐8%)	  (p=0.022).	  Acute	  toxicity	  was	  not	  
increased	  with	   EBRT	   except	   for	   increased	   total	   parental	   nutrition	   requirements.	   It	  
was	   therefore	   postulated	   that	   there	  may	   be	   a	   dose-­‐response	   relationship	   for	   the	  
local	  EBRT	  component	  of	  therapy	  (Haas-­‐kogan	  2003).	  	  
	  
	  A	   German	   study	   examined	   the	   value	   of	   intensified	   local	   radiotherapy	   (36Gy)	   to	  
residual	  tumour	  volumes	  in	  those	  with	  residual	  viable	  tumour.	  The	  initial	  treatment	  
included	   induction	   chemotherapy	   and	   high-­‐dose	   chemotherapy	   with	   stem	   cell	  
transplantation.	  The	  13	  patients	  who	  received	  radiotherapy	  for	  local	  residual	  disease	  
had	  a	  similar	  outcome	  to	  those	  patients	  without	  any	  residual	  mIBG	  positive	  disease.	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Those	   23	   patients	   without	   radiotherapy	   to	   the	   residual	   primary	   did	   worse.	  
Multivariate	  analysis	   found	   radiotherapy	   to	  be	   influential	  on	  EFS	   (HR	  0.27)	  and	  OS	  
(HR	   0.17)	   in	   addition	   to	  MYCN	   amplification	   and	   presence	   of	   primary	   tumour	   site	  
mIBG	  residual	  (Simon	  2006).	  
	  
Pai	   Panandiker	   et	   al.	   found	   that	   loco-­‐regional	   tumour	   control	   had	   an	   impact	   on	  
overall	  survival	  for	  their	  cohort	  of	  neuroblastoma	  patients	  from	  St.	  Jude’s	  Children’s	  
Research	   Hospital.	   Between	   2000	   and	   2006,	   44	   patients	   with	   INSS	   stage	   3	   or	   4	  
disease	  received	  radiotherapy	  to	  the	  primary	  tumour	  at	  a	  median	  dose	  of	  23.4Gy.	  11	  
patients	  (25%)	  progressed	  loco-­‐regionally.	  The	  5	  year	  overall	  survival	  was	  48.3%	  for	  
those	  patients	  with	   local	  control	  compared	  to	  a	  5	  year	  OS	  of	  21.8%	  for	   those	  with	  
local	  failure	  (p=0.06)	  (Pai	  Panandiker	  2010).	  
	  
Within	   the	   current	   SIOPEN	   high-­‐risk	   neuroblastoma	   study,	   external	   beam	  
radiotherapy	  is	  given	  post-­‐operatively	  and	  after	  high-­‐dose	  myeloablative	  therapy	  to	  
the	   post-­‐induction	   chemotherapy	   tumour	   volume.	   It	   is	   delivered	   to	   the	   primary	  
tumour	  bed	  post-­‐surgery	   in	  high-­‐risk	  protocols	  with	  the	  aim	  of	  reducing	  the	  risk	  of	  
local	  recurrence.	  Radiotherapy	  is	  aimed	  at	  any	  gross	  residual	  disease	  as	  well	  as	  any	  
microscopic	  residual	  disease	  that	  may	  be	  present	  during	  surgery.	  	  
	  
Traditionally	   in	   Europe,	   radiotherapy	   has	   been	   delivered	  with	   a	   standard	   parallel-­‐
opposed	  anterior	  and	  posterior	  pair.	  There	  is	  concern	  that	  many	  patients	  have	  their	  
radiotherapy	  dose	  or	  target	  volume	  coverage	  reduced	  to	  stay	  within	  organ	  tolerance	  
doses	  and	  therefore	  do	  not	  receive	  the	  protocol	  dose	  of	  radiotherapy.	  This	  has	  been	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highlighted	  by	  the	  quality	  assurance	  of	  radiotherapy	  in	  the	  current	  SIOPEN	  high-­‐risk	  
neuroblastoma	  trial	  (Gaze	  2010,	  Gaze	  2013).	  	  
	  
External	   beam	   radiotherapy	   also	   has	   a	   significant	   role	   to	   play	   in	   the	   palliation	   of	  
symptomatic	  metastases	   and	   the	   treatment	   of	   spinal	   cord	   compression	   and	   brain	  
metastases.	  	  	  
	  
















Minimal	  Residual	  Disease	  Therapy	  and	  Immunotherapy	  
	  
Patients	  that	  have	  had	  a	  good	  response	  to	  induction	  and	  consolidation	  therapy	  are	  
still	  at	  a	  significant	  risk	  of	  relapse	  and	  this	   is	   thought	  to	  be	  due	  to	  the	  presence	  of	  
minimal	  residual	  disease	  (MRD).	  	  
	  
High-­‐risk	  protocols	  now	   incorporate	  a	  maintenance	  phase	  at	   the	  end	  of	   treatment	  
with	   the	   aim	   of	   eradicating	   MRD.	   This	   incorporates	   two	   different	   treatment	  




Retinoids	  were	  found	  to	  induce	  differentiation	  and	  apoptosis	   in	  neuroblastoma	  cell	  
lines	   30	   years	   ago	   (Sidell	   1982,	   Reynolds	   1991).	   Following	   promise	   in	   early	   phase	  
clinical	  trials	  13-­‐cis-­‐retinoic	  acid	  was	  examined	  in	  a	  large	  prospective	  phase	  III	  trial	  by	  
the	   Childrens’	   Oncology	   Group.	   Patients	   who	   were	   post	   high-­‐dose	   myeloablative	  
therapy	  and	  stem	  cell	  transplant	  were	  randomised	  to	  no	  further	  therapy	  or	  6	  months	  
of	  13-­‐cis-­‐retinoic	  acid	  therapy.	  The	  5	  year	  EFS	  was	  better	  for	  those	  who	  received	  13-­‐
cis-­‐retinoic	   acid	   although	   this	   did	   not	   reach	   statistical	   significance.	   13-­‐cis-­‐retinoic	  
acid	  has	  been	  incorporated	  into	  current	  high-­‐risk	  treatment	  protocols	  for	  patients	  in	  
remission	  post	  high-­‐dose	  therapy	  (Matthay	  1999,	  2009).	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The	  administration	  of	  13-­‐cis-­‐retinoic	  acid	  remains	  problematic	  in	  children	  as	  it	  is	  only	  
available	   in	   large	   capsules	   and	   therefore	   often	   requires	   mixing	   with	   food	   for	  
administration.	  This	  could	  have	   important	   implications	  for	  therapeutic	   levels	  of	  the	  
drug	  as	  it	  vulnerable	  to	  degradation	  by	  light.	  The	  UK	  Children’s	  Cancer	  Study	  Group	  
found	  a	  large	  degree	  of	  variability	   in	  the	  pharmacokinetics	  of	  13-­‐cis-­‐retinoic	  acid	  in	  
children	   being	   treated	   and	   this	   could	   have	   important	   implications	   for	   toxicity	   and	  
effectiveness	  (Veal	  2007).	  
	  
There	  are	  other	  retinoids	  in	  early	  phase	  clinical	  trials	  such	  as	  Fenretinide,	  a	  synthetic	  
retinoid	   derivative	   (Villablanca	   2006,	   Garaventa	   2003).	   This	   agent	   is	   also	   only	  
available	   in	   capsular	   form.	   New	   Approaches	   to	   Neuroblastoma	   Therapy	   (NANT)	  
phase	   I	   clinical	   trials	   examining	   an	   intravenous	   and	   lipid	   matrix	   formulation	   are	  




GD2	   is	   a	   disialoganglioside	   found	   on	   the	   surface	   of	   most	   neuroblastomas	  making	  
monocloncal	  antibodies	  directed	  against	  it	  an	  attractive	  therapeutic	  option.	  It	  has	  a	  
limited	   distribution	   in	   other	   tissues	   –	   peripheral	   pain	   fibres,	   neurons	   and	  
melanocytes.	  There	  have	  been	  several	  anti-­‐GD2	  monoclonal	  antibodies	  developed,	  
both	  murine	   and	   humanised.	   	   The	   earliest	   studies	  were	   on	   the	  murine	   antibodies	  
3F8	  and	  14G2.	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Recent	   focus	  has	  been	  on	  studying	   the	  human-­‐mouse	  chimeric	  antibody,	  ch.14.18.	  
The	   activity	   of	   this	   antibody	   was	   shown	   in	   pre-­‐clinical	   and	   early	   phase	   trials.	   The	  
antibody	   was	   then	   combined	   with	   IL-­‐2	   and	   GM-­‐CSF	   in	   early	   phase	   clinical	   trials.	  
(Gilman	  2009,	  Ozkaynak	  2000).	  There	  were	  considerable	  but	  manageable	   toxicities	  
in	  these	  studies	  –	  fever,	  hypotension,	  pain	  and	  capillary	  leak.	  	  
	  
Ch14.18	  has	   subsequently	  been	   studied	   in	   combination	  with	  GM-­‐CSF	  and	   IL-­‐2	   in	   a	  
randomised	  phase	  III	  trial	  (Yu	  2010).	  Patients	  completing	  multi-­‐modality	  therapy	  for	  
high-­‐risk	  neuroblastoma	  were	  randomised	  to	  receive	  13-­‐cis-­‐retinoic	  acid	  alone	  or	  in	  
addition	   to	   ch14.18,	   GM-­‐CSF	   and	   IL-­‐2.	   The	   trial	   was	   stopped	   early	   as	   superior	  
efficacy	  was	   seen	   in	   the	   immunotherapy	   arm.	   	   At	   2	   years	   there	  was	   a	   statistically	  
significant	  difference	   in	  EFS	   (66%	  v	  46%,	  p=0.01)	  and	  OS	   (86%	  v	  75%).	  There	  were	  
significant	   toxicities	   from	   the	   immunotherapy	   arm,	   pain	   grade	   3,4	   or	   5	   in	   52%,	  
capillary	   leak	  syndrome	  in	  25%	  and	  hypersensitivity	  reactions	   in	  25%.	  Although	  the	  
outcomes	  of	  this	  trial	  are	  the	  most	  significant	  reported	  for	  high-­‐risk	  neuroblastoma,	  
outcomes	   at	   5	   years	   are	   awaited	   to	   see	   if	   this	   significance	   of	   EFS	   and	  OS	   persist.	  
Unanswered	  questions	  remain	  however,	  as	  we	  do	  not	  know	  the	  additional	  benefit	  of	  
each	   of	   the	   three	   treatment	   components	   and	   it	   is	   not	   known	   whether	   there	   is	  
additional	  benefit	  of	   IL-­‐2	  to	  ch14.18	  alone.	   	  The	  current	  European	  SIOPEN	  high-­‐risk	  
neuroblastoma	   trial	   aims	   to	   address	   this.	   This	   is	   important	   as	   the	   use	   of	  




1.10	  Response	  Assessment	  
1.10.1	  International	  Neuroblastoma	  Response	  Criteria	  
	  
Universally	   accepted	   response	   criteria	   are	   highly	   desirable	   as	   they	   allow	   the	  
comparison	   of	   clinical	   trial	   results	   across	   the	   world	   and	   collaborative	   trial	  
development.	   Response	   assessment	   for	   neuroblastoma	   is	   still	   based	   on	   the	  
International	  Neuroblastoma	  Response	  Criteria	  as	  published	  originally	  by	  Brodeur	  et	  
al.	   in	  1988.	  The	  original	   INRC	  did	  not	  take	  into	  account	  mIBG	  scans	  but	  the	  revised	  
INRC	   in	  1993	  did	   recommend	  mIBG	  scanning	   if	   it	  was	  available	  although	   it	  did	  not	  
formally	  appear	  in	  the	  INRC	  criteria	  (Brodeur	  1993).	  	  
	  
The	  original	  INRC	  have	  limitations	  in	  accurately	  defining	  the	  response	  of	  metastatic	  
sites	   including	  bone	  and	  bone	  marrow.	  The	   INRC	  did	  not	  define	  a	  standard	  way	  of	  
assessing	  response	  on	  mIBG	  scanning.	  Problems	  at	  that	  time	  included	  the	  universal	  
availability	  of	  mIBG	  scanning,	  quality	  of	   imaging	  and	  the	   fact	   that	  not	  all	  primaries	  
and	  metastases	  are	  mIBG	  avid.	  The	   INRC	  gives	  no	  guidance	  on	   the	   introduction	  of	  
new	   imaging	   techniques	   such	   as	   18F-­‐FDG	   PET	   or	   evolving	   techniques	   for	   bone	  
marrow	  disease	  quantification.	  
	  
A	  revision	  to	  the	   INRC	  has	  been	  proposed	  and	   is	   likely	  to	  be	   introduced	  within	  the	  
next	  couple	  of	  years.	  Julie	  Park	  et	  al.	  presented	  a	  consensus	  statement	  on	  a	  revised	  
INRC	  at	  the	  Advances	  in	  Neuroblastoma	  Research	  conference	  in	  Toronto,	  June	  2012.	  
This	  revision	  is	  likely	  to	  involve	  semi-­‐quantitative	  scoring	  of	  mIBG	  scans,	  18F-­‐FDG	  PET	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for	   mIBG	   negative	   patients,	   bone	   marrow	   assessment	   by	   cytology	   and	  




The	   International	   Neuroblastoma	   Response	   Criteria,	   adapted	   from	   Brodeur	   et	   al.	  
1993.	  
	  
RESPONSE	   PRIMARY	  TUMOUR	   METASTATIC	  SITES	  
CR	   No	  tumour	   No	  tumour;	  catecholamines	  normal	  
VGPR	   Decreased	  by	  90-­‐99%	  
No	  tumour;	  catecholamines	  
normal;	  residual	  99Tc	  bone	  
changes	  allowed	  
PR	   Decreased	  by	  >50%	  
All	  measurable	  sites	  decreased	  
by	  >50%.	  Bones	  and	  bone	  
marrow:	  numberof	  positive	  
bone	  sites	  decreased	  by	  >50%;	  
no	  more	  than	  1	  positive	  bone	  
marrow	  site	  allowed	  
MR	  
No	  new	  lesions;	  >50%	  reduction	  of	  any	  measurable	  lesion	  (primary	  
or	  metastases)	  with	  <50%	  reduction	  in	  any	  other;	  <25%	  increase	  in	  
any	  existing	  lesion	  
NR	   No	  new	  lesions;	  <	  50%	  reduction	  but	  <25%	  increase	  in	  any	  existing	  lesion	  








1.10.2	  Semi-­‐quantitative	  scoring	  of	  mIBG	  scans	  
	  
For	  the	  staging	  and	  response	  assessment	  of	  mIBG	  scans,	  a	  semi-­‐quantitative	  scoring	  
method	   is	   recommended	   as	   it	   allows	   quantification	   of	   a	   response	   and	   should	  
facilitate	   comparisons	   between	   different	   organisations	   and	   clinical	   trials	  
internationally.	   These	   methods	   should	   also	   improve	   the	   concordance	   between	  
different	  reporters.	  	  
	  
There	  have	  been	  several	  scoring	  systems	  proposed	  but	  essentially	  they	  all	  divide	  the	  
skeleton	   into	   anatomical	   sections	   and	   then	   give	   each	   sector	   a	   score	   for	   extension	  
and	  intensity.	  
	  
The	  two	  most	  frequently	  used	  are:	  
1. The	   Curie	  Method	   –	   divides	   the	   skeleton	   into	   9	   segments	   and	   adds	   a	   10th	  
segment	   for	   any	   soft	   tissue	   involvement.	   The	   extension	   score	   is	   given	   for	  
each	   segment	   and	   graded	   0-­‐3:	   0	   (no	   sites	   per	   segment),	   1	   (one	   site	   per	  
segment),	  2	  (more	  than	  one	  site	  per	  segment),	  3	  (diffuse	  involvement,	  >50%	  
of	   the	   segment).	   Therefore	   giving	   a	  maximum	   score	   out	   of	   30.	   It	   has	   been	  
shown	   to	   have	   good	   concordance	   between	   observers.	   (Matthay	   2003,	  




2. The	  SIOPEN	  method	  –	  divides	  the	  skeleton	  into	  12	  anatomical	  segments.	  The	  
extension	   score	   is	   graded	   from	   0-­‐6	   for	   each	   segment:	   0(no	   involvement),	  
1(one	   discreet	   lesion),	   2	   (2	   discrete	   lesions),	   3	   (3	   discreet	   lesions),	   4	   (>3	  
discrete	   foci	   or	   a	   single	  diffuse	   lesion	   involving	   <50%	  of	   a	   bone),	   5	   (diffuse	  
involvement	  of	  >50	  to	  95%	  whole	  bone),	  6	  (diffuse	  involvement	  of	  the	  entire	  
bone).	  Giving	  a	  maximum	  score	  out	  of	  72.	  This	  is	  the	  method	  used	  in	  Europe.	  
(Lewington	  2009).	  
	  
Figure	  1.2	  	  








1.	  The	  Curie	  Method	   2.	  The	  SIOPEN	  Method	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The	  recent	  INRG	  task	  force	  report	  recommends	  that	  for	  response	  evaluation	  of	  mIBG	  
scans	   the	   relative	   extension	   score	   by	   semi-­‐quantitative	   scoring	   is	   calculated	   by	  
dividing	  the	  absolute	  pre-­‐therapy	  score	  by	  the	  post	  –therapy	  score	  (Matthay	  2010).	  
A	   relative	   score	   of	   0.5	   is	   considered	   a	   partial	   response;	   a	   relative	   score	   of	   0	   is	   a	  
complete	  response	  (Matthay	  2003).	  	  
	  
1.10.3	  The	  prognostic	  significance	  of	  mIBG	  scores	  
	  
Recently	   emerging	   data	   has	   shown	   that	   mIBG	   semi-­‐quantitative	   scores	   can	   have	  
prognostic	  significance	  in	  high-­‐risk	  neuroblastoma.	  
	  
Schmidt	   et	   al.	   examined	   the	   prognostic	   significance	   of	   123I-­‐mIBG	   scans	   in	   stage	   4	  
neuroblastoma	  patients	  >	  1	  year	  of	  age	  on	  the	  German	  Neuroblastoma	  Trial	  NB97.	  
Patients	  with	  residual	  123I-­‐mIBG	  positive	  disease	  after	  four	  or	  six	  cycles	  of	  induction	  
chemotherapy	  had	  a	  significantly	  worse	  outcome	  (Schmidt	  2008).	  
	  
Other	  groups	  have	  used	  a	  semi-­‐quantitative	  scoring	  method	  to	  evaluate	  the	  scans.	  
Yanik	   et	   al.	   within	   the	   COG	   study	   compared	   semi-­‐quantitative	  mIBG	   scores	   (Curie	  
method)	   in	   stage	   4	   neuroblastoma	   patients	   at	   diagnosis	   (n=280),	   post-­‐induction	  
(n=237),	  post	  transplant	  (n=178).	  They	  found	  no	  correlation	  between	  the	  Curie	  score	  
at	  diagnosis	  and	  subsequent	  outcome.	  Patients	  with	  a	  Curie	  score	  >2	  after	  induction	  
therapy	  had	  a	  significantly	  worse	  EFS	  than	  those	  with	  a	  Curie	  score	  ≤2	  at	  the	  end	  of	  
induction	   (3	   year	   EFS	   15.4	   +/-­‐5.3%	   vs	   44.9	   +/-­‐	   3.9%,	   p<0.001).	   Patients	  with	   Curie	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score	   >0	   post-­‐transplant	   had	   a	   worse	   3	   year	   EFS	   than	   patients	   with	   a	   score	   of	   0	  
(28.9+/-­‐	  6.8%	  vs	  49.3	  +/-­‐4.9%,	  p=0.009)	  (Yanik	  2013).	  
	  
Despite	  their	  differences	  both	  the	  scoring	  methods	  were	  able	  to	  predict	  outcome	  in	  
the	  above	  studies.	  The	  Cologne	  Inter-­‐score	  comparison	  study	  compared	  the	  SIOPEN	  
and	   Curie	   scoring	   methods	   on	   stage	   4	   patients	   treated	   within	   the	   same	   German	  
NB97	   trial.	   Both	   scoring	   systems	  were	   found	   to	   be	   equally	   reliable	   and	   predictive	  
(Decarolis	   2013).	   Groups	   form	   the	   US	   and	   Europe,	   are	   currently	   comparing	   the	  
scoring	   systems,	   and	   independently	   evaluating	   both	   scoring	   systems	   in	   a	   large	  
international	  patient	  population.	  
	  
The	   implications	   of	   these	   findings	   are	   that	   a	   potential	   ‘ultra-­‐high	   risk’	   group	   of	  
patients	  could	  be	  identified	  by	  semi-­‐quantitative	  scoring	  of	  mIBG	  scans	  at	  the	  end	  of	  
induction	  therapy.	  These	  patients	  could	  then	  be	  offered	  novel	  therapeutic	  strategies	  









1.10.4	  Detecting	  Minimal	  Residual	  Disease	  
	  
Increasingly	   sensitive	   methods	   of	   detecting	   minimal	   residual	   disease	   (MRD)	   are	  
being	  developed	  using	  real	  time	  RT-­‐PCR	  markers	  for	  example,	  TH,	  PHOX2B	  and	  DCX.	  
The	  markers	  and	  methods	  however	  vary	  and	  are	  being	  validated	  in	  large	  prospective	  
clinical	  trials	  (Esser	  2011,Chambon	  2013,	  Hartomo	  2013).	  A	  recent	  publication	  from	  
the	   European	   HR-­‐NBL1/SIOPEN	   study	   evaluated	   whether	   the	   detection	   of	  
neuroblastoma	   mRNA’s	   by	   reverse	   transcriptase	   quantitative	   polymerase	   chain	  
reaction	  (RTqPCR)	  in	  peripheral	  blood	  and	  bone	  marrow	  aspirates	  at	  diagnosis	  or	  at	  
the	  end	  of	  induction	  could	  predict	  for	  worse	  EFS	  or	  OS	  in	  a	  cohort	  of	  290	  children	  on	  
the	   high-­‐risk	   trial.	   High	   levels	   of	   TH,	   PHOX2B	   or	   DCX	  mRNA	   at	   diagnosis	   strongly	  
predicted	   for	  a	  worse	  EFS	  and	  OS.	  After	   induction	   therapy,	  high	   levels	  of	  mRNA	   in	  












1.11	  Relapsed	  and	  Refractory	  Disease	  
	  
Despite	  intensive	  multi-­‐modality	  therapy	  many	  high-­‐risk	  neuroblastoma	  patients	  are	  
either	  primary	  refractory	  or	  relapse	  further	  down	  the	  line.	  Less	  than	  40%	  of	  high-­‐risk	  
neuroblastoma	   patients	   will	   unfortunately	   become	   long-­‐term	   survivors	   and	  
therefore	  the	  development	  of	  more	  effective	  treatment	  strategies	  for	  refractory	  and	  
relapsed	  patients	  is	  essential.	  
	  
Following	   relapse,	   survival	   is	   very	   poor.	   The	   Italian	   neuroblastoma	   registry	   has	  
published	   the	   outcome	   of	   patients	   within	   prospective	   clinical	   trials,	   with	   disease	  
progression	  or	  relapse.	  Overall	  prognosis	  was	  found	  to	  be	  very	  poor	  with	  a	  median	  
survival	  of	  less	  than	  1	  year	  and	  less	  than	  10%	  of	  children	  surviving	  for	  more	  than	  10	  
years	  post	  relapse.	  For	  relapsed	  or	  progressive	  disease	  stage	  4	  patients	  the	  10	  year	  
OS	  was	  only	  2%	  (Garaventa	  2009).	  
	  
There	   is	   no	  universally	   accepted	   approach	   for	   patients	  with	   relapsed	  or	   refractory	  
disease.	  It	  is	  therefore	  difficult	  to	  compare	  results	  between	  clinical	  trials,	  as	  the	  prior	  
therapy	  patients	  will	  have	  had	  will	  be	  highly	  variable.	  
	  
A	   recent	   report	   from	   the	   INRG	   project	   examined	   clinical	   and	   biological	   features	  
predicting	   survival	   after	   relapse.	   The	   significant	  prognostic	   factors	   for	  post	   relapse	  
survival	   were	   age,	   stage,	   MYCN	   status	   and	   time	   from	   diagnosis	   to	   first	   relapse.	  
Patients	  relapsing	  between	  6	  and	  18	  months	  after	  diagnosis	  had	  the	   lowest	  overall	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survival	   whereas	   those	   relapsing	   after	   36	   months	   or	   longer	   had	   a	   better	   overall	  
survival	  (London	  2011).	  	  
	  
Relapse	  and	  refractory	  strategies	  involve	  the	  use	  of	  conventional	  cytotoxic	  therapies,	  
new	  molecular	  targeted	  agents	  or	  molecular	  radiotherapy	  as	  discussed	  below.	  
	  
1.11.1	  Conventional	  Cytotoxic	  Therapies	  
	  
Cytotoxic	   chemotherapy	   strategies	   for	   relapsed	   or	   refractory	   high-­‐risk	  
neuroblastoma	   have	   in	   recent	   years	   concentrated	   on	   agents	   such	   as	   Irinotecan,	  
Temozolomide	   and	   Topotecan.	   These	   agents	   have	   been	   examined	   alone	   (Rubie	  
2006,	  Vassal	  2008)	  and	  subsequently	  in	  various	  combinations	  with	  each	  other,	  or	  in	  
combinations	  with	   other	  more	   established	   agents	   (Garaventa	   2003,	   Simon	   2007a,	  
Simon	   2007b,	   Wagner	   2009,	   London	   2010,	   Rubie	   2010,	   Bagatell	   2011,	   Kushner	  
2011a,	  Kushner	  2011b).	  
	  
A	   recent	   retrospective	   analysis	   of	   the	   use	   of	   a	   multi-­‐agent	   regime	   of	   high-­‐dose	  
cyclophosphamide,	  topotecan	  and	  vincristine	  found	  major	  responses	  (CR/VGPR	  and	  
PR)	  statistically	  more	  common	  (52%)	  in	  children	  with	  a	  new	  (first)	  disease	  recurrence	  
compared	  with	  children	  with	  primary	  refractory	  disease,	  or	  progressive	  disease	  that	  
occurred	  during	  induction	  therapy	  (0%)	  (Kushner	  2010).	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Repeated	   courses	   of	   cytotoxic	   chemotherapy	   are	   frequently	   limited	   by	   poor	   bone	  
marrow	  reserve	  in	  this	  often	  heavily	  pre-­‐treated	  population.	  Conventional	  cytotoxic	  
chemotherapies	  may	  be	  reaching	  their	  maximum	  potential	   in	  terms	  of	  efficacy	  and	  
toxicity.	  Therefore,	  strategies	  aimed	  at	   improving	  efficacy	  and	  reducing	  toxicity	  are	  
focusing	  on	  new	  molecular	  targets.	  
	  
1.11.2	  New	  Molecular	  Targeted	  Agents	  
	  
Both	  in	  adult	  and	  paediatric	  oncology,	  much	  research	  in	  recent	  years	  has	  focused	  on	  
developing	  new	  molecular	  agents	  to	  target	  the	  increasingly	  diverse	  set	  and	  number	  
of	  ‘drugable’	  targets	  that	  are	  being	  identified.	  
	  
Collaborative	  research	  efforts	  are	  focusing	  on	  rapidly	  evaluating	  and	  screening	  pre-­‐
clinically	   promising	   agents	   that	   hold	   potential	   or	   have	   been	   used	   with	   success	   in	  
adult	  cancers	  and	  bringing	  them	  to	  the	  paediatric	  setting	  for	  early	  clinical	  trials.	  	  
	  
Several	   early	  phase	   trials	  have	  been	   conducted	   including	   those	  on	  Tyrosine	   kinase	  
inhibitors	   (Minturn	   2011),	   Histone	   Deacetylase	   (HDAC)	   inhibitors	   (Fouladi	   2010),	  
Vascular	   Endothelial	   Growth	   Factor	   Receptor	   (VEGFR)	   inhibitors	   (Fox	   2010a),	   β-­‐
Tubulin	  inhibitor	  (Fox	  2010b)	  and	  mTOR	  inhibitors	  (Spunt	  2011,	  Georeger	  2012).	  The	  
relationship	  between	  different	  receptor	  pathways	  are	  complex	  and	  inhibition	  at	  one	  
point	  often	  activates	  another	  pathway	  through	  feedback	  and	  so	  these	  agents	  need	  
to	  be	  further	  tested	  in	  combination	  (Øra	  2011).	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Preliminary	   data	   suggest	   that	   ALK	   is	   a	   therapeutic	   target	   for	   some	   patients	   with	  
neuroblastoma.	  The	  ALK	  gene	  mutation	  has	  been	   found	   to	  occur	   in	  approximately	  
2%	  of	  patients	  with	  a	  familial	  predisposition	  and	  8-­‐14%	  of	  sporadic	  neuroblastomas.	  
ALK	  inhibition	  with	  crizotinib	  has	  been	  reported	  in	  a	  phase	  1	  study	  (Mossé	  2013).	  
	  
There	   is	   currently	   interest	   in	  developing	   randomised	  Phase	   II	   trials	  using	   the	   latest	  
cytotoxics	  as	  a	  ‘back-­‐bone’	  and	  adding	  new	  molecular	  targets	  to	  assess	  a	  multimodal	  
molecularly	   targeted	   therapy	   in	   relapsed	  high-­‐risk	  neuroblastoma,	   for	  example	   the	  
BEACON	  study	  which	  is	  now	  open	  in	  Europe.	  
	  
The	   limitations	   so	   far	   of	   these	   agents	   are	   that	   blocking	   one	   pathway	  may	   not	   be	  
enough	  and	  tumours	  can	  develop	  resistance	  mechanisms	   to	   these	  agents.	  There	   is	  
also	   evidence	   of	   inter-­‐	   and	   intra	   tumour	   heterogeneity	   in	   adult	   oncology	   making	  
treatment	   with	   molecularly	   targeted	   agents	   even	   more	   challenging	   (Fisher	   2013).	  










1.11.3	  Molecular	  radiotherapy	  
	  
Molecular	   radiotherapy	   involves	   giving	   radiation	   systemically	   with	   the	   aim	   of	  
delivering	   tumoricidal	   radiation	   doses	   to	  multiple	   tumour	   deposits	   from	   the	   same	  
administration.	   This	   has	   important	   therapeutic	   implications	   for	   a	   tumour	   such	   as	  
neuroblastoma,	   which	   is	   frequently	   metastatic.	   Although	   it	   is	   a	   radiosensitive	  
tumour,	  and	  external	  beam	  radiotherapy	  is	  essential	  for	  local	  control	  of	  the	  primary	  
tumour	   (as	  discussed	  above)	   it	  has	   technical	   limitations	   to	  a	   tumour	   that	   is	  widely	  
metastatic.	  
	  	  
Neuroblastoma	   expresses	   a	   number	   of	   distinct	   and	   separate	   biological	   features,	  
which	   can	   act	   as	   targets	   for	   molecular	   radiotherapy.	   These	   include	   the	  
disialoganglioside	   GD2,	   which	   can	   be	   targeted	   by	   a	   radio-­‐labeled	   monoclonal	  
antibody,	   for	   example	   3F8	   17	   and	   somatostatin	   receptor	   subtype	   2,	  which	   can	   be	  
targeted	   by	   radiopeptides,	   for	   example	   177Lutetium	   DOTATATE	   (see	   chapter).	   The	  
earliest	  and	  most	  frequently	  used	  form	  of	  molecular	  radiotherapy	  in	  clinical	  use	  for	  
neuroblastoma	  is	  meta-­‐Iodobenzylguanidine	  (mIBG)	  which	  targets	  the	  noradrenaline	  







Figure	  1.3	  	  




Meta-­‐iodobenzylguanidine	   is	   a	   guanethidine	   analogue,	  which	   is	   structurally	   similar	  
to	  noradrenaline.	  131I-­‐mIBG	  was	  first	  developed	  at	  the	  University	  of	  Michigan	  for	  the	  
imaging	  of	  the	  adrenal	  medulla	  in	  the	  late	  1970’s	  (Wieland	  1980).	  The	  first	  imaging	  
studies	  were	  performed	   in	  dogs	  and	  then	  monkeys	   (Wieland	  1980,	  Wieland	  1981).	  
The	  first	  imaging	  of	  phaeochromocytomas	  in	  six	  human	  patients	  with	  131I-­‐mIBG	  was	  
reported	  in	  1981	  (Valk	  1981,	  Sisson	  1981)	  
	  
131I-­‐mIBG	  was	  taken	  forward	  for	   imaging	  and	  therapy	  of	  neuroblastoma	   in	   the	  mid	  
1980’s.	   Being	   a	   tumour	   derived	   from	   the	   sympathetic	   nervous	   system,	  
neuroblastoma	   expresses	   the	   noradrenaline	   transporter	   molecule	   which	   takes	   up	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the	   catecholamine	   analogue	   mIBG	   and	   approximately	   90%	   of	   neuroblastomas	  
express	  NAT.	  	  
	  
Most	  studies	  using	  131I-­‐mIBG	  have	  been	  pilot,	  phase	  I	  or	  II	  clinical	  trials	  with	  variable	  
administered	  activities	  used	  and	  response	  rates	  reported.	  The	  dose	  limiting	  toxicity	  
is	  myelosupression.	   Attempts	   to	   increase	   the	   response	   to	   131I-­‐mIBG	   have	   included	  
dose	  escalation	  and	  the	  addition	  of	  radiosensitisers	  such	  as	  topotecan,	  both	  of	  which	  
have	  used	  peripheral	  blood	  stem	  cell	  support	  to	  circumnavigate	  the	  myelosupression	  
caused	   by	   higher	   administered	   activities	   (Matthay	   2006	   and	   2009,	   Gaze	   2005).	  
Although	   most	   studies	   in	   the	   literature	   have	   used	   131I-­‐mIBG	   in	   the	   relapsed	   or	  
refractory	   setting	   there	   are	   also	   reports	   of	   its	   use	   in	   induction	   and	   consolidation	  
stages.	  
	  
The	  use	  of	  radiolabelled	  somatostatin	  analogues	  for	  neuroblastoma	  is	  presented	  in	  
chapter	   2	   and	   a	   systematic	   review	   of	   131I-­‐mIBG	   therapy	   in	   neuroblastoma	   is	  











1.12	  Special	  Clinical	  Scenarios	  
1.12.1	  Spinal	  Cord	  Compression	  
	  
Neuroblastomas	  may	   invade	   the	   intervertebral	   foramina	   and/or	   the	   spinal	   cord	   in	  
about	   5	   to	   15%	   of	   cases.	   Intra-­‐spinal	   extension	   may	   cause	   acute	   neurological	  
symptoms	  and	  may	  also	  result	  in	  long	  term	  neurological	  sequelae	  affecting	  quality	  of	  
life	  for	  long-­‐term	  survivors	  (Poretti	  2008).	  	  
	  
Patients	   with	   spinal	   cord	   compression	   are	   treated	   as	   medical	   emergencies	   and	  
urgent	   commencement	   of	   chemotherapy	   or	   surgical	   decompression	   is	   required.	  
Retrospective	  reports	  have	  suggested	  equivalent	  neurological	  outcomes	  for	  patients	  
treated	   with	   primary	   chemotherapy	   or	   surgery	   with	   laminectomy	   but	   debate	  
remains	   about	   the	   treatment	   options	   and	   treatment	   algorithms	   vary.	   (Katzenstein	  
2001,	  Plantaz,	  De	  bernardi	  2001,	  Strother	  2006,	  Yiin	  2003,	  Sandberg	  2003).	  	  
	  
Simon	   et	   al.	   have	   recently	   published	   the	   short	   and	   long	   term	   outcome	   of	   122	  
patients	   with	   neuroblastoma	   and	   spinal	   cord	   compression.	   Patients	   from	   four	  
consecutive	   prospective	   German	   clinical	   trials	  were	   retrospectively	   analysed.	   They	  
found	  spinal	  cord	  compression	  to	  be	  present	  in	  5%	  of	  their	  studied	  population.	  The	  
patients	   with	   SCC	   tended	   to	   be	   younger	   and	   have	   less	   frequency	   of	   MYCN	  
amplification.	   The	   authors	   postulated	   that	   this	   may	   be	   because	   the	   highly	  
aggressive,	  often	  MYCN	  amplified	  tumours	  may	  have	  caused	  other	  symptoms	  before	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developing	  SCC.	  Again	  no	  clear	  advantage	  was	  found,	  for	  either	  short-­‐	  or	  long-­‐	  term	  
outcome,	   for	   first	   line	   treatment	  with	   neurosurgery	   or	   chemotherapy.	   Emergency	  
external	  beam	  radiotherapy	  was	  never	  used	  for	  SCC	  in	  this	  study.	  The	  frequency	  of	  
long-­‐term	  sequelae	  in	  this	  study	  was	  71%	  (Simon	  2012).	  
	  
	  
1.12.2	  Brain	  Metastases	  
	  
Many	  chemotherapy	  agents	  do	  not	  cross	  the	  blood-­‐brain	  barrier	  and	  therefore	  the	  
central	  nervous	  system	  (CNS)	  is	  a	  potential	  ‘sanctuary	  site’	  for	  neuroblastoma	  cells.	  
Brain	  metastases	  are	  rare	  at	  the	  time	  of	  diagnosis	  but	  they	  do	  occur	  at	  the	  time	  of	  
relapse	  (approximately	  10%).	  	  
	  
mIBG	  does	  not	  cross	  the	  intact	  blood	  brain	  barrier	  and	  so	  diagnostic	  or	  surveillance	  
imaging	  can	  miss	  CNS	  disease.	  Historically,	  CNS	  relapse	  of	  neuroblastoma	  has	  been	  
universally	   fatal	   but	   earlier	   recognition	   of	   disease	   in	   the	   brain	   may	   improve	  
outcome.	   For	   diagnosis	   of	   brain	  metastases,	   an	   immediate	   brain	   and	   spine	  MRI	   is	  
mandatory	  for	  patients	  with	  symptoms	  or	  signs	  of	  CNS	  disease	  even	  if	  the	  mIBG	  scan	  
is	  negative.	  
	  
There	  is	  concern	  that	  with	  the	  increasing	  survival	  rates	  in	  high-­‐risk	  disease	  that	  the	  
incidence	   of	   brain	  metastases	  may	   increase.	   A	   single	   institutional	   study	   looking	   at	  
patients	  treated	  with	  multi-­‐agent	  regimes	  N4,	  N5,	  N6	  or	  N7	  between	  1980	  and	  1998	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found	   the	   overall	   rate	   of	   CNS	   recurrence	   to	   be	   >10%.	   However,	   those	   treated	   on	  
earlier	  studies	  with	  N4	  and	  N5	  had	  a	  CNs	  recurrence	  incidence	  of	  2%	  versus	  12%	  for	  
those	  treated	  on	  later	  regimes	  with	  N6	  and	  N7	  (Kramer	  2001).	  
	  
Historically,	  the	  mainstay	  of	  treatment	  for	  brain	  metastases	  has	  been	  external	  beam	  
radiotherapy.	   Recent	   developments	   have	   examined	   the	   use	   of	   compartmental	  
radioimmunotherapy	   using	   radioiodinated	   monoclonal	   antibodies	   administered	  
intrathecally	  following	  surgical	  resection	  and	  external	  beam	  radiotherapy.	  These	  131I-­‐	  
labelled	   monoclonal	   antibodies	   are	   targeted	   against	   tumours	   expressing	   GD2	   or	  
B7H3,	  which	  is	  a	  glycoprotein	  preferentially	  expressed	  on	  many	  tumours	  compared	  
to	  normal	  tissue	  (Kramer	  2001).	  
	  
The	   team	   at	   the	   Memorial	   Sloan-­‐kettering	   Cancer	   Center	   has	   published	   their	  
retrospective	   analysis	   of	   children	   with	   CNS	   relapse	   treated	   with	   external	   beam	  
radiotherapy	  and	  radioimmunotherapy.	  Of	  the	  29	  children	  treated,	  16	  had	  received	  
craniospinal	   irradiation	   (CSI)	   at	   a	   median	   dose	   of	   21.6Gy	   and	   13	   had	   focal	  
radiotherapy.	   14	   of	   the	   CSI	   patients	   also	   received	   intra-­‐Ommaya	  
radioimmunotherapy	   (131I-­‐8H9	   or	   131I-­‐3F8)	   but	   only	   one	   patient	   in	   the	   focal	  
radiotherapy	  group.	  At	  a	  median	   follow-­‐up	  of	  28	  months,	  12	  patients	   (75%)	   in	   the	  
CSI	   group	   were	   alive	   without	   CNS	   disease.	   In	   the	   focal	   radiotherapy	   group	   all	   13	  
patients	   had	  died	   at	   a	  median	  of	   8.8	  months	   (Croog	  2010).	   This	   suggests	   that	   the	  
whole	  neuraxis	  is	  at	  risk	  in	  CNS	  relapse	  and	  CSI	  may	  be	  necessary	  rather	  than	  focal	  




The	  ability	  to	  identify	  those	  neuroblastoma	  patients	  with	  a	  high	  risk	  of	  relapse	  within	  
the	  CNS	  would	  be	  highly	  advantageous	  and	  allow	  trials	  of	  prophylactic	  strategies.	  
	  
	  
1.12.3	  Opsoclonus	  Myoclonus	  Syndrome	  
	  
Opsoclonus-­‐myoclonus	   (OMS)	   is	   a	   chronic	   and	   relapsing	   autoimmune	   neurological	  
illness,	  which	   occurs	   in	   2-­‐3%	  of	   patients	  with	   neuroblastoma.	   It	   is	   associated	  with	  
occult	  neuroblastoma	  in	  40%	  of	  cases	  but	  there	  are	  other	  causes	  including	  infection,	  
metabolic	   and	   neoplastic.	   In	   neuroblastoma,	   it	   is	  most	   common	   in	   patients	   under	  
the	  age	  of	  4	  years.	  	  
	  
OMS	   is	   also	   known	   as	   ‘dancing-­‐eye	   syndrome’	   and	   is	   characterised	   by	  
multidirectional	   rapid	   eye	   movements	   (opsoclonus),	   myoclonus,	   ataxia	   and	  
behavioural	  changes	  such	  as	  sleep	  problems	  and	  irritability.	  
	  
Children	  with	  OMS	  and	  neuroblastoma	  typically	  have	  favourable	  outcomes	  but	  the	  
majority	   will	   have	   long-­‐term	   neurological	   deficits	   (Altman	   1976,	   Pranzatelli	   1992,	  
Koh	  1994,	  Russo	  1997,	  Mitchell	  2002).	  	  
	  
As	   the	   mechanism	   for	   developing	   OMS	   is	   thought	   to	   be	   immune	   mediated	   most	  
treatments	   have	   aimed	   at	   being	   immunosuppressive	   for	   example,	   ACTH,	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gammaglobulins,	   corticosteroids,	   plasmapharesis,	   cyclophosphamide	   and	  
azathioprine	  (	  Petruzzi	  1995,	  Borgna-­‐Pignatti	  1996,	  Veneselli	  1998,	  Yiu	  2001).	  
	  
More	   recently	   treatment	  with	   rituximab	   (a	  monoclonal	   antibody	   that	   binds	   to	   the	  
CD20	   antigen	   on	   the	   surface	   of	  mature	   B	   cells)	   has	   been	   reported	   in	   several	   case	  
reports	  (Burke	  2008,	  Alavi	  2012,	  Battaglia	  2012).	  
	  
1.12.4	  Neuroblastoma	  in	  teenagers	  and	  young	  adults	  
	  
Approximately	   3–4%	   of	   neuroblastoma	   cases	   occur	   in	   older	   children,	   adolescents	  
and	   young	   adults	   (Conte	   2006,	   Castel	   2010).	   Neuroblastoma	   in	   this	   age	   group	   is	  
generally	   regarded	   as	   having	   a	   more	   indolent	   course	   but	   with	   a	   poorer	   overall	  
survival.	   The	  biology	  and	   clinical	   course	  of	  neuroblastoma	  are	  different	   in	   this	   age	  
group	  and	  is	  reflected	  in	  patients’	  different	  responses	  to	  therapy	  (Esiashvili	  2007).	  As	  
the	  number	  of	  patients	  in	  this	  age	  group	  is	  small,	  most	  published	  reports	  tend	  to	  be	  
small,	  retrospective	  and	  include	  a	  heterogeneously	  treated	  population.	  
	  
There	  have	  been	  several	  recently	  published	  cohorts	  of	  patients	  with	  neuroblastoma	  
within	   the	   teenage	   and	   young	   adult	   population.	   A	   group	   from	  Milan	   published	   20	  
years	   of	   experience	   with	   patients	   over	   12	   years	   old	   with	   neuroblastoma.	   This	  
included	   27	   patients	   over	   12	   years	   of	   age	   treated	   between	   1982	   and	   2001.	   Three	  
cases	  were	  stage	  1,	  two	  were	  stage	  2,	  six	  were	  stage	  3	  and	  16	  were	  stage	  4.	  These	  
patients	  had	  a	  long	  interval	  between	  onset	  of	  symptoms	  and	  diagnosis	  (mean	  of	  12	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months;	   range	  1–24	  months)	  and	  recurrence	  and	  death	  (median	  12	  months;	   range	  
2–75	   months).	   None	   of	   the	   patients	   had	   MYCN	   amplification.	   Despite	   a	   longer	  
course	  of	  the	  disease,	  this	  did	  not	  translate	  into	  a	  better	  outcome	  with	  an	  OS	  for	  all	  
patients	  of	  40%	  at	  5	  years	  and	  20%	  at	  10	  years	  (Podda	  2010).	  
	  
In	   a	   Spanish	   cohort	   of	   patients	  with	   neuroblastoma	   over	   10	   years	   of	   age,	   treated	  
between	  1992	  and	  2007,	  genetic	  and	  clinical	  characteristics	  were	  examined.	  MYCN	  
was	  not	  amplified	   in	  any	  of	   the	  19	  cases	   studied	  and	  no	  1p	  deletions	  were	   found.	  
More	   frequently,	   11q	   deletions	   and	   unfavorable	   histology	   were	   observed.	   The	  
outcome	  in	  stage	  4	  patients	  (OS	  of	  33%)	  was	  worse	  than	  for	  younger	  children	  with	  
stage	   4	   disease.	   The	   investigators	   concluded	   that	   the	   exact	   age	   cutoff	   for	   older	  
patients	   has	   not	   yet	   been	   established	   and	   should	   probably	   be	   based	   on	   biology	  
(Castel	  2010).	  
	  
More	  recently,	  the	  International	  Neuroblastoma	  Risk	  Group	  Project	  have	  published	  a	  
report	  on	  neuroblastoma	   in	  older	  children,	  adolescents	  and	  young	  adults.	  They	  set	  
out	  to	  determine	  if	  an	  optimal	  age	  cut-­‐off	  exists	  that	  defines	  indolent	  disease	  and	  if	  
established	   prognostic	   factors	   and	   treatments	   used	   for	   younger	   children	   were	  
applicable	  to	  those	  in	  the	  older	  age	  group.	  From	  their	  analysis	  of	  4,027	  patients	  over	  
the	  age	  of	  18	  months,	  older	  age	  was	  found	  to	  be	  prognostic	  for	  poorer	  survival,	  with	  
outcome	  worsening	  gradually	  with	  increasing	  age	  at	  diagnosis	  although	  there	  was	  no	  
specific	   age	   cut-­‐found	   above	   18	   months.	   In	   a	   multivariable	   analyses,	   for	   patients	  
older	  than	  5	  years	  of	  age	  at	  diagnosis,	  factors	  prognostic	  for	  lower	  EFS	  and	  OS	  were	  
INSS	   stage	   4,	   MYCN	   amplification	   and	   unfavourable	   INPC	   histology.	   For	   older	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patients	  with	  stage	  4	  neuroblastoma	  there	  was	  a	  significant	  EFS	  and	  OS	  in	  those	  that	  
had	  received	  an	  autologous	  hematopoietic	  cell	  transplant	  (Mossé	  2014).	  	  
	  
With	  regards	  to	  adult	  patients	  with	  neuroblastoma,	  a	  Sorrentino	  et	  al	  have	  recently	  
published	  the	  Italian	  experience	  of	  21	  adult	  patients.	  EFS	  at	  10	  years	  was	  worse	  for	  
all	   stages	  compared	  to	  younger	  patients	  –	  stage	  1/2	  33.3%,	  stage	  3	  16.7%,	  stage	  4	  
0%.	  All	  6	  stage	  4	  patients	  died	  form	  disease	  and	  the	  overall	  survival	  for	  all	  patients	  
was	  39.8%	  (Sorrentino	  2014).	  
	  
As	   well	   as	   a	   different	   biology	   of	   disease	   in	   the	   adolescent	   and	   young	   adult	  
population	  there	  is	  also	  evidence	  that	  this	  age	  group	  responds	  differently	  to	  therapy,	  
with	  more	  chemoresistant	  disease.	  A	  retrospective	  analysis	  of	  a	  treatment	  regimen	  
of	   high-­‐dose	   cyclophosphamide,	   topotecan	   and	   vincristine	   found	   statistically	  
significant	   reduced	   activity	   in	   adolescents	   and	   adults	   compared	   with	   children	  
(Kushner	  2010).	  
	  
Because	  of	  a	   lack	  of	   separate	   treatment	   recommendations	   for	   this	  age	  group	  with	  
neuroblastoma	   they	   are	   often	   treated	   according	   to	   pediatric	   guidelines.	   It	   is	  
essential,	  therefore,	  to	  examine	  alternative	  treatment	  strategies,	  such	  as	  131I-­‐mIBG.	  
In	  a	  large	  Phase	  II	  trial	  of	  131I-­‐mIBG,	  univariate	  analysis	  indicated	  that	  age	  >12	  years	  
at	   the	   time	   of	   treatment	  was	   a	   positive	   prognostic	   factor	   for	   response,	   compared	  
with	  patients	  who	  were	  aged	  22	  months	  to	  6	  years	  (Matthay	  2007).	  More	  recently,	  a	  
published	  retrospective	  analysis	  on	  131I-­‐mIBG	  in	  adolescents	  and	  young	  adults	  found	  
an	   overall	   response	   rate	   of	   46%.	   Patients	   over	   18	   years	   of	   age	   at	   first	   131I-­‐mIBG	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therapy	  had	  a	  higher	   response	   rate	   (56%)	   than	   those	  between	  10	  and	  17	  years	  of	  
age	   (39%)	   (Polishchuk	   2011).	   Therefore,	   even	  within	   the	   teenage	   and	   young	   adult	  
population,	  there	  is	  variation	  in	  response	  to	  therapy	  depending	  on	  age.	  
	  
The	  concept	  of	   this	   type	  of	   indolent	  or	   smoldering	  disease	  should	  however	  not	  be	  
limited	   just	   to	  the	  teenage	  and	  young	  adult	  population	  as	  there	   is	  also	  a	  cohort	  of	  
children	  who	  develop	  this	  kind	  of	  disease.	  Kushner	  et	  al	  published	  their	  experience	  
of	  a	  cohort	  of	  children	  with	  active	  neuroblastoma	  >	  5	  years	  from	  diagnosis	  (Kushner	  
2002).	  This	  chronic	  type	  of	  disease	  is	  rare	  in	  children	  with	  MYCN	  amplification.	  The	  
effect	  of	  improved	  initial	  therapies	  and	  more	  options	  for	  relapsed	  disease	  in	  the	  last	  
decade	  is	  likely	  to	  have	  had	  an	  impact.	  
	  
It	   is	  essential	   that	  new	  therapeutic	  approaches	  are	  developed	   for	   the	   teenage	  and	  
young	   adult	   age	   group	   and	   their	   development	   is	   likely	   to	   come	   with	   increased	  
understanding	  of	  the	  biology	  of	  the	  disease.	  The	  need	  for	  specific	  clinical	  guidelines	  








1.14	  Late	  effects	  of	  treatment	  
	  
As	   discussed	   previously	   the	   prognosis	   for	   high-­‐risk	   neuroblastoma	   is	   poor	   and	  
therefore	   there	   is	   a	   paucity	   of	   data	   on	   late	   effects	   of	   treatment	   especially	   with	  
regards	   to	   the	   high-­‐intensity	   strategies	   currently	   being	   used.	   Survivors	   of	   high-­‐risk	  
neuroblastoma,	  are	  likely	  to	  face	  the	  huge	  consequences	  of	  intensive	  multi-­‐modality	  
therapy	  often	  given	  at	  an	  early	  age.	  
	  
A	  retrospective	  report	  from	  the	  Memorial	  Sloan-­‐Kettering	  Cancer	  Center,	  published	  
in	   2005,	   looked	   for	   late	   effects	   in	   patients	   previously	   treated	   for	   advanced	   stage	  
neuroblastoma	  (stage	  3	  or	  4).	  The	  study	  included	  63	  survivors	  with	  a	  mean	  age	  of	  3	  
years	   at	  diagnosis	   and	  a	  median	   follow	  up	   from	  diagnosis	  of	  7.06	  years.	  All	   of	   the	  
patients	  had	  received	  surgery	  and	  chemotherapy,	  89%	  external	  bema	  radiotherapy,	  
62%	   immunotherapy	   and	   56%	   autologous	   stem	   cell	   transplantation.	   Late	  
complications	   were	   detected	   in	   95%	   of	   the	   survivors	   in	   their	   cohort.	   The	   most	  
frequent	   complications	   were	   hearing	   loss	   (62%),	   primary	   hypothyroidism	   (24%),	  
ovarian	   failure	   (41%	   of	   females),	   musculoskeletal	   (19%)	   and	   pulmonary	   (19%)	  
(Laverdière	  2005).	  
	  
	  A	   recent	   publication	   by	   Cohen	   et	   al	   reports	   on	   a	   retrospective	   evaluation	   of	   51	  
patients,	   treated	   between	   1994	   and	   2007,	   with	   high-­‐risk	   neuroblastoma	  who	   had	  
survived	   for	   greater	   than	   1	   year	   following	   intensive	   multimodality	   treatment	  
including	   aggressive	   chemotherapy,	   surgery,	   local	   external	   bema	   radiotherapy	   and	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single	   or	   tandem	   autologous	   stem	   cell	   transplantation.	   Of	   note	   the	   majority	   of	  
patients	   received	   tandem	   transplantation	  with	   chemotherapy	   conditioning	   for	   the	  
first	   and	  melphalan	   and	   12Gy	   Total	   Body	   Irradiation	   for	   the	   second.	   There	   was	   a	  
median	   follow	   up	   of	   6.1	   years.	   Patient’s	   linear	   growth	   was	   significantly	   impacted	  
with	  mean	  change	  in	  height	  z-­‐scores	  from	  pre-­‐treatment	  to	  last	  clinic	  visit	  of	  -­‐1.91	  in	  
those	  that	  had	  received	  TBI	  and-­‐0.77	  in	  those	  who	  had	  not	  (p=0.003).	  Pre-­‐diabetes	  
or	   diabetes	   was	   seen	   in	   50%,	   hypothyroidism	   in	   59%	   and	   ovarian	   insufficiency	   in	  
75%.	  Hearing	  loss	  was	  seen	  in	  73%	  and	  cardiac	  dysfunction	  in	  23%.	  14%	  had	  scoliosis	  
and	  dental	  issues	  were	  common	  (51%).	  29%	  of	  patients	  required	  special	  educational	  












1.15	  The	  Radiobiology	  of	  Neuroblastoma	  
	  
Human	   tumours	   show	   wide	   variation	   in	   their	   response	   to	   radiation	   with	   some	  
tumours	  such	  as	  seminoma	  being	  highly	  radiosensitive	  and	  others	  such	  as	  melanoma	  
being	   relatively	   radioresistant.	   There	   is	   both	   laboratory	   and	   clinical	   evidence	   to	  
suggest	  that	  neuroblastoma	  is	  a	  relatively	  radiosensitive	  disease.	  
	  
Deacon	   et	   al.	   examined	   the	   radiation	   response	   of	   a	   neuroblastoma	   xenograpft	  
HX138	  in	  vitro	  and	  in	  vivo	  using	  single	  cells	  in	  suspension,	  multicellular	  spheroids	  and	  
xenografts	  in	  immune	  suppressed	  mice.	  The	  results	  following	  irradiation	  of	  cells	  from	  
all	   three	   different	   experimental	   systems	   were	   consistent	   with	   it	   being	   a	   highly	  
radiosensitive	   tumour.	   The	   results	   from	   split-­‐dose	   experiments	   showed	   some	  
evidence	  or	  repair	  of	  sub-­‐lethal	  damage.	  Tumour	  cells	   irradiated	  as	  spheroids	  or	   in	  
vivo	  were	  more	  resistant	  than	  single	  cells.	  Radio-­‐resistance	  was	  seen	  when	  tumours	  
were	   irradiated	  under	   conditions	  of	   hypoxia.	   The	   lack	  of	   a	   shoulder	  on	   the	   single-­‐
dose	  survival	  curve	  and	  a	  limited	  capacity	  of	  repair	  in	  split-­‐dose	  experiments	  led	  the	  
authors	   to	   postulate	   that	   the	   use	   of	   multiple	   small	   fractions	   or	   low	   dose-­‐rate	  
irradiation	   may	   be	   used	   to	   exploit	   the	   greater	   repair	   capacity	   of	   normal	   tissues	  
(Deacon	  1985).	  Clinically,	  Jacobsen	  et	  al.	  in	  1983	  studied	  children	  with	  Evans	  stage	  II	  
or	   III	  disease	  who	  received	  post	  operative	   radiation	  900	  to	  4500	  rad	  and	   found	  no	  
patient	  had	  a	  local	  recurrence	  or	  died	  of	  disease.	  9	  of	  15	  patients	  received	  doses	  of	  
900-­‐1500	  rad	  only.	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1.16	  Scope	  of	  this	  study	  
	  
Neuroblastoma	  is	  a	  hugely	  diverse	  disease	  but	  the	  outcome	  for	  high-­‐risk	  patients	  is	  
still	  universally	  very	  poor	  and	  the	  long-­‐term	  survival	  rate	  remains	  under	  40%.	  It	  is	  a	  
relatively	  radiosensitive	  tumour	  and	  radiotherapy	  has	  a	  significant	  role	  to	  play	  in	  the	  
management	  of	  high-­‐risk	  disease	  -­‐	  both	  external	  beam	  and	  molecular	  radiotherapy.	  	  
	  
The	  aim	  of	   this	   study	   is	   to	  examine	  potential	  ways	  of	   improving	   the	  outcomes	   for	  
high-­‐risk	   neuroblastoma	   through	   the	   optimisation	   of	   these	   radiotherapeutic	  
techniques.	   These	   strategies	   are	   summarised	   below	   and	   described	   in	   detail	   in	  
chapter	  2-­‐7.	  
	  
Radiolabelled	  somatostatin	  analogues	  have	  been	  successfully	  used	  in	  the	  treatment	  
of	  adult	  neuroendocrine	  tumours	  and	  somatostatin	  receptors	  and	  have	  been	  shown	  
to	   be	   expressed	   by	   many	   neuroblastomas.	   Targeting	   somatostatin	   receptors	  
expressed	  by	  many	  neuroblastomas	  with	  radiolabelled	  somtostatin	  analogues	  gives	  
a	  new,	  distinct	  and	  separate	  target	  to	  that	  used	  with	  mIBG.	  This	  can	  be	  exploited	  for	  
both	  imaging	  (with	  68Gallium	  DOTATATE)	  and	  therapy	  (with	  177Lutetium	  DOTATATE).	  
The	  use	  of	  68Ga-­‐DOTATATE	  PET/CT	  and	  177Lutetium	  DOTATATE,	  will	  be	  reported	  here	  
for	  the	  first	  time	  in	  relapsed	  and	  refractory	  neuroblastoma	  and	  the	  planned	  phase	  II	  
LuDO	  trial	  presented	  (see	  Chapter	  2).	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mIBG	  and	  radiolabelled	  somatostatin	  analogues	  target	  different	  molecular	  receptors	  
expressed	  on	  the	  surface	  of	  neuroblastomas.	  The	  frequency	  of	  expression	  of	  the	  NAT	  
and	  sstr2	  and	  their	  heterogeneity	  of	  distribution	  within	  a	  cohort	  of	  neuroblastoma	  
tissues	  will	  be	  examined	  by	  immunohistochemistry	  (see	  Chapter	  3).	  
	  
Molecular	  radiotherapy	  in	  the	  form	  of	  131I-­‐mIBG	  has	  been	  used	  in	  the	  treatment	  of	  
relapsed	  and	  refractory	  neuroblastoma	  for	  over	  25	  years	  but	  a	  randomised	  control	  
trial	   incorporating	   it	   has	   never	   been	   performed.	   A	   systematic	   review	   of	   131I-­‐mIBG	  
therapy	  in	  neuroblastoma	  is	  therefore	  presented.	  The	  aim	  of	  the	  systematic	  review	  
is	  to	  increasing	  the	  understanding	  of	  the	  role	  of	  131I-­‐mIBG	  and	  to	  highlight	  questions	  
that	   should	  be	  addressed	   in	   future,	   prospective	   and	   randomised	   clinical	   trials	   (see	  
Chapter	  4).	  
	  
For	   children	  undergoing	  molecular	   radiotherapy	   it	   is	  necessary	   for	   them	   to	  have	  a	  
parent,	   relative	   or	   other	   responsible	   adult	   who	   can	   provide	   comfort	   and	   care	   for	  
them	  during	  their	  treatment.	  These	  so	  called	   ‘comforters	  and	  carers’	  must	  consent	  
to	   provide	   the	   care	   and	   they	   will	   inevitably	   receive	   a	   dose	   of	   radiation	   from	  
providing	   that	   care.	   Doses	   received	   by	   comforters	   and	   carers	   whilst	   looking	   after	  
children	   receiving	   molecular	   radiotherapy	   with	   131I-­‐mIBG,	   131I-­‐NaI	   and	   177Lu-­‐
DOTATATE	  will	  be	  presented	  (see	  chapter	  5).	  
	  
Although	  123I-­‐mIBG	  imaging	  is	  the	  gold	  standard	  imaging	  modality	  in	  neuroblastoma	  
the	   role	   of	   18F-­‐FDG	  PET/CT	   in	   neuroblastoma	   remains	   undefined.	  A	   comparison	  of	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123I-­‐mIBG	  scans	  and	  18F-­‐FDG	  PET/CT	  scans	  in	  a	  cohort	  of	  patients	  receiving	  131I-­‐mIBG	  
molecular	  radiotherapy	  for	  neuroblastoma	  is	  reported	  (Chapter	  6).	  
	  
Within	  high-­‐risk	  neuroblastoma	  multi-­‐modality	   treatment	  protocols,	  external	  beam	  
radiotherapy	   to	   the	   primary	   tumour	   bed	   is	   given	  with	   the	   aim	   of	   improving	   local	  
control.	   This	   has	   historically	   been	   delivered	   using	   conventional	   radiotherapy	   fields	  
but	   often	   a	   compromise	   has	   to	   be	  made	   on	   tumour	   volume	   coverage	  with	   these	  
techniques.	   Over	   the	   last	   decade	   there	   have	   been	   significant	   technical	   advances	  
made	   in	   external	   beam	   radiotherapy	   including	   Intensity	   Modulated	   Radiotherapy	  
(IMRT)	   and	   its	   derivatives	   such	   as	   Intensity	   Modulated	   Arc	   Therapy	   (IMAT).	   A	  
planning	   study	   comparing	   conventional	   radiotherapy	   and	   an	   IMAT	   technique	   in	  
abdominal	   neuroblastoma	   is	   reported	   examining	  whether	   IMAT	   offers	   advantages	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The	  outcome	  for	  patients	  with	  relapsed	  or	  refractory	  neuroblastoma	  remains	  very	  poor	  and	  
new	   therapeutic	   treatment	   options	   are	   therefore	   required.	   Cytotoxic	   chemotherapy	   has	  
been	   used	   in	   the	   relapsed	   and	   refractory	   disease	   setting	   but	   response	   rates	   have	   been	  
suboptimal	   due	   to	   drug	   resistance	   and	   toxicity,	   mainly	   bone	   marrow	   suppression	   (see	  
chapter	  1).	  
	  
Neuroblastoma	   is	  a	   radiosensitive	  disease	  and	  molecular	   radiotherapy	  can	  deliver	   tumour	  
specific	   radiation	   targeting	   multiple	   sites	   of	   disease	   from	   the	   same	   administration,	  
important	   in	  metastatic	   neuroblastoma.	  Molecular	   radiotherapy	   has	   played	   an	   important	  
role	  in	  the	  management	  of	  neuroblastoma	  since	  the	  mid	  1980’s	  in	  the	  form	  of	  mIBG.	  mIBG	  
is	   a	   guanethidine	   derivative	   that	   	   targets	   the	   noradrenaline	   transporter	   molecule	   (NAT)	  
expressed	  by	  many	  neuroblastoma	  cells.	  It	  can	  be	  labelled	  with	  123I	  for	  imaging	  and	  131I	  for	  
therapy.	  Its	  main	  toxicity	  is	  myelosupression	  and	  attempts	  to	  increase	  response	  rates	  have	  
included	  the	  use	  of	  higher	  administered	  activities,	   the	  use	  of	  radiosensitisers	  or	  both	  with	  
peripheral	   blood	   stem	   cell	   support	   to	   circumvent	   the	  myelosupression.	   Although	   there	   is	  
some	   evidence	   of	   good	   response	   rates	   to	   131I-­‐mIBG,	   its	   ultimate	   role	   and	   effectiveness	  




Radiolabelled	   somatostatin	   analogues	   can	   be	   used	   as	   radiopharmaceuticals	   to	   target	  
somatostatin	  receptors	  for	  diagnostic	  imaging	  and	  for	  peptide	  receptor	  radionuclide	  therapy	  
(PRRT).	   Radiolabelled	   somatostatin	   analogues	   have	   an	   established	   role	   in	   the	   imaging,	  
staging	  and	  response	  assessment	  as	  well	  as	  for	  therapy	  in	  metastatic,	  somatostatin	  positive	  
neuroendocrine	  tumours	  in	  adults.	  	  
	  
All	   radiolabelled	   somatostatin	   analogues	   have	   a	   radionuclide	   (eg.	   177Lutetium,	   90Yttrium,	  
68Gallium),	   a	   somatostatin	   analogue	   (eg.	   Octreotate	   or	   Octreotide)	   and	   a	   chelating	   agent	  	  
(eg.	  DOTA)	  (see	  Figure	  2.1).	  	  
	  
	  








Octreotate,	  the	  somatostatin	  analogue,	  has	  a	  high	  affinity	  for	  somatostatin	  receptor	  type-­‐2	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Before	  PRRT	  therapy	  was	  utilised	  in	  adult	  neuroendocrine	  tumours,	  imaging	  of	  somatostatin	  
receptor	   positive	   tumours	   with	   [111In-­‐DTPA0]	   octreotide	   (Octreoscan)	   was	   established.	  
Attempts	   at	   treating	   metastatic	   neuroendocrine	   tumours	   with	   high	   dose	   [111In-­‐DTPA0]	  
octreotide	  were	  then	  made.	  Initial	  studies	  were	  encouraging	  but	  partial	  remissions	  were	  not	  
seen	   (Valkema	  2002).	   This	  was	  due	   to	   [111In-­‐DTPA0]	  octreotide,	   in	   addition	   to	   the	  gamma	  
component	   used	   for	   imaging,	   primarily	   emitting	   Auger	   electrons	  which	   have	   a	   very	   short	  
range	   (1-­‐10	   nm),	   and	   therefore	   requiring	   intracellular	   localisation	   to	   cause	   double	   strand	  
breaks	  in	  DNA.	  
	  
The	  next	  development	  was	  a	  modified	  somatostatin	  analogue	  [Tyr3]octreotide	  with	  a	  higher	  
affinity	  for	  the	  SSTR-­‐2	  and	  a	  different	  chelator,	  DOTA,	  which	  	  enabled	  a	  more	  stable	  binding	  
to	   the	   radionuclide	   90Yttrium.	   There	  have	  been	   several	   Phase	   I	   and	   II	   trials	   in	   adults	  with	  
somatostatin	   positive	   neuroendocrine	   tumours	   using	   [90Y-­‐DOTA0,	   Tyr3]octreotide	   with	  
Complete	  Responses	  and	  Partial	  Responses	  in	  10-­‐30%	  of	  patients	  although	  there	  have	  been	  
many	  differences	  in	  the	  protocols	  and	  administered	  activities	  used	  with	  minimal	  dosimetry	  
performed	  (Otte	  1999,	  Chinol	  2002,	  Paganelli	  2002,	  Valkema	  2003).	  	  
	  
The	   somatostatin	   analogue	   [DTPA0,	   Tyr3]octreotate	   differs	   form	   [DTPA0Tyr3]octreotide	   in	  
that	   the	   C-­‐terminal	   threoninol	   is	   replaced	   with	   threonine.	   It	   has	   been	   shown	   to	   have	   a	  
greater	  binding	  to	  somatostatin	  positive	  tumours	  in	  animal	  experiments	  (De	  Jong	  1998).	  Its	  
DOTA-­‐coupled	   counterpart	   [DOTA0Tyr3]octreotate	   labelled	   with	   177Lu	   was	   initially	   very	  
effective	   in	  tumour	  regression	   in	  a	  rat	  model	   (Erion	  1999).	  There	  was	  a	  reported	  nine	  fold	  
increase	  in	  affinity	  for	  the	  somatostatin	  receptor	  subtype	  2	  for	  [DOTA0,Tyr3]octreotate	  when	  
compared	  with	  [DOTA0,Tyr3]octreotide	  in	  vitro	  (Reubi	  2000).	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Kwekkeboom	   et	   al.	   compared	   the	   uptake	   of	   radioactivity	   of	   [177Lu-­‐DOTA0,Tyr3]octreotate	  
and	  [111In-­‐DTPA0]octreotide	  and	  found	  comparable	  uptake	  in	  liver,	  spleen	  and	  kidneys	  but	  3-­‐
4	   fold	   higher	   uptake	   in	   the	   tumours	   in	   the	   [177Lu-­‐DOTA0,Tyr3]octreotate	   patients	   thereby,	  
increasing	  the	  therapeutic	  window	  (Kwekkeboom	  2001).	  
	  
There	   is	   a	   lower	   tissue	   penetration	   range	   for	   177Lu	   as	   compared	   to	   90Y	   which	   may	   be	  
important	   for	   larger	   	   tumours.	   There	   have	   been	   no	   randomized	   trials	   comparing	   [90Y-­‐
DOTA0,Tyr3]octreotide	  and	  [177Lu-­‐DOTA0,Tyr3]octreotate.	  
	  
The	   largest	   published	   study	   of	   177Lutetium	   DOTATATE	   in	   adults	   with	   metastatic	  
gastroenteropancreatic	   neuroendocrine	   tumours	   is	   by	   Kwekkeboom	   et	   al	   (Kwekkeboom	  
2008).	  They	  reported	  toxicity	  analysis	   in	  504	  patients	  and	  efficacy	  analysis	   in	  310	  patients.	  
Patients	  were	  selected	  for	  therapy	  if	  the	  tumour	  uptake	  was	  at	  least	  as	  high	  as	  the	  uptake	  in	  
the	   liver	   on	   [111In-­‐	   DTPA0]octreotide	   scintigraphy	   (OctreoScan).	   Patients	   received	  
177Lutetium	  DOTATAE	  at	  a	  fixed	  administered	  activity	  of	  7.4GBq	  with	  up	  to	  4	  administrations	  
being	  given	  with	  a	  6-­‐10	  week	   interval.	  Although	  there	   is	  no	  specific	  dosimetry	  recorded	  in	  
the	  publication,	  it	  states	  that	  patients	  were	  treated	  up	  to	  a	  cumulative	  dose	  of	  750	  to	  800	  
mCi	   (27.8	  to	  29.6	  GBq;	  corresponding	  with	  a	  radiation	  dose	  to	  the	  bone	  marrow	  of	  2	  Gy),	  
unless	  dosimetric	  calculations	   indicated	  that	  the	  radiation	  dose	  to	  the	  kidneys	  would	  then	  
exceed	   23	   Gy;	   in	   these	   cases	   the	   cumulative	   dose	   was	   reduced	   to	   500	   to	   700	  mCi.	   Any	  
haematological	  toxicity	  grade	  3	  or	  4	  occurred	  in	  3.6%	  of	  administrations.	  Complete	  response	  
was	  seen	  in	  2%,	  partial	  response	  in	  28%	  and	  minor	  response	  in	  16%	  of	  patients.	  There	  was	  a	  
survival	  benefit	  of	  40	  to	  72	  months	  from	  diagnosis	  compared	  to	  historical	  controls.	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Bodei	  et	  al.	  have	  also	  published	  the	  results	  of	  a	  phase	  I-­‐II	  trial	  of	  177Lutetium	  DOTATATE	  in	  
SSTR2	  expressing	  neuroendocrine	  tumours	  in	  51	  patients.	  No	  major	  acute	  or	  delayed	  renal	  
or	  haematological	  toxicity	  was	  seen	  (one	  grade	  3	  leukopenia	  and	  thrombocytopenia).	  Partial	  
and	  complete	  responses	  were	  seen	  in	  32.6%.	  Overall	  survival	  was	  68%	  at	  36	  months	  (Bodei	  
2011).	  	  
	  
In	  these	  adult	  studies,	  177Lutetium	  DOTATATE	  has	  been	  well	  tolerated	  with	  a	  low	  incidence	  
of	  haematological	  and	  renal	  toxicity	  (the	  main	  side	  effects	  reported).	  	  
	  
Renal	   irradiation	   occurs	   by	   the	   proximal	   tubular	   reabsorption	   of	   the	   radiolabelled	  
somatostatin	   analogue	   and	   co-­‐administration	   of	   amino	   acid	   solution	   has	   been	   shown	   to	  
reduce	   the	   risk	   of	   renal	   damage,	   as	   has	   limiting	   the	   estimated	   cumulative	   dose	   to	   the	  
kidneys	  to	  23Gy	  or	  less	  (Bernard	  1997,	  Bodei	  2003).	  	  
	  
As	  can	  be	  seen	  in	  Table	  2.1,	  90Y	  has	  a	   long	  particle	  range	  and	  a	  higher	  β	  mean	  energy	  and	  
therefore	   is	  most	   suitable	   in	   theory	   for	   large	  metastatic	   deposits.	   In	   contrast,	   177Lu	   has	   a	  
much	  lower	  mean	  β	  energy	  and	  particle	  range	  making	  it	  more	  suitable	  for	  the	  treatment	  of	  
small	  metastases.	   For	   these	   reasons	   it	  has	  been	  hypothesised	   that	  a	   combination	  of	  both	  
therapies	  may	   be	   superior	   to	   either	   used	   alone.	   This	   has	   been	   examined	   clinically	   in	   the	  
adult	   neuroendocrine	   tumour	  population.	  Villard	   et	   al.	   published	   their	   results	  of	   a	   cohort	  
study	  of	   a	   total	   of	   486	  patients	  with	  metastatic	   neuroendocrine	   tumours	   to	   compare	   the	  
effectiveness	   of	   single	   versus	   combination	   therapy.	   237	  patients	   received	   [90Y-­‐DOTA]-­‐TOC	  
and	   249	   patients	   received	   [90Y-­‐DOTA]-­‐TOC	   +	   [177Lu-­‐DOTA]-­‐TOC.	   Patients	   receiving	   the	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combination	   therapy	   had	   an	   improved	   overall	   survival	   compared	   to	   the	   single	   therapy	  
patients	  (Villard	  2012).	  	  
	  
Table	  2.1	  Physical	  properties	  of	   the	  three	  most	  commonly	  used	  β	  emitting	  radionuclides	  
used	  for	  molecular	  radiotherapy	  
	   131I	   90Y	   177Lu	  
Half	  Life	  
	  
8.04	  days	   2.67	  days	   6.7	  days	  
Emissions	  
	  








0.45	   4.2	   0.27	  
	  
	  
90Y	   is	   a	  pure	  beta	  emitter	  and	   therefore	  historically	  dosimetry	  and	   imaging	  have	   required	  
concurrent	  administration	  of	   111In-­‐DTPA-­‐D-­‐Phe1-­‐octreotide	  whereas	   177Lu-­‐DOTATATE	  emits	  
gamma	  and	  beta	  radiation,	  allowing	  essential	  dosimetry	  measurements	  and	   imaging	  to	  be	  
performed	  from	  the	  same	  therapeutic	  administration.	  	  
	  
To	   select	   suitable	   patients	   for	   molecular	   radiotherapy	   with	   radiolabelled	   somatostatoin	  
analogues,	  68Gallium	  DOTATATE	  PET/CT	  has	  become	  the	  gold	  standard	  imaging	  modality	  in	  
adult	   patients	  with	   somatostatin	   positive	   neuroendocrine	   tumours.	   It	   has	   been	   shown	   to	  
have	  a	  higher	  sensitivity	  and	  improved	  spatial	  resolution	  for	  the	  detection	  of	  somatostatin	  
receptor	   positive	   tumours	   compared	   to	   somatostatin	   receptor	   scintigraphy	   with	  
conventional	   single	   photon	   emission	   computed	   tomography	   (SPECT)	   gamma	   camera	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imaging	  using	  for	  example,	  [111In-­‐DTPA0]octreotide	  (Octreoscan®)	  (Kowalski	  2003,	  Buchman	  
2007,	  Gabriel	  2007,	  Kayani	  2008).	  68Ga-­‐DOTATATE	  also	  has	  a	  high	  affinity	  for	  somatostatin	  
receptor	   subtype-­‐2,	   enabling	   selection	   of	   patients	   for	   therapy	   with	   radiolabelled	  
somatostatin	  analogues	  (Reubi	  2000,	  Reubi	  2003).	  	  
	  
123I-­‐mIBG	   remains	   the	   gold	   standard	   imaging	   modality	   for	   the	   diagnosis,	   staging	   and	  
response	   assessment	   of	   metastatic	   neuroblastoma.	   However,	   it	   does	   have	   limitations,	  
including	   poor	   spatial	   resolution	   and	   obvious	   difficulties	   in	   the	   10%	   of	   neuroblastoma	  
patients	  with	  mIBG	  negative	  disease.	  
	  
Many	   neuroblastomas	   also	   express	   somatostatin	   receptors.	   There	   are	   five	   subtypes	   of	  
somatostatin	   receptor,	   SSTR1-­‐5,	   but	   the	   most	   frequently	   expressed	   in	   neuroblastoma	  
tissues	  has	  been	  somatostatin	  receptor	  type-­‐2	  (SSTR2)	  (O’Dorisio	  1994,	  Georgantzi	  2010).	  	  
	  
The	  SSTR-­‐2	  gives	  a	  separate	  and	  distinct,	  alternative	  molecular	  target	  to	  the	  Noradrenaline	  
Transporter	  molecule	   (NAT)	   that	   is	   targeted	  by	  mIBG.	   The	   frequency	  of	   SSTR2	  expression	  
has	   been	   reported	   to	   be	   between	   80-­‐90%	   of	   neuroblastomas	   studied	   (Albers	   2000,	  
Georgantzi	  2010)	  but	  we	  have	  found	  it	  to	  be	  highly	  variable	  in	  our	  own	  series	  (see	  chapter	  
3).	  	  
	  
The	   work	   in	   this	   chapter	   reports	   on	   the	   radiolabelled	   somatostatin	   analogue,	   68Ga-­‐
DOTATATE	  PET/CT,	  for	  imaging	  of	  neuroblastoma	  as	  well	  as	  the	  first	  pilot	  study	  on	  the	  use	  
of	  177Lutetium	  DOTATATE	  for	  neuroblastoma	  and	  the	  development	  of	  a	  phase	  II	  trial	  to	  look	  
at	  efficacy	  and	  toxicity	  of	  177Lutetium	  DOTATATE	  in	  refractory	  and	  relapsed	  neuroblastoma.	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2.2	   A	   comparison	   of	   68Ga-­‐DOTATATE	   and	   123I-­‐mIBG	   for	   disease	  
assessment	  in	  high-­‐risk	  neuroblastoma	  
2.2.1	  Materials	  and	  Methods	  
High-­‐risk	  neuroblastoma	  patients	  who	  had	  been	  imaged	  with	  both	  68Ga-­‐DOTATATE	  PET/CT	  
and	  123I-­‐mIBG	  were	  identified.	  Patients	  were	  imaged	  at	  diagnosis	  or	  when	  they	  had	  primary	  
refractory	  or	  relapsed	  disease.	  Patients	  with	  three	  month	  or	  greater	  gap	  between	  the	  two	  
scans	  were	  excluded.	   If	   a	  patient	  had	  more	   than	  one	   set	  of	  paired	   scans	   (e.g.	  before	  and	  
after	  treatment)	  only	  one	  set	  (typically	  that	  before	  treatment	  when	  the	  disease	  burden	  was	  
greater)	  was	  used.	  
	  
For	   the	   68Ga-­‐DOTATATE	   PET/CT,	   all	   patients	   were	   imaged	   according	   to	   local	   protocol	  
(Virgolini	  2010)	  on	  a	  Discovery	  STE	  PET/CT	  system	  (GE	  Healthcare).	  Patients	  were	   injected	  
intravenously	  with	  at	  least	  100MBq	  for	  adequate	  image	  quality.	  Imaging	  took	  place	  at	  least	  
45	  minutes	  but	  no	  longer	  than	  an	  hour	  after	  injection.	  A	  low-­‐dose	  scout	  projection	  (120kVp;	  
10mA;	   pitch,	   1.75)	  was	   used	   to	   localize	   the	   region	   of	   head	   to	   thigh	   for	   transmission	   and	  
emission	   imaging.	   CT	   was	   performed	   at	   140kVp	   and	   40mA	   for	   paediatrics.	   PET	   was	  
performed	  in	  3-­‐dimensional	  mode	  with	  4	  min	  per	  bed	  position.	  Iterative	  reconstruction	  with	  
21	  subsets	  was	  performed	  with	  attenuation	  correction.	  
	  
Prior	  to	  123I-­‐mIBG	   imaging,	  all	  patients	  received	  thyroid	  blockade	  by	  oral	  administration	  of	  
Potassium	  Iodide.	  In	  addition,	  all	  other	  medicines	  known	  to	  interfere	  with	  tumour	  uptake	  of	  
radiolabelled	  mIBG	  were	  discontinued.	  UCLH	  patients	  were	  imaged	  on	  a	  GE	  Infinia	  Hawkeye	  
4	  gamma	  camera	  system.	  Imaging	  was	  performed	  at	  4	  and	  24	  hours	  post-­‐injection.	  Whole-­‐
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body	  images	  were	  obtained	  at	  both	  time-­‐points	  and	  SPECT/CT	  images	  acquired	  immediately	  
after	  the	  24	  hour	  whole	  body	   image.	  Whole-­‐body	   images	  were	  obtained	  using	   low-­‐energy	  
high-­‐resolution	  collimators	  with	  a	  20%	  energy	  window	  centred	  over	  a	  159keV	  photopeak.	  
SPECT/CT	   images	  were	   acquired	  with	   an	   additional	   scatter	  window	   centred	   over	   130keV.	  
Projection	   time	   was	   40s	   and	   120	   projections	   acquired,	   with	   the	   region	   to	   be	   evaluated	  
assessed	   from	   the	   patient	   history	   and	   whole-­‐body	   image.	   Localisation	   was	   aided	   with	   a	  
planar	  x-­‐ray	  scout	  view.	  Following	  SPECT,	  low-­‐dose	  CT	  was	  acquired	  with	  slice	  thickness	  of	  
1mm.	  Data	  was	  reconstructed	  using	  iterative	  reconstruction	  (20	  iterations)	  with	  attenuation	  
correction	  derived	   from	  CT.	  Scatter	   correction	  was	  also	  applied.	  There	  were	  patients	  who	  
had	  for	  logistical	  reasons	  123I-­‐mIBG	  imaging	  in	  other	  nuclear	  medicine	  departments.	  
	  
The	   uptake	   pattern	   of	   68Ga-­‐DOTATATE	   PET/CT	   with	   maximum-­‐intensity	   projection	   (MIP)	  
with	   123I-­‐mIBG	   whole-­‐body	   scan	   (24	   hour	   scan)	   were	   then	   compared.	   The	   scans	   were	  
evaluated	   by	   two	   semi-­‐quantitative	   scoring	   systems	   to	   fully	  map	   the	   extent	   of	   disease	   in	  
bone/bone	  marrow	  and	  soft-­‐tissue.	  
	  
To	  assess	  the	  disease	  extent	  in	  the	  skeleton	  we	  used	  the	  SIOPEN	  semi-­‐quantitative	  scoring	  
system	  (Lewington	  2009).	  The	  score	  divides	  the	  skeleton	  into	  12	  anatomical	  segments.	  The	  
extension	  score	   is	  graded	   from	  0-­‐6	   for	  each	  segment:	  0	   (no	   involvement),	  1	   (one	  discreet	  
lesion),	   2	   (2	   discrete	   lesions),	   3	   (3	   discreet	   lesions),	   4	   (>3	   discrete	   foci	   or	   a	   single	   diffuse	  
lesion	   involving	   <50%	   of	   a	   bone),	   5	   (diffuse	   involvement	   of	   >50	   to	   95%	   whole	   bone),	   6	  
(diffuse	  involvement	  of	  the	  entire	  bone).	  This	  therefore	  gives	  a	  maximum	  score	  out	  of	  72.	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The	  SIOPEN	  scoring	  system	  was	  devised	   for	   scoring	  mIBG	  scans	  and	  does	  not	   include	  soft	  
tissue	  disease.	  There	  are	  other	  semi-­‐quantitative	  scoring	  systems	   in	  use	  such	  as	   the	  Curie	  
system	   (see	  Chapter	   1).	   The	   SIOPEN	   system	  was	   chosen	   in	   this	   situation,	   as	  we	   are	  most	  
familiar	  with	  it,	  it	  has	  more	  anatomical	  segments	  than	  the	  Curie	  system	  and	  a	  wider	  range	  of	  
scores	  so	  potentially	  allowing	  a	  greater	  degree	  of	  discrimination.	  	  
	  
For	  the	  soft	  tissue	  score,	  a	  soft	  tissue	  scoring	  system	  for	  the	  primary	  tumour	  and	  other	  soft	  
tissue	  locations	  was	  used	  giving	  a	  total	  score	  total	  out	  of	  5:	  uptake	  in	  primary	  (0-­‐1),	  uptake	  
in	   liver/lung	   (0-­‐2),	   uptake	   in	   other	   soft	   tissue	   site	   (0-­‐2).	   This	   is	   a	   similar	   approach	   as	  
published	  by	  Papathanasiou	  et	  al.	   (2011).	  There	  is	  no	  recognised	  semi-­‐quantitative	  scoring	  
system	  for	   68Ga-­‐DOTATATE	  PET/CT’s	  so	  the	  same	  SIOPEN	  scoring	  system	  was	  used	   for	   the	  
comparison	   of	   the	   two	   imaging	  modalities.	   The	   SIOPEN	   semi-­‐quantitative	   scoring	   system	  
only	  utilises	  data	  form	  planar	  scintigraphy.	  To	  enable	  a	  fair	  comparison	  between	  the	  scans	  
we	   therefore	   used	   the	  MIP	   from	   the	   68Ga-­‐DOTATATE	   scans.	   The	   scans	  were	   also	   given	   a	  
comment	  on	  overall	  concordance	  of	  the	  lesions	  between	  the	  two	  scans.	  	  
	  
An	  overall	  assessment	  score	  was	  given	  as	  follows:	  
1	  –123I-­‐mIBG	  better	  than	  68Ga-­‐DOTATATE	  at	  mapping	  disease	  extent	  
2	  –	  68Ga-­‐DOTATATE	  better	  than	  123I-­‐mIBG	  at	  mapping	  disease	  extent	  
3	  –	  68Ga-­‐DOTATATE	  and	  123I-­‐mIBG	  equal	  at	  mapping	  disease	  extent	  
	  
Scoring	   of	   the	   scans	   was	   done	   jointly	   by	   a	   nuclear	   medicine	   physician	   and	   myself,	   and	  




There	   were	   32	   high-­‐risk	   neuroblastoma	   patients	   eligible	   for	   the	   study	   and	   their	  
characteristics	  are	  shown	  in	  table	  2.2.	  	  
Table	  2.2	  Characteristics	  of	  patients	  with	  paired	  123I-­‐mIBG	  and	  68Ga-­‐DOTATATE	  scans	  
Patient	  No.	   Age	   Sex	   Disease	  Status	   MYCN	  
1	   7	   M	   Stage	  M	  –	  relapse	   N	  
2	   5	   M	   Stage	  M	  –	  relapse	   N	  
3	   27	   F	   	  Stage	  M	  –	  relapse	   N	  
4	   24	   F	   	  Stage	  M	  –	  relapse	   N	  
5	   18	   M	   Stage	  M	  (LN	  only)	  -­‐
refractory	  
N	  
6	   15	   M	   Stage	  M	  -­‐	  refractory	   N	  
7	   14	   F	   Stage	  L2	  -­‐	  diagnosis	   Y	  
8	   9	   F	   Stage	  M	  –	  relapse	   N	  
9	   7	   F	   Stage	  M	  –	  relapse	   N	  
10	   9	   M	   Stage	  M	  –refractory	   N	  
11	   7	   M	   Stage	  L2	  –	  relapse	   N	  
12	   7	   M	   Stage	  M	  –	  refractory	   N	  
13	   8	   F	   Stage	  M	  –	  relapse	   Y	  
14	   5	   M	   Stage	  M	  –	  relapse	   N	  
15	   6	   F	   Stage	  M	  –	  refractory	   N	  
16	   3	   M	   Stage	  M	  –	  refractory	   N	  
17	   6	   M	   Stage	  M	  –	  refractory	   N	  
18	   3	   M	   Stage	  M	  –	  relapse	   Y	  
19	   46	   M	   Stage	  M	  –	  relapse	   N	  
20	   14	   M	   Stage	  M	  –	  diagnosis	   N	  
21	   4	   F	   Stage	  M	  –	  relapse	   N	  
22	   5	   F	   Stage	  M	  –	  relapse	   N	  
23	   7	   F	   Stage	  M	  –	  relapse	   N	  
24	   9	   F	   Stage	  M-­‐	  relapse	   N	  
25	   8	   M	   Stage	  M	  -­‐	  relapse	   N	  
26	   15	   F	   Stage	  M	  -­‐	  relapse	   N	  
27	   15	   F	   Stage	  M	  -­‐	  relapse	   N	  
28	   9	   F	   Stage	  M-­‐	  relapse	   N	  
29	   21	   M	   Stage	  M	  -­‐	  relapse	   N	  
30	   4	   M	   Stage	  M	  -­‐	  relapse	   N	  
31	   10	   F	   Stage	  M	  -­‐	  refractory	   N	  
32	   2	   M	   Stage	  M	  -­‐	  refractory	   N	  
	  




Table	  2.3	  The	  SIOPEN	  and	  soft	  tissue	  scores	  for	  123I-­‐mIBG	  and	  68Ga-­‐DOTATATE	  scans	  








SIOPEN	   Soft	  
Tissue	  
SIOPEN	   Soft	  
Tissue	  	  
	   	   	   	   	   	   	  
1	   8	   1	   35	   2	   D	   2	  
2	   23	   0	   52	   0	   D	   2	  
3	   8	   2	   17	   2	   C	   2	  
4	   0	   1	   2	   1	   D	   2	  
5	   0	   2	   0	   2	   C	   3	  
6	   4	   3	   26	   4	   D	   2	  
7	   0	   1	   0	   2	   C	   3	  
8	   50	   0	   51	   0	   C	   3	  
9	   6	   1	   0	   1	   D	   1	  
10	   0	   0	   2	   1	   D	   2	  
11	   0	   0	   0	   1	   D	   2	  
12	   0	   1	   0	   1	   C	   3	  
13	   0	   1	   0	   1	   C	   3	  
14	   6	   1	   19	   1	   D	   2	  
15	   0	   2	   6	   1	   D	   2	  
16	   2	   2	   2	   3	   D	   3	  
17	   9	   1	   20	   1	   D	   2	  
18	   0	   1	   0	   1	   C	   3	  
19	   8	   0	   12	   0	   D	   2	  
20	   24	   1	   13	   1	   C	   1	  
21	   1	   1	   2	   1	   C	   3	  
22	   1	   0	   1	   0	   C	   3	  
23	   14	   1	   39	   1	   D	   2	  
24	   4	   0	   43	   0	   D	   2	  
25	   22	   1	   21	   1	   D	   3	  
26	   28	   0	   36	   0	   D	   2	  
27	   0	   1	   5	   2	   D	   2	  
28	   24	   0	   30	   1	   D	   2	  
29	   36	   0	   43	   0	   C	   2	  
30	   1	   0	   13	   1	   D	   2	  
31	   11	   0	   12	   0	   D	   3	  
32	   53	   1	   53	   1	   C	   3	  
	  




68Ga-­‐DOTATATE	  PET/CT	  was	  positive	  in	  all	  32	  patients.	  The	  123I-­‐mIBG	  scan	  was	  positive	  in	  30	  
patients	  and	  negative	   in	  2	  patients.	  Overall	  the	  two	  imaging	  modalities	  were	  discordant	   in	  
19/32	  patients.	  
	  
68Ga-­‐DOTATATE	  PET	   identified	  bone	   lesions	   in	   25/32	  patients	   compared	   to	   22/32	   for	   123I-­‐
mIBG.	   The	  mean	   ±	   SD	   SIOPEN	   scores	   were	   significantly	   lower	   for	   the	   123I-­‐mIBG	   than	   the	  
68Ga-­‐DOTATATE	  (10.7	  ±	  14.5	  v’s	  17.3	  ±	  17.9;	  p<0.002)	  and	  a	  significant	  positive	  correlation	  
between	  the	  two	  scores	  was	  found	  (Pearson’s	  r=0.794,	  <0.001).	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Figure	  2.3	  
The	  SIOPEN	  skeletal	  scores	  were:	  68Ga-­‐DOTATATE	  =	  123I-­‐mIBG	  in	  3/26,	  68Ga-­‐DOTATATE	  <123I-­‐







68Ga-­‐DOTATATE	   identified	   soft	   tissue	   lesions	   in	   24/32	   patients	   compared	   to	   123I-­‐mIBG	   in	  
20/32	  patients.	  No	  significant	  difference	  was	  found	  between	  the	  soft	  tissue	  scores	  (mean	  ±	  
SD	   123I-­‐mIBG	   0.81	   ±	   0.78	   v’s	   68Ga-­‐DOTATATE	   1.06	   ±	   0.91;	   Wilcoxon	   rank	   test	   p=0.06).	   A	  
significant	   positive	   correlation	   was	   found	   between	   the	   two	   soft	   tissue	   scores	   (Spearman	  






The	  soft	  tissue	  scores	  were:	  68Ga-­‐DOTATATE=123I-­‐mIBG	  in	  14/24,	  68Ga-­‐DOTATATE<123I-­‐mIBG	  















Figures	  2.5	  	  –	  2.13	  	  	  Clinical	  examples	  of	  the	  different	  uptake	  patterns	  seen	  for	  patients	  on	  
the	  123I-­‐mIBG	  scan	  and	  68Ga-­‐DOTATATE	  PET.	  	  
Figure	  2.5	  
Patient	   32:	   equal	   SIOPEN	   scores	   for	   skeletal	   deposits	   (score=53)	   and	   soft	   tissue	   scores	  














Figure	  2.6	   	   	  Patient	  8:	  similar	  SIOPEN	  skeletal	  scores	  on	  123I-­‐mIBG	  (score=50)	  (A)	  and	  68Ga-­‐
DOTATATE	   PET	   (score=51)(B)	   and	   the	   areas	   of	   uptake	   were	   concordant.	   The	   soft	   tissue	  















Figure	  2.7	  Patient	  12:	  no	  skeletal	  deposits	  with	  uptake	  in	  the	  soft	  tissue	  mass	  only	  on	  123I-­‐














Figure	   2.8	   Patient	   20:	   Greater	   SIOPEN	   skeletal	   score	   on	   123I-­‐mIBG	   (score=24)	   (A)	   than	   on	  














Figure	  2.9	  	  Patient	  9:	  higher	  SIOPEN	  skeletal	  score	  on	  123I-­‐mIBG	  (SIOPEN	  skeletal	  score	  =	  6)	  
(A)	   than	  68Ga-­‐DOTATATE	  PET	   (SIOPEN	  skeletal	   score	  =	  0)	   (B).	  The	  soft	   tissue	  score	  =	  1	   	  on	  











Figure	   2.10	   	   Patient	   15.	   This	   patient	   had	   higher	   SIOPEN	   and	   soft	   tissue	   scores	   on	   68Ga-­‐
DOTATATE	   (SIOPEN	  skeletal	   score	  =	  6)	   (B)	   than	   123I-­‐mIBG	   (SIOPEN	  skeletal	   score	   	  =	  0)	   (A).	  
However,	  the	  soft	  tissue	  score	  was	  greater	  on	  the	  123ImIBG	  (soft	  tissue	  score	  =	  2)	  than	  the	  












Figure	  2.11	  Patient	  2.	  This	  patient	  had	  higher	  SIOPEN	  skeletal	  scores	  on	  68Ga-­‐DOTATATE	  PET	  
(SIOPEN	   skeletal	   score	   =	   52)	   (B)	   than	   123I-­‐mIBG	   (SIOPEN	   skeletal	   score	   =	   23)	   (A).	   The	   soft	  













Figure	  2.12:	  Patient	  1.	  This	  patient	  had	  higher	  SIOPEN	  skeletal	  scores	  	  and	  soft	  tissue	  score	  
on	  68Ga-­‐DOTATATE	  PET	  (SIOPEN	  skeletal	  score	  =	  35)	  (soft	  tissue	  score	  =	  2)(B)	  than	  123I-­‐mIBG	  









Figure	   2.13:	   Patient	   had	   discordant	   uptake	   on	   the	   two	   imaging	  modalities.	   The	   123I-­‐mIBG	  
scan	   showing	   good	   uptake	   in	   the	   right	   hemithorax	   and	   no	   bone	  metastatases.	   The	   68Ga-­‐
DOTATATE	  scan	  showing	  multiple	  bone	  metastases	  and	  less	  uptake	  in	  the	  right	  hemithorax	  










2.3	  177Lutetium	  DOTATATE	  molecular	  radiotherapy	  for	  neuroblastoma	  
	  
The	  rationale	  for	  using	  177Lutetium	  DOTATATE	  in	  neuroblastoma	  include:	  
1. Neuroblastoma	  is	  a	  radiosensitive	  disease	  
2. The	   outcome	   for	   relapsed	   and	   refractory	   neuroblastoma	   is	   very	   poor	   and	   new	  
therapeutic	  options	  are	  required	  
3. Molecular	  radiotherapy	  can	  target	  multiple	  tumour	  deposits	  with	  radiation	  from	  the	  
same	  administration	  
4. SSTR2	  receptors	  are	  frequently	  expressed	  by	  neuroblastomas	  
5. 177Lutetium	  DOTATATE	  involves	  a	  distinct	  and	  separate	  cell	  surface	  molecular	  target	  
to	  the	  noradrenaline	  transporter	  molecule	  targeted	  by	  mIBG	  
6. PRRT	  has	  been	  used	  with	  good	  response	  rates	  and	  low	  incidence	  of	  toxicity	  in	  adults	  
with	  somatostatin	  positive	  neuroendocrine	  tumours	  
	  
	  
2.3.1	  Materials	  and	  Methods	  
	  
This	   initial	  pilot	  study	  has	   involved	  13	  patients	  with	  relapsed	  or	  refractory	  neuroblastoma,	  
treated	   between	   2008	   and	   2012,	   at	   University	   College	   London	  Hospitals	   NHS	   Foundation	  




All	   patients	   were	   required	   to	   have	   a	   68Ga-­‐DOTATATE	   PET/CT	   prior	   to	   being	   selected	   for	  
therapy.	  Only	  those	  with	  uptake	  in	  the	  tumour	  deposits	  equal	  or	  greater	  than	  the	  uptake	  in	  
the	  liver	  were	  considered	  eligible	  for	  therapy	  with	  177Lu-­‐DOTATATE	  (Figure	  2.3)	  
	  
Figure	  2.14	  Patient	  with	  relapsed	  neuroblastoma	  showing	  different	  uptake	  patterns	  on	  123I-­‐
mIBG	  imaging	  (no	  uptake),	  18F-­‐FDG	  PET/CT	  (low	  grade	  uptake)	  and	  68Ga-­‐DOTATATE	  PET/CT	  
(avid	  uptake).	  This	  patient	  was	  considered	  a	  suitable	  candidate	   for	   177Lutetium	  DOTATATE	  
with	  avid	  uptake	  of	  68Ga-­‐DOTATATE	  in	  tumour	  deposits	  (SUVmax	  =	  )	  greater	  than	  the	  uptake	  
in	   the	   liver	   (SUVmax	  =	   ).	  This	  patient	  would	  not	  have	  been	  suitable	   for	   treatment	  with	  131I-­‐













Other	   eligibility	   criteria	   were	   that	   they	   had	   not	   been	   treated	   with	   prior	   radiolabelled	  
somatostatin	  analogues;	  had	  adequate	  haematological,	  renal	  and	  hepatic	   function;	  and	  an	  
adequate	  performance	  status	  for	  treatment.	  	  
	  
The	   parents	   or	   guardians,	   as	  well	   as	   comforters	   and	   carers,	   of	   each	   patient	   gave	  written	  
informed	   consent	   for	   treatment.	   	   The	   patients	   in	   this	   pilot	   study	   were	   treated	   on	   a	  
compassionate	  basis	  when	  no	  other	  treatment	  options	  were	  available.	  
	  
Patients	  were	   admitted	   into	   a	   dedicated	   radionuclide	   inpatient	   treatment	   room	   for	   their	  
177Lu-­‐DOTATATE	   therapy.	   Patients	   were	   supported	   by	   specialised	   paediatric	   medical	   and	  
nursing	  staff.	  
	  
177Lutetium	  was	   commercially	   obtained	   from	   IDB	   in	   Holland	   and	   the	  DOTATATE	   obtained	  
from	  Erasmus	  University,	  Holland.	  The	  177Luteitum	  DOTATATE	  was	  then	  reconstituted	  in	  at	  
the	  University	  College	  London	  Hospitals	  NHS	  Foundation	  Trust	  in-­‐house	  radiopharmacy.	  
	  
To	  prevent	  nausea	  or	  vomiting,	  Ondansetron	  was	  given	  twice	  daily	  orally	  for	  5	  days	  (5mg	  m-­‐
2;	  maximum	   8mg)	   and	   dexamethasone	   (250µg	   kg-­‐1)	   daily	   orally	   in	   2	   divided	   doses	   for	   5	  
days.	  
	  
Patients	  were	  given	  iv	  hydration	  with	  sodium	  chloride	  0.9%	  (3L/24h/1.7m2).	  To	  reduce	  the	  
dose	  to	  the	  kidneys,	  an	   intravenous	   infusion	  of	  amino	  acids	   (2.5%	   l-­‐lysine	  HCl	  and	  2.5%	  L-­‐
arginine	  in	  water	  for	  injection)	  at	  the	  rate	  of	  1Litre	  over	  4hours	  was	  commenced	  30	  minutes	  
prior	  to	  the	  infusion	  of	  the	  radiopharmaceutical.	  	  
 116 
	  
177Lu-­‐DOTATATE	   was	   administered	   intravenously	   by	   a	   nuclear	   medicine	   physician	   via	   a	  
second	  pump	  over	  30	  minutes.	  
	  
The	  administered	  activity	  of	  177Lu-­‐DOTATATE	  was	  planned	  to	  be	  a	  fixed	  administered	  activity	  
of	   7.4GBq	   but	   due	   to	   various	   problems	   with	   labelling	   and	   production	   it	   ranged	   from	  
2.56GBq	  to	  8GBq	  (median	  7GBq).	  Repeated	  administrations	  were	  planned	  at	  8	  to	  10	  week	  
intervals	  up	  to	  a	  maximum	  of	  4	  administrations.	  
	  
Whole-­‐body	  planar	  scans	  and	  SPECT/CT	  scans	  were	  performed	  after	  treatment	  to	  examine	  
uptake	  of	   the	   therapeutic	  agent	   (see	  Figure	  2.	   ).	  All	   acquisitions	  were	  performed	  on	  a	  GE	  
Infinia	  Hawkeye	  4	  dual	  detector	  system.	  Whole-­‐body	  planar	  scans	  were	  performed	  with	  an	  
emission	   window	   of	   208	   keV	  ±	  10%.	   Bed	   speed	   was	   10	   cm/min.	   SPECT/CT	   imaging	   was	  
performed	  with	  an	  emission	  window	  of	  208	  keV	  ±	  10%,	  with	  120	  projections	  and	  30	  s	  per	  
projection,	   CT	   scanning	  was	  performed	  at	   	   140	   kVp	   and	  2.5	  mA,	  with	   a	   slice	   thickness	   of	  
5mm.	   Iterative	   reconstruction	   was	   used	   (20	   subsets)	   with	   a	   3D	   Butterworth	   filter	   and	  








Figure	   2.15	   –	   A	   pre-­‐therapy	   68Ga-­‐DOTATATE	   PET/CT	  MIP	   image	   (Fig.	   2.15A)	   to	   document	  
disease	  extent	  and	  confirm	  suitability	   for	   therapy;	  and	  whole	  body	  planar	   scans	   following	  
administration	  of	  177Lu-­‐DOTATATE.	  Post	  administration	  1	  (Fig	  2.15B)	  and	  post	  administration	  
4	   (Fig	   2.15C)	   confirming	   uptake	   of	   the	   therapeutic	   agent	   in	   the	   neuroblastoma	   deposits	  






Following	  administration,	  weekly	  full	  blood	  counts,	  urea	  and	  electrolytes	  and	  liver	  function	  
tests	   were	   performed.	   Toxicity	   was	   graded	   using	   the	   Common	   Toxicity	   Criteria	   of	   the	  
National	   Cancer	   Institute	   version	   3.0.	   Patients	   were	   reviewed	   in	   the	   out-­‐patient	   clinic	   2	  
weeks	  after	  therapy,	  and	  re-­‐assessment	   	   68Ga-­‐DOTATATE	  PET/CT	  scans	  were	  performed	  at	  
6–8	  weeks	   post	   treatment.	   123I-­‐mIBG	   imaging	   and	   18F-­‐FDG-­‐PET	   imaging	  were	   also	   used	   in	  
response	  assessment,	  but	  not	  all	  of	  the	  patients	  were	  imaged	  with	  all	  of	  the	  modalities.	  Pre-­‐	  
and	  post-­‐treatment	  bone	  marrow	  aspiration	  and	  trephine	  were	  not	  routinely	  performed.	  




Thirteen	  patients	  with	  neuroblastoma	  have	  been	  treated	  with	  177Lu-­‐DOTATATE	  at	  University	  
College	  London	  Hospitals	  NHS	  Foundation	  Trust	  between	  August	  2008	  and	  March	  2013.	  10	  
had	  relapsed	  neuroblastoma	  and	  3	  had	  refractory	  disease.	  6	  were	  male	  and	  7	  female.	  The	  
median	   age	  was	   8	   years	   (range	  2-­‐23	   years).	   6	   patients	   had	  had	  prior	   131I-­‐mIBG	  molecular	  
radiotherapy	  and	  9	  patients	  had	  had	  prior	  myeloablative	  therapy.	  All	  patients	  were	  treated	  
on	  a	  compassionate	  basis	  when	  no	  other	  treatment	  options	  were	  available.	  
	  
Table	  2.4	  Patient	  characteristics	  of	  those	  treated	  with	  177Lu-­‐DOTATATE	  






1	  	   8	   F	   Relapsed	   Yes	   Yes	  
2	  	   9	   F	   Relapsed	   No	   No	  
3	  	   2	   M	   Refractory	   Yes	   Yes	  
4	   6	   M	   Refractory	   No	   No	  
5	  	   7	   F	   Relapsed	   No	   Yes	  
6	  	   14	   F	   Refractory	   No	   Yes	  
7	  	   9	   M	   Relapsed	   Yes	   Yes	  
8	  	   8	   F	   Relapsed	   Yes	   Yes	  
9	  	   23	   F	   Relapsed	   Yes	   No	  
10	  	   5	   M	   Relapsed	   Yes	   No	  
11	   7	   M	   Relapsed	   Yes	   No	  
12	  	   8	   M	   Relapsed	   Yes	   No	  








Table	  2.5	  The	  number	  of	  cycles	  administered,	  administered	  activities	  of	  177Lu-­‐DOTATATE	  (in	  
GBq)	   and	   maximum	   renal	   and	   haematological	   toxicities	   encountered	   for	   all	   13	   patients	  



















1	   2	   7.4,	  7.4	   Post	  2,	  
plts	  
x	   x	  
2	  	   2	   5.2,	  7.3	   -­‐	   Post	  2,	  
plts	  
x	  
3	  	   3	   7.2,	  7.1,	  7.4	   *	   *	   x	  
4	  	   3	   7.4,	  7.2,	  7.1	   No	   x	   x	  
5	  	   2	   7.4,	  7.5	   Post	  2,	  
plts	  
x	   x	  
6	  	   3	   4.04,	  7.4,	  7.2	   Post	  3,	  
plts	  
x	   x	  
7	  	   2	   7.4,	  7.6	   x	   x	   x	  
8	  	   1	   2.56	   x	   x	   x	  




x	   x	  
10	  	   4	   7.2,	  7.39,	  7.4,	  
7.3	  
*	   *	   x	  
11	  	   1	   7.36	   x	   x	   x	  
12	  	   2	   8,	  7.6	   x	   Post	  2,	  
plts	  
x	  
13	  	   1	   7.75	   *	   *	   x	  
	  








Table	  2.6	  Radiological	  and	  clinical	  responses	  for	  13	  patients	  treated	  with	  177Lu-­‐DOTATATE	  
	  
Patient	  No	   No	  of	  cycles	   Response	  	  
1	   2	   Initial	   metabolic	   response;	   stable	   disease	   by	   RECIST;	  
subsequent	  progressive	  disease	  
2	   2	   Initial	  metabolic	  response;	  stable	  disease	  by	  RECIST	  at	  8	  wk;	  
subsequent	  progressive	  disease	  at	  5	  months	  
3	  	   3	   Partial	  metabolic	  response;	  stable	  disease	  by	  RECIST	  
4	  	   3	   Stable	  disease	  by	  RECIST;	  no	  metabolic	  response	  
5	  	   2	   Stable	  disease	  by	  RECIST;	  no	  significant	  metabolic	  response	  
6	  	   3	   Progressive	  disease	  
7	  	   2	   Progressive	  disease	  
8	  	   1	   Progressive	  disease	  
9	  	   4	   Partial	  response	  by	  RECIST;	  partial	  metabolic	  response	  
10	  	   4	   Clinical	   response	   with	   reduction	   in	   pain	   and	   improved	  
performance	  status	  
11	  	   1	   Progressive	  disease	  
12	  	   2	   Progressive	  disease	  after	  2	  cycles	  















Figure	  2.16	  –	  68Ga-­‐DOTATATE	  PET/CT	  before	  and	  after	  4	  administrations	  of	  177Lu-­‐DOTATATE	  
(7.4GBq	  per	  administration).	  Whole	  body	  planar	  view	  (A	  and	  B)	  and	  axial	  slice	  through	  the	  












Pretreatment	  68Ga-­‐DOTATATE	  PET/CT	  showing	  68Ga-­‐DOTATATE-­‐avid	  lesions	  in	  the	  T4	  vertebral	  
body	  and	  three	  metastases	  in	  the	  liver.	  Physiological	  uptake	  is	  seen	  in	  the	  pituitary,	  kidneys,	  
bladder,	   stomach	   wall,	   liver	   and	   spleen.	   	   Repeat	   68Ga-­‐DOTATATE	   PET/CT	   1	   year	   later	   post	  
three	   administrations	   of	   177Lu-­‐DOTATATE,	   showing	   a	   metabolic	   partial	   response	   with	  
reduction	   in	   the	   SUVmax	   of	   the	   lesion	   in	   T4	   (SUVmax	   reduced	   from	  13.2	   to	  9.9)	   and	   the	   liver	  
(lesion	   segment	   V,	   SUVmax	   	   reduced	   from	   25.8	   to	   11)	   and	   no	   new	   lesions.	   Cross-­‐sectional	  
imaging	   showed	   a	   reduction	   in	   the	   size	   of	   the	   liver	   lesions	   although	   the	   patient	   had	   stable	  






2.4	   LuDO	   –	   a	   phase	   IIa	   trial	   of	   177Luetium	   DOTATATE	   in	   relapsed	   and	  
refractory	  neuroblastoma	  
	  
Following	   the	   demonstration	   on	   imaging	   with	   68Ga-­‐DOTATATE	   PET/CT	   that	   patients	   with	  
relapsed	   or	   refractory	   disease	  may	   benefit	   from	   therapy	   with	   radiolabelled	   somatostatin	  
analogues,	   and	   promising	   data	   of	   safety	   and	   activity	   of	   177Lutetium	   DOTATATE	   in	   a	   pilot	  
study,	   a	   phase	   IIa	   trial	   has	   been	   developed.	   The	   trial	   concept	   was	   initially	   developed	   by	  
myself	  and	  Dr	  Mark	  Gaze	  at	  University	  College	  London	  Hospital	  NHS	  Foundation	  Trust.	  I	  had	  
it	   accepted	   for	   presentation	   and	   development	   by	  myself	   at	   the	   joint	  Methods	   in	   Clinical	  
Cancer	   Research,	   Jointly	   organised	  by	   ECCO,	  AACR,	   EORTC,	   ESMO	   in	   Flims,	   Switzerland	   in	  
June	  2010.	  The	  LuDO	  trial	  was	   then	  presented	  and	  approved	  by	   three	  of	   the	  NCRI	  clinical	  
studies	  subgroups	  -­‐	  CTRad,	  Neuroblastoma	  subgroup	  and	  Novel	  Agents	  subgroup	  and	  then	  
by	  the	  main	  CCLG	  CSG.	  The	  trial	  was	  then	  taken	  on	  by	  the	  CRUK	  Clinical	  Trials	  Unit	  at	   the	  
University	  of	  Birmingham	   for	   statistical	   input	  and	  preparation	   for	   the	  grant	  application	   to	  
CTAAC,	   as	  well	   as	   submission	   to	  ethics	  ARSAC	  and	  Research	  and	  Development.	  The	   LuDO	  
trial	   has	   now	   received	   funding	   through	   CRUK	   via	   CTAAC	   and	   opened	   to	   recruitment	   in	  





The	  LuDO	  trial	  will	  be	  the	  first	  study	  to	  assess	  response	  rate,	  progression	  free	  survival	  and	  
toxicity	  of	   177Lutetium	  DOTATATE	   in	   children	  with	   relapsed	  or	  primary	   refractory	  high	   risk	  
neuroblastoma.	  
	  
LuDO	   is	   a	   Phase	   IIa,	   open	   label,	   single	   centre,	   single	   arm	   Simon	   two	   stage	   design	   clinical	  
trial.	  The	  primary	  objective	   is	  to	  evaluate	  the	  activity	  of	  177Lutetium	  DOTATATE	  in	  children	  
with	   high	   risk	   relapsed	   or	   primary	   resistant	   neuroblastoma.	   The	   secondary	   objectives	  
include	  describing	  the	  safety	  and	  adverse	  effects	  of	  177Lutetium	  DOTATATE	  in	  children	  with	  
primary	  refractory	  or	  relapsed	  neuroblastoma,	  correlating	  tumour	  dosimetry	  (the	  absorbed	  
dose	   in	  Gray)	  with	   response	   in	  patients	   treated	  with	   this	   regime,	  correlating	  somatostatin	  
type	   2	   receptor	   (SSTR2)	   expression	   in	   the	   original	   histology	   with	   68Gallium	   DOTATATE	  
PET/CT	   uptake	   and	   correlating	   the	   uptake	   on	   68Gallium	   DOTATATE	   PET/CT	   by	   SUVmax	  
(maximum	  standardized	  uptake	  value)	  with	  response	  to	  177Lutetium	  DOTATATE	  therapy.	  
	  
The	  trial	  will	  include	  children	  and	  young	  People	  >	  18	  months	  to	  <	  18	  years	  old	  with	  high	  risk,	  
relapsed	  or	  primary	  refractory	  neuroblastoma	  (INSS	  stage	  4	  or	  INRG	  stage	  M).	  Children	  with	  
high	   risk	   relapsed	   or	   refractory	   neuroblastoma	   will	   be	   assessed	   for	   suitability	   with	  
177Lutetium	  DOTATATE	  by	  68Gallium	  DOTATATE	  PET/CT.	  Eligible	  patients	  must	  have	  uptake	  
in	  the	  tumour	  deposits	  at	  least	  as	  high	  as	  the	  uptake	  in	  the	  liver.	  	  
	  
Adequate	  dosimetry	  is	  essential	  for	  safe	  and	  effective	  treatment	  with	  177Lu-­‐DOTATATE	  –	  the	  
kidneys	   and	   the	   bone	  marrow	   being	   the	   dose	   limiting	   organs.	   There	   is	   an	   unpredictable	  
relationship	  between	  the	  administered	  activity	  (in	  GBq)	  of	  a	  molecular	  radiotherapy	  agent	  
and	   the	  absorbed	  dose	   (in	  Gy)	   to	  both	   the	  normal	   tissues	   and	   the	   tumour.	   Individualised	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patient	  dosimetry	  is	  gaining	  International	  recognition	  as	  an	  essential	  part	  of	  treatment	  with	  
molecular	   radiotherapy	   with	   the	   aim	   of	   improving	   the	   therapeutic	   index	   and	   minimising	  
toxicity.	   This	   becomes	   of	   paramount	   importance	   in	   this	   paediatric	   population	   who	   have	  
been	   heavily	   pre-­‐treated	   and	   frequently	   have	   bone	  marrow	   involvement.	   Neuroblastoma	  
patients	   are	   entirely	   different	   to	   the	   adult	   neuroendocrine	   tumour	   patient	   group	   in	   the	  
amount	  of	  treatment	  that	  they	  have	  received,	  the	  frequency	  of	  bone	  marrow	  disease	  and	  
their	  huge	  variations	  in	  size	  of	  the	  patients	  within	  the	  age	  group	  studied.	  Individual	  patient	  
dosimetry	   will	   therefore	   form	   an	   essential	   part	   of	   the	   LuDO	   trial.	   This	   will	   enable	   the	  
maximally	   tolerated	   administered	   activity	   to	   be	   delivered	   per	   patient	   whilst	   minimising	  
toxicity.	   The	   dosimetry	   data	   from	   the	   trial	   will	   help	   inform	   other	   177Lutetium	   DOTATATE	  
studies	  in	  adults	  and	  other	  potential	  somatostatin	  positive	  paediatric	  tumours.	  
	  
The	   administered	   activity	   for	   the	   first	   cycle	   will	   be	   weight	   based.	   The	   second	   cycle	  
administered	  activity	  will	  be	  dependent	  on	  the	  whole	  body	  dose	  (aiming	  for	  0.5Gy	  per	  cycle	  















Patients	  will	  receive	  up	  to	  4	  administrations	  of	  177Lutetium	  DOTATATE.	  The	  statistical	  design	  
is	  a	  Simons	  two-­‐stage	  design.	  14	  patients	  will	  be	  treated	  in	  step	  1	  and	  if	  a	  response	  is	  seen	  in	  
4	  out	  of	  the	  14	  patients	  we	  will	  move	  on	  to	  step	  2	  to	  recruit	  a	  further	  10	  patients.	  Therefore	  
the	  total	  sample	  size	  for	  the	  trial	  is	  24	  patients.	  
	  
The	  primary	  endpoint	  is	  response	  rate	  by	  International	  Neuroblastoma	  Response	  Criteria	  at	  
1	   month	   after	   the	   completion	   of	   therapy.	   Secondary	   endpoints	   include	   progression	   free	  
survival,	  overall	  survival	  and	  toxic	  effects	  and	  response	  rate	  by	  International	  Neuroblastoma	  
Response	  Criteria	  at	  4	  months	  after	  the	  completion	  of	  therapy.	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There	   are	   three	   translational	   studies	   within	   the	   trial.	   The	   tumour	   dose	   (in	   Gray)	   will	   be	  
correlated	  with	  response	  to	  establish	  whether	   it	   is	  only	  those	  tumour	  deposits	  receiving	  a	  
certain	   threshold	   dose	   that	   respond.	   Immunohistochemistry	   will	   be	   preformed	   on	   the	  
original	   histopathology	   samples	   for	   somatostatin	   type	   2	   receptor	   (SSTR2)	   expression	   and	  
then	   this	   will	   be	   correlated	   with	   the	   uptake	   on	   68Ga-­‐DOTATATE	   PET/CT.	   The	   change	   in	  
uptake	  on	  68Gallium	  DOTATATE	  PET/CT	  by	  SUVmax	  (maximum	  standardized	  uptake	  value)	  will	  




















This	   is	   the	   first	   reported	   evidence	   of	   the	   use,	   in	   children	   with	   neuroblastoma,	   of	   68Ga-­‐	  
DOTATATE	  PET/CT	   for	   therapy	   selection	  and	   response	  assessment	  and	  of	   177Lu-­‐DOTATATE	  
for	  molecular	  radiotherapy.	  The	  first	  six	  patients	  within	  the	  pilot	  study	  have	  been	  published	  
in	  the	  Journal	  of	  Nuclear	  Medicine	  by	  Gains	  et	  al.	  2011.	  
	  
The	  established	  effectiveness	  of	  peptide	  receptor	  radionuclide	  imaging	  and	  therapy	  in	  adult	  
neuroendocrine	   tumors	   provided	   the	   rationale	   to	   use	   this	   approach	   in	   children	   with	  
neuroblastoma.	   PRRT	   in	   adults	   with	   somatostatin-­‐positive	   neuroendocrine	   tumors	   has	  
resulted	  in	  improved	  symptoms,	  prolonged	  survival,	  and	  an	  enhanced	  quality	  of	  life.	  	  
	  
The	   use	   of	   68Ga-­‐DOTATATE	   PET/CT	   in	   neuroblastoma	   has	   not	   been	   previously	   reported.	  
There	   is	   one	   small	   study	   in	   the	   literature	   comparing	   68Ga-­‐DOTATOC	   PET	   and	   123I-­‐mIBG	  
imaging	   in	   5	   female	   patients	   with	   neuroblastoma.	   The	   68Ga-­‐DOTATOC	   PET	   was	   able	   to	  
detect	   more	   lesions	   with	   a	   sensitivity	   of	   97.2%	   (p<0.0001)	   compared	   to	   a	   sensitivity	   of	  
90.7%	  with	  123I-­‐mIBG	  (p<0.09)	  (Kroiss	  2011).	  	  
	  
Menda	  et	  al.	  reported	  a	  phase	  I	  trial	  using	  90Y-­‐DOTATOC	  in	  children	  and	  young	  adults	  with	  
tumors	   expressing	   somatostatin	   receptors,	   including	   two	   patients	   with	   neuroblastoma	  
(Menda	  2010).	  From	  their	  dosimetry	  data,	  they	  found	  the	  maximum	  tolerable	  dose	  of	  90Y-­‐
DOTATOC	   to	   be	   highly	   variable	   and	   proposed	   individualized	   dose	   administration	   as	   a	  
preferred	   method	   to	   improve	   efficacy	   and	   reduce	   toxicity.	   90Y	   is	   a	   pure	   β-­‐emitter,	   and	  
therefore	   dosimetry	   and	   imaging	   have	   historically	   required	   concurrent	   administration	   of	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111In-­‐DTPA-­‐D-­‐Phe1-­‐octreotide	   whereas	   177Lu-­‐DOTATATE	   emits	   γ-­‐	   and	   β-­‐radiation,	   allowing	  
essential	   dosimetry	   measurements	   and	   imaging	   to	   be	   performed	   from	   the	   same	  
administration.	  There	  have	  been	  reports	  on	  the	  feasibility	  of	  90Y	  PET/CT;	  the	  main	  limitation	  
is	  the	  data	  acquisition	  time	  (Walrand	  2010,	  Werner	  2010).	  
	  
A	  large	  amount	  of	  discordance	  was	  found	  in	  this	  cohort	  of	  patients	  between	  68Ga-­‐DOTATATE	  
and	  123I-­‐mIBG	  imaging.	  Most	  of	  the	  patients	   in	  this	  cohort	  were	   imaged	  at	  relapse	  or	  with	  
primary	  refractory	  disease	  and	  only	  a	  small	  number	  at	  diagnosis.	  As	  can	  be	  seen	  from	  Table	  
2.3,	   some	   patient’s	   neuroblastoma	   deposits	   preferentially	   took	   up	   123I-­‐mIBG	   and	   some	  
preferentially	   68Ga-­‐DOTATATE.	   This	   has	   implications	   for	   staging,	   response	   assessment	   and	  
treatment	  selection	  in	  neuroblastoma.	  We	  have	  seen	  within	  the	  same	  patient	  inter-­‐tumour	  
heterogeneity	   with	   some	   tumour	   deposits	   preferentially	   taking	   up	   123I-­‐mIBG	   and	   others	  
68Gallium	  DOTATATE	  (see	  figure	  2.13).	  
	  
There	  are	   two	  contributing	   factors	   to	   the	  different	  uptake	  patterns	  on	   the	   123I-­‐mIBG	   scan	  
and	   the	   68Ga-­‐DOTATATE	  PET/CT	  –	  a	  greater	  expression	  of	   SSTR2	   than	  NAT	  by	   the	   tumour	  
deposits	   	   and	  a	  greater	   spatial	   resolution	   for	   the	   68Ga-­‐DOTATATE	  PET/CT.	   124I-­‐mIBG	  PET	   is	  
currently	  being	  examined	  in	  a	  clinical	  trial	  sponsored	  by	  the	  CRUK	  Drug	  Development	  Office	  
and	   its	   potential	   greater	   spatial	   resolution	   will	   be	   examined.	   68Ga-­‐DOTATATE	   PET/CT	   in	  
neuroblastoma	  is	  still	  a	  research	  tool	  and	  its	  widespread	  use	  would	  need	  to	  be	  examined	  in	  
a	   large	  number	  of	  patients	  on	  a	  multicentre	  basis	   ideally	  with	  patients	  being	  treated	  on	  a	  
standard	  protocol	  or	  clinical	  trial	  and	  the	  limited	  availability	  of	  68Ga-­‐DOTATATE	  PET/CT	  will	  
currently	  limit	  this.	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The	  heterogeneity	  of	  uptake	  on	  123I-­‐mIBG	  and	  68Ga-­‐DOTATATE	  PET/CT	  does	  lead	  to	  support	  
for	   the	   use	   radiolabelled	   somatostatin	   analogues	   to	   be	   examined	   as	   a	   molecular	  
radiotherapy	  treatment	  option	  for	  neuroblastoma	  patients	  as	  well	  as	  131I-­‐mIBG.	  Within	  our	  
institution,	   if	   a	   patient	   with	   relapsed	   or	   refractory	   neuroblastoma	   is	   referred	   for	  
consideration	   of	   molecular	   radiotherapy	   we	   now	   image	   them	   with	   123I-­‐mIBG	   and	   68Ga-­‐
DOTATATE	  PET/CT	  to	  fully	  map	  the	  extent	  of	  disease	  and	  to	  enable	  the	  selection	  of	  the	  most	  
appropriate	  molecular	   radiotherapy	   agent	   for	   that	   individual.	   As	   has	   been	   shown	   above,	  
within	  the	  same	  patient	  there	  is	  heterogeneity	  between	  deposits	  of	  neuroblastoma	  and	  this	  
gives	  a	  good	  basis	  for	  possible	  future	  evaluation	  of	  combination	  radionuclide	  therapy.	  
	  
Neuroblastoma	  patients	  with	   somatostatin	   receptor–positive	  disease	   identified	  with	   68Ga-­‐
DOTATATE	  PET/CT	  were	  deemed	  eligible	  for	  therapy	  with	  177Lu-­‐DOTATATE.	  177Lu-­‐DOTATATE	  
offers	  a	  unique	  treatment	  target	  and	  differs	  from	  131I-­‐mIBG	  and	  chemotherapy	  in	  its	  mode	  
of	   action.	   Patients	  were	   considered	   eligible	   for	   therapy	   only	   if	   disease	   sites	   showed	   avid	  
uptake	  of	  68Gallium	  DOTATATE	  equal	  or	  greater	  than	  the	  uptake	  in	  the	  liver.	  	  Patients	  with	  
inadequate	   uptake	   by	   pre-­‐therapy	   functional	   imaging	   are	   likely	   to	   represent	   tumour	  
deposits	  with	  a	  poor	  expression	  of	   SSTR2	  and	   these	   tumours	  would	   therefore	  not	  uptake	  
sufficient	   177Lutetium	  DOTATATE	   to	  have	  a	   cytotoxic	   effect.	   The	   SIOPEN	   semi-­‐quantitative	  
scoring	   system	   used	   for	   assessment	   of	   both	   the	   68Ga-­‐DOTATATE	   and	   123I-­‐mIBG	   imaging	  
assesses	   the	   number	   and	   location	   of	   areas	   of	   uptake.	   The	   intensity	   of	   the	   uptake	   is	   not	  
taken	   into	  account.	   Therefore,	   even	   though	  only	  patients	  with	  uptake	   in	   tumour	  deposits	  
greater	   or	   equal	   to	   the	   uptake	   in	   the	   liver	   on	   68Ga-­‐DOTATATE	   PET	  would	   be	   suitable	   for	  
therapy	   with	   177Lu-­‐DOTATATE,	   68Ga-­‐DOTATATE	   PET/CT	   is	   a	   good	   tool	   for	   imaging	   and	  
response	  assessment	  of	  neuroblastoma.	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177Lu-­‐DOTATATE	  is	  not	  proposed	  as	  a	  competitor	  to	  131I-­‐mIBG	  but	  as	  a	  therapeutic	  option	  for	  
those	  who	  have	  relapsed	  or	  have	  primary	  refractory	  disease	  and	  who	  may	  or	  may	  not	  have	  
already	  received	  131I-­‐mIBG	  therapy.	  A	  combination	  of	  the	  two	  agents	  may	  be	  more	  effective	  
than	  either	  used	  alone.	  Although	  both	  cause	  myelosuppression,	  they	  may	  complement	  each	  
other	  in	  being	  able	  to	  deliver	  targeted	  radiation	  to	  different	  areas	  of	  the	  tumor,	  depending	  
on	  the	  molecular	  target	  expressed.	  We	  have	  seen	  clinically	  within	  our	  practice,	  inter-­‐tumour	  
heterogeneity	   in	   patients	  with	   neuroblastoma,	  with	   some	   tumour	   lesions	   taking	   up	  mIBG	  
and	  some	  octreotate,	  therefore	  showing	  differential	  expression	  of	  NAT	  and	  SSTR2.	  We	  have	  
also	  seen	  this	  on	  immunohistochemical	  analysis	  of	  both	  NAT	  and	  SSTR2	  (see	  chapter	  3).	  
	  
Objective	   responses	   to	   177Lu-­‐DOTATATE	  were	   seen	   in	   4	   patients	   a	   subjective	   response	   in	  
one,	   and	  2	   further	  patients	   had	   stable	  disease.	   The	  patients	   treated	  were	   all	   heavily	   pre-­‐
treated	  and	  referred	  when	  no	  further	  treatment	  options	  were	  available	  and	  it	   is	  therefore	  
not	  surprising	  that	  responses	  were	  not	  seen	  in	  all	  those	  cases.	  The	  treatment	  did	  not	  have	  a	  
detrimental	  impact	  on	  quality	  of	  life	  for	  these	  children.	  	  	  
	  
In	  studies	  of	  adults	  with	  neuroendocrine	  tumors,	  177Lu-­‐DOTATATE	  has	  been	  well	  tolerated,	  
with	  little	  acute	  toxicity.	  The	  dose-­‐limiting	  toxicities	  were	  renal	  and	  hematologic.	  For	  adult	  
neuroendocrine	  tumour	  patients,	  177Luteitum	  DOTATATE	  is	  often	  the	  first	  line	  of	  treatment	  
and	  patients	  very	  rarely	  have	  bone	  marrow	  disease.	  None	  of	  the	  children	  in	  our	  study	  have	  
developed	   any	   significant	   renal	   toxicity	   (although	   follow-­‐up	   duration	   is	   short).	   The	   pilot	  
study	  was	  feasible	  and	  the	  toxicity	  of	  177Luteitum	  DOTATATE	  was	  limited	  to	  haematological	  
toxicity.	   The	   incidence	   of	   haematological	   toxicity	   is	   much	   greater	   than	   in	   the	   adult	  
 132 
neuroendocrine	   tumour	   population	   treated	   with	   177Lutetium	   DOTATATE.	   This	   is	   not	  
surprising	   given	   that	   patients	   with	   neuroblastoma	   frequently	   have	   bone	  marrow	   disease	  
and	  have	  been	  heavily	  pre-­‐treated	  including	  high-­‐dose	  myeloablative	  therapy	  and	  131I-­‐mIBG	  
therapy	   in	   many.	   The	   fixed	   administered	   activity	   of	   7.4GBq	   used	   in	   adult	   studies	   of	  
177Luteitum	  DOTATATE	  does	  not	  reflect	  the	  varying	  size	  of	  children	  and	  published	  reports	  on	  
177Lutetium	  DOTATATE	  in	  adults	   include	  very	   little	  dosimetry	  on	  either	  tumour	  or	  organ	  at	  
risk	  doses.	  	  
	  
All	  of	  the	  patients	  in	  this	  study	  had	  end-­‐stage	  disease	  with	  few	  treatment	  options	  available	  
and	  a	  poor	  prognosis.	  We	  aimed	  principally	  to	  assess	  177Lu-­‐DOTATATE	  as	  a	  feasible	  therapy,	  
not	   its	   response.	   When	   disease	   was	   measurable,	   RECIST	   were	   used.	   Disease	   that	   was	  
evaluable	  but	  not	  measurable	  was	  assessed	  on	  123I-­‐mIBG	  scans	  or	  68Ga-­‐DOTATATE	  PET/CT.	  
An	  account	  of	  the	  metabolic	  response	  is	  also	  given,	  but	  we	  acknowledge	  that	  this	  is	  not	  yet	  
a	  validated	  approach.	  	  
	  
As	   discussed	   in	   chapter	   1,	   the	   standard	   method	   of	   response	   assessment	   for	   metastatic	  
disease	  in	  neuroblastoma	  is	  with	  123I-­‐mIBG.	  Many	  of	  the	  patients	  in	  this	  pilot	  study	  did	  not	  
have	   a	   123I-­‐mIBG	   scan	   for	   assessment	   of	   response	   as	   they	   were	   being	   treated	   on	   a	  
compassionate	  basis	  and	  we	  wanted	  to	  minimise	  the	  imaging	  the	  patients	  had	  to	  undergo	  at	  
this	   stage.	   123I-­‐mIBG	   imaging	   would	   be	   problematic	   in	   those	   patients	   who	   have	   mIBG	  
negative	  disease	  and	  in	  those	  patients	  who	  have	  heterogenous	  uptake	  with	  mIBG	  negative	  
areas	  of	  disease.	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It	  is	  not	  known	  whether	  a	  metabolic	  response	  on	  68Ga-­‐DOTATATE	  PET/CT	  corresponds	  with	  
an	  improved	  outcome	  for	  the	  patient	  and	  this	  is	  something	  that	  will	  be	  explored	  as	  part	  of	  
the	  LuDo	  trial.	  Within	  the	  adult	  neuroendocrine	  tumour	  population,	  who	  have	  been	  treated	  
with	   PRRT,	   decreased	   68Ga-­‐DOTATATE	  uptake	   in	   tumours	   after	   the	   first	   cycle	  was	   able	   to	  
predict	  time	  to	  progression	  and	  improvement	  in	  clinical	  symptoms	  (Haug	  2010).	  Therefore	  I	  
chose	   to	   report	   the	  metabolic	   response	  on	  68Ga-­‐DOTATATE	  PET/CT	  as	  well	  as	   response	  as	  
per	  RECIST	  criteria.	  	  
	  
Dosimetry	   for	   PRRT	   is	   still	   developing	   (Forrer	   2005,	   Cremonesi	   2010)	   and	  will	   become	   an	  
essential	   part	   of	   therapy	   with	   peptide	   receptor	   radionuclides	   because	   the	   same	  
administered	   activity	   results	   in	   a	   variable	   absorbed	   radiation	   dose	   in	   Gray	   to	   both	   the	  
tumour	   and	   the	   dose-­‐limiting	   organs	   at	   risk,	   especially	   the	   kidneys	   and	   bone	   marrow.	  
Individual	  patient	  dosimetry	  becomes	  even	  more	   important	   in	  the	  pediatric	  population,	   in	  
which	  there	  is	  a	  greater	  variation	  in	  body	  surface	  area,	  potentially	  requiring	  a	  modification	  
of	  the	  administered	  activity,	  and	  individuals	  cured	  of	  their	  cancer	  may	  live	  for	  decades	  with	  
late	   effects.	   Individualised	   dosing	   will	   be	   performed	   based	   on	   whole	   body	   dose	  
measurements	  and	  haematological	  toxicity	  within	  the	  LuDO	  trial.	  Tumour	  and	  organ	  at	  risk	  
doses	   will	   also	   be	   calculated.	   This	   data	   will	   be	   essential	   to	   the	   development	   of	   future	  
paediatric	  molecular	  radiotherapy	  trials.	  
	  
If	   177Lutetium	   DOTATATE	   is	   shown	   to	   be	   effective,	   future	   developments	   could	   include	  
potential	  combination	  therapy	  with	  131I-­‐mIBG,	  dose	  escalation	  with	  stem	  cell	  support	  or	  the	  











Immunohistochemical	  evaluation	  of	  
target	  expression	  in	  high-­‐risk	  
neuroblastoma	  tissue	  samples	  to	  





Molecular	  radiotherapy	  targeting	  the	  noradrenaline	  transporter	  (NAT)	  molecule	  with	  
metaiodobenylguanidine	   (mIBG)	   and	   the	   somatostatin	   receptor	   subtype-­‐2	   (SSTR2)	  
with	   177Lutetium	  DOTATATE	  are	   therapeutic	  options	   for	  patients	  with	   relapsed	  and	  
or	  refractory	  high-­‐risk	  neuroblastoma	  (see	  chapters	  2	  and	  4).	  
	  
mIBG	   plays	   an	   important	   role	   in	   the	  management	   of	   neuroblastoma	   as	   previously	  
discussed.	   123I	   labelled	   mIBG	   is	   essential	   for	   the	   diagnosis,	   staging	   and	   response	  
assessment	  of	  neuroblastoma.	  131I	  labelled	  mIBG	  is	  an	  important	  therapeutic	  option	  
for	  patients	  with	  relapsed	  or	  refractory	  disease.	  Response	  rates	  reported	  however,	  
are	   very	   variable	   between	   the	   studies	   reported	   (see	   chapter	   4).	  mIBG	   is	   primarily	  
taken	  up	  by	  the	  noradrenaline	  	  transporter	  molecule	  (NAT)	  encoded	  by	  the	  SLC6A2	  
gene	  (Glowniak	  1993).	  
	  
68Ga-­‐DOTATATE	   and	   177Lutetium	   DOTATATE	   are	   both	   radiolabelled	   somatostatin	  
analogues	  targeting	  SSTR2	  expressed	  by	  many	  neuroblastomas,	  one	  used	  for	  imaging	  
and	   the	   other	   for	   therapy	   (see	   chapter	   2).	   Somatostatin	   is	   a	   14	   or	   28	   amino	   acid	  
peptide	  found	  throughout	  the	  body.	  It	  works	  by	  the	  suppression	  of	  various	  peptide	  
hormones	   including	   pancreatic	   secretion,	   neurotransmission	   and	   gut	   motility.	  
Somatostatin	   acts	   on	   its	   various	   tissues	  mediated	   by	   the	   five	   known	   somatostatin	  
receptors	   –	   SSTR1,	   SSTR2,	   SSTR3,	   SSTR4	   and	   SSTR5.	   SSTR2	   is	   encoded	   for	   by	  
chromosome	  17	  and	  is	  found	  within	  various	  normal	  tissues	  including	  pancreatic	  islet	  
cells,	  kidney,	  stomach,	  duodenum	  and	  pituitary	  (Taniyama	  2005).	  SSTR2	  has	  been	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found	   to	   be	   present	   in	   many	   neuroendocrine	   tumours	   and	   radiolabelled	  
somatostatin	  analogues	  targeted	  against	  the	  SSTR2	  have	  been	  used	  for	  imaging	  and	  
therapy	   (see	   chapter	   2).	   Neuroblastomas	   have	   also	   been	   found	   to	   have	   a	   high	  
expression	  of	  SSTR2	  (Albers	  2000).	  Georgantzi	  et	  al.	  looked	  at	  the	  expression	  of	  the	  5	  
different	   somatostatin	   receptor	   subtypes	   (SSTR1-­‐5)	   by	   immunohistochemistry	   of	  
formalin	  fixed	  paraffin	  embedded	  tissue	  from	  11	  children	  with	  neuroblastoma	  stages	  
II-­‐IV	  (9	  of	  them	  stage	  IV).	  The	  most	  frequently	  expressed	  subtype	  was	  SSTR2,	  which	  
was	   present	   in	   90%	   of	   samples.	   SSTR4	  was	   the	   least	   frequently	   expressed	   in	   only	  
21%,	  with	  the	  others	  showing	  reasonable	  expression	  SSTR5	  in	  79%,	  SSTR1	  74%	  and	  
SSTR3	  in	  68%.	  The	  expression	  did	  not	  change	  significantly	  with	  treatment.	  They	  also	  
tested	  SSTR	  expression	   in	  5	  neuroblastoma	  cell	   lines	  and	  found	  variable	  expression	  
(Georgantzi	  2011).	   
	  
DOTATATE	  and	  mIBG	  therefore	  have	  distinct	  and	  separate	  molecular	  targets.	  As	  has	  
been	   shown	   in	   chapter	  2,	   there	   is	  a	   significant	  variability	  and	  heterogeneity	   in	   the	  
uptake	   on	   functional	   imaging	   of	   the	   two	   agents	   amongst	   neuroblastoma	   patients.	  
We	   have	   observed	   inter-­‐tumour	   variability	   on	   imaging	   with	   some	   patients	   having	  
discordant	  uptake	  patterns	  and	  disease	  distributions	  on	   imaging	  with	  some	   lesions	  





Figure	  3.1	   Heterogeneity	   of	   uptake	  of	   123I-­‐mIBG	   (Figure	   3.1A)	   compared	   to	   68Ga-­‐




Monoclonal	   antibodies	   directed	   against	   SSTR2	   and	  NAT	   for	   immunohistochemistry	  
are	   now	   commercially	   available.	   This	   study	   examines	   whether	   there	   is	   the	   same	  
degree	   of	   heterogeneity	   in	   protein	   expression	   for	   NAT	   and	   SSTR2	   as	   seen	   on	  
functional	   imaging	   and	   also	   examines	   whether	   the	   degree	   of	   expression	   is	   of	  
prognostic	   significance.	   The	   receptor	   expression	   of	   NAT	   and	   SSTR2	   are	   examined	  
across	   an	   unselected	   range	   of	   archival	   neuroblastoma	   tissue	   samples	   to	   allow	  
correlation	  with	  clinical	  parameters	  and	  refine	  understanding	  of	  the	  targets	  used	  for	  




3.2	  Material	  and	  Methods	  
	  
Archived	   formalin	   fixed	   paraffin	   embedded	   (FFPE)	   neuroblastoma	   tissue	   samples	  
were	   received	   from	   the	   Children’s	   Cancer	   and	   Leukaemia	   Group	   tissue	   bank.	  
Immunostaining	   was	   performed	   on	   an	   immunohistochemistry,	   Leica	   Bond-­‐Max	  
machine.	   Commercially	   available	   antibodies	   for	   NAT	   and	   SSTR2	   were	   used	   in	   this	  
study.	  For	  NAT,	  a	  monoclonal	  antibody,	  was	  obtained	  from	  Merck	  Millipore,	  Billerica,	  
Massachusetts	   (catalogue	   number	   MAB5620).	   For	   SSTR2,	   a	   monoclonal	   antibody,	  
UMB1,	   produced	  by	   Epitomics,	   distributed	  by	   Insight	   Biotechnology,	  Wembley,	  UK	  
(catalogue	   number	   3582-­‐1	   AC-­‐0162RUO)	   was	   used.	   The	   antibodies	   underwent	   in	  
house	  checking	  with	  positive	  and	  negative	  control	  tissues.	  This	  was	  adrenal	  medulla	  
for	  the	  NAT	  antibody	  and	  pancreatic	  tissue	  for	  the	  SSTR2.	  
	  
The	   FFPE	   slides	   were	   baked	   at	   60°c for	   1	   hour	   then	   de-­‐waxed	   and	   rehydrated	  
through	  graded	  alcohol	  solution.	  A	  peroxidase	  block	  was	  then	  applied	  to	  the	  slide	  for	  
5	  minutes.	  The	  primary	  antibody	  was	  then	  applied.	  For	  SSTR2	  a	  dilution	  of	  1:200	  was	  
applied	   for	   15	  minutes	   using	   heat	   induced	   epitope	   retrieval	   (HIER).	   For	   the	  NAT	   a	  
dilution	  of	  1:1000	  was	  used.	  Post	  primary	  for	  8	  minutes.	  A	  polymer	  was	  applied	  for	  a	  
further	  8	  minutes	  and	  DAB	  for	  10	  minutes.	  Haematoxylin	  was	  applied	  for	  a	  further	  5	  
minutes.	  
	  
Each	   slide	   was	   examined	   by	   myself	   and	   Neil	   Sebire,	   Professor	   of	   Paediatric	   and	  
Developmental	  Pathology	  at	  The	  Institute	  of	  Child	  Health,	  University	  College	  London,	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at	  Great	  Ormond	  Street	  Hospital	  NHS	  Foundation	  Trust.	  At	   the	  time	  of	  scoring,	  we	  
were	   blinded	   to	   information	   on	   stage,	   age	   and	   mycN	   status	   of	   the	   patient	   and	  
blinded	   to	   the	   results	  of	   the	  other	   immunostaining.	  The	   samples	  were	  categorised	  
on	   morphology	   into	   differentiating,	   poorly	   differentiated	   and	   undifferentiated	  
neuroblastomas.	  	  
	  
Each	   sample	  was	   then	   semi-­‐quantitatively	   scored	   for	   both	   of	   the	   antibodies	   (NAT	  
and	  SSTR2)	  for	  
1. Percentage	  cells	  staining	  with	  the	  antibody	  (0-­‐100%)	  
2. The	  intensity	  of	  expression	  of	  the	  antibody	  (0-­‐100%)	  
	  
These	  scores	  were	  estimated	  to	  the	  nearest	  10%.	  For	  the	  analysis,	  a	  composite	  score	  
combining	   the	   percentage	   cells	   staining	   and	   the	   intensity	   of	   expression	   was	   used	  
(Dubois	  2012,	  Volante	  2007).	  	  
	  
The	   choice	   of	   cut-­‐off	   points	   for	   categorising	   NAT	   and	   STTR2	   is	   not	   clear	   in	  
neuroblastoma	  and	  the	  prognostic	  influence	  of	  NAT	  and	  STTR2	  measures	  is	  unclear,	  
therefore	   analysis	   of	  measures	   in	   their	   original	   form	   (continuous,	  may	   take	   values	  
between	  zero	  and	  100)	  was	  performed.	   	  Categorising	  a	  continuous	  measure	  results	  
in	   loss	   of	   information	   and	  power.	   The	   results	   of	   IHC	   staining	   from	  NAT	  and	   SSTR2	  
were	  linked	  with	  known	  available	  data	  available	  from	  the	  CCLG	  tissue	  bank	  on	  age,	  
stage,	  MYCN	  amplification	  and	  outcome.	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Data	  was	  summarised	  using	  summary	  statistics	  (mean,	  standard	  deviation,	  medians,	  
range	  and	  proportions).	  Overall	  survival	  was	  calculated	  from	  the	  date	  of	  diagnosis	  to	  
date	   of	   death	   or	   date	   last	   seen	   for	   the	   alive	   patients.	   A	   Kaplan-­‐Meier	   curve	   is	  
presented	  for	  survival	  data.	  One,	  two	  and	  three	  year	  survival	  rates	  are	  shown	  with	  
95%	   confidence	   intervals	   (CI).	   Cox	   proportional	   hazards	   model	   used	   to	   compare	  
groups	  and	  calculate	  hazard	  ratios	  (HR).	  Martingale	  residuals	  plotted	  to	  verify	  linear	  


















In	   total,	   100	   tissue	   samples	  were	   received	   from	   the	  CCLG	   tissue	  bank.	   11	  patients	  
were	  excluded	  from	  the	  analysis	  –	  Wilms	  tumour	  (n=2),	  completely	  necrotic	  sample	  
(n=1),	  normal	  tissue	  (n=4),	  ganglioneuroblastoma	  (n=4).	  For	  10	  patients,	  two	  or	  more	  
samples	   were	   sent.	   In	   these	   cases,	   the	   earliest	   tumour	   sample	   was	   used	   for	   the	  
statistical	   analysis	   but,	   the	   cases	  with	  multiple	   samples	   are	   reported	   separately	   to	  
see	  if	  receptor	  expression	  changed	  with	  treatment	  (See	  Table	  3.1).	  
	  
75	  samples	  were	  available	  for	  statistical	  analysis.	  The	  majority	  of	  the	  samples	  were	  
poorly	  differentiated	  neuroblastoma	  (n=62),	  with	  the	  others	  being	  characterised	  on	  
morphology	  as	  differentiating	  (n=10)	  and	  undifferentiated	  (n=3).	  
	  
Marked	  variation	  in	  expression	  was	  seen	  between	  patients	  in	  individual	  tumour	  
samples	  for	  both	  the	  intensity	  and	  percentage	  expression	  of	  cells	  as	  shown	  in	  Figures	  








Figure	  3.2	  Histograms	  showing	  range	  of	  percentage	  intensity	  staining	  of	  cells	  (A),	  











Figure	  3.3	  Histograms	  showing	  range	  of	  percentage	   intensity	  staining	  of	  cells	   (A),	  









Example	  showing	  change	  in	  receptor	  expression	  with	  treatment	  from	  poorly	  
differentiated	  to	  differentiated.	  A	  (NAT	  20%	  expression,	  20%	  intensity)	  B	  (SSTR2	  40%	  
expression,	  intensity	  30%)	  in	  poorly	  differentiated	  neuroblastoma.	  C	  (NAT	  expression	  
80%	  expression,	  20%	  intensity)	  and	  D	  (SSTR2	  100%	  expression	  and	  90%	  intensity)	  in	  











Example	  showing	  intense	  staining	  with	  SSTR2	  (A)	  (100%	  of	  cells	  with	  100%	  intensity)	  
compared	  to	  weak	  staining	  for	  NAT	  (B)	  (30%	  of	  cells	  with	  only	  20%	  intensity)	  in	  the	  















Figure	  3.4C	  Example	  of	  variability	  of	  staining	  within	  a	  tumour	  sample.	  A	  (H	  and	  E	  
stain),	  B	  (NAT	  staining),	  C	  (SSTR2	  staining).	  In	  this	  case	  the	  NAT	  and	  SSTR2	  staining	  














Further	  illustration	  of	  variable	  staining	  pattern	  within	  a	  tumour.	  There	  are	  areas	  of	  
high	  and	  low	  expression	  of	  the	  SSTR2	  and	  NAT	  corresponding	  to	  areas	  of	  well	  and	  










Figure	  3.4E	  Example	  of	  staining	  with	  both	  SSTR2	  (B)	  and	  NAT	  (C)	  compared	  to	  the	  H	  
and	  E	  sample	  (A).	  The	  antibody	  staining	  picks	  out	  the	  ganglion	  cell	  differentiation	  











Where	  multiple	  samples	  were	  received	  for	  the	  same	  patient,	  the	  percentage	  change	  
in	   expression	   of	   SSTR2	   increased	   as	   the	   tumours	   changed	   with	   treatment	   from	  
poorly	  differentiated	  to	  differentiated	  in	  all	  cases	  (n=5)	  compared	  to	  4	  out	  of	  the	  5	  
cases	  for	  NAT.	  
	  
Table	  3.1	  The	  change	  in	  expression	  of	  NAT	  and	  SSTR2	  with	  treatment	  in	  cases	  where	  








































70	   70	   70	   40	   30	   35	  
Sample	  
1B	  
Differentiating	   100	   70	   85	   100	   50	   75	  
Sample	  
1C	  











40	   30	   35	   20	   20	   20	  
Sample	  
2C	  






90	   80	   85	   60	   20	   40	  
Sample	  
3B	  






50	   50	   50	   30	   30	   30	  
Sample	  
4B	  






50	   50	   50	   90	   30	   60	  
Sample	  
5B	  
Differentiating	   100	   90	   95	   30	   40	   35	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There	  was	  no	  correlation	  between	  the	  expression	  of	  NAT	  and	  of	  SSTR2	  for	  all	  
patients	  and	  when	  stage	  4	  only	  patients	  were	  examined.	  Figure	  3.4A	  shows	  no	  
correlation	  between	  NAT	  and	  SSTR2	  for	  all	  patients	  (correlation	  =	  0.23),	  and	  Figure	  
3.4B	  shows	  that	  there	  was	  no	  correlation	  between	  the	  receptors	  when	  just	  the	  stage	  
4	  patients	  were	  examined.	  	  
	  
Figure	  3.5A	  Correlation	  between	  SSTR2	  and	  NAT	  expression	  for	  all	  patients.	  
	  
	  





Table	  3.2	  A-­‐E	  Baseline	  characteristics	  	  
	  
Table	  3.2A	  Gender	  	  
	  






Combined	  SSTR	  100	  
n	   44	   31	   75	  
Mean	  (SD)	   50.9	  (31.6)	   57.1	  (30.9)	   53.5	  (31.3)	  
Median	   50	   55	   55	  
IQR	   22.5,	  77.5	   30,	  85	   30,	  80	  
Range	   0,	  100	   10,	  100	   1,	  100	  
Combined	  NAT	  100	  
n	   44	   31	   75	  
Mean	  (SD)	   44	  (24.9)	   48.7	  (25.8)	   45.9	  (25.2)	  
Median	   45	   50	   45	  
IQR	   25,	  65	   30,	  75	   25,	  65	  





Table	  3.2B	  Age	  (months)	  
	  
	  
	   <	  18	  months	  
(n=35)	  




Combined	  SSTR	  100	  
n	   35	   39	   74	  
Mean	  (SD)	   53.3	  (31.5)	   54.7	  (31)	   54.1	  (31.1)	  
Median	   55	   55	   55	  
IQR	   30,	  80	   30,	  85	   30,	  80	  
Range	   0,	  100	   0,	  100	   1,	  100	  
Combined	  NAT	  100	  
n	   35	   39	   74	  
Mean	  (SD)	   46.9	  (28.1)	   44.7	  (22.9)	   45.7	  (25.3)	  
Median	   50	   45	   45	  
IQR	   15,	  65	   25,	  65	   25,	  65	  







Table	  3.2C MYCN	  
	  






Combined	  SSTR	  100	  
n	   18	   48	   66	  
Mean	  (SD)	   38.6	  (26.8)	   62.1	  (29.4)	   55.7	  (30.4)	  
Median	   40	   67.5	   55	  
IQR	   15,	  55	   45,	  85	   40,	  85	  
Range	   0,	  95	   0,	  100	   1,	  100	  
Combined	  NAT	  100	  
n	   18	   48	   66	  
Mean	  (SD)	   39.7	  (22.8)	   49.8	  (24.6)	   47	  (24.4)	  
Median	   42.5	   50	   45	  
IQR	   15,	  55	   30,	  67.5	   30,	  65	  
Range	   0,	  75	   10,	  95	   0,	  95	  
 
 
Table	  3.2D	  Differentiated	  
	  









Combined	  SSTR	  100	  
n	   10	   62	   3	   75	  
Mean	  (SD)	   79.5	  (17.6)	   50.4	  (30.5)	   30	  (43.6)	   53.5	  (31.3)	  
Median	   82.5	   50	   10	   55	  
IQR	   60,	  95	   15,	  75	   0,	  80	   30,	  80	  
Range	   55,	  100	   0,	  100	   0,	  80	   0,	  100	  
Combined	  NAT	  100	  
n	   10	   62	   3	   75	  
Mean	  (SD)	   72	  (11.6)	   42.7	  (24.5)	   26.7	  (17.6)	   45.9	  (25.2)	  
Median	   70	   42.5	   25	   45	  
IQR	   65,	  85	   20,	  60	   10,	  45	   25,	  65	  







Table	  3.2E	  Stage	  
	  












Combined	  SSTR	  100	  
n	   3	   6	   6	   44	   5	   64	  
Mean	  (SD)	   73.3	  (20.2)	   46.7	  (35.4)	   75	  (22.1)	   51.6	  (31.6)	   28	  (24.9)	  	   52.5	  (31.5)	  
Median	   85	   57.5	   85	   47.5	   10	   55	  
IQR	   50,	  85	   10,	  60	   55,	  90	   22.5,	  77.5	   10,	  50	   22.5,	  80	  
Range	   50,	  85	   0,	  95	   40,	  95	   0,	  100	   10,	  60	   0,	  100	  
Combined	  NAT	  100	  
n	   3	   6	   6	   44	   5	   64	  
Mean	  (SD)	   53.3	  (28.4)	   53.3	  (34.6)	   41.7	  (26.6)	   44.9	  (23.4)	   31	  (18.8)	   44.7	  (24.5)	  
Median	   45	   67.5	   42.5	   45	   30	   45	  
IQR	   30,	  85	   10,	  75	   15,	  60	   27.5,	  65	   15,	  50	   25,	  65	  
Range	   30,	  85	   10,	  90	   10,	  80	   0,	  95	   10,	  50	   0,	  95	  
	  
	  
Figure	  3.6	  Kaplan-­‐Meir	  plot	  showing	  overall	  survival	  for	  the	  whole	  group	  based	  on	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SSTR	  2	  Analysis	  
Table	  3.3A	  The	  spread	  of	  patients’	  status	  for	  each	  value	  of	  combined	  SSTR2	  score.	  
	   Alive	   Died	   Overall	  
Combined	  
SSTR2	  100	  
n	   %	   n	   %	   n	   %	  
0	   3	   6.1%	   2	   7.7%	   5	   6.7%	  
10	   5	   10.2%	   3	   11.5%	   8	   10.7%	  
15	   2	   4.1%	   3	   11.5%	   5	   6.7%	  
30	   1	   2%	   1	   3.8%	   2	   2.7%	  
40	   3	   6.1%	   2	   7.7%	   5	   6.7%	  
45	   5	   10.2%	   2	   7.7%	   7	   9.3%	  
50	   2	   4.1%	   2	   7.7%	   4	   5.3%	  
55	   3	   6.1%	   1	   3.8%	   4	   5.3%	  
60	   3	   6.1%	   0	   0%	   3	   4%	  
65	   2	   4.1%	   0	   0%	   2	   2.7%	  
70	   1	   2%	   2	   7.7%	   3	   4%	  
75	   4	   8.2%	   1	   3.8%	   5	   6.7%	  
80	   3	   6.1%	   1	   3.8%	   4	   5.3%	  
85	   5	   10.2%	   3	   11.5%	   8	   10.7%	  
90	   1	   2%	   0	   0%	   1	   1.3%	  
95	   4	   8.2%	   1	   3.8%	   5	   6.7%	  
100	   2	   4.1%	   2	   7.7%	   4	   5.3%	  
	   	   	   	   	   	   	  
Total	   49	   100	   26	   100	   75	   100	  
	  
	  
Table	  3.3B	  SSTR2	  Univariable	  Cox	  Model	  
	  
The	  Hazard	  Ratio	  (HR)	  with	  corresponding	  95%	  CI	  and	  p-­‐value	  for	  the	  univariable	  Cox	  
model	  for	  SSTR2.	  There	  is	  no	  evidence	  that	  SSTR2	  has	  a	  prognostic	  influence	  on	  
overall	  survival.	  
	  
Variable	   HR	  (95%	  CI)	   p-­‐value	  






Table	  3.3C	  SSTR2	  Multivariate	  Cox	  Model	  
	  
Variable	   Level	   HR	  (95%	  CI)	   p-­‐value	  
Combined	  SSTR2	  100	   	   1.003	   0.743	  





MYCN	   Yes	  
No	  
1.0	  
0.422	  (0.142,	  1.251)	  
	  
0.120	  
Age	  (years)	   	   1.139	  (0.841,	  1.541)	   0.4	  
	  
There	  was	  no	  evidence	  to	  suggest	  that	  SSTR2	  has	  prognostic	  influence	  on	  overall	  
survival	  after	  adjusting	  for	  well	  known	  prognostic	  factors	  such	  as	  stage,	  MYCN	  and	  
age.	  
	  
Figure	  3.7	  Martingale	  residuals	  for	  SSTR2	  
	  
The	  plot	  shows	  the	  Martingale	  residuals	  for	  STTR2.	  The	  plot	  verifies	  the	  linear	  













































Table	  3.4A	  	  	  The	  spread	  of	  patients	  status	  for	  each	  value	  of	  combined	  NAT	  score.	  
	   Alive	   Died	   Overall	  
Combined	  
NAT	  100	  
n	   %	   n	   %	   n	   %	  
0	   0	   0%	   1	   3.8%	   1	   1.3%	  
10	   6	   12.2%	   4	   15.4%	   10	   13.3%	  
15	   3	   6.1%	   2	   7.7%	   5	   6.7%	  
20	   1	   2%	   0	   0%	   1	   1.3%	  
25	   0	   0%	   2	   7.7%	   2	   2.7%	  
30	   4	   8.2%	   1	   3.8%	   5	   6.7%	  
35	   1	   2%	   3	   11.5%	   4	   5.3%	  
40	   3	   6.1%	   2	   7.7%	   5	   6.7%	  
45	   7	   14.3%	   0	   0%	   7	   9.3%	  
50	   5	   10.2%	   0	   0%	   5	   6.7%	  
55	   1	   2%	   2	   7.7%	   3	   4%	  
60	   3	   6.1%	   2	   7.7%	   5	   6.7%	  
65	   4	   8.2%	   1	   3.8%	   5	   6.7%	  
70	   2	   2%	   2	   7.7%	   4	   5.3%	  
75	   3	   6.1%	   2	   7.7%	   5	   6.7%	  
80	   1	   2%	   0	   0%	   1	   1.3%	  
85	   1	   2%	   2	   7.7%	   3	   4%	  
90	   3	   6.1%	   0	   0%	   3	   4%	  
95	   1	   2%	   0	   0%	   1	   1.3%	  
	   	   	   	   	   	   	  




Table	  3.4B	  NAT	  Univariable	  Cox	  model	  
	  
The	  HR	  with	  corresponding	  96%	  CI	  and	  a	  p-­‐value	  for	  the	  univariable	  Cox	  model	  for	  
combined	  NAT.	  There	  is	  no	  evidence	  to	  suggest	  that	  NAT	  has	  prognostic	  influence	  on	  
overall	  survival.	  	  
	  
	  
Variable	   HR	  (95%	  CI)	   p-­‐value	  










Table	  3.4C	  NAT	  Multivariable	  Cox	  model	  
	  
	  
HR	  with	  corresponding	  95%	  CI	  and	  a	  p-­‐value	  for	  the	  multivariable	  Cox	  model	  for	  
NAT.	  There	  is	  no	  evidence	  to	  suggest	  that	  NAT	  has	  prognostic	  influence	  on	  the	  




Variable	   Level	   HR	  (95%	  CI)	   p-­‐value	  
Combined	  NAT	  100	   	   1.0	  (0.976,	  1.024)	   0.989	  











Age	  (years)	   	   1.141	  (0.842,	  1.547)	   0.394	  
	  
	  
Figure	  3.8	  NAT	  Martingale	  residuals	  
	  
The	  plots	  below	  show	  the	  Martingale	  residuals	  for	  NAT.	  The	  plots	  verifies	  the	  linear	  
assumption	  of	  NAT	  in	  the	  model	  (the	  line	  looks	  approximately	  horizontal)	  for	  both	  




















































This	   study	   is	   the	   first	   to	   compare	   the	   protein	   expression	   of	   NAT	   and	   SSTR2	   in	   a	  
cohort	   of	   archived	   neuroblastoma	   samples.	   We	   found	   highly	   variable	   protein	  
expression	   of	   NAT	   and	   SSTR2	   both	   between	   patients	   and	   within	   individual	   tissue	  
samples.	  There	  was	  no	  correlation	  found	  between	  the	   level	  of	  NAT	  and	  SSTR2.	  We	  
investigated	  whether	  there	  was	  a	  prognostic	  influence	  of	  SSTR2	  and	  NAT	  but	  found	  
no	  evidence	  for	  this	  either	  alone	  or	  when	  corrected	  for	  other	  known	  variables	  such	  
as	  age,	  stage	  and	  MYCN	  amplification.	  
	  
The	  majority	  of	  the	  previous	  studies	  examining	  the	  expression	  of	  NAT	  and	  SSTR2	  in	  
neuroblastoma	   have	   looked	   at	   the	   mRNA	   levels	   rather	   than	   protein	   expression.	  
There	   have	   been	   several	   in	   vitro	   studies	   that	   have	   shown	   that	   neuroblastoma	   cell	  
lines	   that	   lack	   the	   expression	   of	  NAT	  mRNA	   fail	   to	   accumulate	  mIBG	   (Carlin	   2003,	  
Lode	  1995,	  Mairs	  1994).	  In	  other	  in	  vitro	  studies	  the	  NAT	  mRNA	  level	  has	  correlated	  
with	  the	  extent	  of	  mIBG	  uptake	  (Mairs	  1994,	  Montaldo	  1996,	  More	  2011).	  	  
	  
A	   recent	   publication	   by	   Dubois	   et	   al.	   however,	   examined	   whether	   there	   was	   an	  
association	  between	  both	   the	   tumour	  NAT	  mRNA	  and	   the	  NAT	  protein	   expression	  
with	   mIBG	   avidity	   in	   patients	   with	   neuroblastoma.	   In	   contrast	   to	   the	   previous	  
studies,	  they	  found	  no	  correlation	  between	  NAT	  mRNA	  expression	  and	  mIBG	  uptake	  
[the	  median	  NAT	  expression	  level	  for	  19	  patients	  with	  mIBG	  avid	  tumours	  was	  12.9%	  
compared	  to	  5.9%	  in	  the	  8	  patients	  with	  mIBG	  non-­‐avid	  tumours	  (p=0.31)].	  They	  did	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however	   find	   a	   correlation	   between	   the	  NAT	   protein	   expression	   and	  mIBG	   avidity	  
[the	  median	  percent	  expression	  was	  50%	  in	  the	  mIBG	  avid	  patients	  compared	  to	  10%	  
in	  the	  mIBG	  non-­‐avid	  patients	  (p=0.027)].	  They	  also	  examined	  whether	  patients	  with	  
mIBG	  avid	  tumours	  had	  higher	  NAT	  intensity	  scores.	  There	  was	  a	  trend	  towards	  this	  
with	  mIBG	  avid	  tumours	  having	  higher	  NAT	  intensity	  scores	  than	  non-­‐avid	  tumours	  
(p=0.06).	  Only	  1	  out	  of	  the	  8	  mIBG	  non-­‐avid	  tumours	  had	  a	  NAT	  protein	  expression	  
>2.	  There	  were	  patients	  in	  the	  study	  who	  had	  low	  NAT	  protein	  expression	  and	  were	  
still	  mIBG	  avid	  and	  therefore	  the	  authors	  have	  suggested	  that	  tumours	  with	  low	  NAT	  
expression	  may	  accumulate	  mIBG	  via	  other	  transporters	  (Dubois	  2012).	  There	  have	  
been	  no	  studies	  examining	  whether	  those	  with	  greater	  NAT	  protein	  expression	  have	  
a	  better	  response	  to	  131I-­‐mIBG	  molecular	  radiotherapy.	  	  
	  
There	   has	   been	   only	   one	   study,	   with	   5	   patients,	   that	   examined	   the	   correlation	  
between	   the	   protein	   expression	   of	   SSTR2	   by	   IHC	   and	   mRNA	   of	   SSTR2.	   A	   positive	  
correlation	  was	  found	  but	  the	  comparison	  was	  only	  performed	  on	  5	  patients	  (Raggi	  
2000).	  	  
	  
No	  correlation	  was	   found	   in	   this	   study	  between	  expression	   levels	  of	  NAT	  or	  SSTR2	  
and	   outcome.	   Previous	   studies	   have	   found	   that	   patients	   with	   high	   expression	   of	  
SSTR2	  mRNA	  had	  a	  better	  survival	  (Sestini	  1996,	  Brigganti	  1997,	  Raggi	  2000).	  Kogner	  
et	   al.	   examined	   somatostatin	   concentrations	   (not	   SSTR2	   mRNA	   or	   protein	  
expression)	  by	  radioimmunoassay	  in	  39	  children,	  >12	  months	  of	  age	  and	  with	  stage	  3	  
or	   4	   neuroblastoma	   and	   found	   that	   the	   16	   children	   with	   high	   somatostatin	  
concentration	   had	   better	   survival	   than	   the	   23	   patients	   with	   low	   somatostatin	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concentrations	   (p=0.005).	   In	   15	   children	   somatostatin	   receptor	   scintigraphy	   was	  
performed	   with	   111In-­‐pentetreotide.	   There	   was	   no	   significant	   correlation	   between	  
somatostatin	   concentrations	   in	   tumour	   tissue	   and	   receptor	   expression	   as	  
investigated	  by	  somatostatin	  receptor	  scintigraphy	  (Kogner	  1997).  
 
Orlando	  et	   al	   performed	  RT-­‐PCR	  on	  49	  neuroblastoma	   samples	   and	   found	  a	  wide-­‐
range	  of	   SSTR2	  mRNA	  expression	  but	   the	   lowest	   in	   stage	   IV	  patients.	   The	  patients	  
with	  SSTR2	  expression	  had	  a	  better	  survival.	  For	  9	  patients,	  they	  were	  able	  to	  find	  a	  
good	   correlation	   between	   the	   concentration	   of	   SSTR2	   on	   RT-­‐PCR	   and	   uptake	   by	  
imaging	  with	  111In-­‐pentetreotide	  (Orlando	  2001).	  
	  
Several	   studies	   have	   shown	   that	   patients	   with	   MYCN	   amplification	   have	   lower	  
expression	  of	  SSTR2	  mRNA	  (Sestini1996,	  Kogner	  1997)	  and	  Dubois	  et	  al	  reported	  for	  
the	   first	   time	   a	   correlation	   between	   MYCN	   amplification	   and	   low	   NAT	   protein	  
expression	   (Dubois	   2012).	   	  Within	   our	   cohort	   of	   patients,	   the	   patients	  with	  MYCN	  
amplification	   had	   lower	   composite	   scores	   for	   NAT	   and	   SSTR2	   but	   the	   numbers	   in	  
both	  groups	  were	  too	  small	  to	  establish	  whether	  this	  was	  significant.	  
 
 
As	  discussed	  above,	  previous	  studies	  have	  used	  varying	  techniques	  to	  look	  for	  SSTR2	  
and	   NAT	   in	   neuroblastomas.	   None	   of	   the	   studies	   have	   correlated	   SSTR2	   or	   NAT	  
protein	  expression	  and	  survival.	  In	  terms	  of	  the	  relevance	  to	  functional	  imaging	  and	  
molecular	   radiotherapy	   the	   protein	   expression	   is	   more	   relevant	   than	   the	  
measurement	  of	  mRNA.	  	  There	  have	  been	  studies	  in	  adult	  neuroendocrine	  tumours	  
that	  have	  found	  patients	  with	  negative	  octreotide	  and	  positive	  mRNA	  (John	  1996).	  As	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well	  as	  studies	  in	  neuroblastoma	  that	  have	  found	  mIBG	  uptake	  in	  patients	  with	  low	  
levels	  of	  NAT	  mRNA	  (Carlin	  2003).	  It	  is	  also	  well	  recognized	  that	  that	  there	  can	  be	  a	  
poor	  correlation	  between	  mRNA	  and	   functional	  protein	  expression	  possibly	  due	   to	  
post	  translational	  modification	  .	  	  
	  
For	   cases	  with	  multiple	   samples	  we	   found	   that	   the	   percentage	   of	   cells	   expressing	  
NAT	   and	   SSTR2	   increased	   as	   the	   tumours	   went	   from	   poorly	   differentiated	   to	  
differentiated.	   It	   is	   unclear	   from	   the	   published	   data	   whether	   the	   uptake	   of	  mIBG	  
correlates	  with	  the	  differentiation	  of	  neuroblastoma	  cells.	  The	  in	  vitro	  data	  available	  
has	   supported	   an	   increase	   in	  mIBG	   uptake	   after	   cellular	   differentiation	   (Montaldo	  
1992,Iavarone	   1993).	   	   In	   contrast,	   the	   first	   reported	   in	   vivo	   studies,	   supported	   a	  
correlation	   between	   higher	   mIBG	   uptake	   in	   the	   more	   undifferentiated	  
neuroblastomas	  (Moyes	  1989,	  Hadj-­‐Djilani	  1995).	  However,	   this	  was	  not	  confirmed	  
in	   the	   in	   vivo	   study	   by	   Brans	   et	   al	   who	   found	   	   that	   the	   more	   differentiated	  
neuroblastomas	  in	  their	  group	  did	  not	  have	  lower	  mIBG	  uptake.	  They	  concluded	  that	  
it	  was	   impossible	  to	  make	  judgements	  about	  the	  differentiation	  of	  neuroblastomas	  
depending	  on	  their	  mIBG	  uptake	  (Brans	  1998).	  	  
	  
The	   uptake	   of	   mIBG	   is	   potentially	   influenced	   by	   many	   other	   variables	   such	   as	  
technical	   factors	   related	   to	   the	   imaging	   technique	   itself	   and	   other	   tumour	   related	  
factors	   for	   example,	   tumour	   size,	   tumour	   heterogeneity,	   blood	   supply,	   prior	  
treatment	  and	  this	  is	  likely	  to	  be	  the	  same	  for	  uptake	  of	  DOTATATE	  by	  SSTR2.	  There	  
are	   agents	   in	   clinical	   investigation	   such	   as	   Vorinostat,	   a	   HDAC	   inhibitor,	   that	   can	  
increase	  the	  NAT	  expression	  (More	  2011).	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In	   more	   recent	   years,	   there	   have	   been	   many	   developments	   in	   positron	   emission	  
tomography	   and	   these	   techniques	   have	   been	   shown	   to	   improve	   sensitivity	   for	  
detection	   of	   somatostatin	   positive	   neuroendocrine	   tumours	   compared	   to	   planar	  
scintigraphy	   (Kowalski	   2003,	   Gabriel	   2007).	   The	   gold	   standard	   would	   now	   be	   to	  
correlate	   uptake	   on	   the	   latest	   imaging	   techniques	   such	   as	   68Ga-­‐DOTATATE	   PET/CT	  
(see	  chapter2)	  rather	  than	  octreotide	  planar	  scintigraphy	  and	  protein	  expression	  of	  
SSTR2.	  124I-­‐mIBG	  PET/CT	  is	  currently	  under	  investigation	  to	  establish	  whether	  it	  has	  
improved	  sensitivity	  over	  123I-­‐mIBG	  planar	  scinitigraphy.	  
	  
This	  study	  has	  shown	  that	  there	  is	  a	  large	  and	  variable	  (between	  patients	  and	  within	  
patients)	   protein	   expression	   of	   NAT	   and	   SSTR2	   in	   neuroblastoma.	   This	   has	  
implications	   for	   both	   functional	   imaging	   and	   molecular	   radiotherapy	   in	   the	  
management	  of	  neuroblastoma.	  The	  variable	  expression	  of	  the	  receptors	  mean	  that	  
not	  all	  of	   the	  tumour	  cells	  may	  receive	   the	  radionuclide	  by	   the	  chosen	  target.	  This	  
study	  supports	  the	  role	  for	  both	  mIBG	  and	  radiolabelled	  somatostatin	  analogues	  for	  
imaging	   and	   therapy	   to	   fully	  map	   and	   target	   neuroblastoma.	   Further	  more,	   in	   the	  
future	  a	  possible	  combination	  of	  both	  molecular	  radiotherapy	  treatments	  targeting	  
the	  two	  different	  receptors	  may	  be	  more	  effective	  than	  either	  used	  alone.	  	  
	  
Having	   refined	   the	  methodology	  here,	  we	  will	  be	  able	   to	  apply	   this	   in	   the	  planned	  
future	   clinical	   trials	  of	  mIBG	  and	  LuDO.	  Within	   these	  prospective	   studies,	  NAT	  and	  
SSTR2	  expression	  by	  IHC	  will	  be	  correlated	  with	  degree	  of	  uptake	  with	  123I-­‐mIBG	  and	  
68Ga-­‐DOTATATE	  PET/CT	  and	  with	  response.	  These	  translational	  studies	  will	  help	  us	  to	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understand	  whether	   those	  patients	  with	  higher	   intensity	  and	  expression	  of	  NAT	  or	  
SSTR2	  will	  have	  a	  better	  clinical	  response	  to	  their	  particular	  molecular	  radiotherapy.	  
	  
In	  conclusion,	  there	  is	  huge	  variation	  and	  heterogeneity	  in	  the	  protein	  expression	  of	  
NAT	  and	  SSTR2	  between	  patients	  and	  also	  within	  the	  same	  patient.	  The	  use	  of	  
immunohistochemistry	  could	  facilitate	  the	  appropriate	  selection	  of	  patients	  for	  











A	  Systematic	  Review	  of	  	  
131I-­‐meta-­‐iodobenzylguanidine	  (mIBG)	  




Meta-­‐iodobenzylguanidine	   (mIBG)	   is	   a	   catecholamine	   derivative	  which	   has	   a	   high	  
specificity	  for	  the	  Noradrenaline	  transporter	  molecule	  (NAT).	  Approximately	  90%	  of	  
neuroblastomas	   express	   the	   noradrenaline	   transporter	  molecule	   (NAT)	   and	  mIBG	  
can	  be	  radiolabelled	  with	  either	  123I	  for	  imaging,	  or	  131I	  for	  therapy.	  	  
	  
mIBG	  was	  developed	  at	   the	  University	  of	  Michigan	   in	  the	  mid	  1980’s	  and	  the	  first	  
tumours	   to	   be	   imaged	   and	   then	   treated	   with	   mIBG	   were	   phaeochromocytomas	  
(Sisson	  1981,	  Sisson	  1983,	  Vetter	  1983).	  	  
	  
In	   1987,	   just	   four	   years	   after	   the	   first	   reports	   of	   131I-­‐mIBG	   therapy	   in	  
pheochromocytoma	  were	  published,	  nine	  groups	  presented	  results	  of	  early	  clinical	  
experience	   with	   this	   agent	   in	   neuroblastoma	   (Beierwaltes	   1987,	   Bestagno	   1987,	  
Cottino	   1987,	   Fischer	   1987,	   Hartmann	   1987,	   Sanguinetti	   1987,	   Treuner	   1987,	  
Troncome	   1987,	   Voûte	   1987).	   As	   is	   often	   the	   case	   with	   the	   introduction	   of	   new	  
cancer	   treatments,	   early	   clinical	   evaluation	   was	   performed	   on	   end-­‐stage	  
neuroblastoma	   patients,	   for	   whom	   there	   was	   no	   conventional	   treatment	   or	  
established	  benefit	  available.	  Among	  these	  patients,	  there	  were	  four	  patients	  with	  a	  
complete	   response,	   28	   with	   a	   partial	   response,	   and	   12	   patients	   without	   disease	  
progression.	   These	   results	   need	   to	   be	   viewed	   with	   a	   degree	   of	   caution,	   as	   the	  
patient	  population	  was	  heterogeneous,	  the	  administration	  of	  131I-­‐mIBG	  therapy	  was	  
not	   standardized,	   and	   the	   criteria	   to	   judge	   a	   response	   were	   not	   uniform.	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Nonetheless,	  these	  early	  results	  indicated	  that	  131I-­‐mIBG	  was	  a	  promising	  treatment	  
for	  neuroblastoma,	  and	  worthy	  of	  further	  evaluation.	  	  
	  
The	   dose-­‐limiting	   toxicity	   of	   131I-­‐mIBG	   is	  myelosupression.	   Haemopoietic	   support,	  
typically	   with	   peripheral	   blood	   stem	   cells	   (PBSC),	   has	   been	   used	   to	   circumvent	  
myelosuppression,	  and	  to	  safely	  facilitate	  the	  use	  of	  higher	  Administered	  Activities	  
(AAs).	   Other	   attempts	   to	   improve	   outcome	   include	   the	   use	   of	   concomitant	  
chemotherapy	   or	   radiosensitisers,	   hyperbaric	   oxygen	   and	   dosimetry-­‐guided	  
administrations.	   131I-­‐mIBG	   therapy,	   originally	   used	   for	   refractory	   or	   relapsed	  
neuroblastoma,	   has	   also	   been	   incorporated	   into	   induction	   and	   consolidation	  
treatments.	  	  
	  
Despite	   nearly	   30	   years	   of	   use	   of	   131I-­‐mIBG	   molecular	   radiotherapy	   in	  
neuroblastoma,	   the	   effectiveness	   of	   131I-­‐mIBG	   therapy	   remains	   uncertain,	   and	   its	  
optimal	   use	   remains	   undefined.	   A	   systematic	   review	   of	   131I-­‐mIBG	   therapy	   in	  
neuroblastoma	   has	   therefore	   been	   undertaken	   with	   the	   aim	   of	   improving	   the	  
understanding	  of	  the	  published	  data	  and	  defining	  uncertainties	  to	  be	  addressed	  in	  
future	  clinical	  trials.	  
	  
This	  work	  was	  undertaken	   in	   collaboration	  with	   Jayne	  Wilson	  who	   is	   a	   systematic	  
reviewer	  at	  the	  Cancer	  Research	  UK,	  Clinical	  Trials	  Unit,	  University	  of	  Birmingham.	  




4.2	  Materials	  and	  Methods	  
	  
Standard	   systematic	   review	   methods	   were	   employed	   following	   a	   pre-­‐defined	  
protocol.	   We	   searched	   MEDLINE,	   EMBASE,	   and	   Cochrane	   CENTRAL	   bibliographic	  
databases	   from	   inception	   to	   July	   2012	   using	   terms	   for	   neuroblastoma	   and	   131I-­‐	  
mIBG.	  
	  
The	  Inclusion	  criteria	  were:	  
• Population/setting	  –	  patients	  with	  neuroblastoma	  of	  any	  age	  and	  no	  matter	  
what	   prior	   therapy	   they	   had	   received	   (including	   chemotherapy,	   surgery,	  
radiotherapy	  or	  other	  treatments)	  
• Intervention	  –	  131I-­‐mIBG	  therapy	  (distinct	  from	  diagnostic	  mIBG	  scans)	  alone	  
or	   in	   combination	   with	   other	   treatments	   given	   at	   any	   stage	   of	   disease	  
trajectory	   (induction,	   refractory,	  consolidation	  or	  relapse)	   for	  both	  curative	  
and	  palliative	  intent	  
• Comparator	  –	  any	  or	  none	  
• Design	   -­‐	   systematic	   reviews,	   Phase	   I,	   Phase	   II,	   and	   Phase	   III	   trials,	  
	  prospective	  and	  retrospective	  non-­‐comparative	  case	  series	  with	  10	  or	  more	  
	  patients;	  
• Outcomes	   –	   at	   least	   one	   of	   tumour	   response,	   overall	   survival	   (OS),	   event	  
free	  survival	  (EFS),	  	  toxicity,	  adverse	  events,	  quality	  of	  life,	  symptom	  control	  
and	  dosimetry.	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All	  references	  were	  reviewed	  by	  the	  two	  reviewers	  (JG	  and	  JW)	  and	  independently	  
assessed	  for	  inclusion/	  exclusion	  criteria	  using	  the	  title	  and	  abstract.	  Disagreements	  
about	  inclusion/exclusion	  of	  papers	  were	  resolved	  by	  discussion.	  Full	  copies	  of	  the	  
potentially	  relevant	  papers	  were	  then	  obtained	  for	  detailed	  examination.	  	  
	  
Study	   characteristics	   and	   results	   were	   extracted	   using	   a	   pre-­‐designed	   data	  
extraction	   form	   by	   one	   reviewer	   and	   checked	   by	   a	   second	   reviewer	   with	  
discrepancies	  discussed	  where	  identified.	  	  
	  
Mean	  cumulative	  administered	  activity	  (AA)	  per	  patient	  per	  study	  was	  calculated	  by	  
summing	  the	  total	  AA	  per	  patient	  and	  dividing	  by	  the	  number	  of	  patients	  who	  were	  
prescribed	   or	   received	   131I-­‐mIBG.	   Six	   studies	   reported	   AA/kg	   of	   body	   weight,	  
meaning	   it	   was	   not	   possible	   to	   calculate	   cumulative	   AA.	   However,	   these	   studies	  
gave	   individual	   patient	   results	   (resulting	   in	   18	   data	   plots)	   according	   to	   AA/kg,	  
therefore	  we	  were	  able	  to	  test	  for	  AA	  against	  response.	  
	  
Data	   from	   studies	   with	   multiple	   publications	   were	   extracted	   and	   reported	   as	   a	  
single	  study,	  in	  case	  of	  data	  discrepancies	  the	  most	  recent	  data	  was	  utilized.	  Study	  
quality	  was	   assessed	   using	   an	   adaption	   of	   the	   tool	   from	   York	   CRD	   (Wilson	   2005)	  
with	  the	  aim	  to	  identify	  selection,	  detection	  and	  attrition	  bias.	  
	  
Studies	  were	   assigned	   to	   one	   of	   three	   groups.	   Induction	   studies	   included	   studies	  
where	   131I-­‐mIBG	   therapy	   was	   used	   as	   the	   first	   line	   treatment,	   up-­‐front	   in	   newly	  
diagnosed	  patients.	  Consolidation	  studies	  included	  those	  where	  131I-­‐mIBG	  was	  given	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in	   conjunction	  with	  myeolablative	   chemotherapy	   after	   a	   response	   had	   been	   seen	  
with	   induction	   chemotherapy.	   Relapsed/refractory	   studies	   included	   those	   where	  
131I-­‐mIBG	  therapy	  was	  used	  in	  patients	  whose	  disease	  had	  progressed	  after	  an	  initial	  
response	   to	   therapy	   or	   those	   who	   had	   not	   responded	   to	   induction	   therapy.	  
Relapsed	  and	   refractory	  patients	  are	   likely	   to	  be	  different	  and	   respond	  differently	  
and	   ideally	   would	   be	   reported	   separately	   but	   most	   papers	   put	   the	   two	   groups	  
together	  and	  did	  not	  report	  the	  outcomes	  separately.	  
	  
Objective	   tumour	   response	   was	   defined	   using	   the	   International	   Neuroblastoma	  
Response	   Criteria	   as	   complete	   response	   (CR),	   or	   partial	   response	   (PR)	   (Brodeur	  
1993,	   Brodeur	   1998).	  Mixed	   response	   (MR),	   stable	   disease	   (SD)	   and	   no	   response	  





For	  each	  study,	  the	  proportion	  of	  patients	  with	  objective	  tumour	  response	  with	  95%	  
confidence	  interval	  (CI)	  was	  presented.	  Odds	  ratios	  (OR)	  with	  CIs	  were	  derived	  using	  
logistic	   regression	   for	   grouped	   data	   with	   robust	   standard	   errors.	   Two	   covariates	  
were	   included	   in	   the	   model:	   AA	   (numerical)	   and	   concurrent	   chemotherapy	  
administration.	   Odds	   ratios	   greater	   than	   1.0	   indicated	   an	   increased	   likelihood	   of	  





Overall	  Quantity	  of	  Literature	  
	  
The	  electronic	   searches	   yielded	  1,216	   citations	  of	  which	  51	  publications	   reporting	  
30	  studies	  met	  the	  inclusion	  criteria	  (see	  Figure	  4.1	  PRISMA	  diagram).	  	  
	  
Of	  these,	  two	  studies	  examined	  the	  role	  of	  131I-­‐mIBG	  as	  an	   induction	  therapy,	  one	  
study	  as	  consolidation	  therapy	  and	  27	  studies	  as	  a	  treatment	  option	  in	  relapsed	  and	  
refractory	   patients.	   Twenty-­‐two	   were	   prospective	   case	   series,	   four	   were	  
retrospective	   case	   series,	   and	   four	   studies	   had	   non-­‐randomly	   allocated	   control	  
groups.	  No	  randomized	  controlled	  trials	  (RCTs)	  were	  identified	  in	  the	  search.	  	  
	  
The	  main	  reasons	  for	  exclusion	  were	  because	  the	  study	  focus	  was	  purely	  dosimetry	  
based	  (n=36),	  or	  because	  the	  studies	  were	  either	  single	  case	  studies	  or	  prospective	  





























Reason	  for	  exclusion	   Total	  n	  
Unsures	  –	  NA	  after	  full	  text	  
scrutinized	  
14	  	  
Single	  case	  study,	  prospective	  
and	  retrospective	  case	  series	  
(<10	  pts	  total)	  	  
32	  	  
Dosimetry	  studies	  	   36	  	  
Recent	  (from	  2005)	  narrative	  
reviews	  	  
	  19	  	  
Miscellaneous	  	   4	  

























Publications	  identified	  through	  
database	  searching	  
(n	  =	  1216	  )	  




(n	  =	  306)	  
Full-­‐text	  publications	  
assessed	  for	  eligibility	  
(n	  =156)	  
Publications	  included	  	  
	  
Total	  (n	  =	  51)	  
	  
Induction	  (n	  =	  8)	  
Consolidation	  (n	  =	  1)	  
Relapsed	  &	  refractory	  (n	  =	  42	  )	  
	  
Studies	  included	  	  
	  
Total	  n	  =	  30	  (979pts)	  
	  
Induction	  n	  =	  2	  (57pts)	  
Consolidation	  n	  =	  1	  (11pts)	  





Eight	  papers	  reporting	  two	  studies	  involving	  57	  patients	  where	  131I-­‐mIBG	  was	  used	  
in	   the	   induction	   setting	   were	   identified	   (see	   Table	   4.1)	   (De	   Kraker	   2008,	  
Mastrangelo	  2011).	  	  
	  
Patients	  within	  these	  studies	  had	  INSS	  stages	  3	  and	  4	  disease	  with	  a	  mean	  age	  of	  2.6	  
years.	  131I-­‐mIBG	  was	  given	  alone	  (median	  3	  administrations	  –	  range	  2	  to	  5)	  followed	  
by	   surgery	   (De	   Kraker	   2008)	   or	   as	   a	   single	   administration	   with	   concomitant	  
chemotherapy	   (Mastrangelo	  2011).	  Mean	   cumulative	  AA	  was	  11.1GBq	   (De	  Kraker	  
2008)	  and	  6.26GBq	  (Mastrangelo	  2011).	  
	  
Study	   quality	   was	   good	   for	   de	   Kraker	   (2008)	   but	   there	   may	   have	   been	   some	  
selection	  bias	  in	  Mastrangelo	  (2011)	  (see	  table	  4.4).	  Inconsistent	  reporting	  between	  
the	  large	  number	  of	  multiple	  publications	  was	  problematic.	  
	  
Overall	  between	  the	  two	  studies	  objective	  tumour	  response	  was	  measured	  in	  39/57	  
(68%)	   patients,	   the	   majority	   classed	   as	   a	   PR	   (see	   table	   4.5).	   For	   de	   Kraker	   the	  
objective	   tumour	   response	   was	   measured	   in	   27/44	   (61%)	   patients	   and	   for	  
Mastrangelo	  12/13	  (92%)	  patients.	  	  
	  
In	  De	  Kraker	  (2008)	  median	  OS	  was	  reported	  as	  15	  months	  (CI	  7	  to	  23),	  with	  5	  year	  
OS	  at	  15%.	  Mastrangelo	  (2011)	  reported	  3	  deaths,	  with	  four	  patients	  alive	  with	  CR	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(range	  of	  duration	  1.5	  to	  8.4	  years)	  and	  one	  patient	  alive	  with	  SD.	  Median	  OS	  was	  
not	  reported,	  median	  EFS	  was	  10	  months	   (CI	  7	   to	  13	  months)	  and	  5	  year	  EFS	  was	  
12%.	  
	  
De	  Kraker	  et	  al.	  also	  evaluated	  surgical	  success	  following	  131I-­‐mIBG	  induction.	  Out	  of	  
24	  patients	  who	  received	  131I-­‐mIBG	  alone,	  18	  (75%)	  had	  tumours	  surgically	  resected.	  
In	  17	  patients,	  there	  was	  an	  initial	  poor	  response	  to	  131I-­‐mIBG	  and	  so	  chemotherapy	  
was	  also	  administered.	  Of	  these	  17	  patients,	  8	  (45%)	  went	  on	  to	  have	  their	  tumours	  
surgically	   resected.	   Overall,	   9	   patients	   did	   not	   receive	   surgery	   because	   of	  
progressive	  disease,	  2	  because	  of	  multiple	  inoperable	  tumors	  and	  2	  did	  not	  have	  a	  
primary	  tumour.	  One	  patient	  died	  form	  surgical	  complications	  (De	  Kraker	  2008).	  
	  
	  
Table	  4.1	  Induction	  Studies	  Interventions	  
Study	   Total	  no.	  
patients	  
Intervention	   131I-­‐mIBG	  AA	  
per	  cycle	  
(range)	  










De	  Kraker	  2008	  
	  
Hoefnagel	  1995	  









131I-­‐mIBG	  therapy	  alone	  
followed	  by	  re-­‐
assessment	  after	  2	  
cycles.	  
Group	  A	  responding	  –	  
further	  131I-­‐mIBG	  before	  
surgery.	  





























131I-­‐mIBG	  combined	  with	  
chemotherapy.	  131I-­‐mIBG	  




















Only	  one	  study	  met	  the	  inclusion	  criteria	  for	  a	  consolidation	  study	  (Klingebiel	  1998).	  
This	   study	   recruited	   11	   patients,	   all	   with	   INSS	   stage	   4	   disease	   after	   initial	  
chemotherapy	   on	   the	   German	   Neuroblastoma	   Study	   BN90	   and	   were	   given	   the	  
option	   to	   enrol	   for	   131I-­‐mIBG	   treatment.	   The	   mean	   age	   was	   5	   years.	   Patients	  
received	  a	  single	  cycle	  of	  131I-­‐mIBG,	  AA	  0.58GBq/kg.	  This	  was	  immediately	  followed	  
by	   high-­‐dose	   chemotherapy,	   PBSC	   support	   and	   then	   antiGD2	   antibody	   (see	   Table	  
4.2).	  
	  
It	   is	  noted	   that	   those	  studies	  which	  used	   intensive	  or	  myeloablative	  schedules	   for	  
the	   treatment	   of	   patients	   who	   were	   not	   in	   remission	   because	   they	   had	   had	   no	  
response,	  or	  only	  a	  poor	  response,	  to	  induction	  treatment	  are	  reported	  as	  studies	  in	  
refractory	  and	  relapsed	  disease,	  not	  as	  consolidation	  studies.	  
	  
Table	  4.2	  Consolidation	  Study	  Interventions	  
Study	   Total	  no.	  
patients	  























4-­‐8	  cycles	  of	  
induction	  
chemotherapy	  on	  
























Objective	  tumour	  responses,	  assessed	  after	  recovery	  from	  stem	  cell	  transplantation,	  
were	   identified	   in	  4/11	  patients	  and	  4/11	  patients	  had	  a	  continued	  response	  from	  
induction.	  Two	  had	  PD	  and	  one	  suffered	  a	  relapse.	  OS	  was	  70%	  at	  19	  months,	  EFS	  
was	  not	  reported.	  
	  
	  
Relapsed	  and	  Refractory	  Studies	  
	  
Twenty	  seven	  studies	  met	  the	   inclusion	  criteria.	  By	   ‘refractory	  patients’	  we	  meant	  
those	   patients	   whose	   disease	   had	   responded	   poorly	   or	   not	   at	   all	   to	   initial	  
(induction)	   chemotherapy,	   and	   who	   had	   not	   proceeded	   to	   consolidation	   with	  
myeloablative	   therapy.	  By	   ‘relapsed	  patients’	  we	  meant	   those	  whose	  disease	  had	  
progressed	   after	   an	   initial	   partial	   or	   complete	   response,	   and	   often	   after	  
consolidation	   with	  myeloablative	   therapy.	   However,	   in	   various	   publications	   there	  
was	  not	  always	  a	  clear	  distinction	  between	  refractory	  and	  relapsed	  disease.	  	  
	  
Eight	   of	   the	   relapsed	   and	   refractory	   studies	   had	  multiple	   publications	   (Hoefnagel	  
1987,	   Treuner	   1988,	   Lumbroso	   1991,	  Hutchinson	   1992,	   Lashford	   1992,	  Garaventa	  
1999,	  Dubois	  2004,	  Matthay	  2007).	  There	  were	  a	  total	  of	  42	  publications	  (see	  Table	  
4.3).	   Including	   the	   control	   patients,	   the	   total	   number	   of	   patients	   was	   1,121.	   The	  
study	  size	  ranged	  from	  10	  to	  164	  patients.	  Publication	  dates	  spanned	  from	  1987	  to	  
2012.	  One	  study	  each	  came	  from	  the	  UK,	  France	  and	  Spain,	  two	  studies	  came	  from	  
The	  Netherlands,	  six	  from	  Germany	  and	  Italy	  and	  10	  from	  the	  USA.	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Sixteen	   studies	   gave	   recruitment	   dates,	   the	   earliest	   to	   start	   was	   1984	   (Treuner	  
1988,	   Klingebiel	   1991a	   and	   1991b)	   and	   the	   latest	   2005	   (Matthay	   2007,	  Matthay	  
2009).	   The	   mean	   recruitment	   duration	   was	   5	   years	   but	   ranged	   form	   1	   (Treuner	  
1988)	  to	  10	  years	  (DuBois	  2004).	  
	  
The	  lowest	  mean	  age	  range	  in	  a	  study	  was	  1.9	  years	  (Castel	  2000),	  the	  highest	  was	  8	  
years	  (Castellani	  1991,	  Matthay	  2012).	  Median	  mean	  age	  across	  the	  studies	  was	  4.5	  
years,	   with	   a	   wide	   range	   of	   individual	   ages	   from	   0.3	   years	   to	   36	   years.	   Thirteen	  
studies	  reported	  age	  at	  diagnosis,	   two	  reported	  age	  at	  both	  diagnosis	  and	  start	  of	  
treatment,	  five	  reported	  age	  at	  start	  of	  treatment	  and	  in	  eight	  it	  was	  unclear.	  
	  
Three	   different	   neuroblastoma	   staging	   systems	   for	   diagnosis	   had	   been	   utilized	  
(Evans	   1971,	   Brodeur	   1988,	   Brodeur	   1993).	   Eleven	   studies	   used	   Evans	   1971,	   two	  
used	  INSS	  1988,	  seven	  used	  INSS	  1993	  and	  8	  studies	  did	  not	  give	  stage	  information.	  	  
	  
Two	  patients	  had	  stage	  1	  disease	  (Dubois	  2004,	  Johnson	  2011),	  three	  patients	  had	  
stage	  2	  disease	  (Castel	  2000,	  Johnson	  2011,	  Voûte	  1995)	  and	  2	  patients	  had	  stage	  4S	  
disease	  (Dubois	  2004,	  Miano	  2001).	  The	  majority	  of	  patients	  had	  either	  stage	  3	  (n	  =	  
192	  patients)	  or	  stage	  4	  disease	  (n	  =	  403	  patients).	  The	  proportion	  of	  patients	  with	  
MYCN	   amplification	   was	   reported	   in	   only	   five	   studies:	   39%	   (Dubois	   2004);	   33%	  
(Yanik	  2002);	  25%	  (Matthay	  2006);	  12%	  (Castel	  2000),	  15%	  (Schmidt	  2006).	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The	   most	   frequent	   disease	   sites	   were	   the	   abdomen,	   bone	   and	   bone	   marrow.	  
However,	  inconsistent	  reporting	  gives	  an	  unreliable	  estimate	  as	  to	  the	  total	  extent	  
of	  the	  disease	  burden.	  
	  
Where	   it	   was	   reported,	   the	   vast	   majority	   of	   patients	   had	   had	   extensive	   prior	  
treatments.	   This	   included	   a	   range	   of	   multi-­‐drug	   induction	   regimens	   in	   refractory	  
patients,	  and	  a	  greater	  number	  of	  second	  and	  third	  line	  chemotherapy	  schedules	  in	  
relapsed	  patients.	  Around	  a	  quarter	  of	  the	  patients	  were	  reported	  to	  have	  had	  high-­‐	  
dose	  (HD)	  chemotherapy	  and	  PBSC,	  and	  a	  third	  had	  had	  prior	  surgery,	  with	  a	  small	  
proportion	   having	   had	   external	   radiotherapy.	   Again,	   inconsistent	   reporting	   may	  
mean	  that	  the	  true	  figures	  are	  higher	  and	  cannot	  give	  us	  an	  accurate	  assessment	  of	  
prior	  treatment.	  
	  
131I-­‐mIBG	   was	   given	   alone	   in	   20	   studies	   and	   with	   concurrent	   chemotherapy	   in	  
seven.	   For	   the	   131I-­‐mIBG	   alone	   studies	   the	   number	   of	   cycles	   ranged	   from	   1	   to	   6,	  
whereas	   131I-­‐mIBG	   given	   with	   concurrent	   chemotherapy	   tended	   to	   have	   fewer	  
cycles	   ranging	   from	   1	   to	   3.	   A	   wide	   range	   of	   AA	   were	   given	   [Table	   4.3].	   Authors	  








Table	  4.3	  Relapsed	  and	  refractory	  study	  interventions	  



























































Group	  2:	  9.05GBq	  
1	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  6	  for	  
advanced	  



























































































































































































































































































30	  pts	  in	  control	  










Stage	  III	  mean	  
2	  (1-­‐5)	  


















Group	  B=	  8(0/8)	  
(multimodal	  
assessment	  also	  
had	  BMT	  and	  
immunotherapy)(
Stage	  III	  0/3)	  
131I-­‐mIBG	  alone	  
(stage	  III	  and	  Iv	  






(Stage	  IV	  Group	  
B)	  w	  
Planned	  dose:	  
Stage	  III:	  median	  
0.322GBq/kg	  
Stage	  IV	  Group	  A:	  
median	  
0.296GBq/kg	  








median	  2	  (1-­‐5)	  
Group	  B	  all	  1	  
cycle	  	  





25	  (0/25)	   131I-­‐mIBG	  alone	   AA	  prescribed	  to	  
WB	  dose	  from	  
tracer	  study:	  
range	  2.4-­‐12.1	  
GBq	  to	  achieve	  
WB	  dose	  of	  1-­‐
2.5Gy	  
1	   6.38	   No	   No	  
Lumbroso	  
1991	  













5	   No	   No	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given	  on	  day	  10.	  
	  
Fixed	  AA	  7.4GBq	   1	   6.26	   Yes	   No	  
Matthay	  
2006	  



























cycles	  (up	  to	  
4)	  
AA/Kg	   No	   Yes	  
Matthay	  
2009	  
21	  (16/5)	   131I-­‐mIBG	  and	  
ASCT	  





1	   AA/Kg	   No	   Yes	  
Matthay	  
2012	  






1	   AA/Kg	   No	   Yes	  
Miano	  2001	   Intervention	  17	  
(0/17)	  
Control	  (NS	  15)	  
131I-­‐mIBG	  
followed	  by	  HD	  




























11	  (NS)	   131I-­‐mIBG	  alone	   Planned	  dose,	  
activity	  divided	  
into	  2	  single	  




given	  if	  WB	  dose	  
<2Gy	  and	  liver	  
<5Gy	  
	  
1-­‐6	   14.69	   No	   No	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10	  (NS)	   131I-­‐mIBG	  alone	   Observed	  mean	  
AA:	  6GBq	  (1.9-­‐
13.5GBq)	  
Mean	  2.5	   NC	   No	   No	  
Treuner	  
1988	  
27(12/15)	   131I-­‐mIBG	  alone	   Observed	  dose	  
mean:	  5GBq	  (1.3-­‐
16.6GBq)	  
Mean	  2.6	  (1-­‐6)	   13.21	   No	   No	  
Troncone	  
1991	  




AA	  (2.6GBq	  to	  
9.5GBq)	  
Up	  to	  4	   13.64	   No	   NO	  
Voute	  1995	   131I-­‐mIBG	  
alone=36	  (36/0)	  
131I-­‐mIBG	  +	  HBO=	  
27	  (27/0)	  
131I-­‐mIBg	  alone	  or	  
with	  HBO.	  1-­‐2	  
monthly	  intervals	  





Up	  to	  4	   N/A	   No	   No	  
Yanik	  2002	   12	  (12/0)	   131I-­‐mIBG	  
combined	  with	  
myeloablative	  
chemo	  and	  ASCT	  
WB	  AA:	  
0.444GBq/Kg	  

















The	  quality	  of	  the	  studies	  was	  highly	  variable	  (see	  Table	  4.4).	  Overall,	  the	  reporting	  
of	  recruitment	  processes	  and	  patient	  description	  at	  study	  entry	  appears	  to	  be	  highly	  
variable	  across	  and	  within	  studies,	  meaning	  that	  most	  of	  the	  studies	  would	  be	  
subject	  to	  a	  degree	  of	  selection	  bias.	  	  
	  
There	  also	  appears	  to	  be	  a	  high	  possibility	  of	  detection	  bias,	  although	  there	  is	  less	  
variation	  within	  the	  studies	  than	  between	  studies,	  meaning	  that	  some	  studies	  were	  
relatively	  unbiased	  and	  some	  heavily	  biased.	  	  
	  
Six	  scales	  for	  assessing	  tumour	  response	  were	  used	  over	  the	  studies	  (see	  Table	  4.6)	  
and	  there	  was	  variability	  as	  to	  at	  what	  time	  point	  response	  was	  measured.	  There	  
was	  a	  low	  probability	  of	  attrition	  bias	  with	  most	  of	  the	  studies	  accounting	  for	  all	  of	  
the	  patients	  recruited.	  The	  main	  problem	  across	  the	  studies	  was	  inconsistency	  of	  





Table	  4.4	  Study	  quality	  assessment.	  A	  matrix	  showing	  objective	  assessment	  of	  the	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All	  but	  two	  studies	  (Voûte	  1995,	  Schmidt	  2006)	  measured	  tumour	  response	  [Table	  
4.5].	  Overall	  mean	  tumour	  response	  was	  32%	  (253/782),	  but	  as	  can	  be	  seen	  in	  
Figure	  4.2	  there	  are	  a	  wide	  range	  of	  proportions	  for	  each	  individual	  study.	  For	  
refractory	  patients,	  the	  overall	  tumour	  response	  was	  37%	  (61/164),	  for	  relapsed	  
patients	  it	  was	  38%	  (43/113),	  and	  in	  the	  studies	  with	  mixed	  populations,	  where	  
response	  was	  not	  reported	  separately	  for	  relapsed	  and	  refractory	  patients,	  it	  was	  
30%	  (149/505).	  
	  
In	  the	  multivariable	  analysis	  of	  cumulative	  AA,	  and	  chemotherapy	  (used	  or	  not),	  
there	  is	  a	  positive	  association	  between	  response	  rate	  and	  cumulative	  AA	  (OR	  1.15;	  
CI	  1.06	  to	  1.24;	  p	  =	  0.001)	  and	  for	  chemotherapy	  (1.80;	  CI	  1.04	  to	  3.15;	  p	  =	  0.035).	  
Similar	  results	  were	  obtained	  when	  the	  studies	  with	  chemotherapy	  are	  omitted	  
(univariate	  analysis	  OR	  1.17	  :	  CI	  1.07-­‐1.27;	  p<0.001).	  However,	  there	  was	  no	  clear	  
evidence	  of	  a	  relationship	  between	  response	  and	  AA/kg	  (OR	  0.52;	  CI	  0.21	  to	  1.30;	  p	  
=	  0.16)	  nor	  chemotherapy	  with	  OR	  0.66	  (CI	  0.32	  to	  1.36;	  p	  =	  0.26),	  with	  the	  point	  
estimates	  being	  suggestive	  of	  a	  possible	  negative	  association.	  Again	  omitting	  the	  
chemotherapy	  studies	  and	  undertaking	  a	  univariate	  analysis	  gives	  similar	  values	  (OR	  
0.54;	  CI	  0.22-­‐1.34	  p=0.183).	  
	  
Median	  OS	  was	  reported	  (Dubois	  2004,	  Huthinson	  1992,	  Matthay	  2007,	  Klingebiel	  
1991,	  Matthay	  2009,	  Johnson	  2011,	  Matthay	  2006)	  in	  seven	  studies.	  This	  ranged	  
from	  6	  months	  (Huthinson	  1992)	  to	  48	  months	  (	  Matthay	  2006).	  OS	  at	  1	  year	  varied	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from	  a	  low	  38%	  to	  100%	  and	  was	  reported	  in	  eight	  studies	  (Huthinson	  1992,	  
Matthay	  2007,	  Treuner	  1988,	  Klingebiel	  1991b,	  Matthay	  2009,	  Castel	  2000,	  Johnson	  
2011,	  Matthay	  2006).	  
	  
Table	  4.5	  Tumour	  response	  results.	  	  The	  response	  rates	  and	  the	  scales	  used	  to	  
assess	  response	  are	  shown.	  









	   Induction	  
*de	  Kaker	  J	  2008	   61%	   44	   27	   1	   26	   4	   9	   1	  
Mastrangelo	  S	  2011	   92%	   13	   12	   2	   10	   0	   1	   0	  
Total	  	   68%	   57	   39	   3	   36	   4	   8	   3	  
	   Relapsed	  and	  Refractory	  
131I-­‐mIBG	  plus	  Chemotherapy	   	   	   	   	   	   	   	   	  
Castel	  V	  2000	   17%	   35	   6	   NS	   NS	   6	   3	   	  
Dubois	  SG	  2012	   25%	   24	   6	   NS	   NS	   	   	   	  
Klingebiel	  T	  1991	   32%	   25	   8	   2	   6	   	   4	   2	  
Mastrangelo	  S	  2001	   75%	   16	   12	   	   12	   	   4	   	  
Matthay	  KK	  2006	   25%	   24	   6	   1	   5	   1	   15	   	  
Miano	  M	  2001	   47%	   17	   8	   5	   3	   	   9	   	  
Yanik	  GA	  2002	   67%	   12	   8	   6	   2	   1	   3	   	  
Total	  	   39%	   124	   48	   14	   28	   5	   35	   2	  
	   	   	   	   	   	   	   	   	  
131I-­‐mIBG	  alone	   	   	   	   	   	   	   	   	  
Castellani	  MR	  2000	  Group	   14%	   14	   2	   	   2	   	   9	   	  
Castellani	  MR	  2000	  Group	   38%	   8	   3	   	   3	   1	   4	   	  
Claudiani	  F	  1991	   17%	   42	   7	   2	   5	   12	   23	   	  
Garaventa	  A	  1999	   30%	   43	   13	   1	   12	   1	   24	   	  
Hoefnagel	  1987	   44%	   16	   7	   2	   5	   	   5	   	  
Hutchinson	  RJ	  1992	   7%	   14	   1	   	   1	   	   3	   	  
Johnson	  K	  2011	   30%	   76	   23	   5	   18	   16	   37	   	  
Kang	  TI	  2003	   24%	   17	   4	   	   4	   	   10	   3	  
Klingebiel	  T	  1991	  Stage	  III	   45%	   11	   5	   1	   4	   	   6	   	  
Klingebiel	  T	  1991	  Stage	  IV	   47%	   36	   17	   8	   9	   	   19	   	  
Lashford	  LS	  1992	   32%	   25	   8	   	   8	   7	   9	   1	  
Lumbroso	  J	  1991	   4%	   26	   1	   	   1	   7	   6	   10	  
Matthay	  KK	  2001	  (part	  of	  Dubois	  SG2004	  53pts)	   38%	   42	   16	   	   16	   9	   17	   	  
Matthay	  KK	  2007	   36%	   164	   59	   13	   46	   44	   60	   	  
Matthay	  KK	  2009	   10%	   21	   2	   	   2	   7	   12	   	  
Matthay	  KK	  2012	   27%	   15	   4	   1	   3	   4	   7	   	  
Schwabe	  D	  1987	   64%	   11	   7	   1	   6	   	   1	   3	  
Treuner	  J	  1987	   40%	   10	   4	   2	   2	   1	   5	   	  
Treuner	  J	  1988	   52%	   27	   14	   4	   10	   5	   5	   	  
Troncone	  L	  1991	   18%	   11	   2	   1	   1	   2	   5	   	  
Total	  	   32%	   629	   199	   41	   158	   116	   267	   17	  
	   	   	   	   	   	   	   	   	  
Total	  relapsed	  and	  refractory	   32%	   782	   253	   55	   186	   124	   305	   19	  
TR	  =	  tumour	  response,	  OR	  =	  overall	  response	  (CR	  +	  VGPR	  +	  PR),	  CR	  =	  complete	  response,	  PR	  =	  partial	  
response,	  SD	  =	  stable	  disease,	  NR	  =	  no	  response,	  PD	  =	  progressive	  disease,	  MIX	  =	  mixed	  response,	  
Min	  =	  minimal	  response,	  NE	  =	  not	  evaluated.	  NS	  =	  response	  not	  stated,	  therefore	  totals	  for	  CR	  and	  
PR	  missing	  12	  patients.	  Not	  all	  patients	  accounted	  for	  therefore	  totals	  will	  not	  add	  up.	  NB	  individual	  
%	  rounded	  up.	  	  







Table	  4.6	  Response	  Scales	  used	  
	  
 
Scale	  used	   Compatibility	  with	  INCR?	  
International	  Neuroblastoma	  Response	  
Criteria	  (INRC)	  
Yes	  (Dubois	  2004,	  Garaventa	  1999,	  Matthay	  2007,	  
Matthay	  2009,	  Yanik	  2002,	  Matthay	  2006,	  
Mastrangelo	  2001,	  Kang	  2003	  
European	  Neuroblastoma	  Study	  Group	  
(ENSG)	  
No	  (Lashford	  1992)	  
International	  Union	  Against	  Cancer	   PR	  similar	  to	  definition	  in	  INCR	  (Castellani	  1991)	  
New	  Approaches	  to	  Neuroblastoma	  Therapy	  
(NANT)	  
Yes,	  modified	  INCR	  (Matthay	  2012,	  Dubois	  2012)	  
Modified	  INCR	   Yes	  (Johnson	  2011)	  
Not	  stated	   Unknown	  (Treuner	  1988,	  Kilngebiel	  1991a	  and	  b,	  
Castel	  2000,	  Miano	  2001,	  Treuner	  1987)	  





Table	  4.7	  Planned	  or	  observed	  doses	  
	  
	   Planned	  study	  	   Observed	  study	  	   Total	  
Cumulative	  AA	   (n	  =	  5)	  
(Hutchinson	  1992,	  
Klingebiel	  1991,	  Yanik	  
2002,	  Mastrnagelo	  2001,	  
Schwabe	  1987)	  
(n	  =	  8)	  	  
(Garaventa	  1999,	  Lashford	  
1992,	  Lumbroso	  1991,	  
Hutchinson	  1992,	  
Klingebiel	  1991,	  Castel	  




AA/kg	   (n	  =	  6)	  
(Matthay	  2006,	  2007,	  
2009,	  2012,	  Johnson	  
2011,	  Dubois	  2012)	  
	   6	  studies	  
Not	  included	  in	  graphs	  
as	  mean	  dose	  not	  
calculable	  
(n	  =	  3)	  
(Dubois	  2004,	  Hoefnagel	  
1987,	  Claudiani	  1991)	  
(n	  =	  4)	  
(Treuner	  1986,	  1988,	  
Miano	  2001,	  Kang	  2003)	  
7	  studies	  








Some	  trials	  report	  planned	  doses	  i.e.	  the	  dose	  the	  patient	  was	  intended	  to	  receive,	  whereas	  some	  
studies	  reported	  observed	  doses	  i.e.	  the	  actual	  dose	  received.	  Only	  one	  study15	  reported	  both.	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Figure	   4.2	   Overall	   Objective	   Tumour	   Response	   for	   relapsed	   and	   refractory,	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Figure	   4.3	   shows	   the	   scatter	   plot	   of	   proportion	   of	   responders	   against	   mean	  
cumulative	   administered	   activity	   (AA)	   to	   assess	   whether	   a	   dose	   response	  
relationship	  existed	  and	  whether	  there	  was	  an	  additional	  effect	  of	  chemotherapy.	  N	  
represents	  the	  number	  of	  patient	  in	  each	  study	  and	  is	  proportional	  to	  the	  size	  of	  the	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Variable	   Odds	  ratio	   Lower	  95%	  CI	   Upper	  95%	  CI	   p-­‐value	  
Dose	   1.15	   1.06	   1.24	   0.001	  
Chemotherapy	  	   	   	   	   	  
No	   1	   -­‐	   -­‐	   -­‐	  




Figure	  4.4.	  Scatter	  plot	  of	  response	  rate	  versus	  administered	  activity	  (AA)	  per	  Kg	  to	  
assess	  the	  existence	  of	  a	  dose	  response	  relationship	  and	  the	  effect	  of	  chemotherapy	  
in	  addition	  to	  131I-­‐mIBG	  therapy.	  For	  each	  study	  N	  represents	  the	  number	  of	  



































.2 .3 .4 .5 .6 .7 .8 .9 1 1.1 1.2 1.3 1.4 1.5 1.6




Multivariate	  analysis,	  outcome	  is	  proportion	  	  
Variable	   Odds	  ratio	   Lower	  95%	  CI	   Upper	  95%	  CI	   p-­‐value	  
Dose	   0.52	   0.21	   1.30	   0.164	  
Chemotherapy	  	   	   	   	   	  
No	   1	   -­‐	   -­‐	   -­‐	  








Four	  studies	  had	  control	  arms	  and	  all	  were	  in	  the	  relapsed	  and	  refractory	  patients.	  
No	   control	   group	   had	   been	   chosen	   by	   randomisation.	   In	  Hutchinson	   et	   al.	   (1992)	  
investigators	   matched	   patients	   with	   neuroblastoma	   who	   had	   received	  
chemotherapy	   consisting	   of	   ifosfamide	   and	   etoposide	   with	   patients	   who	   had	  
received	   131I-­‐mIBG.	   The	   control	   group	   in	  Klingebiel	   et	   al.	   (1991a)	  was	  made	  up	  of	  
patients	  who	  had	  refused	   131I-­‐mIBG	  therapy.	   In	  Schmidt	  et	  al.	   (2006),	   the	  controls	  
came	   from	   patients	   whose	   local	   paediatric	   oncologist	   and	   nuclear	   medicine	  
specialist	   decided	   against	   131I-­‐mIBG	   treatment.	   In	  Miano	   et	   al.	   (2001)	   the	   control	  
patients	  were	  not	  mIBG	  avid	  at	   123I-­‐mIBG	  scanning	  suggesting	   that	   they	  may	  have	  
had	   neuroblastoma	   with	   different	   biological	   behavior.	   Information	   as	   to	   the	  
treatment	   patients	   received	   instead	  of	   131I-­‐mIBG	  was	   not	   given	   (Klingebiel	   1991a,	  
Miano	  2001,	  Schmidt	  2006).	  
	  
None	   of	   the	   studies	   presented	   tumour	   response	   data	   for	   the	   control	   groups.	  
Survival	   outcomes	   were	   similar	   between	   131I-­‐mIBG	   patients	   and	   controls	   across	  
three	  studies,	  with	  median	  survival	  around	  6	  months	  in	  Hutchinson	  et	  al.	  (1992)	  and	  
15	  months	  in	  Klingebiel	  et	  al.	  (1991a).	  By	  undertaking	  a	  multivariate	  Cox	  regression	  
analysis,	  Schmidt	  et	  al.	   (2006)	   found	  a	   statistically	   significant	  difference	   in	  OS	  and	  
EFS,	  ascribing	  the	  difference	  to	  the	  131I-­‐	  mIBG	  group	  receiving	  ASCT,	  though	  the	  Cox	  
analysis	  also	  pointed	  towards	  an	  increase	  in	  OS	  related	  to	  external	  beam	  radiation	  
therapy	  and	  MYCN	  status.	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Miano	  et	  al.	  (2001)	  reported	  that	  patients	  in	  the	  131I-­‐mIBG	  group	  had	  a	  longer	  time	  


























This	   systematic	   review	  aimed	   to	   assess	   the	   activity	   and	  effectiveness	  of	   131I-­‐mIBG	  
therapy	  	   and	   to	   assess	   the	   overall	   quality	   and	   reliability	   of	   the	   current	   evidence	  
base.	   The	   review	   also	   examined	   whether	   there	   was	   any	   evidence	   of	   a	   dose-­‐
response	   relationship	  and	  whether	   there	  was	  any	  additional	   value	  of	   concomitant	  
chemotherapy.	  
	  
No	   randomised	   controlled	   trials	   were	   identified	   comparing	   either	   131I-­‐mIBG	  
molecular	  radiotherapy	  with	  other	  treatments	  or	  different	  131I-­‐mIBG	  schedules.	  We	  
did	   find	   four	   studies	   that	   had	   non-­‐randomised	   comparators,	   but	   believe	   that	  
confounding	   variables,	   especially	   patient	   selection,	   make	   the	   validity	   of	   these	  
comparisons	   highly	   doubtful.	  We	   therefore	  were	   unable	   to	   ascertain	   the	   relative	  
effectiveness	  of	  131I-­‐mIBG	  in	  the	  treatment	  of	  neuroblastoma.	  
	  
Most	   studies	   assessed	   the	   activity	   of	   131I-­‐mIBG	   using	   tumour	   response	   as	   an	  
outcome	  measure.	   Three	   evaluated	   131I-­‐mIBG	   during	   induction	   and	   consolidation.	  
The	   majority	   of	   studies	   looked	   at	   its	   use	   in	   patients	   with	   relapsed	   or	   refractory	  
disease,	   though	   only	   a	   third	   of	   the	   studies	   gave	   separate	   results	   for	   these	   two	  




Objective	  tumour	  rates	  of	  response	  to	  131I-­‐mIBG	  therapy	  were	  of	  clinical	  
significance,	  but	  there	  was	  no	  evidence	  that	  these	  responses	  lead	  to	  better	  long-­‐
term	  outcome	  as	  measured	  by	  EFS	  or	  OS.	  	  
	  
It	  remains	  unclear	  whether	  or	  not	  there	  is	  a	  true	  dose	  response	  relationship.	  For	  the	  
studies	  that	  reported	  cumulative	  AA	  we	  found	  a	  statistically	  significant	  association	  
between	  higher	   cumulative	  AA	  and	   response	   rates	   (OR	  1.15).	   For	   the	   studies	   that	  
reported	  AA/kg,	  no	  statistically	  significant	  association	  was	  found,	  though	  the	  point	  
estimate	   for	   the	  OR	   (0.52)	  was	   in	   the	   opposite	   direction.	   These	   divergent	   results	  
suggest	  that	  chance	  or	  confounding	  factors	  may	  have	  contributed	  to	  these	  findings.	  
The	   regression	   analysis	   on	   the	   studies	   that	   reported	   cumulative	   AA	   found	   a	  
statistically	   significant	   relationship	   between	   tumour	   response	   and	  
chemotherapy	  (OR	   1.80).	   In	   the	   studies	   reporting	   AA/kg,	   it	   was	   not	   statistically	  
significant,	  the	  point	  estimate	  for	  the	  OR	  (0.66)	  being	  in	  the	  opposite	  direction.	  We	  
were	  unable	  to	  directly	  compare	  studies	  with	  and	  without	  chemotherapy	  as	  AA	  of	  
131I-­‐mIBG	  was	  reduced	  when	  given	  with	  chemotherapy.	  
	  
Heterogeneity	   of	   the	   populations,	   131I-­‐mIBG	   treatment	   schedules	   and	   other	  
treatments	  will	  have	  influenced	  the	  tumour	  response	  results.	  Although	  most	  studies	  
used	   tumour	   response	  measures	  equivalent	   to	   the	   INRC	   (Brodeur	  1988	  and	  1993)	  
[Table	   4.6],	   there	  was	   variation	   in	   the	   timing	  of	   tumour	   response	  measurements.	  
Given	   the	   inconsistency	   of	   reporting	   regarding	   key	   prognostic	   factors,	   it	   is	  
impossible	  to	  determine	  the	  influence	  of	  confounding	  factors	  on	  this	  dose	  response	  
result.	  ”Temporal	  drift‟	  may	  also	  compound	  the	  problem	  (Tang	  2010).	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Similarly,	   the	  survival	  data	  also	  showed	  a	  wide	  spectrum	  of	  results	  and	  again	  may	  
well	   be	   a	   reflection	   of	   the	   clinical	   heterogeneity	   between	   studies,	   with	   further	  
confounding	   by	   subsequent	   treatment,	   therefore	   the	   true	   effect	   of	   131I-­‐mIBG	   on	  
survival	  is	  unknown.	  
	  
The	   only	   significant	   acute	   toxicity	   reported	   was,	   as	   expected,	   myelosuppression.	  
Haematopoietic	  stem	  cell	  support	  allows	  circumvention	  of	  this,	  and	  the	  safe	  use	  of	  
higher	   AA.	   Few	   papers	   report	   long-­‐term	   toxicities,	   but	   hypothyroidism	   and	  
secondary	  thyroid	  cancer	  and	  myelodysplastic	  have	  been	  encountered.	  
	  
We	  chose	   to	  use	  systematic	   review	  methodology	  because	  systematic	   reviews	   -­‐	  by	  
defining	   the	   scope	   of	   the	   review,	   setting	   out	   clear	   study	   objectives	   a	   priori,	  
performing	   reproducible	   searches	   for	   studies,	   and	  performing	   tasks	   such	  as	   study	  
selection	  and	  data	  extraction	  according	  to	  set	  criteria	  and	  in	  duplicate	  -­‐	  ensure	  that	  
bias	  in	  the	  selection	  of	  studies	  and	  selection	  of	  data	  summarized	  is	  minimized.	  This	  
has	  enabled	  us	  to	  present	  a	  comprehensive,	  summary	  of	  the	  research	  evidence	  to	  
date	  on	  the	  use	  of	  131I-­‐mIBG	  in	  neuroblastoma.	  One	  consequence	  of	  this	  is	  that	  we	  
identified	  multiple	  publications	   reporting	   the	  same	  patient	  group.	  This	   shows	   that	  
the	  evidence	  base	  is	  in	  fact	  smaller	  than	  seems	  at	  first	  to	  be.	  	  
	  
If	  we	  had	  assumed	  that	  the	  eight	  publications	  identified	  in	  induction	  were	  separate	  
studies	   we	   would	   have	   148	   patients	   instead	   of	   57.	   For	   relapsed	   and	   refractory	  
studies,	  counting	  each	  publication	  as	  a	  separate	  study	  would	  have	  given	  339	  extra	  
 195 
patients.	  Multiple	  publications	  made	  data	  extraction	  difficult,	   and	   it	   could	  be	   that	  
we	  may	  have	  double	  counted	  some	  patients	  or	  reduced	  the	  data	  set	  by	  mistakenly	  
thinking	  some	  studies	  were	  related	  when	  they	  were	  not.	  By	  only	   including	  studies	  
with	  10	  or	  more	  patients	  [Figure	  4.1]	  will	  also	  have	  reduced	  the	  number	  of	  potential	  
patients.	  This	   is	  an	  arbitrary	  cut	  off	  point	  often	  used	  in	  systematic	  reviews	  to	  save	  
time	   critically	   appraising	   studies	   yielding	   very	   little	   information,	   or	   reporting	  
exceptional	  cases	  which	  wouldn’t	  be	  generalizable.	  In	  rare	  diseases	  this	  cut	  off	  point	  
may	  be	  too	  high.	  
	  
Systematic	   reviews	   also	   undertake	   quality	   assessment	   of	   the	   included	   studies,	  
allowing	  for	  the	  review	  authors	  to	  to	  assess	  the	  validity	  of	  the	  results	  of	  each	  study,	  
and	   thus	   the	   reliability	   of	   the	   review’s	   summary	   findings.	   Selection	   bias	   was	   the	  
most	  common	  problem,	  which	  along	  with	  the	  heterogeneity	  of	   the	  administration	  
of	   131I-­‐	  mIBG	  and	   the	   response	  assessment	   in	   the	  different	   studies,	  plus	   the	   small	  
size	  of	  many	  studies	  which	  could	  lead	  to	  chance	  effects;	  these	  factors	  are	  probably	  
the	  cause	  of	  the	  very	  wide	  range	  of	  response	  rates	  observed.	  We	  may	  be	  criticized	  
that	  we	  have	  presented	  these	  data	  quantitatively,	  but	  we	  have	  presented	  the	  data	  
in	  this	  way	  to	  illustrate	  the	  challenges	  faced	  by	  anyone	  trying	  to	  make	  sense	  of	  the	  
many	  publications	  in	  this	  field.	  	  
	  
Although	   we	   strongly	   advise	   caution	   in	   its	   interpretation,	   the	   data	   trend	   suggest	  
that	  131I-­‐mIBG	  is	  an	  “active”	  treatment	   in	  the	  short	  term,	  but	  provide	  no	  evidence	  
on	  either	   its	   comparative	  efficacy	   relative	   to	  other	   therapeutic	  options	  or	   its	   long	  
term	  benefits;	  and	  this	  enables	  us	  to	  justify	  the	  need	  for	  RCTs.	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The	  currently	  available	  literature	  leads	  us	  to	  suggest	  that	  the	  greatest	  uncertainties	  
are:	  
• How	  effective	  is	  131I-­‐mIBG	  compared	  to	  chemotherapy	  regimens	  (including	  
high-­‐dose	  therapy)?	  	  
• Is	  there	  a	  benefit	  of	  concomitant	  chemotherapy	  compared	  to	  giving	  131I-­‐
mIBG	  alone?	  	  
• Is	  there	  an	  AA	  response	  relationship	  –	  i.e.	  what	  is	  the	  optimum	  dose?	  	  	  
	  
We	  suggest	  that	  future	  trials	  should	  also	  take	  account	  of	  the	  following:	  	  
• There	  should	  be	  separate	  trials	  for	  relapsed	  and	  refractory	  patients;	  or	  
at-­‐least	  the	  two	  populations	  should	  be	  stratified	  and	  reported	  separately	  
if	  included	  in	  the	  same	  trial.	  	  
• Fixed	  AA	  should	  be	  replaced	  by	  scaling	  to	  some	  proxy	  of	  size	  such	  as	  
weight,	  body	  surface	  area,	  or	  prescribed	  to	  give	  a	  desired	  whole	  body	  
dose,	  given	  the	  heterogeneity	  of	  the	  patient	  population.	  	  
• The	  resulting	  whole-­‐body	  and	  tumour	  doses	  should	  be	  measured	  and	  
reported	  to	  evaluate	  correlation	  between	  these	  parameters	  and	  
response	  and	  other	  outcomes.	  	  	  	  
	  
Over	  the	  last	  almost	  30	  years,	  many	  studies	  have	  demonstrated	  the	  activity	  of	  131I-­‐
mIBG	   therapy	   in	   neuroblastoma.	   There	   have	   however	   been	   no	   randomized	  
controlled	   trials	   of	   its	   use	   and	   therefore	   its	   effectiveness	   compared	   with	   other	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treatments	   remains	   unknown.	   There	   is	   too	   little	   data	   to	   assess	   whether	   it	   has	  
efficacy	  during	  induction	  and	  consolidation.	  The	  true	  value	  of	  higher	  than	  standard	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Paediatric	  molecular	  radiotherapy	  can	  cause	  a	  great	  deal	  of	  anxiety	  for	  parents	  and	  
other	   caregivers	  when	   thinking	   about	   radiation	  exposure.	   This	   study	  examines	   the	  
radiation	  doses	  received	  by	  adults	  whilst	   looking	  after	  children	  receiving	  molecular	  
radiotherapy.	  When	  adult	  patients	  are	   in	  hospital	   receiving	  molecular	  radiotherapy	  
they	   are	   generally	  well	   and	   self-­‐caring.	  However	   children,	   especially	   younger	   ones	  
and	   babies,	   may	   require	   considerable	   personal	   care	   and	   emotional	   support	   from	  
adults.	   Radioactive	   patients,	   and	   radioactive	   bodily	   products,	   including	   urine	   and	  
vomit,	  and	   in	  the	  case	  of	   iodine-­‐131	  sodium	  iodide	  (131I-­‐NaI)	  also	  sweat,	  saliva	  and	  
faecal	   matter,	   represent	   a	   potential	   radiation	   hazard	   to	   those	   caring	   for	   children	  
receiving	  molecular	  radiotherapy.	  	  
	  
Radiation	  exposure	  is	  governed	  by	  national	  legislation,	  which	  varies	  from	  country	  to	  
country.	   In	   the	   United	   Kingdom,	   hospitals	   are	   bound	   by	   the	   Ionising	   Radiation	  
Regulations	  1999	  (IRR99)	  which	  are	  derived	  from	  the	  European	  Union’s	  Basic	  Safety	  
Standards	  Directive	  1996	  96/29	  (Council	  Directive	  96/29/Euratom	  of	  13th	  May	  1996)	  
as	  supplemented	  by	  the	  EU	  Medical	  Exposure	  Directive	  1997	  97/43	  (Council	  Directive	  
97/43/Euratom	   of	   30th	   June	   1997).	   These	   regulations	   require	   that	   all	   radiation	  
exposures	  shall	  be	  justified	  and	  optimized	  to	  a	  level,	  which	  is	  ‘as	  low	  as	  reasonably	  
achievable’	  (the	  ALARA	  principle).	  
	  
The	  direct	   involvement	   of	   doctors	   and	  nurses	   in	   the	   period	   immediately	   following	  
administration	   of	   the	   molecular	   radiotherapy	   agent	   is	   essential	   if	   radioactive	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patients	  require	  specific	  medical	  or	  nursing	  interventions,	  and	  in	  carrying	  out	  these	  
duties	   they	  will	   inevitably	  be	  exposed	   to	   some	   radiation.	   Staff	  may	  over	   time	   look	  
after	  many	  patients.	   	  Therefore,	  respecting	  annual	  dose	   limits,	  and	   in	  keeping	  with	  
the	  ALARA	  principle,	   it	   is	  essential	  that	  they	  do	  not	  receive	  any	  avoidable	  radiation	  
exposure.	   To	   minimize	   staff	   exposure,	   normal	   child-­‐care	   tasks	   such	   as	   feeding,	  
washing,	  dressing,	  comforting	  and	  entertainment	  are	  delegated	  to	  other	  responsible	  
adults	  during	  molecular	  radiotherapy.	  
	  
These	   responsible	   adults	   are	   called	   comforters	   and	   carers	   and	   are	   usually	   family	  
members,	   most	   often	   the	   parents,	   and	   less	   frequently	   other	   relatives	   such	   as	  
grandparents,	  aunts,	  uncles	  or	  older	  siblings.	  ‘Comforters	  and	  carers’	  are	  defined	  by	  
UK	  IRR99	  as	  individuals	  ‘knowingly	  and	  willingly	  helping	  (other	  than	  as	  part	  of	  their	  
occupation)	  in	  the	  support	  and	  comfort	  of	  patients	  undergoing	  medical	  diagnosis	  or	  
treatment’	  (Ionising	  Radiation	  Regulations	  1999	  (IRR99)	  and	  European	  Union’s	  Basic	  
Safety	  Standards	  Directive	  1996	  96/29).	  
	  
	  Comforters	   and	   carers,	   unlike	   healthcare	   workers,	   are	   not	   subject	   to	   a	   specific	  
cumulative	   dose	   limit,	   although	   incidental	   radiation	   exposure	   is	   governed	   by	   the	  
ALARA	   principle.	   The	   International	   Commission	   on	   Radiological	   Protection	  
(Publication	  103)	  recommends	  the	  use	  of	  dose	  constraints	  rather	  than	  dose	  limits	  for	  
Comforters	  and	  Carers.	  They	  suggest	  a	  dose	  constraint	  of	  5	  mSv	  per	  episode	  (i.e.	  for	  
the	   duration	   of	   the	   risk	   of	   radiation	   exposure	   after	   therapy)	   but	   state	   that	   these	  
constraints	  need	  to	  be	  used	   flexibly.	  They	  give	   the	  example	   that	  higher	  doses	  may	  
well	   be	   appropriate	   for	   parents	   of	   very	   sick	   children.	   The	   ICRP	   2007’s	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recommendations	  are	  endorsed	  by	  the	  UK	  Health	  Protection	  Agency	  (previously	  the	  
UK	  National	  Radiological	  Protection	  Board).	  	  
	  
Comforters	  and	  carers	  dose	  constraints	  are	  an	  important	  means	  of	  planning	  effective	  
ways	  of	  reducing	  unnecessary	  exposure	  to	  these	   individuals.	  The	  UK	  HSE	  Approved	  
Code	  of	  Practice	  to	   IRR99	  (L121)	  states	  that	   it	  should	  always	  be	  appropriate	  to	  use	  
dose	  constraints	  for	  comforters	  and	  carers	  and	  states	  that	  in	  most	  circumstances,	  it	  
should	  be	  possible	  to	  design	  control	  measures	  that	  result	   in	  doses	   less	  than	  this.	   It	  
also	  states	   that	  comforters	  and	  carers	  are	   likely	   to	  receive	  1mSv	  or	  more	   in	  a	  year	  
resulting	   from	   direct	   radiation	   or	   contamination	   during	   the	   comfort	   and	   support	  
they	  offer.	  	  
	  
In	  order	  to	  be	  designated	  as	  a	  comforter	  and	  carer	  for	  a	  child	  undergoing	  a	  medical	  
exposure	  to	  radiation,	   it	   is	  necessary	  for	  that	   individual	  to	  be	  fully	   informed	  of	  the	  
fact	  that	  he	  or	  she	  will	  be	  exposed	  to	  radiation,	  and	  given	  clear	  expectation	  of	  the	  
risk	   of	   harm	   this	  may	   cause.	   In	   our	   institution,	  when	   a	   child	   is	   being	   assessed	   for	  
molecular	   	   radiotherapy,	   potential	   comforters	   and	   carers	   are	   given	   a	   full	   verbal	  
explanation	   together	   with	   a	   written	   information	   leaflet.	   Unsealed	   source	  
radiotherapy:	   information	   for	   comforters	   and	   carers.	   The	   leaflet	   includes	   the	  
following	  statement	  on	  risk:	  
	   	   There	  is	  no	  legal	   limit	  to	  the	  amount	  of	  radiation	  dose	  you	  are	  allowed	  to	  receive	  as	  a	  
comforter	   and	   carer.	   Consequently	   you	   may	   receive	   more	   radiation	   dose	   than	   is	  
allowed	  for	  a	  member	  of	  the	  public.	  It	  is	  thought	  that	  exposure	  to	  even	  a	  small	  amount	  
of	  radiation	  may	  result	  in	  a	  small	  increased	  chance	  of	  developing	  cancer	  in	  later	  years.	  
For	  instance,	  the	  chance	  of	  harm	  resulting	  from	  the	  radiation	  dose	  a	  normal	  member	  of	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the	  public	  is	  allowed	  to	  receive	  is	  1	  in	  20,000.	  This	  chance	  of	  harm	  is	  similar	  to:	  	  
	   	   •	  Smoking	  40	  cigarettes	  during	  a	  lifetime.	  	  
	   	   •	  Driving	  a	  car	  for	  one	  year.	  	  
	   	   •	  Nine	  months	  of	  normal	  home	  life.	  	  
	  	   	   The	  chance	  that	  radiation	  will	  cause	  harm	  increases	  with	  the	  amount	  of	  radiation	  dose	  
received.	  We	  will	  therefore	  aim	  to	  limit	  your	  radiation	  dose	  to	  no	  more	  than	  5	  times	  the	  
public	   radiation	   dose	   limit.	   This	   is	   about	   twice	   the	   annual	   radiation	   dose	   we	   each	  
receive	  from	  natural	  sources	  of	  radiation	  that	  exist	  in	  our	  normal	  environment.	  It	  is	  also	  




Individuals	   are	   taught	   how	   to	   minimize	   their	   personal	   radiation	   exposure.	   This	  
involves	   both	   avoidance	   of	   direct	   contamination	   by	   contact	   with	   radioactive	  
materials,	   and	   minimizing	   exposure	   to	   the	   radiation	   emanating	   from	   the	   patient.	  
Disposable	  plastic	  gloves,	  aprons	  and	  overshoes	  are	  used	  to	  reduce	  the	  risk	  of	  direct	  
contamination	   by	   patient	   excreta	   –	   in	   the	   form	   of	   vomit,	   urine,	   sweat	   or	   faeces.	  
Eating	   and	   drinking	   by	   comforters	   and	   carers	   in	   the	   ensuite	   inpatient	   bedroom	   is	  
prohibited	  to	  reduce	  the	  risk	  of	   ingestion	  of	  radioactive	  substances.	   Individuals	  are	  
advised	   to	  minimize	   the	   time	   spent	   in	   close	   contact	  with	   the	   child	   they	   are	   giving	  
care	   to,	   to	   maximize	   the	   distance	   between	   themselves	   and	   the	   child	   when	   close	  
contact	   is	   not	   necessary,	   and	   to	   use	   mobile,	   shielded	   protection	   screens	   where	  
possible.	   Again,	   this	   advice	   is	   given	   verbally	   and	   re-­‐iterated	   in	   the	   information	  
leaflet.	  If	  the	  individual	  agrees	  to	  be	  a	  comforter	  and	  carer,	  written	  consent	  is	  then	  
required.	  By	  signing	  the	  consent	  form	  the	  person	  certifies:	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I	  am	  over	  18	  years	  of	  age.	  
I	   have	   been	   informed	   that,	   to	   give	   the	   extended	   support	   I	   want	   to	   provide	   to	   my	  
relative/friend	  undergoing	  treatment	  with	  radioactive	  material,	  I	  am	  likely	  to	  receive	  a	  
dose	  of	  ionising	  radiation	  in	  excess	  of	  the	  legal	  limit	  for	  a	  member	  of	  the	  public.	  
I	  have	  been	  informed	  about	  the	  possible	  risks	  involved	  with	  the	  exposure	  I	  may	  receive.	  
I	  have	  understood	  the	  instructions	  that	  specify	  how	  my	  dose	  may	  be	  restricted	  as	  far	  as	  
reasonably	  practicable.	  
And	  for	  females	  aged	  between	  12	  and	  55:	  	  	  
I	   understand	   that	   I	   should	   not	   be	   pregnant	   or	   breastfeeding	   whilst	   being	   a	  
Comforter/Carer	   and	   that	   if	   there	   is	   any	   possibility	   of	   this	   I	   should	   inform	   the	  
doctor/radiographer/nurse	  before	  becoming	  a	  Comforter	  or	  Carer.	  
	  
Comforters	  and	  carers	  may	  be	  exposed	  to	  radiation	  both	  during	  that	  child’s	  stay	   in	  
hospital	  and	  after	  discharge.	  The	  period	  in	  hospital	  is	  the	  time	  of	  greater	  risk,	  as	  their	  
in	   vivo	   activity	   is	   much	   higher.	   On	   discharge	   from	   hospital,	   patients	   are	   provided	  
with	  a	  yellow,	  radionuclide	  instruction	  card	  detailing	  the	  molecular	  radiotherapy	  that	  
was	   given	   and	   precautions,	   including	   a	   time	   frame,	   to	   be	   taken	   to	   reduce	   the	  
exposure	   of	   other	   individuals	   in	   particular	   pregnant	   women	   and	   young	   children.	  
These	   restrictions	   and	   advice	   are	   based	   on	   the	   dose	   rate	   measurements,	   the	  
effective	   half-­‐life	   of	   the	   isotope	   given,	   and	   take	   into	   account	   individual	   personal	  
circumstances	   (Working	  Party	  of	   the	  Radiation	  Protection	  Committee	  of	   the	  British	  
Institute	  of	  Radiology	  1999,	  Institute	  of	  Physics	  and	  Engineering	  in	  Medicine	  with	  the	  
support	  of	  National	  Radiological	  Protection	  Board,	  Health	  and	  Safety	  Executive,	  The	  
Health	  Departments	  and	  The	  Environment	  Agencies	  2002).	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The	  medical	   use	   of	   radioactive	   substances	   can	   arouse	   anxiety	   in	   people	  who	  may	  
misunderstand	   and	   overestimate	   the	   associated	   risks.	   This	   fear	   of	   radiation	   may	  
affect	  both	  the	  relatives	  of	  patients,	  and	  even	  hospital	  staff	  who	  have	  been	  trained	  
in	  radiation	  protection.	  	  
	  
This	  work	  includes	  data	  on	  comforters	  and	  carers	  looking	  after	  relapsed	  or	  refractory	  
neuroblastoma	  patients	  receiving	  131I-­‐mIBG	  or	  177Lutetium	  DOTATATE	  therapy.	  I	  have	  
also	  included	  in	  this	  work	  comforter	  and	  carer	  doses	  for	  the	  few	  patients	  who	  have	  
received	   131I-­‐mIBG	  or	   177Lutetium	  DOTATATE	   for	  neuroendocrine	   tumours	  and	  also	  
those	   comforters	   and	   carers	   looking	   after	   patients	   receiving	   131I-­‐NaI	   for	   thyroid	  
carcinoma.	  	  
	  
Thyroid	   cancer	   in	   children	   is	   rare.	   Data	   from	   the	   European	   database	   of	   the	  
Automated	  Childhood	  Cancer	  Information	  System	  (ACCIS)	  reported	  age-­‐standardised	  
incidence	  rates	  for	  children	  aged	  0-­‐14	  years	  varied	  in	  European	  regions	  from	  0.5	  to	  
1.2	  per	  million	  and	  age-­‐specific	  incidence	  for	  1-­‐19	  year	  olds	  varied	  between	  4.4	  to	  11	  
per	  million	  (Steliarova-­‐Foucher	  2006).	  In	  England	  and	  Wales	  the	  annual	  incidence	  is	  
0.5/million/year.	  Thyroid	  cancers	  occurring	  under	   the	  age	  of	  21	  years	  accounts	   for	  
<10%	  of	  thyroid	  cancer.	  Children	  commonly	  present	  with	  advanced	  disease	  with	  40-­‐
80%	   having	   regional	   lymph	   node	   involvement	   at	   diagnosis	   and	   10-­‐20%	   having	  
metastases,	  usually	  lung,	  at	  presentation	  (Papendieck	  2011,	  Dinauer	  2008	  ).	  Despite	  
this,	  the	  prognosis	  for	  children	  with	  thyroid	  cancer	   is	  excellent	  with	  mortality	  rates	  
of	   less	   than	   10%	   (Stelliarova-­‐Foucher	   2006,	   Alessandri	   2000).	   The	   presence	   of	  
metastases	   requires	   repeated	   administrations	   of	   131I-­‐NaI,	   usually	   given	   6	   months	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apart.	   131I-­‐NaI	   molecular	   radiotherapy	   has	   an	   established	   role	   in	   the	   effective	  
treatment	   of	   paediatric	   thyroid	   cancer	   and	   several	   studies	   have	   shown	   that	  
successful	   treatment	   with	   131I-­‐NaI	   may	   be	   due	   to	   the	   higher	   expression	   of	   the	  
sodium	  iodide	  symporter	  (Patel	  2002,	  Faggiano	  2004).	  It	  is	  therefore	  important	  that	  
the	  comforters	  and	  carer’s	  doses	  for	  this	  group	  of	  patient’s	  is	  monitored	  over	  time.	  	  
	  
	  
This	  study	  examines	  the	  in-­‐hospital	  radiation	  exposure	  of	  comforters	  and	  carers,	  to	  
see	   whether	   these	   were	   within	   the	   established	   dose	   constraint.	   The	   aim	   was	   to	  
provide	  real	  data	  that	  might	  help	  to	  reassure	  potential	  comforters	  and	  carers,	  and	  to	  
better	   educate	   hospital	   staff,	   who	   might	   otherwise	   seek	   to	   restrict	   reasonable	  
parental	  access	  to	  children	  undergoing	  molecular	  radiotherapy,	  and	  cause	  emotional	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5.2	  Materials	  and	  Methods	  
	  
University	  College	  London	  Hospitals	  NHS	  Foundation	  Trust	   is	  a	  UK	  national	   referral	  
centre	   for	   paediatric	   molecular	   radiotherapy.	   We	   use	   three	   different	   types	   of	  
molecular	   radiotherapy	   in	   children:	   iodine-­‐131	   meta-­‐iodobenzylguanidine	  
(131I-­‐mIBG)	   and	   lutetium-­‐177	   DOTATATE	   (177Lu-­‐DOTATATE)	   for	   neuroblastoma	   and	  
other	  neuroendocrine	  tumours,	  and	  131I-­‐NaI	  for	  thyroid	  cancer.	  	  
	  
In	  neuroblastoma,	  we	  used	  a	  protocol	  that	  requires	  higher	  than	  standard	  activities	  of	  
131I-­‐mIBG	   in	   two	   administrations	   with	   concurrent	   topotecan	   as	   a	   radiosensitiser,	  
(mIBG	   and	   topotecan	   in	   neuroblastoma	   –	   the	  MATIN	   protocol),	   two	  weeks	   apart,	  
followed	  by	  peripheral	  blood	  stem	  cell	  support.	  We	  used	  a	  weight-­‐based	  activity	  of	  
444	   MBq	   kg-­‐1	   for	   the	   first	   administration,	   aiming	   to	   give	   a	   whole	   body	   radiation	  
absorbed	  dose	  of	  about	  2	  Gy.	  The	  actual	  whole	  body	  dose	  achieved	  was	  determined	  
via	  the	  whole	  body	  monitoring	  of	  radionuclide	  retention	  using	  monitors	  installed	  in	  
the	  inpatient	  bedroom.	  The	  activity	  required	  for	  the	  second	  administration	  to	  deliver	  
a	  total	  whole	  body	  dose	  for	  both	  administrations	  of	  4	  Gy	  was	  then	  calculated	  (Gaze	  
2005).	   Patients	   with	   neuroendocrine	   tumours	   and	   some	   patients	   with	  
neuroblastoma	  received	  a	  single	  weight	  based	  administered	  activity	  of	  444MBq	  kg-­‐1.	  
	  
The	   administered	   activity	   of	   177Lu-­‐DOTATATE	   was	   a	   fixed	   administered	   activity	   of	  
7.4GBq	  (Gains	  2011).	  Fixed	  standard	  administered	  activities	  of	  131I-­‐NaI	  were	  used	  in	  
thyroid	  cancer	  patients:	  3.0	  GBq	  for	  ablation,	  and	  5.5GBq	  for	  therapy	  of	  residual	  or	  
metastatic	  disease.	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Potential	   comforters	   and	   carers	  were	   given	   verbal	   and	  written	   explanation	   on	   the	  
radiation	  risks	  and	  methods	  to	  reduce	  their	  radiation	  exposure.	  Methods	  to	  reduce	  
their	   radiation	   exposure	   such	   as	   time,	   distance	   and	   use	   of	   shielding,	   as	   well	   as	  
methods	   to	   avoid	   contamination	   such	   as	   gloves,	   aprons	   and	   overshoes	   were	  
explained.	   Informed	   consent	   to	   be	   a	   comforter	   and	   carer	   was	   then	   obtained.	   The	  
designated	   comforters	   and	   carers	   were	   given	   an	   instant	   readout	   whole	   body	  
personal	  dosimeter	  (‘Bleeper	  Sv’	  from	  Vertec	  Scientific	  Ltd,	  Silchester,	  UK)	  to	  use	  for	  
the	   duration	   of	   the	   patient’s	   stay	   in	   hospital.	   They	  were	   instructed	   in	   its	   use,	   and	  
asked	  to	  record	  their	  exposure	  following	  each	  contact,	  in	  a	  written	  log	  kept	  outside	  
the	  patient’s	  room.	  
	  
The	  HPA	   advised	   dose	   constraint	   is	   5mSv	   per	   episode,	   for	   the	   duration	   of	   a	   given	  
release	   of	   therapy.	   Therefore	   an	   episode,	   for	   this	   study,	   was	   defined	   as	   a	   single	  
administration	  of	  177Lu-­‐DOTATATE	  or	  131I-­‐NaI.	  For	  the	  131I-­‐mIBG	  patients,	  an	  episode	  
was	  defined	  as	  either	  a	  single	  high-­‐administered	  activity	  treatment	  schedule	  (MATIN	  
-­‐	   2	   administrations	   of	   131I-­‐mIBG,	   2weeks	   apart)	   or	   a	   single	   administration	   of	  
131I-­‐mIBG.	  	  
	  
We	   collected	   the	   comforter	   and	   carer	   data	   for	   paediatric	   molecular	   radiotherapy	  
episodes	   between	   November	   2002	   and	   March	   2012.	   We	   then	   compared	   the	  
recorded	   comforter	   and	   carer	   exposures	   against	   national	   and	   international	  
recommendations	   for	   the	   applied	   dose	   constraint.	   We	   looked	   for	   associations	  
between	   the	   radionuclide,	   the	   administered	   activity	   received	   and	   age	   of	   the	  
patients;	  the	  comforter	  and	  carer	  exposure,	  the	  administered	  activity	  and	  the	  age	  of	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the	   patients,	   and	   the	   total	   number	   of	   comforters	   and	   carers	   per	   child.	   Data	   are	  
presented	   descriptively	   and	   linear	   regression	   analysis	   was	   used	   to	   test	   for	  








































For	  131I-­‐mIBG,	  the	  MATIN	  protocol	  was	  used	  in	  57	  instances	  and	  there	  were	  12	  single	  
administrations	   of	   131I-­‐mIBG.	   The	   MATIN	   protocol	   was	   used	   in	   patients	   with	  
refractory	   or	   relapsed	   neuroblastoma.	   The	   12	   single	   administrations	   of	   131I-­‐mIBG	  
were	   used	   in	   nine	   instances	   of	   neuroblastoma	   and	   three	   for	   a	   neuroendocrine	  
tumour.	  Comforter	  and	  carer	  data	  were	  available	  for	  all	  the	  single	  administrations	  of	  
131I-­‐mIBG,	   and	   for	   50	   of	   the	   57	   MATIN	   administrations	   (88%).	   Twenty-­‐four	  
administrations	   of	   177Lu-­‐DOTATATE	   (18	   for	   neuroblastoma	   and	   six	   for	   other	  
neuroendocrine	   tumours)	   were	   given.	   Data	   were	   available	   for	   15	   of	   these	  
administrations	   (72%).	   Forty-­‐one	   administrations	   of	   131I-­‐NaI	   for	   thyroid	   carcinoma	  
were	  given.	  Data	  were	  available	  for	  28	  (68%)	  of	  these	  administrations.	  
	  
The	  median	  age	  of	  the	  children	  for	  all	  administrations	  was	  7	  years	  (range	  1-­‐18	  years).	  
For	   patients	   receiving	   131I-­‐mIBG	   the	   median	   age	   was	   6	   years	   (range	   1-­‐18	   years);	  
177Lu-­‐DOTATATE	  7	  years	  (range	  2-­‐14)	  and	  131I-­‐NaI	  median	  9	  years	  (range	  5-­‐17	  years).	  
	  
The	  median	  administered	  activity	  of	   131I-­‐mIBG	  per	  MATIN	  was	  16.2GBq	   (range	  6.8-­‐
59GBq)	  and	  for	  a	  single	  administered	  activity	  of	  131I-­‐mIBG	  was	  8.1GBq	  (range	  5.26-­‐
16.25GBq).	  The	  median	  administered	  activity	  of	  177Lu-­‐DOTATATE	  per	  administration	  
was	  7.2GBq	  (range	  2.5-­‐7.5GBq).	  For	  thyroid	  carcinoma	  patients	  receiving	  131I-­‐NaI,	  11	  
administrations	  were	   for	   ablation	   at	   a	   fixed	   administered	   activity	   of	   3GBq	   and	   17	  
were	  therapy	  doses	  given	  at	  a	  fixed	  administered	  activity	  of	  5.5GBq.	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The	  median	  number	  of	  comforters	  and	  carers	  per	  131I-­‐mIBG	  MATIN	  course	  was	  two	  
(range	  one	  to	  nine);	  single	  administration	  of	  131I-­‐mIBG	  median	  two	  (range	  one-­‐five);	  
177Lu-­‐DOTATATE	  median	  one	  (range	  one-­‐two);	  131I-­‐NaI	  median	  two	  (range	  one-­‐two).	  	  
	  
	  For	   131I-­‐mIBG	   patients	   the	   administered	   activity	   increased	  with	   increasing	   age	   for	  
both	  the	  MATIN	  (Figure	  1.5A)	  and	  single	  administered	  activity	  patients	  (Figure	  5.1B)	  
as	  the	  administered	  activity	  prescribed	  was	  weight	  based.	  
	  
	  
Figure	  5.1	  The	  administered	  activity	  (GBq)	  increased	  with	  the	  patient’s	  age	  for	  both	  
the	  MATIN	  (Figures	  5.1A)(R2=0.6201,	  p<0.001)	  and	  single	  administration	  of	  131I-­‐mIBG	  





There	   was	   no	   correlation	   between	   the	   administered	   activity	   and	   the	   age	   for	   the	  
177Lutetium	   DOTATATE	   and	   131I-­‐NaI	   patients	   as	   fixed	   administered	   activities	   were	  
used.	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The	  median	  comforter	  and	  carer	  exposure	  for	  a	  single	  course	  of	  MATIN	  was	  302	  µSv	  
(range	  0	  –	  5,282	  µSv)	  and	  for	  a	  single	  administration	  of	  131I-­‐mIBG	  was	  163	  µSv	  (range	  
3-­‐3,104	  µSv);	  for	  177Lu-­‐DOTATATE	  the	  median	  exposure	  per	  administration	  was	  6	  µSv	  
(range	   1-­‐79	   µSv);	   for	   131I-­‐NaI	   the	  median	   exposure	   per	   administration	  was	   37	   µSv	  
(range	  0-­‐274	  µSv)	  (Figure	  5.2).	  
	  
Figure	   5.2	   A-­‐D	   show	   the	   highest	   individual	   comforter	   and	   carer	   dose	   per	  
administration	  of	  MATIN	  (Figure	  A),	  a	  single	  administration	  of	  131I-­‐mIBG	  (Figure	  5B),	  





*	  This	  patient	  was	  2	  years	  old,	  in	  nappies	  and	  visually	  impaired.	  	  
♦	  This	  patient	  was	  only	  2	  years	  old	  and	  in	  nappies.	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For	  MATIN	  patients:	  1/50	  >	  5mSv,	  16/50	  >1mSv	  and	  <3	  mSv;	  33/50<1mSv.	  Highest	  
individual	   comforter	   and	   carer	   dose	   for	   the	   single	   131I-­‐mIBG	   administrations:	   2/12	  
>1mSv;	   10/12	   <1mSv.	   Highest	   individual	   comforter	   and	   carer	   dose	   for	   the	   177Lu-­‐
DOTATATE	  and	  131I-­‐NaI	  administrations:	  all	  comforters	  and	  carers	  were	  below	  1mSv.	  
	  
Over	  the	  10-­‐year	  period	  examined,	  only	  one	  comforter	  and	  carer	  had	  a	  measured	  in-­‐
hospital	  radiation	  exposure	  greater	  than	  the	  dose	  constraint	  of	  5mSv	  per	  course	  of	  
treatment	   as	   proposed	   by	   the	   Health	   Protection	   Agency.	   In	   86%	   of	   cases	   the	  
comforter	  and	  carer	  dose	  was	  <1mSv.	  
	  
Figures	   5.3	   A-­‐D	   display	   the	   highest	   individual	   comforter	   and	   carer	   exposure	  
(equivalent	   dose	   in	   µSv)	   and	   the	   administered	   activity	   (GBq)	   for	   each	   of	   the	   four	  
different	  treatment	  schedules.	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For	  the	  131I-­‐mIBG	  patients	  (both	  MATIN	  and	  single	  administered	  activity)	  the	  highest	  
administered	  activities	  did	  not	   result	   in	  higher	  comforter	  and	  carer	  doses.	   	  For	   the	  
177Lu-­‐DOTATATE	   and	   131I-­‐NaI	   patients,	   a	   fixed	   administered	   activity	   was	   used,	   and	  
the	   graphs	   show	   a	   range	   of	   comforter	   and	   carer	   doses	   for	   the	   same	   fixed	  
administered	  activity.	  	  
	  
Figure	   5.4	   shows	   the	   correlation	   between	   the	   age	   of	   the	   child	   and	   the	   highest	  
individual	  comforter	  and	  carer	  exposure	  for	  each	  of	  the	  different	  therapies.	  	  For	  both	  
the	  MATIN	   and	   single	   administration	   of	   131I-­‐mIBG	   patients	   the	   highest	   comforters	  
and	   carer	   doses	  were	   seen	   in	   the	   youngest	   patients	   and	   the	   lowest	   in	   the	   older	  
patients	  (A	  and	  B).	  This	  was	  also	  true	  for	  the	  majority	  of	  cases	  in	  the	  177Lu-­‐DOTATATE	  
patients	  (C)	  and	  the	  131I-­‐NaI	  patients	  (D);	  there	  was	  one	  older	  patient	  with	  a	  higher	  
comforter	  and	  carer	  dose	  (D).	  
	   	  
	  




This	  study	  reports	  on	  10	  years	  of	  comforter	  and	  carer	  exposure	  data	   for	   131I-­‐mIBG,	  
177Lu-­‐DOTATATE	  and	  131I-­‐NaI.	  There	  were	  higher	  comforter	  and	  carer	  doses	   for	   the	  
131I-­‐mIBG	   groups	   than	   the	   177Lu-­‐DOTATATE	   or	   131I-­‐NaI	   groups	   as	  would	   have	   been	  
expected	  due	  to	  significantly	  higher	  administered	  activities	  being	  used.	  
	  
The	  greatest	  proportion	  of	  our	  data	  came	  from	  comforters	  and	  carers	   looking	  after	  
patients	   receiving	   131I-­‐mIBG	   molecular	   radiotherapy.	   The	   administered	   activity	   in	  
these	   patients	   is	   weight	   based,	   and	   therefore	   the	   administered	   activity	   increases	  
with	   increasing	   age	   as	   older	   patients	   are	   usually	   heavier	   (Fig.5.1A	   and	   5.1B).	  
Although	   the	  older	  patients	  got	  significantly	  higher	  administered	  activities,	   this	  did	  
not	   result	   in	   higher	   doses	   to	   the	   comforters	   and	   carers	   as	   these	   older	   patients	  
required	  less	  input	  and	  support.	  The	  highest	  comforter	  and	  carer	  doses	  were	  seen	  in	  
the	   younger	   patients	   (Fig.	   5.4A-­‐D).	   The	   two	   patients	   with	   the	   highest	   individual	  
comforter	   and	   carer	  doses	   (5282µSv	  and	  3104	  µSv)	  were	   in	   cases	  where	   the	   child	  
was	   2	   years	   of	   age,	   still	   in	   nappies	   and	   in	   the	   highest	   case	   the	   patient	   was	   also	  
visually	   impaired,	   requiring	   more	   care,	   therefore	   explaining	   the	   higher	   exposure	  
received	  (Figure	  5.2A	  and	  5.2B).	  
	  
The	   comforter	   and	   carer	   doses	   from	   the	   177Lu-­‐DOTATATE	   and	   131I-­‐NaI	  
administrations	  were	  much	   lower	  then	  for	  131I-­‐mIBG	  administrations	  and	  showed	  a	  
range	   of	   doses	   received	   for	   the	   same	   fixed	   administered	   activity	   (Figure	   5.2C	   and	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5.2D).	  The	  comforter	  and	  carer	  doses	  were	  again,	  in	  the	  majority	  of	  cases,	  lower	  for	  
the	  older	  patients	  reflecting	  the	  less	  input	  required	  for	  this	  age	  group.	  	  
	  
There	   was	   no	   correlation	   between	   the	   number	   of	   comforters	   and	   carers	   and	   the	  
highest	  individual	  or	  total	  comforter	  and	  carer	  dose.	  The	  majority	  of	  patients	  had	  2	  
comforters	  and	  carers	  and	  the	  number	  of	  patients	  with	  more	  comforters	  and	  carers	  
was	  in	  comparison	  very	  small.	  	  
	  
Molecular	  radiotherapy	  has	  an	   increasingly	  significant	  role	  to	  play	   in	  the	  treatment	  
of	   several	  paediatric	  malignancies	   including	   thyroid	  carcinoma	  and	  neuroblastoma.	  
To	  enable	   the	   successful	   delivery	  of	  molecular	   radiotherapy	   to	   children,	   teenagers	  
and	   young	   adults	   it	   is	   essential	   that	   they	   are	   allowed	   comfort	   and	   support	   from	  
relatives	   and	   other	   care	   givers	   during	   their	   treatment,	   but	   there	   is	   often	   anxiety	  
amongst	   the	  public,	   and	   staff,	   in	   caring	   for	   paediatric	   patients	   receiving	  molecular	  
radiotherapy,	  especially	  when	  higher	  than	  standard	  administered	  activities	  are	  used.	  	  	  
	  
There	   are	   minimal	   data	   in	   the	   literature	   on	   comforter	   and	   carer	   doses	   during	  
paediatric	   molecular	   radiotherapy.	   With	   regards	   to	   131I-­‐mIBG	   therapy	   there	   have	  
been	  two	  published	  papers	  on	  parental	  exposures.	  One	  included	  three	  patients	  and	  
the	  other	  only	  one	  (Van	  der	  Steen	  1986,	  Tristam	  2001).	  Published	  data	  on	  doses	  to	  
family	   members	   during	   131I-­‐NaI	   therapy	   is	   on	   spouses	   and	   partners	   during	   the	  
outpatient	  phases	  of	  their	  treatment	  and	  not	  on	  comforters	  and	  carers	  looking	  after	  
paediatric	   patients	   who	   have	   received	   treatment	   (Harbet	   1974,	   Thomson	   1995,	  
Monsieurs	  1998,	  Mathieu	  1999).	  Barrington	  et	  al.	  have	  published	  the	  internal	  doses	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received	   by	   family	  members	   of	   outpatients	   treated	  with	   131I	   for	   the	   treatment	   of	  
hyperthyroidism	  (Barrington	  1999,	  2008).	  
	  
The	  published	  report	  ‘Dose	  constraints	  for	  comforters	  and	  carers’	  produced	  by	  Royal	  
Hallamshire	  Hospital	  for	  the	  Health	  and	  Safety	  Executive	  includes	  small	  amounts	  of	  
contributed	  but	  unpublished	  data	  on	  parental	  radiation	  exposure	  from	  131I-­‐NaI	  and	  
131I-­‐mIBG	  therapy	  (Singleton	  2003).	  
	  
A	  recent	  publication	  by	  Markelewicz	  et	  al.	  reported	  on	  the	  radiation	  exposure	  to	  the	  
parents	   and	   nursing	   staff	   for	   14	   neuroblastoma	   patients	   treated	   with	   131I-­‐mIBG	  
therapy.	   The	   administered	   activity	   of	   131I-­‐mIBG	   ranged	   from	  5.92GBq	   to	   23.31GBq	  
(mean	   13.65GBq).	   All	   nurses	   and	   caregivers	   in	   this	   study	   received	   exposures	   of	  
<5mSv	  during	   the	   in-­‐patient	  hospital	   stay	  of	   the	  patient.	  No	   significant	   correlation	  
was	  found	  between	  the	  caregiver	  or	  nursing	  exposure	  and	  the	  administered	  activity	  
of	  131I-­‐mIBG	  and	  no	  significant	  correlation	  was	  found	  with	  patient	  age	  (Markelewicz	  
2013).	  	  
	  
Limitations	  of	  this	  study	  include	  a	  lack	  of	  knowledge	  of	  the	  radiation	  exposure	  to	  the	  
comforters	  and	  carers	  following	  discharge	  home	  from	  hospital.	  Under	  our	  local	  rules,	  
patients	  may	  be	  discharged	  with	  no	  restrictions	  when	  the	  residual	  radioactivity	  level	  
has	   fallen	   to	  30MBq	  of	   131I.	  Patients	  may	  be	  discharged	  with	  a	   residual	   level	  up	   to	  
150MBq	  131I	  provided	  contact	  with	  children	  or	  women	  who	  are	  or	  might	  be	  pregnant	  
is	   avoided.	   Our	   recorded	   comforters	   and	   carers	   data	   represent	   exposure	   from	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administration	  to	  discharge	  from	  hospital,	  and	  so	  these	  include	  the	  majority	  of	  loss	  
of	   the	   radiopharmaceutical	   through	   excretion	   or	   decay.	   For	   example,	   a	   20kg	   child	  
receiving	   444MBq/kg	   (total	   administered	   activity	   8.88GBq)	   loses	   over	   99%	   of	  
radiation	   prior	   to	   discharge	   with	   a	   residual	   activity	   of	   30MBq.	   Our	   recorded	  
comforter	  and	  carer	   doses	   therefore	   represent	  a	  very	   significant	  proportion	  of	   the	  
exposure	  extrapolated	  to	  infinity.	  	  	  In	  collecting	  the	  data	  we	  relied	  on	  comforters	  and	  
carers	   accurately	   inputting	   the	   data	   and	   in	   the	   majority	   of	   cases	   this	   was	   very	  
detailed.	  Overall	  we	  had	  comforter	  and	  carer	  radiation	  exposure	  data	  for	  85%	  of	  our	  
administrations	  over	  a	  10	  year	  period.	  
	  
In	  conclusion,	  over	  a	  10	  year	  period,	  the	  absorbed	  radiation	  dose	  to	  comforters	  and	  
carers	  during	  paediatric	  molecular	  radiotherapy	  with	  131I-­‐mIBG,	  177Lu-­‐DOTATATE	  and	  
131I-­‐NaI	  was	  in	  all	  but	  one	  case	  within	  the	  recommended	  dose	  constraints	  stipulated	  
by	   the	  Health	  Protection	  Agency.	   Even	  when	  high	   administered	   activities	   are	  used	  
we	  have	  shown	  that	  with	  the	  appropriate	  information,	  education	  and	  guidance,	  dose	  
constraints	  for	  comforters	  and	  carers	  can	  be	  respected.	  For	  the	  high-­‐dose	  131I-­‐mIBG	  
patients,	   the	  main	  determinant	  of	  a	  high	  comforter	  and	  carer	  dose	  was	   the	  age	  of	  
the	   child	   and	   nappy	   requirements	   rather	   than	   the	   high	   administered	   activities	   as	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6.1	  Introduction	  
	  
Functional	   imaging	   plays	   an	   essential	   role	   in	   the	   diagnosis,	   staging	   and	   response	  
assessment	  of	  metastatic	  neuroblastoma.	  Over	  90%	  of	  neuroblastomas	  express	  the	  
noradrenaline	  transporter	  molecule	  and	  this	  enables	  imaging	  with	  the	  guanethidine	  
derivative,	  mIBG.	  	  
	  
Most	  commonly,	  mIBG	  is	  labeled	  with	  123I	  for	  imaging	  and	  123I-­‐mIBG	  scintigraphy	  has	  
become	   the	   most	   frequent	   functional	   imaging	   modality	   for	   assessing	   metastatic	  
disease	   in	  high-­‐risk	  neuroblastoma.	   123I	   emits	  gamma	  photons	  only	  –	  principally	  at	  
159keV	  (83%	  abundance)	  and	  it	  has	  a	  physical	  half-­‐life	  of	  13.13	  hours.	  These	  physical	  
characteristics	   mean	   both	   that	   the	   use	   of	   123I	   results	   in	   better	   image	   quality,	  
especially	  when	  using	  SPECT,	  and	   that	   it	  has	  a	  more	   favorable	  profile	   for	   radiation	  
protection,	   than	   131I,	   which	   is	   preferred	   for	   therapy.	   131I	   principally	   emits	   gamma	  
photons,	  364keV	   (81%	  abundance),	  and	  also	  emits	  beta	  particles	  –	  0.61MeV	  (max)	  
and	  0.192MeV	  (mean).	  It	  has	  a	  physical	  half-­‐life	  of	  8.04	  days.	  	  
	  
A	   recent	   report	   from	   the	   INRG	   task	   force	   has	   recommended	   guidelines	   for	   the	  
performing	   of	   mIBG	   scans	   to	   allow	   standardization	   between	   institutions	   and	  
facilitate	   their	   use	   within	   clinical	   studies	   (Matthay	   2010).	   The	   report	   also	  
recommended	   that	   mIBG	   scans	   should	   be	   scored	   by	   a	   semi-­‐quantitative	   scoring	  
system	   to	   reduce	   inter-­‐observer	   variability	   and	   to	   improve	   the	   comparison	   of	  
response	  rates	  between	  different	  clinical	  trials	  (see	  chapter	  1).	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Although	  mIBG	  remains	  the	  gold	  standard,	   it	  does	  have	  limitations.	   	  Approximately	  
10%	   of	   patients	   with	   neuroblastoma	   will	   have	   mIBG	   negative	   disease	   making	   it	  
necessary	  to	  have	  other	  methods	  of	  disease	  assessment	  in	  these	  patients.	  123I-­‐mIBG	  
scintigraphy	   has	   limited	   spatial	   resolution	   and	   the	   ability	   to	   accurately	   quantify	  
results	   is	   challenging.	   Semi-­‐quantitative	   scoring	   systems	   of	   123I-­‐meta-­‐
iodobenzylguanidine	   (mIBG)	  scans	   for	   response	  assessment	   in	  neuroblastoma	  have	  
been	   validated	   and	   give	   a	   good	   quantification	   of	   anatomical	   disease	   extent.	   The	  
extent	  of	  disease	  on	  mIBG	  scanning	  before	  and	  after	  treatment	  has	  been	  shown	  to	  
be	  of	  prognostic	  significance	  (see	  chapter	  1).	  
	  
123I-­‐mIBG	  scans	  often	  require	  correlation	  with	  radiological	  examinations,	  either	  CT	  or	  
MRI,	   especially	   in	   cases	   of	   uncertain	   uptake.	   The	   introduction	   of	   SPECT	   (single	  
photon	  emission	  tomography),	  and	  co-­‐registration	  with	  CT	   images	  acquired	  as	  part	  
of	   the	   same	   investigation,	   can	   improve	   the	   visualisation	   of	   small	   foci	   of	  
neuroblastoma	   that	   can	   be	   difficult	   to	   detect	   on	   planar	   scintigraphy,	   and	   their	  
anatomical	  localization,	  but	  it	  is	  not	  always	  performed	  at	  present,	  and	  the	  additional	  
information	  which	  may	   be	   gained	   is	   not	   used	   in	   current	   semi-­‐quantitative	   scoring	  
systems.	  	  
	  
The	  challenges	  mentioned	  above	  may	   to	   some	  extent	  be	  overcome	  with	   124I-­‐mIBG	  
PET/CT,	  but	  this	  functional	  imaging	  modality	  is	  only	  just	  entering	  early	  phase	  clinical	  
trials	  within	  the	  UK	  and	  will	  not	  be	  a	  solution	  for	  the	  10%	  of	  patients	  who	  are	  mIBG	  
negative.	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18F-­‐FDG	  PET	  makes	  use	  of	  a	  glucose	  analogue,	  flurodeoxyglucose	  (FDG),	  labeled	  with	  
the	  positron	  emitting	   isotope	  of	   fluorine,	   18F.	   18F-­‐FDG,	   like	  glucose	   itself,	   is	  actively	  
transported	   from	   the	   bloodstream	   into	   cells	   with	   high	   metabolism.	   It	   is	   retained	  
within	  them	  in	   its	  phosphorylated	  form,	  as	   lacking	  the	  2’-­‐hydroxyl	  group	   it	  cannot,	  
like	  glucose,	  undergo	  normal	  glycolysis.	  The	  degree	  of	  uptake	  of	  FDG	  is	  proportional	  
to	   the	   tumour	   cell	   metabolism	   and	   the	   tumour	   burden	   of	   the	   patient.	   Positron	  
emission	  tomography	  can	  be	  used	  to	  map	  areas	  of	  high	  18F-­‐FDG	  accumulation	  within	  
the	   body,	   at	   sites	   of	   high	   metabolism	   including	   normal	   structures	   like	   the	   brain,	  
brown	   fat	   and	   the	   heart,	   and	   also	   in	   deposits	   of	  metabolically	   active	   cancers.	   Co-­‐
registration	   with	   CT	   imaging,	   acquired	   as	   part	   of	   the	   same	   investigation,	   allows	  
reporting	  physicians	  to	  see	  exactly	  where	  in	  the	  body	  the	  tracer	  is	  localized.	  18F-­‐FDG	  
PET/CT	  therefore	  has	  a	  unique	  ability	  to	  give	  anatomical	  and	  metabolic	  information	  
and	   has	   established	   its	   role	   in	   staging	   and	   response	   assessment	   for	   many	   adult	  
tumours.	  For	  example,	   in	   the	  early	   response	  assessment	  of	   lymphoma	  patients,	  by	  
demonstrating	   those	   which	   have	   responsive	   disease,	   it	   helps	   to	   risk	   stratify	   the	  
disease,	   and	   thereby	   guide	   the	   intensity	   of	   further	   treatment	   (Hutchings	   2006,	  
Jerusalem	  2001).	  	  
	  
The	  precise	  role	  of	   18F-­‐FDG	  PET/CT	   in	  neuroblastoma	  response	  assessment	  has	  not	  
been	   defined	   and	   the	  methods	   used	   not	   standardised.	   The	   current	   INRC	   (Brodeur	  
1993)	  does	  not	   include	  semi-­‐quantitative	  scoring	  of	  mIBG	  scans	  or	  other	  functional	  
imaging	  modalities	  such	  as	  18F-­‐FDG	  PET/CT,	  but	  these	  are	  likely	  to	  be	  incorporated	  in	  
future	   revisions.	   The	   methods	   for	   response	   assessment	   of	   18F-­‐FDG	   PET	   in	  
neuroblastoma	  have	  also	  not	  been	  established	  and	  vary	  in	  the	  limited	  reports	  in	  the	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literature	   (Shulkin	   1996,	   Sharp	   2009,	   Taggart	   2009,	   Melzer	   2011,	   Papathanasiou	  
2011).	  
	  
This	   study	   compares	   two	   different	   methods	   of	   response	   assessment	   for	   18F-­‐FDG	  
PET/CT	   in	   neuroblastoma,	   and	   evaluates	   whether	   18F-­‐FDG	   PET/CT	   imaging	   adds	  
additional	   information	   to	   that	   gained	   from	   123I-­‐mIBG	   scintigraphy	   in	   the	   response	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6.2	  Materials	  and	  Methods	  
	  
Patients	   with	   relapsed	   or	   refractory	   neuroblastoma	   who	   had	   received	   high-­‐
administered	   activity	   131I-­‐mIBG	   therapy	   with	   concurrent	   Topotecan	   (the	   MATIN	  
protocol)	   (Gaze	   2005)	   between	   2006	   and	   2010	   at	   University	   College	   London	  
Hospitals	  NHS	  Foundation	  Trust	  were	  retrospectively	  identified.	  Eligible	  patients	  for	  
this	   study	  were	   required	   to	   have	   paired	   123I-­‐mIBG	   and	   18F-­‐FDG	   PET/CT	   scans	   both	  
pre-­‐	  and	  post-­‐high	  dose	  131I-­‐mIBG	  therapy.	  	  
	  
All	   scans	   were	   performed	   within	   the	   same	   institution	   with	   standardised	   imaging	  
protocols.	  Prior	  to	  123I-­‐mIBG	   imaging,	  all	  patients	  received	  thyroid	  blockade	  by	  oral	  
administration	   of	   Potassium	   Iodide.	   In	   addition,	   all	   other	   medicines	   known	   to	  
interfere	  with	  tumour	  uptake	  of	  radiolabelled	  mIBG	  were	  discontinued.	  All	  patients	  
were	   imaged	   on	   a	   GE	   Infinia	   Hawkeye	   4	   gamma	   camera	   system.	   Imaging	   was	  
performed	  at	  4	  and	  24	  hours	  post-­‐injection.	  Whole-­‐body	   images	  were	  obtained	  at	  
both	   time-­‐points	   and	   SPECT/CT	   images	   acquired	   immediately	   after	   the	   24	   hour	  
whole	   body	   image.	   Whole-­‐body	   images	   were	   obtained	   using	   low-­‐energy	   high-­‐
resolution	  collimators	  with	  a	  20%	  energy	  window	  centred	  over	  a	  159keV	  photopeak.	  
SPECT/CT	   images	   were	   acquired	   with	   an	   additional	   scatter	   window	   centred	   over	  
130keV.	  Projection	  time	  was	  40s	  and	  120	  projections	  acquired,	  with	  the	  region	  to	  be	  
evaluated	  assessed	  from	  the	  patient	  history	  and	  whole-­‐body	  image.	  Localisation	  was	  
aided	  with	   a	   planar	   x-­‐ray	   scout	   view.	   Following	   SPECT,	   low-­‐dose	   CT	  was	   acquired	  
with	  slice	   thickness	  of	  1mm.	  Data	  was	   reconstructed	  using	   iterative	   reconstruction	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(20	   iterations)	  with	  attenuation	  correction	  derived	   from	  CT.	  Scatter	  correction	  was	  
also	  applied.	  
	  
For	  the	  18F-­‐FDG	  PET/CT	  imaging,	  all	  patients	  were	  imaged	  on	  a	  Discovery	  STE	  PET/CT	  
system	   (GE	   Medical	   Systems).	   Patients	   were	   asked	   to	   fast	   for	   6	   hours	   prior	   to	  
imaging.	  A	  minimum	  of	  14MBq	  to	  a	  maximum	  of	  400MBq	  18F-­‐FDG	  was	  administered	  
with	   an	   uptake	   time	   of	   50	   to	   75	   minutes.	   Whole	   body	   images	   were	   acquired	   to	  
define	   the	   axial	   range	  of	   the	   PET/CT	   study,	   covering	   the	   area	   from	   the	   top	  of	   the	  
head	   to	  mid-­‐thighs.	   A	   CT	  was	   acquired	  with	   pitch	   1.5	   and	   5mm	   collimation.	   Tube	  
voltage	  was	   120-­‐140kVp	  and	   tube	   current	   80mA.	   PET	  was	  performed	   immediately	  
after	  CT	  with	  the	  number	  of	  bed	  positions	  appropriate	  for	  the	  axial	  range.	  PET	  was	  
acquired	  in	  2D	  mode	  (5mins/bed	  position).	  PET	  was	  reconstructed	  using	  2	  iterations	  
and	   28	   subsets	   with	   attenuation	   correction	   calculated	   from	   transmission	   maps	  
derived	  from	  CT.	  
	  
Scans	   were	   retrospectively	   analysed	   by	   two	   independent	   nuclear	   medicine	  
physicians	  experienced	  in	  interpreting	  nuclear	  medicine	  imaging	  including	  123I-­‐mIBG	  
and	  18F-­‐FDG	  PET/CT	  imaging.	  	  
	  
The	   response	   on	   123I-­‐mIBG	   scans	  was	   evaluated	   by	   a	  modified	   SIOPEN	  method	   of	  
semi-­‐quantitative	   scoring	   (Lewington	   2011).	  mIBG	   semi-­‐quantitative	   scores	   take	   in	  
to	   account	   skeletal	   disease	   only.	   The	   skeleton	   is	   divided	   in	   to	   12	   segments	   and	   a	  
score	  of	  0-­‐6	  assigned	  for	  each	  segment	  therefore	  giving	  a	   total	  score	  out	  of	  72	   for	  
the	  skeleton.	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A	  soft	   tissue	   score	  was	  also	  added	   for	   the	  purpose	  of	   this	  analysis	   to	  map	   the	   full	  
extent	  of	  the	  disease	  –	  the	  soft	  tissue	  compartments	  were	  divided	  into	  8	  segments	  
with	  a	  score	  0-­‐2	  assigned	  for	  each	  soft	  tissue	  segment	  giving	  a	  total	  score	  out	  of	  16	  
for	  the	  soft	  tissue	  disease.	  An	  example	  of	  the	  semi-­‐quantitative	  score	  sheet	  is	  shown	  
in	  Figure	  6.1.	  	  
 




Skeleton	  Score	   	   	   	   Soft	  tissue	  score	   	  
	   Pre	  treatment	   Post	  Treatment	   	   Pre	  treatment	   Post	  treatment	  
Skull/facial	  bones	   	   	   Head	  and	  Neck	   	   	  
Thoracic	  cage	   	   	   Thorax	   	   	  
Right	  humerus	   	   	   Right	  upper	  limb	   	   	  
Left	  humerus	   	   	   Left	  upper	  limb	   	   	  
Right	  forearm	   	   	   	   	   	  
Left	  forearm	   	   	   	   	   	  
Spine	   	   	   Abdomen	   	   	  
Pelvis	   	   	   Pelvis	   	   	  
Right	  femur	   	   	   Right	  lower	  limb	   	   	  
Left	  femur	   	   	   Left	  lower	  limb	   	   	  
Right	  tibia/fibula	   	   	   	   	   	  
Left	  tibia/fibula	   	   	   	   	   	  




SKELETAL	  SCORE	  	   	   	   	   SOFT	  TISSUE	  SCORE	  
0 No	  abnormality	   	   	   	   0	  No	  abnormality	  
1 1	  focal	  lesion	   	   	   	   1	  Solitary	  lesion	  
2 2	  focal	  lesions	   	   	   	   2	  Multiple	  lesions	  
3 3	  focal	  lesions	   	   	   	   X	  Unevaluable	  
4 Diffuse	  <50%	  of	  bone	  or	  >3	  focal	  lesions	  
5 Diffuse	  50-­‐95%	  of	  bone	  
6 Diffuse	  involving	  whole	  bone	  
X	   Unevaluable	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18F-­‐FDG	  PET	  scans	  were	  evaluated	  by	  two	  methods:	  a	  semi-­‐quantitative	  score	  and	  by	  
PET	   Response	   Criteria	   in	   Solid	   Tumours	   (PERCIST)	   (Wahl	   2009).	   	   The	   semi-­‐
quantitative	  method	  uses	  maximum	  intensity	  projection	   (MIP)	   images	  only,	  exactly	  
as	  per	  the	  above	  method	  for	  123I-­‐mIBG	  scans.	  It	  therefore	  relies	  on	  the	  number	  and	  
distribution	   of	   lesions	   identified,	   and	   does	   not	   take	   into	   account	   the	   degree	   of	  
uptake	  –	  a	  single	  faint	  lesion	  scores	  the	  same	  as	  a	  single	  intense	  lesion	  of	  the	  same	  
size.	  In	  contrast,	  the	  PERCIST	  system	  takes	  intensity	  into	  account	  by	  requiring	  SUVmax	  
scores	   to	   be	   recorded	   for	   each	   anatomical	   segment	   with	   disease	   pre-­‐	   and	   post-­‐	  




Table	  6.2	  Semi-­‐quantitative	  response	  criteria	  –	  for	  both	  123I-­‐mIBG	  scans	  and	  18F-­‐FDG	  
PET/CT	  scans	  was	  defined	  as	  follows.	  The	  relative	  score	  of	  both	  scans	  was	  obtained	  
by	  dividing	  the	  post-­‐score	  by	  the	  pre-­‐score.	  	  
	  
Score	  (post	  score	  /	  pre	  score)	   Response	  Grouping	  
0	   Complete	  Response	  
0-­‐0.1	   Very	  Good	  Partial	  Response	  
0.1-­‐0.5	   Partial	  Response	  
0.5-­‐0.75	   Minor	  Response	  
0.75-­‐1.25	   Stable	  Disease	  
>1.25	   Progressive	  Disease	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Table	   6.3	   For	   the	   18F-­‐FDG	   PET/CT	   scans	   a	   PERCIST	   score	   was	   also	   obtained	   by	  
measuring	  the	  percentage	  change	  in	  SUVmax	  scores	  pre	  and	  post	  treatment	  with131I-­‐
mIBG	  molecular	  radiotherapy:	  
	  
SUVmax	  	   PERCIST	  SCORE	  
Score	  0	   Complete	  Metabolic	  Response	  
>	  30%	  reduction	  in	  SUVmax	   Partial	  Metabolic	  Response	  
Criteria	   not	   met	   for	   partial	   metabolic	  
response	  or	  progressive	  metabolic	  response	  
Stable	  Disease	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6.3 	  Results	  
	  
All	  patients	  were	  treated	  at	  University	  College	  London	  Hospitals	  NHS	  Foundation	  
Trust	  between	  March	  2006	  and	  May	  2010.	  
	  
15	   patients	   with	   neuroblastoma	   who	   had	   been	   treated	   with	   131I-­‐mIBG	   molecular	  
radiotherapy	  were	  identified	  who	  had	  paired	  123I-­‐mIBG	  and	  18F-­‐FDG	  PET/CT	  scans	  pre	  
and	  post	  treatment.	  A	  total	  of	  17	  paired	  123I-­‐mIBG	  and	  18FDG-­‐PET/CT	  scans	  pre	  and	  
post	  131I-­‐mIBG	  therapy	  were	  identified	  as	  2	  patients	  had	  received	  131I-­‐mIBG	  therapy	  
twice	  (patient	  4A/B	  and	  13A/B).	  
	  
13	   of	   the	   patients	   had	   INSS	   stage	   4	   neuroblastoma	   and	   2	   patients	   INSS	   stage	   3	  
disease.	  The	  median	  age	  was	  5	  years,	  range	  1	  to	  18	  years.131I-­‐mIBG	  was	  given	  in	  the	  
relapse	  setting	  in	  7	  instances	  and	  for	  refractory	  disease	  on	  10	  occasions.	  	  
	  
The	   131I-­‐mIBG	   was	   given	   as	   per	   the	   MATIN	   protocol	   (mIBG	   and	   topotecan	   in	  
neuroblastoma).	  131I-­‐mIBG	  was	  given	  in	  two	  administrations,	  two	  weeks	  apart,	  with	  
concurrent	   topotecan	   as	   a	   radiosensitiser.	   This	   was	   followed	   by	   peripheral	   blood	  
stem	  cell	  support.	  A	  weight-­‐based	  activity	  of	  444	  MBq	  kg-­‐1	  of	  131I-­‐mIBG	  for	  the	  first	  
administration	  was	  given,	  aiming	   to	  give	  a	  whole	  body	   radiation	  absorbed	  dose	  of	  
about	   2	   Gy.	   The	   actual	   whole	   body	   dose	   achieved	  was	   determined	   via	   the	  whole	  
body	  monitoring	  of	   radionuclide	  retention	  using	  monitors	   installed	   in	   the	   inpatient	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bedroom.	   The	   activity	   required	   for	   the	   second	   administration	   was	   calculated	   to	  
deliver	  a	  total	  whole	  body	  dose	  for	  both	  administrations	  of	  4	  Gy	  (Gaze	  2005).	  
	  
Table	   6.4	   Characteristics	   of	   the	   15	   patients	   studied.	   Patient	   4	   and	   13	   had	   two	  












1	  	   18	   M	   4	   Relapsed	  	   23	  weeks	  
2	  	   2	   F	   4	   Refractory	   6	  weeks	  
3	  	   5	   M	   3	   Relapsed	   39	  weeks	  
4A	  	   3	   M	   4	   Refractory	   9	  weeks	  
4B	   3	   M	   4	   Refractory	   6	  weeks	  
5	  	   8	   M	   4	   Relapsed	   8	  weeks	  
6	  	   5	   F	   4	   Refractory	   17	  weeks	  
7	  	   5	   F	   4	   Relapsed	   8	  weeks	  
8	  	   12	   F	   4	   Relapsed	   8	  weeks	  
9	  	   14	   M	   4	   Refractory	   6	  weeks	  
10	  	   5	   M	   4	   Refractory	   5	  weeks	  
11	  	   7	   M	   4	   Refractory	   7	  weeks	  
12	   18	   M	   3	   Refractory	   11	  weeks	  
13A	   1	   M	   4	   Refractory	   5	  weeks	  
13B	   2	   M	   4	   Refractory	   7	  weeks	  
14	  	   7	   M	   4	   Relapsed	   12	  weeks	  
15	  	   7	   F	   4	   Relapsed	   8	  weeks	  
	  
	  
Pre-­‐treatment	   123I-­‐mIBG	   and	   18F-­‐FDG	   PET/CT	   scans	   were	   in	   all	   but	   one	   case	  
performed	   within	   3	   weeks	   of	   the	   start	   of	   131I-­‐mIBG	   therapy.	   Post-­‐treatment	   123I-­‐
mIBG	  and	  18F-­‐FDG	  PET/CT	  scans	  were	  performed	  at	  a	  median	  of	  8	  weeks	  (range	  5	  to	  
39	  weeks)	  after	  high-­‐administered	  activity	  131I-­‐mIBG	  therapy.	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The	  extent	  of	  disease	  on	  the	  pre-­‐therapy	  131I-­‐mIBG	  and	  18F-­‐FDG	  scans	  was	  variable	  
between	  the	  two	  imaging	  modalities	  as	  shown	  in	  table	  6.5	  	  
	  
Table	  6.5	  shows	  the	  semi-­‐quantitative	  scores	  and	  distribution	  of	  disease	  on	  123I-­‐
mIBG	  and	  18F-­‐FDG	  PET/CT	  before	  treatment	  with	  131I-­‐mIBG.	  
	  






Distribution	  of	  disease	  
123I-­‐mIBG	  v	  18F-­‐FDG	  PET/CT	  
1	  	   Skeleton	   7	   3	   123I-­‐mIBG	  >	  18F-­‐FDG	  PET/CT	  	  
Soft	  Tissue	   0	   0	  
2	  	   Skeleton	   4	   0	   123I-­‐mIBG	  >	  18F-­‐FDG	  PET/CT	  
Soft	  Tissue	   0	   0	  
3	  	   Skeleton	   11	   11	   18F-­‐FDG	  PET/CT>123I-­‐mIBG	  
Soft	  Tissue	   3	   4	  
4A	  	   Skeleton	   16	   12	   123I-­‐mIBG	  >	  18F-­‐FDG	  PET/CT	  
Soft	  Tissue	   1	   1	  
4B	   Skeleton	   11	   0	   123I-­‐mIBG>18F-­‐FDG	  PET/CT	  
Soft	  Tissue	   1	   1	  
5	  	   Skeleton	   54	   30	   123I-­‐mIBG>18F-­‐FDG	  PET/CT	  	  
Soft	  Tissue	   2	   2	  
6	  	   Skeleton	   13	   32	   18F-­‐FDG	  PET/CT>123I-­‐mIBG	  
Soft	  Tissue	   2	   2	  
7	  	   Skeleton	   26	   9	   123I-­‐mIBG>18F-­‐FDG	  PET/CT	  
Soft	  Tissue	   0	   1	  
8	  	   Skeleton	   1	   11	   18F-­‐FDG	  PET/CT>123I-­‐mIBG	  
Soft	  Tissue	   3	   8	  
9	  	   Skeleton	   0	   0	   123I-­‐mIBG=18F-­‐FDG	  PET/CT	  
Soft	  Tissue	   4	   4	  
10	  	   Skeleton	   8	   16	   18F-­‐FDG	  PET/CT>123I-­‐mIBG	  	  
Soft	  Tissue	   0	   1	  
11	  	   Skeleton	   0	   0	   123I-­‐mIBG=18F-­‐FDG	  PET/CT	  
Soft	  Tissue	   2	   2	  
12	  	   Skeleton	   0	   0	   18F-­‐FDG	  PET/CT>123I-­‐mIBG	  
Soft	  Tissue	   1	   3	  
13A	  	   Skeleton	   0	   0	   123I-­‐mIBG=18F-­‐FDG	  PET/CT	  
Soft	  Tissue	   2	   2	  
13B	  	   Skeleton	   0	   0	   123I-­‐mIBG=18F-­‐FDG	  PET/CT	  
Soft	  Tissue	   2	   2	  
14	   Skeleton	   24	   24	   123I-­‐mIBG=18F-­‐FDG	  PET/CT	  
Soft	  Tissue	   1	   1	  
15	  	   Skeleton	   9	   19	   18F-­‐FDG	  PET/CT>123I-­‐mIBG	  
Soft	  Tissue	   0	   0	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For	  mapping	  of	  disease	  extent	  prior	  to	  131I-­‐mIBG	  therapy,	  the	  123I-­‐mIBG	  scan	  showed	  
more	  disease	  in	  6	  out	  of	  17	  cases;	  the	  18F-­‐FDG	  scans	  showed	  more	  disease	  in	  6	  out	  of	  
17	  cases;	  the	  18F-­‐FDG	  PET/CT	  and	  123I-­‐mIBG	  showed	  the	  same	  extent	  of	  disease	  in	  5	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Table	  6.6	  Response	  on	  123I-­‐mIBG	  and	  18F-­‐FDG	  PET/CT	  by	  semi-­‐quantitative	  scoring	  
	  


























1	  	   Skeleton	   7	   0	   0	   CR	   3	   0	   0	   CR	  
	   Soft	  Tissue	   0	   0	   -­‐	   	   0	   0	   0	   	  
2	  	   Skeleton	  	   4	   0	   0	   CR	   0	   0	   -­‐	   -­‐	  
	   Soft	  Tissue	   0	   0	   -­‐	   	   0	   0	   -­‐	   	  
3	  	   Skeleton	   11	   5	   0.45	   PR	   11	   10	   0.9	   PR	  
	   Soft	  Tissue	   3	   3	   1	   	   4	   2	   0.5	   	  
4A	  	   Skeleton	   16	   11	   0.7	   MR	   12	   0	   0	   PR	  
	   Soft	  Tissue	   1	   1	   1	   	   1	   1	   1	   	  
4B	   Skeleton	   11	   3	   0.3	   PR	   0	   0	   -­‐	   CR	  
	   Soft	  Tissue	   1	   1	   	   	   1	   0	   0	   	  
5	  	   Skeleton	   54	   47	   0.9	   SD	   30	   18	   0.6	   PR	  
	   Soft	  Tissue	   2	   1	   0.5	   	   2	   1	   0.5	   	  
6	  	   Skeleton	   13	   4	   0.3	   PR	   32	   0	   0	   PR	  
	   Soft	  Tissue	   2	   2	   1	   	   2	   2	   1	   	  
7	  	   Skeleton	   26	   4	   0.15	   PR	   9	   0	   0	   PR	  
	   Soft	  Tissue	   0	   0	   	   	   1	   1	   1	   	  
8	  	   Skeleton	   1	   0	   0	   SD	   11	   3	   0.3	   PR	  
	   Soft	  Tissue	   3	   3	   1	   	   8	   4	   0.5	   	  
9	  	   Skeleton	   0	   0	   -­‐	   SD	   0	   0	   -­‐	   SD	  
	   Soft	  Tissue	   4	   4	   1	   	   4	   4	   1	   	  
10	  	   Skeleton	   8	   8	   1	   SD	   16	   0	   0	   VGPR	  
	   Soft	  Tissue	   0	   0	   -­‐	   	   1	   1	   1	   	  
11	  	   Skeleton	   0	   0	   -­‐	   SD	   0	   0	   -­‐	   SD	  
	   Soft	  Tissue	   2	   2	   1	   	   2	   2	   1	   	  
12	  	   Skeleton	   0	   0	   -­‐	   SD	   0	   0	   -­‐	   SD	  
	   Soft	  Tissue	   1	   1	   1	   	   3	   3	   1	   	  
13A	  	   Skeleton	   0	   0	   -­‐	   SD	   0	   0	   -­‐	   SD	  
	   Soft	  Tissue	   2	   2	   1	   	   2	   2	   1	   	  
13B	  	   Skeleton	   0	   0	   -­‐	   SD	   0	   0	   -­‐	   SD	  
	   Soft	  Tissue	   2	   2	   1	   	   2	   2	   1	   	  
14	   Skeleton	   24	   30	   1.25	   PD	   24	   18	   0.75	   SD	  
	   Soft	  Tissue	   1	   1	   1	   	   1	   1	   1	   	  
15	  	   Skeleton	   9	   14	   1.5	   PD	   19	   26	   1.3	   PD	  
	   Soft	  Tissue	   0	   0	   	   	   0	   0	   -­‐	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Table	  6.7	  Skeletal	  scores	  only.	  Patients	  9,	  11,	  12,	  13A	  and	  13B	  had	  soft	  tissue	  
disease	  only	  (shaded)	  
	  























1	  	   7	   0	   0	   CR	   3	   0	   0	   CR	   CMR	  
2	  	   4	   0	   0	   CR	   0	   0	   -­‐	   -­‐	   -­‐	  
3	  	   11	   5	   0.45	   PR	   11	   10	   0.9	   SD	   PMR	  
4A	  	   16	   11	   0.7	   MR	   12	   0	   0	   CR	   CMR	  
4B	   11	   3	   0.3	   PR	   0	   0	   -­‐	   -­‐	   -­‐	  
5	  	   54	   47	   0.9	   SD	   30	   18	   0.6	   MR	   PMR	  
6	  	   13	   4	   0.3	   PR	   32	   0	   0	   CR	   CMR	  
7	  	   26	   4	   0.15	   PR	   9	   0	   0	   CR	   CMR	  
8	  	   1	   0	   0	   CR	   11	   3	   0.3	   PR	   PMR	  
9	  	   0	   0	   -­‐	   -­‐	   0	   0	   -­‐	   SD	   -­‐	  
10	  	   8	   8	   1	   SD	   16	   0	   0	   CR	   CMR	  
11	  	   0	   0	   -­‐	   -­‐	   0	   0	   -­‐	   -­‐	   -­‐	  
12	  	   0	   0	   -­‐	   -­‐	   0	   0	   -­‐	   -­‐	   -­‐	  
13A	  	   0	   0	   -­‐	   -­‐	   0	   0	   -­‐	   -­‐	   -­‐	  
13B	  	   0	   0	   -­‐	   -­‐	   0	   0	   -­‐	   -­‐	   -­‐	  
14	   24	   30	   1.25	   PD	   24	   18	   0.75	   SD	   SMD	  
15	  	   9	   14	   1.5	   PD	   19	   26	   1.3	   PD	   PD	  
	  
	  
18F-­‐FDG	  PET/CT	  gave	  additional	  information	  to	  123I-­‐mIBG	  scintigraphy	  in	  5	  out	  of	  12	  
cases	   with	   skeletal	   disease.	   In	   2	   patients	   the	   123I-­‐mIBG	   scan	   had	   showed	   stable	  
disease	  but	  the	  18F-­‐FDG	  PET/CT	  showed	  a	  partial	  or	  complete	  metabolic	  response	  by	  
PERCIST.	  In	  2	  patients	  the	  123I-­‐mIBG	  scan	  had	  showed	  a	  partial	  response	  to	  therapy	  
but	   the	   18F-­‐FDG	   PET/CT	   showed	   a	   complete	  metabolic	   response	   in	   both	   cases	   by	  
PERCIST.	  In	  the	  case	  of	  patient	  4A,	  the	  123I-­‐mIBG	  scan	  only	  showed	  a	  minor	  response	  
but	   the	   18F-­‐FDG	  PET/CT	   showed	  a	   complete	   response	  by	   semi-­‐quantitative	   scoring	  
and	   a	   complete	   metabolic	   response	   by	   PERCIST.	   Conversely,	   patient	   8	   had	   a	  
complete	  response	  on	  the	  123I-­‐mIBG	  scan	  but	  only	  a	  partial	  response	  on	  the	  18F-­‐FDG	  
PET/CT	  by	  semi-­‐quantitative	  and	  PERCIST	  scoring.	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Table	  6.8	  Patients	  with	  soft	  tissue	  disease	  only	  prior	  to	  therapy	  with	  131I-­‐mIBG.	  	  























9	  	   Soft	  
Tissue	  
4	   4	   1	   SD	   4	   4	   1	   SD	   CMR	  
11	  	   Soft	  
Tissue	  
2	   2	   1	   SD	   2	   2	   1	   SD	   SMD	  
12	  	   Soft	  
Tissue	  
1	   1	   1	   SD	   3	   3	   1	   SD	   PMR	  
13A	  	   Soft	  
Tissue	  
2	   2	   1	   SD	   2	   2	   1	   SD	   PMR	  
13B	  	   Soft	  
Tissue	  
2	   2	   1	   SD	   2	   2	   1	   SD	   SMD	  
	  
For	  patients	  with	  soft	  tissue	  only	  disease,	  with	  the	  semi-­‐quantitative	  scoring	  on	  123I-­‐
mIBG	  and	  18F-­‐FDG	  PET/CT	  they	  all	  had	  stable	  soft	  tissue	  disease	  following	  treatment.	  
In	  3	  instances,	  additional	  information	  was	  gained	  from	  the	  18F-­‐FDG	  PET/CT	  as	  there	  
was	  a	  metabolic	  response	  by	  PERCIST	  criteria	  on	  18F-­‐FDG	  PET/CT	  indicting	  a	  response	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Figure	   6.2A	   Patient	   12,	   an	   18	   year	   old	   male,	   with	   Stage	  M	   (LN	   only	   metastases)	  
refractory	   neuroblastoma	   treated	   with	   high-­‐administered	   activity	   131I-­‐mIBG	   and	  
topotecan	   with	   peripheral	   blood	   stem	   cell	   support.	   This	   patient	   had	   soft	   tissue	  
disease	  within	   the	  abdomen	  and	  pelvis	  only.	  As	   the	   semi-­‐quantitative	   scoring	  only	  
took	  into	  account	  a	  single	  or	  multiple	  soft	  tissue	  lesion	  for	  the	  score	  the	  disease	  was	  
stable	  on	  18F-­‐FDG	  PET	  and	  123I-­‐mIBG	  imaging.	  There	  has	  been	  obvious	  regression	  of	  
the	  mass	  on	  the	  CT	  component	  as	  well	  as	  a	  partial	  metabolic	   response	  by	  PERCIST	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Figure	  6.2B	  123I-­‐mIBG	  planar	  scintigraphy	  (A	  and	  C)	  and	  18F-­‐FDG	  PET	  MIP	  images	  (B	  
and	  D)	  pre	  and	  post	  therapy	  with	  131I-­‐mIBG	  for	  patient	  6.	  In	  image	  D	  there	  is	  an	  
artifact	  due	  to	  uptake	  of	  the	  tracer	  in	  the	  central	  venous	  access	  line.	  A	  partial	  
response	  to	  131I-­‐mIBG	  therapy	  was	  seen	  with	  the	  SIOPEN	  skeletal	  score	  changing	  
from	  13	  to	  4	  on	  123I-­‐mIBG	  planar	  scintigraphy	  but	  a	  complete	  response	  on	  18F-­‐FDG	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Figure	  6.2C	  123I-­‐mIBG	  planar	  scintigraphy	  (A	  and	  C)	  and	  18F-­‐FDG	  MIP	  images	  (B	  and	  D)	  
for	  patient	  9	  pre	  and	  post	  131I-­‐mIBG	  therapy.	  There	  is	  significant	  uptake	  within	  
brown	  fat	  seen	  in	  the	  18F-­‐FDG	  MIP	  images.	  There	  were	  no	  skeletal	  metastases	  but	  a	  
soft	  tissue	  mass	  in	  the	  left	  para-­‐aortic,	  external	  and	  iliac	  chain	  and	  left	  inguinal	  none.	  
The	  soft	  tissue	  masses	  were	  stable	  on	  semi-­‐quantitative	  scoring	  of	  123I-­‐mIBg	  and	  18F-­‐
FDG	  PET	  but	  had	  a	  complete	  metabolic	  response	  by	  PERCIST	  criteria	  with	  a	  SUVmax	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Figure	  6.2D	  123I-­‐mIBG	  planar	  scintigraphy	  and	  18F-­‐FDG	  PET	  MIP	  images	  for	  Patient	  15	  
pre	  and	  post	  131I-­‐mIBG	  therapy.	  This	  patient	  had	  progressive	  disease	  on	  both	  imaging	  
modalities	  with	  SIOPEN	  score	  for	  123I-­‐mIBG	  increasing	  from	  9	  to	  14	  and	  increasing	  on	  















123I-­‐mIBG	   imaging	   is	   the	   current	   gold-­‐standard	   modality	   for	   imaging	   metastatic	  
neuroblastoma.	  In	  a	  recent	  meta-­‐analysis,	  123I-­‐mIBG	  was	  found	  to	  have	  a	  sensitivity	  
of	  97%	   (95%	  CI,	  95%-­‐99%)	   for	   the	  detection	  of	  neuroblastoma	  although	   there	  was	  
insufficient	  data	  to	  estimate	  specificity	  (Jacobson	  2010).	  	  
	  
There	  are	  limited	  prior	  reports	  on	  the	  use	  of	  18F-­‐FDG	  PET	  in	  neuroblastoma	  and	  this	  
study	   looked	   to	   examine	   whether	   imaging	   with	   18F-­‐FDG	   PET/CT	   gave	   additional	  
information	   to	   123I-­‐mIBG	   scintigraphy	   in	   neuroblastoma	   patients	   treated	   with	   131I-­‐
mIBG	  molecular	  radiotherapy.	  	  
	  
The	   first	   report	   of	   18F-­‐FDG	  PET	   in	   neuroblastoma	  was	   in	   by	   Shulkin	  et	   al.	   in	   1996.	  
They	   compared	   131I-­‐mIBG	   and	   18F-­‐FDG	   PET	   in	   seventeen	   patients	   with	  
neuroblastoma	   at	   various	   stages	   of	   disease	   and	   time	   points.	   Seven	   patients	   were	  
examined	  at	  diagnosis	  prior	  to	  systemic	  therapy	  and	  ten	  patients	  were	  assessed	  at	  
the	  time	  of	  suspected	  residual	  or	  recurrent	  disease.	  In	  all	  patients	  assessed	  prior	  to	  
systemic	   therapy,	   the	  primary	   tumour	  was	  easily	   visualized	  with	   FDG	  PET.	  Overall,	  
mIBG	  imaging	  was	  superior	  to	  FDG	  PET	  in	  3	  patients,	  FDG	  PET	  was	  considered	  to	  be	  
superior	   to	   mIBG	   in	   2	   patients	   and	   the	   scans	   were	   found	   to	   be	   equivalent	   in	   2	  
patients.	  In	  the	  thirteen	  instances	  where	  the	  imaging	  techniques	  were	  compared	  in	  
the	  recurrent	  or	  residual	  disease	  setting,	  FDG	  PET	  was	   found	  to	  be	  superior	   in	   just	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two	  instances,	  in	  one	  instance	  the	  images	  were	  similar	  and	  in	  10	  the	  mIBG	  imaging	  
was	  found	  to	  be	  superior.	  Overall,	  they	  found	  that	  the	  tumour	  uptake	  of	  FDG	  to	  be	  
lower	  after	  patients	  had	  received	  therapy	  than	  before.	  The	  SUV	  before	  therapy	  was	  
greater	   than	   2	   but	   was	   less	   than	   2	   in	   those	   examined	   after	   systemic	   therapy	   or	  
radiation.	  The	  other	  problem	  highlighted	  in	  this	  early	  study	  was	  the	  accumulation	  of	  
FDG	  in	  the	  bone	  marrow	  whether	  or	  not	  it	  was	  infiltrated	  with	  neuroblastoma.	  They	  
suggested	  that	  the	  main	  use	  of	  18F-­‐FDG	  PET	  is	  likely	  to	  be	  in	  those	  neuroblastoma’s	  
that	  are	  mIBG	  negative	  (Shulkin	  1996).	  
	  
Sharp	  et	  al.	  performed	  a	  retrospective	  review	  comparing	  123I-­‐mIBG	  and	  18F-­‐FDG	  PET	  
scans	  at	  the	  time	  of	  diagnosis.	  A	  total	  of	  113	  123I-­‐mIBG	  and	  18F-­‐FDG	  PET	  paired	  scans	  
in	   60	   neuroblastoma	   patients	   were	   analysed.	   For	   the	   10	   patients	   with	   13	   paired	  
scans	  in	  stage	  1	  or	  2	  neuroblastoma,	  18F-­‐FDG	  PET	  was	  able	  to	  detect	  more	  primary	  
tumour	   or	   local	   or	   regional	  metastases	   in	   9	   out	   of	   the	   13	   scans,	   the	   two	   imaging	  
modalities	   were	   equal	   in	   1	   scan	   and	   3	   scans	   were	   normal.	   For	   the	   10	   stage	   3	  
patients,	  123I-­‐mIBG	  detected	  more	  extensive	  primary	  disease	  or	  regional	  metastases	  
in	  5	  of	  15	  scans,	  and	  18F-­‐FDG	  PET	  was	  able	  to	  do	  this	  in	  4	  of	  the	  15	  scans.	  For	  the	  40	  
stage	   4	   neuroblastoma	   patients	   there	   were	   85	   paired	   scans	   evaluated.	   123I-­‐mIBG	  
depicted	  more	  neuroblastoma	  than	  18F-­‐FDG	  PET	   in	  44	  of	  85	  scans	  and	  18F-­‐FDG	  PET	  
depicted	  more	   disease	   in	   11	   out	   of	   85	   scans.	   They	   concluded	   that	   123I-­‐mIBG	   was	  
better	   for	   the	   evaluation	   of	   stage	   4	   disease	   as	   it	   can	   detect	   more	   bone	   or	   bone	  
marrow	  disease	  (Sharp	  2009).	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Melzer	   et	   al.	  performed	   18F-­‐FDG	   PET	   scans	   in	   a	   cohort	   of	   neuroblastoma	   patients	  
with	  123I-­‐mIBG	  negative	  scans,	  discrepancy	  on	  123I-­‐mIBG	  and	  morphological	   imaging	  
or	   in	   patients	  whose	   clinical	   findings	  were	   inconsistent	  with	   initial	   imaging.	   There	  
were	  23,	  paired	  123I-­‐mIBG	  and	  18F-­‐FDG	  PET	  scans	  in	  19	  paediatric	  patients.	  Out	  of	  a	  
total	  of	  58	  suspicious	  lesions	  the	  sensitivity	  of	  123I-­‐mIBG	  was	  50%	  compared	  to	  78%	  
for	  18F-­‐FDG	  PET.	  The	  specificity	  was	  75%	  for	  123I-­‐mIBG	  and	  92%	  for	  18F-­‐FDG	  PET.	  They	  
concluded	   that	   18F-­‐FDG	   PET	   could	   be	   recommended	   if	   there	   were	   inconclusive	  
findings	  or	  discrepancies	  on	  the	  123I-­‐mIBG	  imaging	  (Melzer	  2011).	  
	  
	  Papathanasiou	   et	   al	   compared	   123I-­‐mIBG	  and	   18F-­‐FDG	  PET/CT	   scans	   in	   28	  patients	  
with	   relapsed	   or	   refractory	   neuroblastoma	   prior	   to	   treatment	  with	   high-­‐dose	   131I-­‐
mIBG	  therapy.	  123I-­‐mIBG	  was	  superior	  to	  18F-­‐FDG	  PET/CT	  in	  mapping	  disease	  extent	  
for	   these	  patients.	  However,	   in	   the	  14%	  of	  patients	  who	  had	  more	  disease	  on	   18F-­‐
FDG	   PET/CT	   than	   123I-­‐mIBG,	   the	   outcome	   was	   statistically	   worse	   (Papathanasiou	  
2011).	  
	  
One	  other	   group	  has	   explored	   the	   role	  of	   18F-­‐FDG	  PET/CT	   in	  patients	   treated	  with	  
131I-­‐mIBG	  molecular	   radiotherapy	   (Taggart	  2009).	   The	   study	   included	  patients	  who	  
had	  poorly	  responsive	  or	  progressive	  high-­‐risk	  neuroblastoma.	  Patients	  were	  treated	  
within	  a	  dose	  escalation	  study	  of	  131I-­‐mIBG	  given	  on	  days	  0	  and	  14	  with	  autologous	  
peripheral	  blood	  stem	  cell	  re-­‐infusion	  on	  day	  28.	  14	  patients	  had	  both	  18F-­‐FDG	  PET	  
and	  123I-­‐mIBG	  scans	  performed	  but	  only	  9	  patients	  had	  paired,	  concomitant	  18F-­‐FDG	  
PET	   and	   123I-­‐mIBG	   scans	  pre	   and	  post	   treatment	  with	   131I-­‐mIBG.	   	   The	   imaging	  was	  
performed	   in	   multiple	   treatment	   centres	   and	   the	   authors	   state	   that	   there	   was	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variation	   in	   the	   body	   views	   obtained.	   For	   both	   soft	   tissue	   and	   bone	   lesions	  
combined,	  they	  found	  123I-­‐mIBG	  imaging	  to	  be	  significantly	  more	  sensitive	  than	  18F-­‐
FDG	  PET	  both	  pre	   and	  post	   131I-­‐mIBG	   therapy.	   This	   remained	   the	   case	  when	  bone	  
lesions	   only	   were	   examined.	   There	   was	   a	   suggestion,	   although	   not	   statistically	  
significant,	  that	  18F-­‐FDG	  PET	  may	  be	  more	  sensitive	  than	  123I-­‐mIBG	  for	  detecting	  soft	  
tissue	   lesions.	   The	   18F-­‐FDG	   PET	   scans	   became	   completely	   negative	   post	   treatment	  
more	   often	   than	   123I-­‐mIBG	   scans.	   The	   analysis	   on	   response,	   comparing	   the	   two	  
different	  imaging	  modalities,	  looked	  only	  at	  the	  number	  of	  lesions	  on	  the	  two	  scans	  
and	  did	  not	   include	  metabolic	   response	   information	  from	  changes	   in	  SUVmax	  scores	  
from	   the	   18F-­‐FDG	   PET	   scans	   as	   we	   performed	   in	   our	   study.	   Within	   the	   study,	  
discussed	  above	  by	  Taggart	  et	  al.,	   there	  were	  some	  patients	  who	  had	  had	  18F-­‐FDG	  
PET	  scans	  performed	  at	  day	  13	  and	  day	  56	  post	   131I-­‐mIBG	  therapy.	  Two	  of	  the	  five	  
patients	  showed	  a	  response	  at	  day	  56	  which	  was	  not	  seen	  on	  the	  day	  13	  18F-­‐FDG	  PET	  
scan	  (Taggart	  2009).	  
	  
For	  the	  cohort	  of	  patients	  discussed	  in	  this	  chapter,	  the	  distribution	  of	  disease	  on	  the	  
two	  different	  imaging	  modalities	  was	  often	  discordant	  before	  the	  start	  of	  treatment.	  
The	   distribution	   of	   skeletal	   disease	   was	   often	   highly	   variable	   between	   the	   two	  
imaging	  modalities.	  For	  those	  patients	  with	  soft	  tissue	  disease	  only,	  the	  disease	  was	  
seen	  on	  both	   scans	   in	   the	   same	  areas	   and	   therefore	  direct	   comparison	  was	  much	  
easier.	  
	  
The	  SUVmax	  scores	  on	  18F-­‐FDG	  PET/CT	  in	  the	  bones	  were	  low	  and	  there	  is	  no	  way	  of	  
knowing	  whether	  they	  were	  all	  disease	  related,	  especially	  if	  they	  did	  not	  correspond	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to	  areas	  of	  disease	  on	  the	  123I-­‐mIBG	  scans.	  All	  of	  the	  patients	  in	  this	  study	  had	  mIBG	  
positive	   disease	   as	   they	  were	   pre-­‐selected	   patients	  who	  were	   going	   to	   undertake	  
mIBG	  therapy.	   In	  6	  patients,	  the	   initial	   18F-­‐FDG	  PET/CT	  semi-­‐quantitative	  score	  was	  
higher	  than	  on	  the	  123I-­‐mIBG	  scan.	  	  
	  
For	   those	   four	   patients	   with	   soft	   tissue	   only	   disease,	   the	   extent	   of	   disease	   was	  
identical	   between	   the	   123I-­‐mIBG	   and	   18F-­‐FDG	   PET/CT	   scans	   on	   semi-­‐quantitative	  
scoring,	  showing	  stable	  disease	   in	  all	  cases.	  The	  18F-­‐FDG	  PET/CT	  PERCIST	  score	  was	  
able	   to	   give	   additional	   response	   information	   and	   demonstrated	   a	   complete	  
metabolic	  response	  or	  partial	  metabolic	  response	   in	  three	  patients.	  The	  number	  of	  
patients	   examined	   in	   this	   study	   was	   too	   few	   to	   establish	   whether	   the	   metabolic	  
response	   seen	   on	   18F-­‐FDG	   PET/CT	   translates	   to	   improved	   outcome	   for	   those	  
patients.	  
	  
The	  optimal	  time	  for	  response	  assessment	  imaging	  following	  131I-­‐mIBG	  is	  not	  clearly	  
defined	  but	  should	  be	  performed	  at	  least	  6	  weeks	  after	  therapy.	  The	  majority	  of	  the	  
post	   treatment	   scans	   in	   this	   series	  were	  performed	  within	  3	  months	  after	   therapy	  
but	  there	  were	  some	  that	  occurred	  considerably	  later	  than	  this	  for	  logistical	  reasons.	  
For	   those	  patients	  who	  had	  a	  metabolic	   response	  on	   18F-­‐FDG	  PET/CT	  compared	   to	  
stable	   disease	   or	   partial	   response,	   it	   is	   possible	   that	   metabolic	   response	   is	   seen	  
earlier	  on	  FDG	  PET	  as	  the	  glucose	  uptake	  mechanism	  is	  the	  first	  to	  be	  turned	  off.	  For	  
one	  of	  the	  patients	  who	  had	  a	  complete	  response,	  the	  scan	  wasn’t	  performed	  until	  5	  
months	  after	  treatment	  and	  we	  don’t	  know	  if	  the	  same	  response	  would	  have	  been	  
seen	  at	  an	  earlier	  time	  point.	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Limitations	  of	  18F-­‐FDG	  PET	   in	  the	  setting	  of	  refractory	  and	  relapsed	  disease	   include	  
low-­‐grade	   uptake	   in	   bones,	   which	   may	   have	   been	   a	   result	   of	   bone	   marrow	  
hyperplasia	  in	  patients	  treated	  with	  recent	  cytotoxic	  chemotherapy	  or	  the	  use	  of	  G-­‐
CSF.	   18F-­‐FDG	   PET/CT	   may	   be	   of	   limited	   value	   for	   the	   evaluation	   of	   bone	   marrow	  
involvement	   due	   to	   the	   mild	   accumulation	   of	   FDG	   in	   normal	   bone	   marrow.	   The	  
principal	   drawback	   of	   18F-­‐FDG	   PET/CT	   is	   its	   low	   accuracy,	   during	   staging	   and	  
restaging,	  in	  detecting	  NB	  localization	  in	  bone	  and	  bone	  marrow,	  which	  are	  the	  most	  
frequent	   sites	  of	  disease	  progression	   (Kushner	  2001,	   Taggart	  2009,	  Papathanasiou	  
2011).	  
	  
None	  of	  the	  patients	  in	  this	  series	  were	  known	  to	  have	  brain	  metastases.	  mIBG	  is	  not	  
thought	   to	   cross	   the	   blood-­‐brain	   barrier	   and	   has	   limited	   ability	   for	   detecting	  
intracranial	  disease.	  The	  high	  uptake	  of	  FDG	  within	  brain	  tissue	  also	  limits	  the	  use	  of	  
18F-­‐FDG	  PET/CT	  for	  the	  detection	  of	  brain	  and	  skull	  metastases.	   If	  brain	  metastases	  
were	  suspected	  a	  MRI	  would	  still	  be	  required	  (see	  chapter	  1).	  
	  
One	  of	  the	  difficulties	  when	  examining	  a	  new	  functional	  imaging	  modality	  is	  knowing	  
how	   best	   to	   score	   and	   interpret	   the	   scans.	   For	   mIBG	   scans,	   a	   semi-­‐quantitative	  
scoring	  system	  is	  recommended	  (see	  chapter	  1).	  The	  2	  most	  commonly	  used	  semi-­‐
quantitative	  scoring	  systems,	  SIOPEN	  and	  Curie,	  do	  not	  take	  into	  account	  soft	  tissue	  
disease	  and	  only	  score	  the	  extent	  of	  disease	   in	  the	  skeleton.	  Their	  main	  evaluation	  
has	   been	   in	   the	   assessment	   of	   response	   to	   primary	   treatment	   rather	   than	   in	   the	  
relapsed	  or	   refractory	   setting.	  Metastatic	   soft	   tissue	  disease	   is	   very	  unusual	  at	   the	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initial	  presentation	  of	  metastatic	  neuroblastoma.	  The	  response	  on	  mIBG	  scans	  post	  
induction	  chemotherapy	  is	  what	  determines	  progressive	  to	  high-­‐dose	  myeloablative	  
therapy	  and	  patients	  will	  have	  subsequent	  surgical	  resection	  of	  their	  primary	  tumour	  
as	   part	   of	   their	   multi-­‐modality	   treatment.	   Soft	   tissue	   metastases	   are	   much	   more	  
common	   in	   relapsed	   disease	   and	   therefore	   our	   scoring	   of	   disease	   extent	  
incorporated	  a	  measure	  of	  soft-­‐tissue	  disease	  as	  well	  as	  skeletal	  disease.	  	  
	  
Introducing	  new	   functional	   imaging	  modalities	   for	   assessment	   in	  neuroblastoma	   is	  
complicated.	  Most	  published	   reports	  do	   initially	   include	   small	  numbers	  of	  patients	  
from	   single	   institutional	   studies.	   The	   scans	   need	   to	   be	   performed	   in	   addition	   to	  
standard	   imaging	   modalities	   and	   this	   has	   implications	   in	   terms	   of	   time,	   expense,	  
radiation	  exposure	  and	  for	  smaller	  children	  an	  extra	  general	  anaesthetic.	  
	  
The	  debate	  remains	  as	  to	  when	  and	  in	  which	  patients	  18F-­‐FDG	  PET/CT	  may	  be	  most	  
useful.	  Response	  on	  18F-­‐FDG	  PET/CT	  indicating	  a	  biological	  response	  to	  therapy	  may	  
be	   of	   clinical	   value	   in	   early	   response	   assessment	   to	   induction	   therapy	   or	   the	  
assessment	   of	   response	   to	   novel	   agents	   in	   early	   phase	   clinical	   trials.	  With	   current	  
high-­‐risk	   neuroblastoma	   regimes,	   patients	   receiving	   induction	   chemotherapy	   are	  
assessed	   at	   the	   end	   of	   therapy	  with	   a	   123I-­‐mIBG	   scan.	   Approximately	   one	   third	   of	  
patients	  will	  not	  respond	  to	  induction	  therapy.	  	  If	  these	  patients	  could	  be	  identified	  
as	   ‘poor	   responders’	   earlier	   on	   in	   their	   treatment	   course	   by	   an	   18F-­‐F-­‐FDG	   PET/CT	  
then	  they	  could	  be	  offered	  alternative	  treatment	  strategies.	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In	   a	   small	   study,	  Chawla	  et	   al	   evaluated	   the	   role	  of	   18F-­‐FDG	  PET/CT	   in	   staging	  and	  
early	  treatment	  response	  to	  chemotherapy	  in	  17	  children	  with	  neuroblastoma.	  They	  
concluded	   that	   it	   was	   a	   good	   modality	   for	   response	   assessment	   in	   patients	   with	  
moderate	  or	  high	  FDG	  uptake	  on	  the	  baseline	  scans	  but	  that	  it	  was	  of	  no	  benefit	  in	  
patients	  with	  low	  baseline	  FDG	  uptake	  (Chawla	  2010).	  	  
	  	  
18F-­‐FDG	   PET/CT	   gives	   supplementary	   information	   to	   123I-­‐mIBG	   scintigraphy	   in	   the	  
response	   assessment	   of	   relapsed	   or	   refractory	   neuroblastoma	   in	   some	   cases.	  
Because	  of	  the	  discrepancy	  in	  mapping	  skeletal	  disease	  in	  this	  cohort	  of	  heavily	  pre-­‐
treated	   patients,	   the	   main	   benefit	   for	   18F-­‐FDG	   PET/CT	   appeared	   to	   be	   in	   giving	  
additional	   information	   on	   metabolic	   response	   in	   patients	   with	   soft	   tissue	   disease	  
only,	   who	   otherwise	   may	   have	   been	   scored	   as	   stable	   disease	   only.	   The	   clinical	  
significance	  of	  this	  is	  uncertain	  and	  requires	  further	  evaluation	  and	  correlation	  with	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External	  beam	  radiotherapy	  forms	  part	  of	  the	  multi-­‐modality	  treatment	  of	  high-­‐risk	  
neuroblastoma.	  It	  is	  given,	  along	  with	  surgical	  resection	  of	  the	  primary	  tumour,	  with	  
the	  aim	  of	  reducing	  the	  risk	  of	  local	  recurrence	  (see	  chapter	  1).	  New	  treatments	  for	  
high-­‐risk	   neuroblastoma	   will	   hopefully	   improve	   the	   outcome,	   but	   so	   may	  
improvements	  in	  the	  delivery	  of	  existing	  treatments,	  including	  radiotherapy.	  
	  
High-­‐risk	   neuroblastoma	   trial	   protocols	   from	   around	   the	  world	   are	   similar	   in	   their	  
multi-­‐modality	   approach.	   Patients	   within	   the	   UK	   are	   currently	   treated	   on	   the	  
International	   Society	   of	   Paediatric	   Oncology	   (Europe)	   Neuroblastoma	   (SIOPEN)	  
Group’s	  high-­‐risk	  neuroblastoma	  protocol	  –	  SIOP	  HR-­‐NBL1.	  
	  
	  
Figure	  7.1	  	  
Illustration	  of	  where	  the	  different	  components	  of	  multi-­‐modality	  therapy	  fit	  into	  the	  
SIOP	  HR-­‐NBL1	  trial.	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Radiotherapy	  is	  given	  after	  myeloablative	  chemotherapy	  and	  peripheral	  blood	  stem	  
cell	   rescue	   and	   prior	   to	   the	   patient	   commencing	   differentiating	   therapy	   or	  
immunotherapy.	  The	  reasons	  for	  the	  timing	  of	  radiotherapy	  are	  a)	  because	  radiation	  
effects	   on	   bone	   marrow	   or	   other	   organs	   (gastrointestinal	   system,	   liver,	   kidneys)	  
could	   potentially	   interfere	   with	   chemotherapy	   delivery	   and	   b)	   in	   theory	   a	   large	  
primary	   tumor	   in-­‐situ	   is	   more	   likely	   to	   be	   hypoxic	   and	   therefore	   relatively	  
radioresistant	   compared	   to	   smaller	   tumors	   or	   microscopic	   residual	   disease.	   The	  
interval	   after	   BUMEL	   myeloablative	   therapy	   /	   stem	   cell	   rescue	   and	   radiotherapy	  
must	  be	  greater	  than	  60	  days	  in	  the	  SIOP	  HR-­‐NBL1	  study,	  due	  to	  the	  risk	  of	  busulfan	  
enhancing	   the	   toxicity	   of	   radiotherapy	   (Seddon	   2005).	   There	   is	   also	   a	   negative	  
association	  between	   isoretinoin	  (used	  for	  differentiating	  therapy)	  and	  radiotherapy	  
and	   therefore	   13-­‐cis-­‐retinoic	   acid	   is	   not	   commenced	   until	   after	   the	   completion	   of	  
radiotherapy.	  	  
	  
Within	   the	   SIOP	   HR-­‐NBL1	   trial,	   radiotherapy	   is	   given	   to	   all	   patients	   to	   the	   initial	  
tumour	   site,	   independent	   of	   the	   extent	   of	   surgical	   resection.	   Similarly,	   the	  
prescribed	   dose	   is	   standardised,	   regardless	   of	   the	   presence	   of	   any	   macroscopic	  
residual	   disease,	   the	   tumour	   biology	   or	   the	   age	   of	   the	   patient.	   The	   radiotherapy	  
planning	  is	  based	  on	  the	  post	  induction	  chemotherapy,	  pre-­‐operative	  gross	  tumour	  
volume	   (GTV)	   as	   shown	  by	   imaging.	   Post-­‐operative	  notes	   and	  pathological	   reports	  
are	  also	  taken	  into	  account	  when	  defining	  the	  GTV.	  The	  Clinical	  Target	  Volume	  (CTV)	  
is	   the	   sum	   of	   the	   pre-­‐operative	   GTV,	   areas	   of	   persistent	   adjacent	   lymph	   node	  
enlargement	   after	   induction	   therapy	   and	   all	   areas	   of	   microscopic	   spread	   on	   the	  
surgical	  and	  pathological	  reports.	  A	  margin	  is	  added	  for	  uncertainties	  in	  positioning	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to	   create	   the	   final	   Planning	   Target	   Volume	   (PTV).	   Total	   margins	   are	   therefore	  
typically	  2cm	  in	  each	  direction.	  
	  
External	   beam	   radiotherapy	   for	   high-­‐risk	   neuroblastoma	   within	   Europe	   has	   been	  
traditionally	  delivered	  with	  an	  anterior	  and	  posterior	  parallel-­‐opposed	  pair	  of	  fields.	  
Customised	  blocks	  or	  multi	   leaf	  collimation	  have	  been	  used	  to	  reduce	  unnecessary	  
irradiation	  of	  normal	  tissues.	  The	  dose	  prescribed	  is	  21Gy	  in	  14	  fractions,	  1.5Gy	  per	  
fraction,	  treating	  5	  fractions	  a	  week.	  
	  
Delivery	   of	   the	   full	   protocol	   dose	  with	   the	   conventional	   radiotherapy	   technique	   is	  
frequently	  limited	  by	  the	  proximity	  of	  the	  kidneys	  and	  liver	  and	  this	  compromise	  on	  
target	   volume	   coverage	   could	   impact	   on	   local	   control	   and	   ultimately	   outcome	   for	  
patients	  with	  high-­‐risk	  neuroblastoma.	  	  
	  
The	   dose	   received	   by	   critical	   organs	   at	   risk	   such	   as	   the	   kidneys	   and	   liver	   are	  
especially	  important	  in	  this	  paediatric	  population	  who	  have	  received	  intensive	  multi-­‐
modality	  therapy	  including	  high	  dose	  myeloablative	  chemotherapy	  and	  nephrotoxic	  
agents.	  Within	  the	  paediatric	  population	  there	  are	  additional	  long-­‐term	  factors	  to	  be	  
taken	   into	   account	  when	  using	   radiotherapy	   such	  as	   the	  effect	  on	   growing	   tissues	  
and	  the	  risk	  of	  developing	  a	  second	  malignancy.	  
	  
Within	   University	   College	   London	   Hospital	   NHS	   Foundation	   Trust	   we	   audited	   41	  
patients	  who	  had	  been	   treated	  with	   conventional	   radiotherapy	  between	  2006	  and	  
2010	  and	  found	  that	  20	  (49%)	  of	   them	  had	  required	  a	  modification	   in	  dose	  or	  PTV	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coverage	   to	   stay	   within	   organ	   at	   risk	   dose	   constraints	   with	   the	   conventional	  
radiotherapy	   technique.	  A	   compromise	  on	   target	   volume	   coverage	  or	   reduction	   in	  
dose,	  or	  both,	  could	  have	  an	  impact	  on	  local	  control.	  
	  
Within	  Europe,	  I	  have	  been	  part	  of	  the	  SIOPEN	  high-­‐risk	  neuroblastoma	  radiotherapy	  
quality	   assurance	   programme	   (Gaze	   2010).	   The	   SIOPEN	   trial	   electronic	   central	  
database	   has	   the	   ability	   for	   individual	   treatment	   centres	   to	   remotely	   upload	  
diagnostic	   imaging	   and	   radiotherapy	   planning	   data	   for	   central	   review.	   A	   quality	  
scoring	  system	  was	  devised	  to	  allocate	  cases	  to	  one	  of	  five	  quality	  assurance	  scores	  
as	  shown	  below.	  
	  






Central	  review	  of	  diagnostic	  and	  radiotherapy	  planning	  data	  sets	  was	  retrospectively	  
performed	  by	  a	  team	  of	  international	  paediatric	  radiologists	  and	  clinical	  oncologists.	  
Quality	   assurance	   review	   of	   radiotherapy	   delivered	   in	   100	   patients	   in	   the	   trial	  
showed	  only	  a	  48%	  compliance	  with	  the	  radiotherapy	  protocol	  recommendations.	  In	  
29%	  of	   the	   patients	   there	  was	   a	   justifiable	   reason	   for	   the	   deviation	  with	   no	   likely	  
long-­‐term	   consequences,	   most	   commonly	   to	   spare	   organs	   at	   risk.	   In	   5%	   of	   cases	  
there	   were	   justifiable	   reasons	   for	   the	   deviation	   but	   with	   likely	   long-­‐term	  
consequences.	   In	   1%	   there	  was	   a	   non-­‐justifiable	   deviation	  but	  without	   likely	   long-­‐
term	  effects.	  In	  17%,	  the	  protocol	  was	  deviated	  for	  unjustifiable	  reasons	  with	  a	  risk	  
of	  adverse	  events	  as	  a	  result.	  Results	  of	  this	  work	  were	  published	  in	  the	  International	  
Journal	   of	   Radiation	   Oncology	   Biology	   and	   Physics.	   (Gaze	   2013).	   On	   going	   work	  
within	   the	  SIOPEN	  radiotherapy	  group	  will	  examine	  whether	   radiotherapy	  protocol	  
deviations	   have	   impacted	   on	   local	   recurrence	   or	   outcome	   in	   a	   larger	   cohort	   of	  
patients.	  	  
	  
The	   past	   decade	   has	   seen	   significant	   developments	   in	   radiotherapy	   techniques.	  
Intensity	  Modulated	  Radiotherapy	  (IMRT)	  offers	  a	  high	  degree	  of	  conformity	  to	  the	  
target	  volume	  and	  a	   reduction	   in	  dose	   to	  nearby	  organs	  at	   risk	  and	  normal	   tissue.	  
IMRT	   involves	   the	   production	   of	   non-­‐uniform	   beam	   intensity	   across	   a	   field	   using	  
advanced	  planning,	  verification	  and	  delivery	  techniques.	  
	  
One	   form	  of	   IMRT	   is	   Intensity	  Modulated	  Arc	  Therapy	   (IMAT).	   IMAT	  was	  originally	  
proposed	  by	  Yu	  in	  1995	  and	  there	  are	  now	  several	  commercially	  available	  forms	  of	  
IMAT.	  RapidArcTM	  (Varian	  Medical	  Systems)	  is	  one	  such	  IMAT	  technique	  which	  uses	  
 253 
single	  or	  multiple	  arc	  gantry	  rotations	  with	  variable	  dose	  rate,	  gantry	  speed	  and	  MLC	  
aperture	   to	   produce	   highly	   conformal	   dose	   distributions.	   RadpidArcTM	   is	   the	  
technique	  available	  within	  my	  research	  institution	  and	  therefore	  the	  IMAT	  technique	  
discussed	  here.	  
	  
IMRT	  techniques	  can	  often	  result	  in	  a	  larger	  volume	  of	  normal	  tissue	  receiving	  a	  low	  
dose	  of	  radiation.	  The	   long-­‐term	  effects,	  especially	  carcinogenesis,	  of	   this	  so	  called	  
‘low-­‐dose	  bath	  effect’,	  has	  not	  been	  quantified	  in	  the	  paediatric	  setting	  and	  remains	  
controversial.	  It	  is	  essential	  therefore	  that	  these	  techniques,	  which	  have	  theoretical	  
advantages	   for	   tumour	   volume	   coverage,	   are	   scientifically	   evaluated	   before	   their	  
routine	  adoption	  into	  paediatric	  radiotherapy	  practise.	  
	  
A	   retrospective	   planning	   study	   was	   therefore	   performed	   to	   compare	   RapidArcTM	  
IMAT	   with	   the	   current	   standard	   practise	   in	   a	   cohort	   of	   high-­‐risk	   neuroblastoma	  
patients	  who	  had	  already	  been	  treated	  with	  a	  conventionally	  planned	  radiotherapy	  
technique.	  	  
	  
The	  aim	  of	  the	  planning	  study	  was	  to	  establish	  whether	  IMAT	  enabled	  
1. a	  greater	  proportion	  of	  patients	  able	  to	  receive	  the	  full	  protocol	  dose	  within	  
normal	  dose	  constraints	  
2. improved	   tumour	   volume	   coverage	   and	   reduced	   organ	   at	   risk	   doses	   in	  
patients	  who	  had	  been	  able	  to	  receive	  the	  full	  protocol	  dose.	  
Three	  cases	  where	  the	  IMAT	  technique	  have	  been	  used	  clinically	  are	  also	  presented	  
at	  the	  end	  of	  the	  planning	  study.	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Twenty	   children	   who	   had	   received	   conventional	   radiotherapy	   between	   2006	   and	  
2010	   were	   identified.	   All	   patients	   had	   been	   treated	   at	   University	   College	   London	  
Hospitals	  NHS	  Foundation	  Trust.	  	  
	  
The	  median	  age	  was	  3	  years	  (range	  1-­‐9	  years).	  There	  were	  11	  boys	  and	  9	  girls.	  The	  
INSS	  stage	  was	  4	  in	  12	  patients	  and	  INSS	  stage	  3	  in	  8	  patients.	  Eleven	  of	  the	  patients	  
had	  well-­‐lateralised	  tumours	  (6	  left-­‐sided,	  5	  right-­‐sided)	  and	  9	  patients	  had	  midline	  
tumours.	  
	  
Of	  the	  20	  children,	  10	  were	  what	  we	  termed	  ‘protocol	  compliant’	  and	  had	  received	  
the	  full	  prescribed	  and	  intended	  protocol	  dose	  of	  21Gy	  to	  the	  PTV	  in	  a	  single	  phase	  
with	  conventional	  radiotherapy	  planning	  and	  within	  the	  organ	  dose	  constraints.	  	  
	  
The	  other	  10	  patients	  were	  termed	  ‘protocol	  non-­‐compliant’.	  In	  this	  group	  it	  had	  not	  
been	   possible	   to	   deliver	   the	   full	   protocol	   dose	   of	   21Gy	   to	   the	   PTV	   within	   the	  
tolerance	   doses	   of	   organs	   at	   risk.	   These	   protocol	   non-­‐compliant	   patients	   had	  






Table	   showing	   the	   radiotherapy	   doses	   received	   by	   the	   10	   patients	   in	   the	   protocol	  
non-­‐complaint	   group.	   There	   was	   either	   compromise	   in	   dose,	   tumour	   volume	  
coverage	  or	  both.	  The	  phase	  2	  did	  not	  take	  the	  full	  PTV	  to	  21Gy.	  
	  
Patient	  Number	   Phase	  I	  dose	  
(Gy)	  
Phase	  II	  dose	  
(Gy)	  
Total	  dose	  (Gy)	  
11	   12	   9	   21	  
12	   10.5	   10.5	   21	  
13	   18	   3	   21	  
14	   15	   6	   21	  
15	   15	   0	   15	  
16	   15	   6	   21	  
17	   15	   0	   15	  
18	   15	   6	   21	  
19	   13.5	   7.5	   21	  









All	   20	   patients	   had	   a	   Computed	   Tomography	   (CT)	   scan	   (GE	   light	   speed	   16	   slice)	  
simulation	   with	   2.5mm	   slices.	   The	   GTV	   was	   based	   on	   the	   extent	   of	   the	   primary	  
tumour	   and	   abnormal	   adjacent	   lymph	   nodes	   –	   on	   post-­‐induction	   chemotherapy,	  
pre-­‐operative	   imaging.	  This	   imaging	  was	  fused	  with	  the	  planning	  CT	  scan	  for	  target	  
volume	  definition.	  There	  are	  potential	  geometric	  errors	  in	  this	  method	  but	  fusing	  the	  
pre-­‐operative	  imaging	  is	  used	  as	  a	  guide	  to	  target	  volume	  definition	  and	  planning	  is	  
performed	   post-­‐operatively	   when	   there	   are	   significant	   anatomical	   changes	   and	  
location	  of	  organs	  post	  surgical	  resection	  of	  the	  primary	  tumour.	  	  
	  
Once	  the	  GTV	  had	  been	  defined	  a	  1.5	  cm	  margin	  was	  added	  in	  3	  dimensions	  to	  form	  
a	  CTV	  to	  cover	  areas	  of	  microscopic	  disease.	  The	  CTV	  was	  edited	  back	  in	  the	  areas	  of	  
liver	   and	   kidney	   to	   a	   margin	   of	   0.5cm	   unless	   there	   was	   evidence	   from	   imaging,	  
surgery	   or	   pathology	   that	   there	   had	   been	   infiltration	   by	   the	   primary	   tumour.	   A	  
further	  0.5cm	  margin	  was	  added	  to	  the	  CTV	  to	  allow	  for	  uncertainties	  in	  positioning	  
and	  organ	  motion	  to	  form	  a	  PTV.	  	  
	  
Both	  kidneys	  and	  liver	  were	  contoured	  as	  organs	  at	  risk.	  The	  vertebrae	  at	  the	  level	  of	  
the	  PTV	  were	  also	  contoured	  so	  that	  the	  dose	  homogeneity	  within	  theses	  irradiated	  
vertebrae	  could	  be	  calculated.	  For	  all	  patients,	   there	  was	  significant	  overlap	  of	   the	  
PTV	  and	  vertebra	  and	  therefore	  the	  contiguous	  vertebrae	  were	  included	  in	  the	  PTV	  





The	  conventional	   radiotherapy	  plans	  were	  optimised	  on	  Oncentra	  masterplan	  v3.2	  
(Nucleotron).	  All	   but	   one	  of	   the	  patients	   had	  been	   treated	  with	   a	   standard	  AP/PA	  
technique.	  The	  other	  patient	  had	  been	  treated	  with	  a	  3-­‐field	  technique.	  	  
	  
Nineteen	  patients	  had	  been	  treated	  with	  6MV	  photons	  and	  one	  with	  10MV	  photons.	  
The	  upper	  and	  lower	  field	  borders	  for	  the	  conventional	  plans	  had	  been	  extended	  to	  






The	   IMAT	   (RapidArcTM)	   plans	   were	   optimised	   on	   Eclipse	   v8.6	   (Varian	   Medical	  
Systems).	  After	  the	  first	  few	  patients	  had	  been	  planned	  with	  the	  IMAT	  technique,	  we	  
found	   superior	   coverage	   with	   2	   arcs	   compared	   to	   a	   single	   arc	   and	   therefore	   all	  
subsequent	   plans	   were	   done	   using	   dual	   arcs.	   The	   first	   arc	   was	   applied	   clockwise	  
from	  179°	  to	  181°	  with	  a	  20°	  collimator	  angle	  (Varian	  IEC	  scale).	  The	  second	  arc	  was	  







Dose	  distributions	  for	  the	  conventional	  treatments	  were	  achieved	  through	  iterative	  
forward	   planning	   and	   in	   multiple	   phases	   if	   necessary,	   to	   respect	   normal	   tissue	  
tolerance.	  	  
	  
IMAT	   plans	   utilised	   the	   Eclipse	   Progressive	   Resolution	   Optimiser	   (PRO	   II)	   -­‐	   an	  
algorithm	   developed	   from	   that	   first	   proposed	   by	   Otto	   in	   2008.	   The	   algorithm	  
optimizes	  dose	  rate,	  gantry	  speed	  and	  MLC	  aperture	  with	  the	  convergence	  towards	  
a	  final	  solution	  which	  improves	  through	  five	  resolution	  levels.	  	  
	  
Dose	  volume	  objectives	  were	  added	   for	   target	  volumes,	  organs	  at	   risk	  and	  normal	  













Plan	  Dose	  Calculation	  and	  Normalisation	  
	  
The	  conventional	  plans	  were	  calculated	  using	  the	  Oncentra	  Masterplan	  Pencil	  Beam	  
Convolution	  Algorithm.	  Plans	  were	  normalised	  with	  100%	  prescription	  to	  a	  point	   in	  
accordance	  with	  ICRU	  report	  62	  (Prescribing,	  Recording	  and	  Reporting	  Photon	  Beam	  
Therapy).	  
	  
The	   IMAT	  plans	  were	   calculated	   using	   the	   Eclipse	  Anisotropic	   Analytical	   Algorithm	  
(AAA).	   Plans	   were	   normalised	   with	   100%	   prescription	   to	   the	   target	   volume	  mean	  
dose	   in	   accordance	   with	   ICRU	   report	   83	   (Prescribing,	   recording	   and	   reporting	  
photon-­‐beam	  intensity-­‐modulated	  radiotherapy).	  
	  
It	   is	  noted	  that	  a	  different	  treatment	  planning	  algorithm	  has	  been	  used	  for	  both	  of	  
the	  techniques	  and	  therefore	  a	  cohort	  of	  conventionally	  planned	  patients	  were	  re-­‐
planned	   with	   the	   AAA	   algorithm	   to	   see	   if	   there	   was	   a	   significant	   change	   in	   dose	  
distribution.	  	  No	  significant	  difference	  was	  observed	  and	  therefore	  the	  dose	  volume	  
statistics	   from	   the	   Oncentra	   Masterplan	   Pencil	   Beam	   Convolution	   Algorithm	   has	  














To	  asses	  the	  plan	  quality	  with	  respect	  to	  the	  PTV	  coverage	  we	  looked	  at:	  
1. The	  D98%	  -­‐	  the	  dose	  received	  by	  98%	  of	  the	  PTV	  volume	  
2. The	  D2%	  -­‐	  the	  dose	  received	  by	  2%	  of	  the	  PTV	  volume	  
3. The	   Conformity	   Index	   (CI)	   –	   the	   ratio	   of	   the	   volume	   covered	   by	   the	   95%	  
	   isodose	  to	  the	  volume	  of	  the	  PTV	  
4. The	  homogeneity	  Index	  (HI)	  –	  the	  ratio	  of	  (D2%	  -­‐	  D98%)	  /	  D50%	  
	   (D50%	  =	  dose	  receive	  by	  50%	  of	  the	  PTV	  volume)	  
	  
These	  4	  criteria	  are	  those	  recommended	  by	  ICRU	  83.	  	  
	  
Organs	  at	  Risk	  
Kidneys	  
For	   lateralised	   tumours,	   where	   the	   ipsilateral	   kidney	   would	   receive	   21Gy,	   the	  
contralateral	   kidney	   dose	   limit	  was	   a	   V12≤	   10%.	   For	  midline	   tumours,	   a	   combined	  






A	  V19	  ≤100%	  and	  a	  V21	  ≤	  25%	  were	  used	  as	  per	  the	  liver	  dose	  constraints	  used	  in	  the	  
current	  SIOPEN	  high-­‐risk	  protocol.	  
	  
Vertebrae	  
A	  homogenous	  distribution	  of	   dose	   to	   the	   vertebrae	   in	   children	   receiving	   external	  
beam	  radiotherapy	   is	   critical	   to	   future	  growth	  and	   the	   risk	  of	  deformities	   in	   spinal	  
growth	   (Hogeboom	   2001,	   Paulino	   2000).	   Dose	   homogeneity	   to	   the	   vertebra	   was	  
assessed	  by	  the	  dose	  received	  by	  98%	  of	  the	  vertebrae	  and	  a	  homogeneity	  index	  for	  
the	  vertebra	  [(D2%	  -­‐	  D98%)	  /	  D50%].	  
	  
Normal	  Tissue	  
To	  measure	  the	  volume	  of	  normal	  tissue	  receiving	  a	  low	  dose	  of	  radiation,	  the	  non-­‐
PTV	   integral	  dose	  (NPID)	  was	  calculated	  for	  both	  conventional	  and	   IMAT	  plans	  and	  
then	   compared.	   The	  NPID	  was	   calculated	  by	   the	  product	  of	   the	  mean	  dose	   to	   the	  










The	   data	   was	   summarised	   using	   median	   and	   range.	   The	   normality	   was	   assessed	  
using	  histograms.	  The	  Wilcoxon	  rank-­‐sum	  and	  Wilcoxon	  matched-­‐pairs	   signed-­‐rank	  
tests	  were	  used	  to	  compare	  groups.	  To	  account	  for	  multiple	  testing,	  the	  results	  were	  
considered	   significant	   if	   the	   p	   value	   was	   less	   the	   0.01.	   The	   calculations	   were	  
performed	  using	  Stata	  v11.	  (StataCorp.	  2009.	  Stata	  Statistical	  Software:	  Release	  11.	  





















In	   the	   protocol	   compliant	   group,	   nine	   tumours	   were	   lateralised	   and	   one	   was	   a	  





There	   was	   no	   significant	   difference	   in	   the	   tumour	   volume	   between	   the	   protocol	  
complaint	  and	  protocol	  non-­‐complaint	  groups.	  
	  
Median	  PTV	  volume	  	  	  
Protocol	  compliant	  group	   	   	   	   392cm3	  (range	  149-­‐851)	  





The	  PTV	  coverage	  was	  compared	  for	  all	  20	  patients	  between	  conventional	  and	  IMAT	  
plans.	  The	  tumour	  coverage	  was	  improved	  with	  IMAT	  plans	  as	  shown	  by	  statistically	  
significant	  improvements	  in	  D98%,	  CI	  and	  HI	  as	  shown	  below:	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Table	  7.2	   shows	   the	   comparison	  of	  PTV	  coverage	   for	   the	   IMAT	  and	  conventional	  
techniques	  for	  all	  20	  patients	  in	  the	  study.	  
	  
































The	  homogeneity	  of	  dose	  to	  the	  vertebra	  was	  improved	  with	  the	  IMAT	  technique.	  	  
Median	  D98%	  
Conventional	  	   	   	   17Gy	  (range	  0.8-­‐20.4Gy)	  	  
IMAT	   	   	   	   20.5Gy	  (Range	  19-­‐20.7Gy)	  
p	  <	  0.001	  
Median	  Homogeneity	  Index	  
Conventional	  	   	   	   0.24	  (0.07-­‐0.97)	  	  
IMAT	   	   	   	   0.06	  (range	  0.05	  –	  0.14)	  
p	  <	  0.001	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Protocol	  Compliant	  Group	  
	  
There	  were	  nine	  patients	   in	   this	  group	  with	   lateralised	   tumours,	  and	   therefore	  we	  
directly	  compared	  21Gy	  delivered	  by	  the	  conventional	  and	  IMAT	  techniques	  to	  look	  
at	  kidney	  and	  liver	  doses.	  
	  
There	  was	   no	   significant	   difference	   between	   the	   conventional	   and	   IMAT	   plans	   for	  
both	  the	  ipsilateral	  and	  contralateral	  V15’s	  and	  ipsilateral	  mean	  kidney	  doses.	  There	  
was	  an	  increase	  in	  the	  contralateral	  mean	  kidney	  dose	  with	  IMAT.	  
	  
There	  was	  no	  significantly	  significant	  difference	  in	  the	  mean	  liver	  dose	  between	  the	  
two	  plans	  but	  the	  V19	  was	  significantly	  reduced	  with	  the	  IMAT	  technique.	  	  
	  
For	  the	  three	  patients	  with	  right-­‐sided	  tumours	  in	  this	  group	  there	  was	  a	  reduction	  
in	   the	   mean	   liver	   dose	   (median	   of	   10.7Gy	   versus	   12.9Gy)	   and	   V19	   (median	   0.1%	  
versus	  0.5%)	  with	   IMAT.	   For	   left	   sided	   tumours	   (6	  patients)	   the	  mean	  dose	   to	   the	  
liver	   was	   increased	   with	   IMAT	   (median	   7.2Gy	   versus	   4.1Gy)	   but	   there	   was	   a	  







Table	  7.3	   shows	   the	   liver	   and	  kidney	  doses	   for	   the	  nine	  patients	  with	   lateralised	  
tumours	  in	  the	  protocol	  compliant	  group	  comparing	  21Gy	  given	  conventionally	  and	  
with	  the	  IMAT	  technique.	  
	  
Variable	   Plan	   Wilcoxon-­‐
rank	  sum	  Conventional	   IMAT	  
Kidneys	  






p	  =	  0.4	  






p	  =	  0.04	  






p	  =	  0.008	  






p	  =	  0.2	  
Liver	  


























Examples	  in	  the	  protocol	  compliant	  
	  
Figure	  7.3	  Left-­‐sided	  lateralised	  tumour	  
	  
Figure	  7.3A	  	  
Comparison	  of	  conventional	   (left)	  and	   IMAT	  (right)	  plans	  for	  a	   left-­‐sided	   lateralised	  
neuroblastoma	  in	  the	  protocol-­‐compliant	  group.	  
	  
PTV	  =	  red,	  Liver	  =	  green,	  ipsilateral	  (left)	  kidney	  =	  blue,	  contralateral	  (right)	  kidney=	  
orange.	  The	  95%	  isodose	  curve	  is	  shown	  in	  red	  colourwash	  illustrating	  the	  increased	  








Figure	  7.3B	  	  
	  
Dose	  Volume	  Histogram	  (DVH)	   for	   the	  patient	   in	  Figure	  7.3A,	  conventional	   (∆)	  and	  
IMAT	   (□)	  plans.	  The	  PTV	  coverage	   is	  comparable	   for	   the	   two	  plans.	  The	   IMAT	  plan	  
allows	  some	  sparing	  of	  the	  ipsilateral	  kidney	  (blue)	  but	  with	  an	  increased	  dose	  to	  the	  














Comparison	  of	  conventional	  (left)	  and	  IMAT	  (right)	  plans	  for	  a	  right-­‐sided	  abdominal	  
neuroblastoma	  in	  the	  protocol	  compliant	  group.	  PTV	  =	  red,	   liver	  =	  green,	   ipsilateral	  
(right)	  kidney	  =	  blue,	  contralteral	  (left)	  kidney	  =	  orange.	  
	  
The	  95%	  isodose	  curve	  is	  shown	  in	  colourwash	  illustrating	  the	  avoidance	  of	  the	  high	  











The	  DVH	  for	  the	  patient	  in	  figure	  7.4A.	  Conventional	  plan	  (∆)	  and	  IMAT	  plans	  (□).	  The	  
PTV	  coverage	   (red)	  between	  plans	  was	  comparable	  but	   the	   IMAT	  plan	  was	  able	   to	  
spare	  some	  of	  the	  ipsilateral	  kidney	  (orange)	  and	  the	  liver	  (green)	  at	  the	  expense	  of	  









Protocol	  Non-­‐compliant	  Group	  
	  
The	  majority	  of	  the	  tumours	  in	  this	  group	  were	  mid-­‐line	  location	  and	  none	  of	  them	  
had	  been	  able	  to	  receive	  21Gy	  to	  the	  whole	  PTV	  with	  conventional	  AP/PA	  fields.	  	  
	  
The	  IMAT	  technique	  could	  deliver	  the	  full	  protocol	  dose	  to	  the	  PTV	  within	  renal	  and	  
hepatic	  dose	  constraints	  in	  8	  out	  of	  10	  cases.	  	  
	  
The	  two	  cases	  where	   IMAT	  was	  unable	  to	  deliver	   the	   full	  protocol	  dose	  were	  both	  
very	   large	   mid-­‐line	   tumours.	   The	   plans	   were	   compared	   to	   see	   what	   percentage	  
increase	  in	  dose	  could	  be	  achieved	  with	  the	  IMAT	  technique	  by	  comparing	  the	  V19.95%	  
(the	  volume	  receiving	  95%	  of	  21Gy).	  For	  one	  patient,	  the	  increase	  was	  from	  64%	  to	  
89%	  and	  the	  other	  (in	  whom	  only	  15Gy	  had	  been	  possible	  conventionally)	  form	  0%	  
to	  94%	  with	  IMAT.	  	  
	  
The	   two	   lateralised	   tumours	   in	   this	   group	   were	   both	   right–sided	   and	   the	   IMAT	  









Example	  from	  the	  protocol	  non-­‐compliant	  group	  
	  
Figure	  7.5	  A	  mid-­‐line	  neuroblastoma	  
Figure	  7.5A	  
Comparison	  of	  conventional	  (left)	  and	  IMAT	  (right)	  plans	  in	  a	  patient	  in	  the	  protocol	  
non-­‐compliant	  group	  with	  a	  midline	  tumour	  (PTV	  in	  red).	  The	  colourwash	  shows	  the	  
dose	  coverage	  between	  15Gy	  and	  21Gy,	  highlighting	  the	  under-­‐coverage	  of	  the	  PTV	  












Figure	  7.5	  B	  
DVH	  for	  the	  patient	  in	  7.5A,	  conventional	  (∆)	  and	  IMAT	  (□)	  plans.	  The	  PTV	  coverage	  
(red)	   is	   improved	  with	   the	   IMAT	  plans.	   The	  doses	   to	  both	  kidneys	   (right	  =	  orange,	  














The	  monitor	  units	  (MU)	  were	  increased	  with	  the	  IMAT	  technique.	  
Median	  MU	  
Conventional	   	   	   	   162MU	  (range	  131-­‐334)	  
IMAT	   	   	   	   	   328MU	  (range	  261-­‐432)	  
p	  <0.001	  
	  
Non-­‐PTV	  Integral	  dose	  
	  
The	  NPID	  was	   variable	   between	   the	   patients	  with	   some	  having	   an	   increased	  NPID	  
with	  the	  IMAT	  technique	  and	  some	  a	  reduced	  one.	  The	  protocol	  compliant	  patients	  






Clinical	  Experience	  of	  IMAT	  in	  neuroblastoma	  
	  
Following	  our	  experience	  in	  the	  planning	  study	  discussed	  above,	  as	  well	  as	  data	  from	  
both	  our	  own	  institution	  and	  the	  European	  High-­‐risk	  neuroblastoma	  trial,	  that	  many	  
patients	   have	   a	   compromise	   on	   target	   volume	   coverage	   with	   conventional	  
radiotherapy	   techniques	   we	   have	   recently	   taken	   the	   IMAT	   technique	   forward	  
clinically	  in	  a	  select	  number	  of	  difficult	  cases.	  	  
	  
The	   following	   three	   clinical	   cases	   illustrate	   current	   experience	   in	   using	   IMAT	   in	  
clinical	  practise	  at	  UCLH	  for	  the	  treatment	  of	  high-­‐risk	  neuroblastoma.	  	  
	  
Clinical	  Case	  1	  
	  
A	  4	  year	  old	  girl	  with	  stage	  4	  neuroblastoma	  receiving	  treatment	  on	  the	  SIOP	  HR-­‐NBL	  
1	   trial.	   Planned	   to	   receive	   external	   beam	   radiotherapy	   to	   the	   primary	   abdominal	  
tumour	  as	  part	  of	  the	  multi-­‐modality	  treatment	  approach.	  Delivery	  of	  the	  full	  21Gy	  
in	   14 fractions	  was	   unlikely	   to	   be	   possible	   in	   view	   of	   the	   large	  midline	   tumour	   in	  
relation	  to	  the	  position	  of	  both	  kidneys.	  This	  patient	  was	  referred	  to	  us	  from	  another	  





The	   patient	   was	   4	   years	   old	   and	   with	   the	   expertise	   of	   our	   radiotherapy	   play	  
specialists	   was	   able	   to	   have	   her	   3	   weeks	   of	   radiotherapy	   without	   a	   general	  
anaesthetic.	  Treatment	  was	  tolerated	  well	  with	  no	   increased	  bowel	  or	  skin	  toxicity	  
acutely.	  
	  
Figure	   7.7A	   illustrates	   the	   2	   phase	   AP/PA	   conventional	   plan	   generated	   showing	  
that	   PTV	   coverage	   up	   to	   the	   dose	   of	   21Gy	   in	   14	   fractions	   was	   not	   possible	   with	  
conventional	   radiotherapy	   techniques.	   	   This	   plan	   would	   have	   involved	   a	   2	   phase	  
technique	  with	   compromise	   on	   PTV	   coverage	   for	   the	   phase	   2	   to	   stay	  within	   renal	  
tolerance.	  The	  Phase	  1	  (15Gy	  in	  10 fractions)	  is	  shown	  in	  blue	  colourwash	  (15Gy)	  and	  







Figure	  7.7B	  illustrates	  the	  DVH	  for	  the	  conventional	  plan	  showing	  under	  coverage	  
of	  the	  PTV.	  Green	  =	  left	  kidney,	  blue	  =	  liver,	  yellow	  =	  right	  kidney,	  PTV	  =	  red	  ,	  dotted	  














An	   IMAT	   plan	   was	   generated	   which	   allowed	   full	   coverage	   of	   the	   PTV	   with	   the	  
prescribed	  protocol	  dose	  of	  21Gy.	  
	  
Figure	   7.7C	   illustrates	   the	   IMAT	   plan	   showing	   dull	   coverage	   of	   the	   PTV	   to	   21Gy	  
(red	  colourwash).	  As	  within	  the	  planning	  study	  the	  PTV	  was	  modified	  to	  include	  the	  
vertebra	   to	  ensure	  homogenous	  dose	   to	   the	  vertebra	  and	   reduce	   the	   risk	  of	   long-­‐











Figure	  7.7D	  The	  DVH	  for	  the	  IMAT	  plan.	  Green	  =	  left	  kidney,	  blue	  =	  liver,	  yellow	  =	  
right	  kidney,	  PTV	  =	  red	  ,	  dotted	  green	  =	  combined	  kidneys.	  	  The	  IMAT	  plan	  enabled	  















Clinical	  Case	  2	  
A	  14	  year	  old	  girl	  with	  high-­‐risk,	  stage	  M	  neuroblastoma	  being	  treated	  on	  the	  SIOPEN	  
HR-­‐NBL-­‐1	  trial	   referred	   for	   radiotherapy	  to	   the	  primary	   tumour	   in	   the	  abdomen	  as	  
part	   of	   the	  multi-­‐modality	   treatment	   of	   her	   high-­‐risk	   neuroblastoma.	   At	   diagnosis	  
there	  was	   a	   right	   suprarenal	  mass	   and	  metastases	   in	   the	   bone	  marrow	   as	  well	   as	  
meningeal	  disease.	  	  Following	  surgical	  resection	  of	  the	  right	  suprarenal	  mass,	  there	  
was	  residual	  disease	  within	  the	  abdomen.	  It	  was	  decided	  that	  she	  should	  have	  post-­‐
operative	  radiotherapy	  but	  at	  a	  higher	  dose	  of	  36Gy	  in	  20 fractions	  (1.8Gy/fraction).	  
It	   would	   not	   have	   been	   possible	   to	   stay	   within	   normal	   tissue	   constraints	   with	  
conventional	  radiotherapy	  and	  therefore	  the	  IMAT	  technique	  was	  adopted.	  
	  
Figure	  7.8A	  An	  axial	  image	  of	  the	  IMAT	  plan	  generated.	  The	  36Gy	  isodose	  is	  shown	  





Figure	   7.8B	   The	   DVH	   from	   the	   IMAT	   plan	   seen	   in	   Figure	   7.8A.	   The	   PTV	   (red)	   is	  
receiving	   36Gy	   whilst	   keeping	   within	   the	   normal	   tissue	   constraints	   for	   the	   liver	  













Clinical	  Case	  3	  
	  
7	   year	   old	   boy	   with	   stage	   M	   neuroblastoma.	   Originally	   treated	   on	   the	   high-­‐risk	  
SIOPEN	  HR-­‐NBL1	  trial.	  Treated	  with	  multi-­‐modality	  approach	  but	  required	  131I-­‐mIBG	  
and	  topotecan	  for	  poor	  response	  to	  initial	  therapy	  prior	  to	  high-­‐dose	  myeloablative	  
therapy	   and	   then	   received	   immunotherapy	   in	  Germany.	  Original	   surgical	   resection	  
was	  very	  difficult	  and	  there	  was	  thought	  to	  be	  residual	  disease	  within	  the	  abdomen.	  
Received	  standard	  abdominal	  radiotherapy	  using	  AP/PA	  fields	  in	  November	  2010	  as	  
part	  of	  his	  multi-­‐modality	  therapy.	  A	  two-­‐phase	  technique	  was	  used	  (phase	  I	  13.5Gy	  
in	  9 fractions	  and	  phase	  II	  7.5Gy	  in	  5	  fractions)	  to	  stay	  within	  renal	  tolerance	  and	  this	  
resulted	   in	  under-­‐coverage	  of	   the	  PTV	   in	  phase	   II.	  The	   left	  kidney	   received	   the	   full	  
21Gy	  and	  90%	  of	  the	  right	  kidney	  received	  12-­‐14Gy.	  
	  
On	  follow-­‐up	  imaging	  in	  Jan	  2013,	  an	  123I-­‐mIBG	  scan	  showed	  an	  increase	  in	  the	  size	  
of	   local	   residual	   disease	   within	   the	   abdomen.	   A	   68Ga-­‐DOTATATE	   PET/CT	   scan	  
confirmed	  the	  uptake	  within	   the	  abdomen.	  As	   this	  was	   the	  only	  area	  of	  disease,	   it	  
was	   decided	   to	   re-­‐treat	   this	   area	   with	   external	   beam	   radiotherapy	   and	   an	   IMAT	  
technique	  was	   chosen	   to	   reduce	   the	   dose	   to	   both	   kidneys.	   A	   dose	   of	   30Gy	   in	   20	  
fractions	  at	  1.5Gy	  per	  fraction	  was	  used	  with	  the	  aim	  of	  maximizing	  disease	  control.	  
An	  EDTA	  showed	  a	  satisfactory	  corrected	  creatinine	  clearance	  of	  71mls/min/1.73m2	  
and	   a	   DMSA	   scan	   showed	   differential	   kidney	   function	   with	   the	   right	   kidney	  
contributing	  68%	  of	  the	  total	  function	  and	  the	  left	  32%.	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The	  CT	  planning	  scan	  was	  fused	  with	  the	  68Ga-­‐DOTATATE	  PET/CT	  for	  biological	  target	  
volume	  definition	  (BTV).	  The	  BTV	  was	  then	  modified	  to	  form	  a	  CTV	  and	  included	  the	  
disease	  seen	  on	  the	  planning	  CT	  and	  a	  diagnostic	  CT.	  A	  margin	  of	  0.7cm	  was	  added	  
























The	  radiotherapy	  planning	  study	  presented	  here	  has	  been	  published	  by	  Gains	  et	  al.	  
(Future	  Oncology	   2013).	   This	   is	   the	   largest	   study	   evaluating	   an	   IMRT	   technique	   in	  
neuroblastoma	   and	   comparing	   it	   to	   the	   current	   standard	   conventional	   techniques	  
employed	   over	   Europe	   to	   treat	   abdominal	   neuroblastoma.	   It	   has	   added	   to	   our	  
knowledge	   of	   the	   possible	   benefits	   of	   IMAT	   in	   an	   unselected	   clinical	   series	  
encompassing	  the	  heterogeneity	  of	  target	  volume	  and	  location	  seen	  in	  patients	  with	  
abdominal	  neuroblastoma.	  
	  
There	  have	  been	  two	  previous	  reports	  in	  the	  literature	  comparing	  IMRT	  techniques	  
to	   conventional	   radiotherapy	   in	   neuroblastoma.	   Previous	   studies	   have	   had	   small	  
patient	   numbers,	   often	   with	   mixed	   abdominal	   pathologies	   and	   radiation	   doses,	  
which	   have	   not	   fully	   reflected	   the	   complexity	   of	   challenges	   faced	   by	   the	   clinical	  
oncologist	  treating	  neuroblastoma.	  
	  
A	  planning	   study	  by	  Paulino	  et	  al.	   compared	   conventional	   radiotherapy	  plans	  with	  
fixed	  field	  IMRT	  plans	  in	  six	  children	  with	  neuroblastoma.	  They	  found	  an	  advantage	  
with	   IMRT	   for	   midline	   tumours	   but	   found	   fixed	   field	   IMRT	   to	   be	   no	   better	   than	  
conventional	   AP/PA	   fields	   for	   lateralised	   tumours	   because	   of	   an	   increased	   mean	  
dose	   to	   the	   contralateral	   kidney	   (Paulino	   2006).	   Our	   study	   however,	   has	   shown	   a	  
benefit	  for	  IMAT	  in	  some	  patients	  with	  lateralised	  tumours	  who	  were	  protocol	  non-­‐
compliant	  with	  conventional	  radiotherapy.	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Shaffer	   et	   al.	   reported	   a	   planning	   study	   comparing	   IMAT,	   fixed-­‐field	   IMRT,	   3D	  
conformal	   radiotherapy	   (3D-­‐CRT)	   and	   parallel-­‐opposed	   beams	   in	   eight	   paediatric,	  
retroperitoneally	   located	   tumours	   including	   five	   with	   neuroblastoma.	   Consistent	  
with	   the	   findings	   by	   Paulino	   et	   al.	   they	   found	   an	   increase	   in	   mean	   contralateral	  
kidney	   doses	   for	   lateralised	   tumours	   for	   the	   3D-­‐CRT,	   fixed-­‐field	   IMRT	   and	   IMAT	  
techniques	  (Shaffer	  2011).	  
	  
In	   this	   study,	   we	   found	   statistically	   significant	   improved	   conformity	   and	   dose	  
distributions	   to	   the	   PTV	   with	   RapidArcTM.	   In	   the	   protocol	   compliant	   group,	   which	  
included	   in	   the	   majority	   lateralized	   tumours,	   we	   found	   no	   statistically	   significant	  
change	   in	   the	   contralateral	   or	   ipsilateral	   kidney	   V15’s,	   or	   ipsilateral	   mean	   kidney	  
doses.	  There	  was	  a	  statistically	  significant	  increase	  in	  the	  contralateral	  mean	  kidney	  
dose	  with	  RapidArcTM,	  consistent	  with	  the	  two	  studies	  mentioned	  above.	  	  
	  
With	   regards	   to	   liver	   doses	   for	   right-­‐sided	   tumours,	   there	  was	   an	   advantage	  with	  
RapidArcTM	  for	  patients	  in	  both	  groups	  although	  the	  numbers	  in	  each	  group	  were	  too	  
small	   for	   statistical	   analysis	   (see	   Figure	  7.4).	  Reducing	   the	  high-­‐dose	   to	   the	   liver	   is	  
important	  for	  those	  patients	  with	  veno-­‐occlusive	  disease,	  a	  recognized	  complication	  
of	  myeloablative	  therapy	  (Horn	  2002).	  	  
	  
The	   difference	   in	   anatomical	   location	   of	   tumours	   in	   the	   two	   different	   groups	  
probably	   had	   a	   large	   influence	   on	   whether	   they	   were	   protocol	   complaint	   when	  
treated	   conventionally	   or	   not.	   With	   lateralised	   tumours,	   it	   is	   easier	   to	   spare	   the	  
contralateral	  kidney	  with	  the	  conventional	  treatment	  approach	  as	  opposed	  to	  large	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midline	  tumours	  where	  both	  kidneys	  can	  fall	  within	  the	  treatment	  field.	  The	  greatest	  
benefit	   from	   an	   IMAT	   technique	   therefore,	   is	   likely	   to	   be	   seen	   in	   large,	   midline	  
abdominal	  neuroblastomas	  (see	  Figure	  7.5).	  
	  
In	   the	   protocol	   non-­‐compliant	   group,	   the	   majority	   of	   tumors	   were	   midline	   and	  
conventional	  planning	  had	   compromised	  dose,	   treated	  volume	  or	  both.	   There	  was	  
an	  advantage	  for	  RapidArcTM	  in	  this	  group,	  with	  eight	  of	  the	  ten	  cases	  being	  able	  to	  
receive	  the	  full	  21Gy,	  and	  in	  the	  other	  two	  cases,	  an	  improvement	  in	  the	  dose	  being	  
received	  by	  the	  PTV	  compared	  to	  conventional	  planning.	  
	  
When	   using	   conventional	   radiotherapy	   in	   children	   that	   may	   involve	   irradiating	  
vertebrae,	   it	   has	   been	   recommended	   to	   include	   the	   whole	   vertebra	   within	   the	  
radiation	   field	   to	   avoid	   partial	   irradiation	   which	   may	   lead	   to	   future	   growth	  
asymmetry.	  In	  this	  study	  we	  compared	  the	  homogeneity	  of	  dose	  distribution	  across	  
the	  vertebra	  (vertebral	  HI)	  and	  found	  this	  to	  be	  significantly	  improved	  with	  the	  IMAT	  
compared	  to	  the	  conventional	  plans	  (p<0.001).	  
	  
Advantages	  of	  RapidArcTM	  over	  fixed	  field	  IMRT	  are	  reduced	  treatment	  times	  and	  a	  
reduction	  in	  monitor	  units	  (Cozzi	  2008,	  Vieillot	  2010,	  Wiezoreck	  2011).	  A	  reduction	  in	  
treatment	   time	   may	   reduce	   the	   intra-­‐fraction	   patient	   motion	   and	   a	   reduction	   in	  
monitor	   units	   has	   important	   implications	   with	   regards	   to	   the	   development	   of	  
secondary	  malignancies.	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With	   the	   increased	  use	  of	   IMRT	  techniques	   it	   is	  essential	   to	   re-­‐evaluate	   traditional	  
treatment	  planning	  margins.	  With	  the	   increased	  conformity	  with	  new	  radiotherapy	  
techniques	  and	  image–guided	  radiotherapy	  techniques	  it	  may	  be	  possible	  to	  reduce	  
the	   treatment	   margins	   resulting	   in	   less	   normal	   tissue	   being	   irradiated.	   A	   recent	  
report	   showed	  an	  effective	   reduction	   in	   setup	  margin	   for	   children	  with	   abdominal	  
neuroblastoma	   based	   on	   daily	   cone	   beam	   CT	   rather	   than	   conventional	   weekly	  
imaging	  (Beltran	  2010).	  
	  
As	   external	   beam	   radiotherapy	   improves	   local	   control	   in	   children	   with	  
neuroblastoma,	  regardless	  of	   the	  extent	  of	  surgical	   resection,	  being	  able	   to	  deliver	  
the	  full	  protocol	  dose	  to	  the	  PTV	   in	  more	  cases	  may	  reduce	   local	   recurrence.	  Dose	  
escalation,	   respecting	   current	   normal	   tissue	   constraints,	   is	   difficult	   with	   current	  
radiotherapy	  techniques.	  It	  is	  not	  known	  whether	  dose	  escalation	  beyond	  21Gy	  may	  
improve	  local	  control.	  Some	  groups	  have	  reported	  the	  routine	  use	  of	  up	  to	  40Gy	  in	  
patients	   with	   gross	   residual	   disease	   post	   surgical	   resection	   (Simon	   2006).	   Dose	  
escalation	   for	   residual	  disease	   is	  being	  assessed	   in	   the	  current	  Children’s	  Oncology	  
Group	  (COG-­‐ANBL0532)	  high-­‐risk	  neuroblastoma	  trial.	  Dose	  escalation	  is	  unlikely	  to	  
be	  possible	  with	  conventional	  radiotherapy	  fields	  and	  therefore	  if	  a	  dose	  escalation	  
question	   is	   to	   be	   asked	   in	   the	   next	   European	   high-­‐risk	   study,	   techniques	   such	   as	  
IMAT	  will	  need	  to	  be	  employed.	  
	  
The	  possibility	  that	  IMRT	  may	  increase	  the	  risk	  of	  radiation-­‐induced	  second	  cancers	  
in	  children	  is	  important.	  The	  increased	  volume	  of	  normal	  tissue	  receiving	  a	  low	  dose	  
from	  multiple	  beams	  and	  leakage	  of	  radiation	  from	  the	  linac	  head	  both	  contribute	  to	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this	  risk.	  The	  second	  malignancy	  risk	  from	  IMRT	  in	  children	  was	  originally	  estimated	  
to	   be	   double	   that	   of	   conventional	   treatment	   (Hall	   2006)	   but	   more	   recent	  
publications	  challenge	  this	  (Schneider	  2008).	  We	  noted	  improved	  conformity	  of	  the	  
high	  dose	  regions	  with	  the	  RapidArc	  technique.	  The	  non-­‐PTV	  integral	  dose,	  acting	  as	  
a	  proxy	   for	   the	  normal	   tissue	  receiving	  a	   low	  dose,	  was	  variable	  and	  not	   increased	  
with	  RapidArc	  in	  all	  cases	  as	  would	  have	  been	  postulated	  (see	  Figure	  7.6).	  	  
	  
I	   am	   currently	   involved	   in	   an	   on-­‐going	   project	   in	   collaboration	  with	   the	   paediatric	  
radiotherapy	  group	  at	  looking	  at	  Addenbrookes	  Hospital,	  Cambridge.	  We	  are	  looking	  
at	  three	  secondary	  malignancy	  risk	  models	  in	  our	  cohort	  of	  neuroblastoma	  patients	  
discussed	   here	   in	   the	   planning	   study	   and	   a	   smaller	   cohort	   of	   patients	   from	  
Cambridge	   treated	  with	   tomotherapy	  and	  comparing	   to	   conventional	   radiotherapy	  
techniques.	  
	  
This	   study	   highlights	   the	   fact	   that	   there	   are	   a	   number	   of	   children	  with	   abdominal	  
neuroblastoma	   where	   the	   current	   SIOPEN	   high-­‐risk	   neuroblastoma	   clinical	   trial	  
protocol’s	   standard	   radiotherapy	   technique,	   AP/PA	   fields,	   is	   unable	   to	   deliver	   the	  
prescribed	  protocol	  dose.	  This	  protocol	  was	  written	  ten	  years	  ago,	  before	  IMRT	  and	  
IMAT	   techniques	  were	  widely	   available.	   This	   study	   shows	   that	   for	   patients	   where	  
conventional	  radiotherapy	  fields	  cannot	  deliver	  the	  full	  protocol	  dose,	  IMAT	  may	  be	  
able	   to	   improve	   dose	   delivery	   and	   potentially	   impact	   on	   local	   control	   rates	   in	  
neuroblastoma.	  However,	  it	  is	  not	  a	  class	  solution.	  There	  remain	  concerns	  including	  
secondary	   carcinogenesis	   risk	   and	   an	   increased	  mean	   contralateral	   kidney	   dose	   in	  
lateralised	  tumours	  with	  the	  IMAT	  technique.	  Any	  amendment	  to	  protocol	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recommendations	   should	   be	   based	   on	   clear	   evidence	   of	   potential	   benefit,	   rather	  
than	  an	  assumption	  that	  more	  modern	  techniques	  ‘must’	  be	  better.	  	  
	  
We	  have	  also	  shown	  that	   the	   technique	  we	  used	   in	   the	  planning	  study	  can	  be	  put	  
into	  clinical	  practise.	  The	   three	  cases	   illustrated	  here	  would	  not	  have	  been	  able	   to	  
receive	  the	  full	  protocol	  dose	  with	  conventional	  radiotherapy	  and	  we	  hope	  that	  this	  
will	  have	  had	  an	  impact	  on	  local	  control	  for	  these	  patients.	  
	  
Within	   the	  US	   there	   is	   an	  early	   phase	   trial	   based	  at	   St	   Judes	   examining	   fixed	   field	  
IMRT	  for	  neuroblastoma.	  The	  same	  group	  from	  St	  Judes	  have	  recently	  reported	  on	  
20	   children	   with	   high-­‐risk	   neuroblastoma	   treated	   with	   IMRT.	   Radiotherapy	   doses	  
varied	   depending	   on	   the	   degree	   of	   surgical	   resection	   –	   23.4Gy,	   30Gy,	   30.6Gy	   or	  
36Gy.	  With	  a	  median	   follow-­‐up	  of	  2.2	  years,	   there	  were	  no	  primary	  site	   in-­‐field	  or	  
loco-­‐regional	  failures	  (Pai	  Panandiker	  2013).	  
	  
Before	   theoretically	   attractive	   innovative	   therapies	   are	   introduced	   into	   routine	  
clinical	  practice,	  it	  is	  essential	  that	  they	  are	  scientifically	  evaluated	  in	  clinical	  trials.	  A	  
clinical	  trial	  within	  the	  UK	  has	  been	  proposed	  and	  supported	  form	  the	  relevant	  NCRI	  
clinical	  studies	  groups	  and	  has	  now	  received	  support	  from	  CRUK	  via	  CTAAC.	  	  
	  
This	  study	  addresses	  a	  possible	  solution	  for	  the	  real	  clinical	  problem	  that	  a	  significant	  
number	  of	  patients	  with	  neuroblastoma	  cannot	  receive	  adequate	  radiotherapy	  with	  
conventional	   radiotherapy	   techniques.	   We	   have	   demonstrated	   that	   IMAT	   can	  
improve	   dose	   distributions	   and	   the	   number	   of	   patients	   receiving	   the	   full	   protocol	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dose.	  The	  real	  value	  of	  IMAT	  in	  neuroblastoma	  will	  be	  investigated	  in	  a	  prospective	  



























The	   overall	   survival	   for	   high-­‐risk	   neuroblastoma	   remains	   under	   40%	   despite	  
therapeutic	   advances	   and	   intensification	   of	   therapy.	   Radiotherapy,	   both	   external	  
beam	   and	   molecular	   radiotherapy,	   form	   an	   essential	   part	   of	   the	   multi-­‐modality	  
treatment	  of	   this	  disease.	  This	  work	  has	  shown	  several	  ways	  of	  optimising	  existing	  
therapies	  and	  developing	  new	  potential	  radiotherapeutic	  techniques	  and	  treatments	  
for	  the	  management	  of	  high-­‐risk	  neuroblastoma.	  	  
	  
Molecular	  radiotherapy	  is	  an	  attractive	  systemic	  treatment	  option	  for	  a	  disease	  such	  
as	   high-­‐risk	   neuroblastoma	  which	   is	   often	  widely	  metastatic.	   Historically,	   the	   only	  
molecular	  radiotherapy	  agent	  in	  use	  for	  neuroblastoma	  was	  131I-­‐mIBG	  targeting	  the	  
noradrenaline	  transporter	  molecule.	  Unfortunately,	  despite	  its	  widespread	  use	  since	  
the	  mid	  1980’s,	   the	  systematic	  review,	  presented	   in	  Chapter	  4,	  revealed	  that	  not	  a	  
single	   randomised	   trial	  of	   131I-­‐mIBG	   in	  neuroblastoma	  has	  been	  performed	   (Wilson	  
2013).	  The	  studies	  have	  been	  Phase	  I,	  Phase	  II,	  or	  case	  series	  and	  they	  have	  all	  used	  a	  
variety	  of	  schedules	  and	  administered	  activities	  in	  a	  highly	  heterogenous	  population.	  
The	  studies	  reflect	  the	  fact	  that	  neuroblastoma	   is	  a	  relatively	  rare	  disease	  and	  131I-­‐
mIBG	  delivery	  has	  been	  only	  possible	  in	  select	  centres	  with	  appropriate	  facilities	  to	  
deliver	   molecular	   radiotherapy	   to	   children	   and	   young	   people.	   Despite	   this,	   the	  
systematic	  review	  analysis	  revealed	  an	  overall	  mean	  tumour	  response	  of	  32%	  in	  the	  
relapsed	  and	  refractory	  setting	  which	  is	  highly	  promising	  compared	  to	  conventional	  
chemotherapy	  regimes	  in	  this	  setting.	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The	  systematic	  review	  of	  131I-­‐mIBG	  therapy	  will	  be	  valuable	  in	  aiding	  future	  areas	  of	  
research.	  It	  is	  essential	  that	  131I-­‐mIBG	  is	  evaluated	  in	  prospective,	  randomised	  clinical	  
trials.	  Both	  within	  Europe	  and	  the	  United	  States,	  131I-­‐mIBG	  is	  to	  be	  used	  in	  planned	  
prospective	  trials	  for	  poor	  responders	  to	  initial	  induction	  therapy.	  	  
	  
This	  work	  has	  shown	  that	  neuroblastomas	  also	  express	  somatostatin	  receptor	  type	  2	  
and	   therefore	   give	   an	   alternative	   molecular	   radiotherapy	   target,	   radiolabelled	  
somatostatin	  analogues,	  for	  both	  the	  imaging	  and	  treatment	  of	  neuroblastoma.	  The	  
feasibility	  of	  performing	  68Ga-­‐DOTATATE	  PET/CT	  for	  disease	  extent	  assessment	  and	  
selection	  of	  patients	  for	  treatment	  with	  177Lu-­‐DOTATATE	  has	  been	  shown.	  In	  a	  small	  
pilot	  study	  of	  patients	  with	  relapsed	  or	   refractory	  neuroblastoma	   it	  was	  shown	  for	  
the	  first	  time	  that	  177Lu-­‐DOTATATE	  therapy	  is	  a	  potential	  treatment	  option	  and	  was	  
shown	   to	   be	   safe	   in	   the	   short	   follow	   up	   of	   the	   study	   (Gains	   2011).	   The	   formal	  
evaluation	   of	   safety	   and	   response	   to	   177Lu-­‐DOTATATE	   in	   relapsed	   and	   refractory	  
neuroblastoma	   is	  currently	  underway	   in	  a	  phase	   II	   trial	  –	  the	  LuDO	  trial,	  which	  has	  
been	  developed	  as	  a	  result	  of	  the	  work	  presented	  here.	  
	  
This	   collection	   of	   work	   has	   shown	   that	   the	   expression	   of	   NAT	   and	   SSTR2	   in	  
neuroblastomas	  is	  not	  homogenous	  both	  on	  functional	  imaging	  (see	  Chapter	  2)	  and	  
by	  immunohistochemistry	  of	  archived	  neuroblastoma	  tissue	  (see	  Chapter	  3).	  This	  has	  
important	   implications	   for	   the	   diagnosis,	   staging,	   response	   assessment	   and	  
treatment	   of	   high-­‐risk	   neuroblastoma.	   It	   suggests	   that	   somatostatin	   receptor	  
imaging	  may	  have	  a	  significant	  role	  to	  play	  alongside	  mIBG.	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We	   have	   changed	   our	   molecular	   radiotherapy	   practise.	   Prior	   to	   this	   work	   on	  
radiolabelled	   somatostatin	   analogues	   the	   only	   agent	   used	   for	   molecular	  
radiotherapy	   in	   neuroblastoma	   was	   131I-­‐mIBG.	   This	   work	   has	   shown	   that	   imaging	  
with	   radiolabelled	   somatostatin	   analogues	   provide	   additional	   information	   from	  
functional	   imaging	  compared	  to	  123I-­‐mIBG	  alone.	  The	  use	  of	  177Lutetium	  DOTATATE	  
may	   provide	   a	   better	   molecular	   radiotherapy	   therapeutic	   option	   due	   to	   the	  
distribution	   of	   disease	   in	   some	   patients	   with	   neuroblastoma.	   The	   results	   of	   the	  
phase	   II,	   LuDO	   study	   are	   awaited	   to	   assess	   response	   rate	   and	   toxicity	   but	   having	  
seen	   such	   heterogeneity	   in	   distribution,	   a	   combination	   of	   both	   agents	   may	   be	   a	  
potential	  future	  therapeutic	  option.	  
	  
Over	   the	   past	   decade,	   investigators	   have	   looked	   to	   increase	   the	   response	   to	   131I-­‐
mIBG	  by	  using	  higher	  administered	  activities,	  requiring	  stem	  cell	  support	  and	  the	  use	  
of	   radiosensitisers	   such	   as	   topotecan	   and	   irinotecan	   (Gaze	   2005,	   Dubois	   2012).	  
Recent	   preclinical	   studies	   have	   shown	   that	   Vorinostat	   (an	   inhibitor	   of	   HDAC)	   can	  
increase	  the	  expression	  of	  the	  norepinephrine	  transporter	  in	  neuroblastoma	  in	  vitro	  
and	  in	  vivo	  which	  could	  have	  potential	  for	  enhancing	  131I-­‐mIBG	  therapy	  (More	  2011).	  
The	   combination	   of	   vorinostat	   and	   131I-­‐mIBG	   is	   now	   being	   evaluated	   in	   a	   phase	   I	  
study.	   Pre-­‐clinical	   evidence	   has	   shown	   additional	   benefit	   for	   the	   use	   of	   PARP	  
inhibitors,	   which	   also	   act	   as	   radiation	   sensitisers.	   They	   have	   been	   shown	   in	  
laboratory	   models	   to	   have	   synergy	   with	   131I-­‐mIBG	   molecular	   radiotherapy	  
(McCluskey	   2012).	   Clinical	   evaluation	   of	   PARP	   inhibitors	   in	   combination	   with	   131I-­‐
mIBG	  is	  awaited.	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As	  well	  as	  the	  above	  mentioned	  strategies	  to	  improve	  the	  response	  rate	  to	  131I-­‐mIBG	  
there	  are	  several	  potential	  reasons	  why	  patients	  with	  neuroblastoma	  fail	  to	  respond	  
to	  molecular	   radiotherapy	  which	  must	   be	   considered	   for	   future	   development	   and	  
strategies.	   Although	   neuroblastoma	   is	   commonly	   described	   as	   a	   radiosensitive	  
tumour	  there	  is	  likely	  to	  be	  a	  range	  of	  radioresponsiveness,	  especially	  in	  heavily	  pre-­‐
treated	  patients.	  Neuroblastoma	  is	  a	  very	  heterogenous	  disease	  and	  the	  laboratory	  
data	  available	  is	  on	  a	  limited	  umber	  of	  neuroblastoma	  cell	  lines	  and	  therefore,	  not	  all	  
neuroblastomas	  may	  be	  intrinsically	  radiosensitive.	  	  
	  
The	  findings	  of	  non-­‐homogenous	  distribution	  of	  the	  NAT	  and	  SSTR2	  receptor	  targets	  
could	   result	   in	   a	   non-­‐uniform	   distribution	   of	   radiation	   dose	   to	   the	   tumour	   cells.	  
Molecular	  radiotherapy	  uptake	  is	  likely	  to	  be	  heterogenous	  and	  the	  poor	  vascularity	  
of	  tumours	  and	  central	  necrosis	  of	  larger	  lesions	  can	  add	  to	  the	  variable	  distribution.	  
Some	   of	   the	   heterogeneity	   of	   uptake	  will	   be	   overcome	   by	   the	   potential	   cross	   fire	  
effect	  between	  adjacent	  cells	  as	  well	  as	  the	  bystander	  effect	  (Boyd	  2006,	  Gow	  2013).	  
	  
Tumour	   hypoxia	  may	  be	   another	   reason	   for	   inadequate	   response	   to	   radiotherapy.	  
There	  have	  been	  no	  studies	  looking	  at	  neuroblastoma	  tumour	  hypoxia	  on	  functional	  
imaging	  but	  tumour	  hypoxia	  has	  been	  demonstrated	  on	  histopathological	  specimens	  
by	   immunohistochemistry	   using	   the	   HIF-­‐1α	   antibody.	   High	   levels	   of	   HIF-­‐1α	   were	  
associated	  with	  aggressive	  clinical	  behaviour	  of	  neuroblastoma	  (Dungwa	  2012).	  	  
	  
The	   physical	   properties	   of	   radioisotope	   are	   important	   for	   targeting	   the	   receptor	  
positive	  cells	  but	  also	  for	  targeting	  cells	  not	  expressing	  the	  receptor.	  When	  selecting	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radioisotopes	   for	   therapy	   rather	   than	   imaging	   it	   is	   important	   to	   take	   in	   to	  account	  
the	  type	  and	  energy	  of	  the	  emitted	  radiation,	  the	  distance	  over	  which	  the	  energy	  is	  
deposited,	  as	  well	  as	  the	  physical	  half-­‐life	  of	  the	  radioisotope.	  	  
	  
In	  the	  vast	  majority	  of	  studies	  on	  molecular	  radiotherapy	  within	  the	  literature	  there	  
has	  been	  no	  dosimetry	  performed	   so	   that	  we	  do	  not	   know	  what	   range	  of	   tumour	  
doses	  patients	  are	  receiving.	  Historically	  dosimetry	  has	  been	  difficult	  to	  perform	  and	  
came	  with	  inherent	  problems	  with	  regards	  to	  accuracy.	  If	  molecular	  radiotherapy	  is	  
to	  earn	   its	  role	   in	  the	  management	  of	  high-­‐risk	  neuroblastoma	  dosimetry	  will	  need	  
to	  be	  performed.	  It	  is	  essential	  to	  know	  the	  absorbed	  dose	  to	  the	  tumour	  as	  well	  as	  
critical	   organs	   at	   risk	   as	   we	   would	   do	   in	   every	   day	   external	   beam	   radiotherapy	  
practise.	  Within	  the	  phase	   II	  LuDO	  trial,	  developed	  as	  a	  result	  of	   this	  work,	  we	  will	  
measure	   tumour	   dosimetry	   and	   correlate	   this	  with	   response	   as	  well	   as	   looking	   at	  
organ	  dosimetry.	  
	  
The	  role	  of	  18F-­‐FDG-­‐PET	  is	  unclear	  in	  neuroblastoma	  and	  there	  is	  little	  available	  data	  
in	   the	   published	   literature.	   The	   additional	   benefit	   of	   18F-­‐FDG-­‐PET	   for	   assessing	  
response	   to	   131I-­‐mIBG	   therapy	   was	   explored	   in	   this	   work.	   For	   this	   particular	  
indication,	   18F-­‐FDG	  PET/CT	   is	  unlikely	   to	  be	  a	  valuable	  tool	   in	  assessing	  relapsed	  or	  
refractory	  disease	  in	  high-­‐risk	  neuroblastoma	  patients	  due	  to	  the	  low-­‐grade	  uptake	  
seen	  and	  difficulty	  in	  interpreting	  scans	  in	  heavily	  pre-­‐treated	  patient	  and	  those	  who	  
have	   received	   recent	   chemotherapy	   or	  G-­‐CSF.	   The	   role	   of	   18F-­‐FDG	  PET/CT	   is	  more	  
likely	   to	   be	   of	   benefit	   in	   assessing	   early	   response	   to	   induction	   chemotherapy	  
following	   initial	   diagnosis	   but	   this	   requires	   prospective	   examination.	   	   Other,	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alternative	  functional	  imaging	  techniques	  are	  being	  examined	  around	  the	  world	  such	  
as	  18F-­‐dopa	  PET/CT	  (Piccardo	  2012).	  
	  
The	   development	   of	   new	   functional	   imaging	   modalities	   for	   the	   management	   of	  
neuroblastoma	  is	  an	  exciting	  area	  of	  research.	  However,	  these	  newer	  techniques	  are	  
unlikely	   to	   be	   widely	   available	   which	   does	   limits	   their	   use,	   reproducibility	   and	  
inclusion	  in	  large	  prospective	  clinical	  trials	  for	  evaluation.	  123I-­‐mIBG	  is	  therefore	  likely	  
to	   remain,	   for	   the	   foreseeable	   future,	   the	   gold-­‐standard	   imaging	  modality	   for	   the	  
diagnosis,	   staging	   and	   response	   assessment	   of	   metastatic	   neuroblastoma	   and	   we	  
await	  the	  evaluation	  of	  124I-­‐mIBG	  PET/CT	  which	  is	  now	  in	  an	  early	  phase	  clinical	  trial.	  
	  
With	   regards	   to	   local	   control	   in	   neuroblastoma,	   most	   current	   high-­‐risk	  
neuroblastoma	  protocols	  from	  around	  the	  world	  include	  external	  beam	  radiotherapy	  
to	   the	   primary	   tumour.	   There	   is	   evidence	   to	   support	   that	   using	   external	   beam	  
radiotherapy	   improves	   local	   control	  and	  some	  small	   studies	   that	   suggest	   that	   local	  
control	  in	  high-­‐risk	  neuroblastoma	  may	  impact	  on	  overall	  survival	  for	  these	  patients.	  
We	  have	  seen	  in	  this	  study	  that	  almost	  50%	  of	  the	  patients	  treated	  historically	  with	  
external	   beam	   radiotherapy	   had	   a	   compromise	   on	   their	   tumour	   volume	   coverage	  
due	   to	   an	   inability	   to	   safely	   deliver	   the	   protocol	   dose	   within	   organ	   at	   risk	   dose	  
constraints.	  Within	  the	  planning	  study	  performed,	  dose	  delivery	  to	  the	  target	  volume	  
was	  significantly	  improved	  with	  an	  IMAT	  technique	  compared	  to	  traditional	  parallel-­‐
opposed	  radiotherapy	  techniques.	  There	  were	  also	  significant	  advantages	  in	  terms	  of	  
doses	   to	   the	   liver	   with	   the	   IMAT	   technique	   for	   right-­‐sided	   tumours	   (Gains	   2012).	  
 299 
There	   have	   been	   concerns	   over	   adopting	   IMRT	   techniques	   for	   paediatric	   tumours	  
because	   of	   the	   low-­‐dose	   volume	   spread	   and	   the	   potential	   risk	   of	   secondary	  
malignancies.	   It	   is	   right	   that	   theses	   techniques	   are	   not	   universally	   adopted	   in	  
paediatrics	   as	   in	   the	   adult	   oncology	   population	   and	   rather	   they	   should	   be	  
investigated	   prospectively	   in	   clinical	   trials	   as	   is	   proposed	   here.	   The	   evaluation	   of	  
secondary	   malignancy	   risk	   comparing	   IMAT	   and	   conventional	   radiotherapy	   in	  
abdominal	   neuroblastoma	   is	   an	  on	   going	   collaboration	  with	   another	  UK	  paediatric	  
radiotherapy	  centre.	  	  
	  
If	  the	  next	  European	  high-­‐risk	  neuroblastoma	  study	  wants	  to	  ask	  a	  dose	  escalation	  of	  
local	  radiotherapy	  question,	   it	   is	  unlikely	  to	  be	  possible	  without	  the	  introduction	  of	  
new	  radiotherapeutic	   techniques	  as	  too	  many	  patients	  receive	  an	   inadequate	  dose	  
or	  tumour	  coverage	  with	  conventional	  techniques	  already.	  	  
	  
There	  is	  retrospective	  quality	  assurance	  of	  radiotherapy	  in	  the	  current	  SIOPEN	  high-­‐
risk	   neuroblastoma	   study	   but	   it	   will	   be	   essential	   that	   this	   becomes	   prospective	   if	  
these	   new	   techniques	   are	   employed	   over	   Europe	   (Gaze	   2010,	   Gaze	   2013).	   Poor	  
compliance	  with	  radiotherapy	  protocols	  within	  clinical	  trials	  has	  been	  found	  to	  have	  
an	  adverse	  affect	  on	  clinical	  outcomes	  (Ohri	  2013).	  
	  
Another	  way	  of	  potentially	  sparing	  the	  dose	  to	  normal	  tissues	  is	  to	  examine	  the	  role	  
of	   proton	   beam	   therapy.	   Protons	   are	   heavy,	   positively	   charged	   particles	   that	   stop	  
within	  tissues	  depositing	  90%	  of	  their	  energy	  (the	  Bragg	  peak).	  Following	  the	  ‘Bragg	  
peak’	  there	  is	  a	  sharp	  fall	  off	  of	  dose	  so	  that	  even	  tumours	  next	  to	  critical	  organs	  at	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risk	  can	  often	  be	  treated.	  With	  regards	  to	  paediatric	  patients,	  the	  greatest	  potential	  
for	   protons	   comes	   from	   the	   reduced	   likelihood	   of	   long	   term	   toxicities	   and	  
complications	  of	   treatment	   resulting	   from	  a	   reduced	  dose	   to	  normal	   tissues	  and	  a	  
potential	  reduction	  in	  secondary	  malignancies.	  There	  are	  three	  reports	  on	  the	  use	  of	  
proton	  therapy	  for	  the	  treatment	  of	  neuroblastoma	  in	  the	  literature	  (Hillbrand	  2008,	  
Hattanhadi	  2011,	  Hill-­‐Kayser	  2013).	  
	  
In	   conclusion,	   this	   work	   has	   shown	   several	   ways	   in	   which	   radiotherapeutic	  
techniques,	   both	   external	   beam	   and	   molecular	   radiotherapy,	   could	   be	   optimised	  
with	  the	  aim	  of	  improving	  the	  outcome	  for	  patients	  with	  high-­‐risk	  neuroblastoma.	  As	  
a	  result	  of	  this	  work	  we	  have	  opened	  the	  phase	  II	  trial	  of	  177Lutetium	  DOTATATE	  in	  
relapsed/refractory	   high-­‐risk	   neuroblastoma	   and	   have	   secured	   CTAAC	   funding	   via	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